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The Detection of Potential Drug Resistance Markers Using Proteomic Technologies
Abstract
This thesis sets out to increase our knowledge of mechanisms by which lung cancer cells 
develop resistance to chemotherapeutic agents To further investigate drug resistance in 
lung cancer, a panel of four cell lines were chosen for pulse-selection with 
chemotherapeutic agents The cell lines include two squamous (SKMES-1 and DLRP) and 
two small cell lung carcinoma (DMS-53 and NCI-H69) cell lines The chemotherapy naive 
cell lines were pulse-selected rather than continuously selected with clinically relevant 
concentrations of taxotere, taxol, carboplatin and/or VP-16 The resulting twelve novel cell 
lines were tested for resistance to a cross-section of chemotherapeutic agents, for changes 
in invasiveness, motility, adhesiveness and for expression of the multidrug resistance 
(MDR) efflux pump proteins, P-gp and MRP-1 The SKMES-taxane selected variants were 
chosen for further analysis because the resistance profile was unstable and the 
concentration of drug used for selection was at a clinically achievable level Proteomic 
analysis was used to identify proteins associated with the development of taxol and taxotere 
resistance m these cell lines Proteomic analysis also revealed the differences between 
resistance to taxol and taxotere Loss of resistance was observed in both taxane resistant 
variants of SKMES-1 By monitoring the differential protein expression over time, proteins 
involved in the loss of resistance were identified
Adriamycin and mitoxantrone resistance was also studied in the squamous lung cell line 
DLKP While the main mechanism of resistance in these cell lines is associated with a drug 
pump, little information on cytoplasmic changes is available Proteomic analysis 
investigated these changes and elucidated the mechanisms involved in adriamycin and 
mitoxantrone resistance to identify putative markers with possible prognostic/diagnostic 
value A comparison of the proteins altered in adriamycin and mitoxantrone-resistant 
variants was carried out as these drugs are intercalating agents with mitoxantrone being an 
analogue of adriamycin and inducing less cardiotoxicity Multidrug resistance is a major 
problem in lung cancer, there is a need to understand the common mechanisms involved 
The proteins involved in the development of taxane resistance in SKMES-1 showed some 
cross over with other chemotherapeutic drugs namely adriamycin or mitoxantrone in 
DLKP
i
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Section 1.0: Introduction
1 Introduction
Cancer is a major health issue accounting for 1 in 4 deaths in the United States in 2002, 
second only to heart disease (American Cancer Society statistics, 2005) Of the different 
types, lung cancer is the most lethal with 1 2 million cases diagnosed world wide each 
year and 1 2 million deaths (Seve and Dumontet, 2005) At approximately 20%, lung 
cancer is the leading cause of cancer deaths in Ireland Statistics show the incidences to 
be below the European average for men but over double for women (O’ Connell, 2004) 
Less than 1% of cases occur before the age of 40, with a rapid increase thereafter 
particularly m the 65-70 age group Over 90% of lung cancers are due to smoking 
tobacco and are therefore preventable However, despite numerous programmes aimed 
at stopping smokers, 29% of adults and over 30% of teenagers still smoke Currently 
greater than 75% present with advanced stage disease Despite recent advances in 
research, there has only been a modest increase in survival and this scenario presents an 
important area for the detection of early stage cancers and identification of more 
effective treatments
Surgery provides the only curative treatment for lung cancer but resection is only 
possible in 30% of patients at diagnosis (Sandler et a l , 2004) due to the late stage of 
presentation (Danesi et a l , 2003) The poor survival rates are due to the cancer’s 
propensity for early spread, the lack of effective screening for early diagnosis, the 
inability of systemic therapy to cure metastatic disease and the poor understanding of 
the biology of the tumours (Bunn, 2002, Niklinski and Hirsch, 2002)
Histologically lung cancers are classified into four groups, namely small cell lung 
cancer, adenocarcinoma, squamous cell carcinoma and large cell carcinoma However, 
for clinical and therapeutic purposes, lung cancers are divided into two groups, small 
cell carcinoma (SCLC) and non-small cell carcinomas (NSCLC)
While non small cell lung carcinomas (which constitute 80% of lung cancers) often 
show intrinsic multidrug resistance, small cell lung carcinomas, which causes 20% of 
all lung cancers, usually respond well to various anticancer agents initially However, 
SCLC acquires drug resistance with a two-year survival rate less than 10% (Wilhelm 
and Kolesar, 2005) This type of lung cancer differs both biologically and clinically
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from the other histological types of lung cancer in that it has unique neuroendocrine and 
metastatic phenotypes SCLC cells can secrete up to 30 regulatory peptides and 
hormones and express receptors for over half of these factors Many of these peptides 
function as autocnne growth factors, which activate G protein-coupled receptors This 
establishes a positive feed-back loop which stimulates cell proliferation (Strassheim et 
a l , 2000) This factor and the metastatic phenotype contribute to the greater mortality 
rate of SCLC patients
Non-small cell lung carcinomas have more phenotypic heterogeneity than SCLC 
(Gazdar, 1985) and are less sensitive to cytotoxic drugs The overall 5 year survival rate 
of patients with NSCLC has remained at less than 15% for the past 20 years (Rosel et 
a l , 2004) Nearly all patients with NSCLC eventually develop metastatic disease 
(Boonstra et a l , 2004) with an average survival period of 8 to 10 months The standard 
chemotherapy regime consists of a range of combinations of carboplatin, cisplatin, 
taxol, taxotere, gemcitabine, vinorelbine, lfosfamide and VP-16 However, results from 
randomised trials have illustrated that the following combinations - cisplatin and 
gemcitabine, cisplatin and vinorelbine and cisplatin or carboplatin with taxol or 
taxotere, failed to show differences in response rates and thus failed to improve survival 
rates The response rates in question failed to exceed 40% regardless of the combination 
used (Scaghatti et a l , 1999)
The treatment of patients with chemotherapeutic drugs is seriously hampered by the 
development of resistance (both single agent and or multiple) (Boonstra et a l , 2004) 
There are multiple mechanisms of drug resistance in lung cancer, acquired in SCLC and 
often inherent in NSCLC (Scaghatti et a l , 1999) Acquired resistance is particularly 
problematic as tumours not only develop resistance to the original treatment but can 
also become cross-resistant to other drugs thereby developing multiple drug resistance 
(Longely and Johnston, 2005)
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1.1 Multidrug resistance (MDR)
One of the major factors leading to drug resistance is decreased drug accumulation. 
Drug resistance mechanisms develop at many levels including drug inactivation, 
alterations in the target, increased drug efflux, processing of drug-induced damage and 
evasion of apoptosis (Longely and Johnston, 2005). Multidrug resistance occurs when 
cells are exposed to only one drug, yet display cross-resistance to an array of 
structurally unrelated compounds. Huge advances have been made in understanding the 
biology of lung cancer and the mechanisms of drug resistance. MDR has been classified 
based on the specific cellular targets involved: they are -  classical multidrug resistance 
(MDR/P-gp), non P-gp MDR (MRP), atypical MDR (mediated through altered 
expression of topoisomerases II) and lung cancer resistance-related protein (LRP) 
(Scagliotti, et a l , 1999). However, other mechanisms of resistance include, an increase 
in detoxification due to enhanced activity of glutathione s-transferase, failure to engage 
the proper response, which leads to apoptosis of damaged cells and an increase in the 
metabolism of the drug to less toxic molecules (Longely and Johnston, 2005).
To help identify these molecular mechanisms, cell lines resistant to chemotherapeutic 
drugs have been developed. From analysis of lung cancer, it is apparent that a range of 
resistance mechanisms exist. The two most commonly found mechanisms are the 
overexpression of P-glycoprotein and the MDR related protein MRP -  both of which 
are involved in the first stage of the development of multidrug resistance. It has been 
recognised that the development of MDR is a multifactorial process involving several 
cellular pathways. The first line of defence is to prevent accumulation of 
chemotherapeutics within the cell and this is achieved by means of the following 
membrane pumps.
1.1.1 P-glycoprotein (P-gp)
P-gp is one of the most widely studied and best characterised markers of MDR. 
Identified by Juliano and Ling in 1976, it is a 170 kDa member of the superfamily of 
ATP-binding cassette (ABC) membrane transporters (Tellingen, 2001). It is composed 
of 12 transmembrane domains and 2 ATP-binding domains (Figure 1.1). The protein is 
naturally expressed in the epithelial cells of the liver and kidney and also in the 
capillaries of the testes, ovaries and adrenal gland. In these cells, P-gp functions to 
pump toxins and xenobiotics (including anticancer agents) out of cells (Scagliotti et al., 
1999; Filipits, 2004).
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Encoded by the mdr-1 gene, P-gp is one of the key proteins that confer MDR in cancer. 
It is an ATP-dependant drug efflux pump which mediates drug resistance by actively 
extruding drugs from the cells (Lavie and Liscovitch, 2000).
The drugs most often involved in P-gp-mediated MDR are of fungal or plant origin, 
including anthracyclines, taxanes, epipodphyllotoxins and vinca alkaloids. Cancers that 
are intrinsically resistant to cytotoxic drugs such as renal, pancreatic and hepatocellular 
carcinomas often (over-) express P-gp. Interestingly, cancers with no or low basal levels 
of P-gp such as small cell lung carcinomas show higher expression levels after 
chemotherapy treatment (Filipits, 2004). It appears that P-gp alone is not sufficient in 
conferring a complete MDR phenotype in all cancer cells. Acquisition of MDR involves 
other mechanisms that often act concurrently to prevent or circumvent the lethal effects 
of chemotherapy drugs (Lavie and Liscovitch, 2001).
Drug efflux
Plasma
membrane
Daunomycin
Taxol
Vinblastine
Doxorubicin
F ig u re  1.1 P-glycoprotein as a transmembrane drug efflux pump (Sorrentino, 2002).
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The expression and/or activity of P-gp has been associated with unfavourable outcome 
m for example, paediatric acute lymphoblastic leukaemia, ovarian and diffuse large B- 
cell lymphoma patients (Swerts et a l , 2006, Yakirevich et a l , 2006, Ohsawa et a l , 
2005)
A possible strategy against MDR is to co-admimster efflux pump inhibitors, although 
these agents may actually increase the side effects of chemotherapy by blocking 
physiological anticancer drug efflux from normal cells Even though efforts to 
overcome MDR using first and second generation reversal agents (eg  verapamil, 
cyclosponne A, quimdme) or analogues of the first-generation drugs (e g 
dexverapamil, valspodar, cinchonine), have begun, few significant advances have 
resulted Clinical trials with third generation modulators (e g bincodar, zosuquidar, and 
laniquidar) specifically developed for MDR reversal are ongoing Results are not 
encouraging, as the perfect reversing agent may not exist
Antisense strategies targeting the MDR1 messenger RNA have been developed Guo et 
al (2005) used the antisense peptide nucleic acid delivery system via liposomes to 
inhibit the expression of P-gp in the human neuroblastoma cell line, SK-N-SH The 
result was an efficient and specific decrease in P-gp expression of SK-N-SH cells
1 1 2  Multidrug resistance protein 1 (MRP1)
The subfamily C of the ABC transporter family comprises six members of the multidrug 
resistance protein (MRP) family (Figure 1 2) They function in the transport of organic 
anions (MRP1-3) and nucleotides (MRP5) (Schrenk et a l , 2001) First discovered by 
Cole and Deeley in 1992, MRP1 is a 190 kDa protein, mainly localised in the plasma 
membrane (Borst et a l , 1999)
The genes encoding MRP1 and P-gp are evolutionary very distant, with the primary 
structure of the two proteins being dissimilar, sharing only 15 percent ammo acid 
identity (Cole et a l , 1992) The resistance profile of MRP 1 is somewhat different to that 
of P-gp-mediated resistance although many cancer drugs are affected by both 
mechanisms Overexpression of MRP1 increases resistance to several anticancer drugs, 
such as anthracyclines, vincristine, vinblastine, and VP-16 The specific exceptions are 
the taxanes and mitoxantrone (Filipits, 2004)
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Figure 1.2 Schematic representation of MRP1 (adapted from this website: www.sigma- 
aldrich.com). PM=Plasma membrane; 1 -17=Transmembrane domains 1-17; COOH=Carboxy 
terminus; NH2=Amino terminus
MRP1 has been detected in almost all solid and haematological cancers. The clinical 
significance of high levels of MRP 1 has been associated with poor patient outcomes in 
lung, endometrial, breast, gastric carcinomas, neuroblastomas and acute myeloid 
leukaemia (Chauncey, 2000; Young etal., 2001).
1.1.3 MRP2 (cMOAT)
Canalicular multi-specific organic anion transporter (cMOAT or MRP2), an isoform of 
MRP1, is mainly expressed in the canalicular membrane of hepatocytes and the 
proximal tubules of the kidney. It shows 49% identity with human MRP1 at the protein 
level and is associated with hepatobiliary secretion of bilirubin-glucuronide (Young et 
al., 2001; Filipits, 2004). The substrate specificity is similar to MRP1, but in contrast to 
MRP1 it can confer resistance to cisplatin.
In recombinant systems, MRP2 expression enhanced resistance to VP-16, vincristine, 
cisplatin, doxorubicin, and epirubicin. Using antisense cDNA, sensitivity to cisplatin, 
vincristine and doxorubicin was restored in cell lines expressing MRP2 (Lockhart eta l.,
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2003) MRP2 has been demonstrated to transport vinblastine in association with 
glutathione (GSH) The GSH co-transport mechanism provides a plausible explanation 
of how MRP2 and MRP1 confer resistance to some of the anti-cancer agents that form 
conjugates in vivo (Leslie et a l , 2001) To date, there has been no demonstrated 
correlation between MRP2 expression and clinical outcome (Lockhart et a l , 2003)
1 1 4  Lung resistance protein
The lung resistance protein, also known as the major vault protein (MVP), is not an 
ABC transporter but is often expressed in high levels in non P-gp drug-resistant cell 
lines and tumours The LRP gene codes for a protein that has a molecular mass of 110 
kDa (Scagliotti et a l , 1999) The LRP/MVP is the most abundant protein of the vault 
complex Vaults are large, abundant nbonucleoprotein particles localised in the 
cytoplasm The function of vault proteins is still unclear However, it has been 
suggested that vaults may regulate nucleocytoplasmic as well as vesicular transport of 
different substrates, including cytostatic drugs
Analysis of advanced ovarian tumour samples has illustrated that the expression of 
LRP/MVP at diagnosis was an independent poor prognostic factor for response to 
chemotherapy Lung resistance protein is also an indicator of poor response to platin or 
alkylating agents (Filipits, 2004)
1 2 Chemotherapy drugs
Currently, chemotherapy can offer improvement in medium term survival of lung 
cancer but overall survival is poor Chemotherapy is the use of pharmaceutical agents 
for the treatment of a disease and overall has been very successful in the treatment of 
certain types of cancer Chemotherapeutic drugs have been discovered through many 
different approaches ranging from empirical screening to rational design with a strong 
contribution from serendipity along the way
The aim of chemotherapy is to kill the tumour cells with the least possible effect on 
normal cells (Debatin, 2000) Chemotherapy is often used in combination with surgery 
or other therapies such as radiotherapy, known as adjuvant chemotherapy It is 
especially important for increased survival in cancer patients where these other 
treatments have failed (Akehurst et a l , 2002)
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1 2 1  The taxanes (Taxol and Taxotere)
The taxanes are a group of drugs, which include taxol and taxotere Taxol, purified by 
Bnstol-Meyers Squibb, was originally isolated from the bark of the slow-growing 
Pacific yew, Taxus brevifoha by Wall and Warn in 1979 Taxol is a complex diterpene 
with a taxane ring structure fused with a 4-membered oxetan ring, an ester side chain at 
position C-13 and a benzoyl side chain at position C-2 (see Figure 1 3)
F ig u re  1 3 Structure o f  taxol
Taxol was approved by the Federal Drug Agency (FDA) for treatment of breast, ovarian 
and NSCLC (He et a l , 2001) Schiff et al (1979), were the first group to report that 
taxol promoted the assembly of microtubules in vitro in the absence of guanosine 
triphosphate (GTP), which is usually required The resulting microtubules were also 
discovered to be stable against conditions favouring depolymensation 
Taxotere is synthesised from a precursor, isolated from the needles of the European 
yew, Taxus baccata Taxotere is not identical in structure to taxol, having two 
modifications, a tert-butoxycarbonyl group at C-3’ and a hydroxyl group on the C-10 
position (see Figure 1 4) The two drugs have similar mechanisms of action even though 
taxotere is approximately twice as potent an inhibitor of microtubule depolymensation 
relative to taxol (Gelman, 1994)
OH
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Figure 1 4 Structure of taxotere
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Microtubules which primarily consist of alpha (a) and beta ((3) tubulin heterodimers, are 
intrinsically dynamic polymers They play a crucial role in mitotic spindle assembly, the 
mitotic checkpoint and chromosomal development (Yvon et a l , 1999) The taxane 
drugs cause interruption of mitotically-specific microtubule processing at the G2-M 
phase of cell division They promote the assembly of microtubules and block their 
disassembly thereby preventing cancer cells from dividing The result is cancer cell 
death and the promotion of dysfunctional microtubules (Calderom and Cemy, 2001) 
Interestingly, both taxanes bind to the p-subunit of tubulin but the microtubules 
produced by taxotere are larger than those produced by taxol This may explain why 
taxotere appears to be approximately twice as potent as taxol (Vaishampayan et a l , 
1999)
There are at least two important mechanisms of resistance to the taxanes The MDR 
phenotype is acquired resistance conferred by both taxanes and many other 
chemotherapeutic drugs The energy-dependent P-gp efflux pump transports 
chemotherapeutic drugs through the cell membrane reducing the accumulation of 
intracellular taxol/taxotere (Chiou et a l , 2003) The other major mechanism involves a 
mutation of the gene encoding for one of the tubulin subunits (Schibler and Cabral, 
1986) or alterations in the expression of the subunits The result is the production of 
structurally altered tubulm subunits with have diminished capacity of depolymerisation 
(Calderom and Cemy, 2001) Studies have shown that taxane treatment has improved 
clinical outcome and survival For example, taxotere as a neoadjuvant single agent is 
effective in treating patients with large locally advanced breast cancer, giving durable 
clinical and pathological responses, and good survival outcome in patients with clinical 
responses (Tham et a l , 2005)
Recent advances in the design and prechmcal evaluations are leading to the generation 
of new synthetic taxane anticancer agents These agents have been designed to have 
fewer side effects, superior pharmacological properties and improved activity against 
drug-resistant human cancers Structure-activity relationship studies discovered a series 
of highly active second-generation taxanes such as Ortataxel, DJ-927 and BAY 59-8862 
(Geney et a l , 2005, Shionoya et a l , 2003? Ferlim et a l , 2003)
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Ortataxel (SB-T-101131, IDN5109, BAY59-8862), currently in phase II trials, exhibits 
excellent activity against a variety of drug-sensitive and drug-resistant cancer cell lines, 
as well as human tumour xenografts in mice. Photoaffinity labelling of the microtubules 
and P-gp revealed the drug-binding domain in tubulin as well as in P-gp (Geney et al.,
2005). The drug is characterized by its high tolerance, antitumour efficacy, ability to 
overcome multidrug resistance and oral bioavailabilty. After treatment of head and neck 
squamous cell carcinoma with ortataxel in vitro, Bcl-2 and Bcl-XL were down- 
regulated, Bax was up-regulated, and caspase-3 was activated. Supernatant 
concentration of vascular endothelial growth factor and interleukin-8 were decreased. 
Immunohistochemistry analysis showed that ortataxel inhibited tumour angiogenesis 
and induced apoptosis, producing a decreased blood vessel density and increased 
apoptosis index (Sano et a l , 2006).
Taxol and taxotere are substrates for P-gp. In contrast, ortataxel is effective against P- 
gp-expressing cells by virtue of modulation of P-gp-mediated transport. Modulation of 
the drugs mitoxantrone, daunorubicin and adriamycin retention and cytotoxicity by 
ortataxel was studied in cell lines overexpressing P-gp, MRP-1 and breast cancer 
resistance protein. Ortataxel effectively modulated drug retention and cytotoxicity in all 
cell lines (Minderman et a l , 2004).
1.2.3 The platinum drugs (Cisplatin and Carboplatin)
In 1965, Rosenberg and co-workers first reported the inhibition of cell division in 
Eschericia coli by the electrolysis products from a platinum electrode. As a result 
cisplatin was the first platinum complex discovered to have a broad range of antitumour 
activity (Figure 1.5). Further research resulted in the synthesis of more platinum 
analogues, carboplatin being the most widely studied.
Cisplatin is an established antitumour agent for the treatment of advanced NSCLC and 
in cisplatin-based adjuvant chemotherapy. Cisplatin is a square planar coordination 
complex with a central platinum atom surrounded by two labile chlorine atoms and two 
relatively inert ammonia moieties in the cis configuration (Wang and Lippard, 2005). 
The ability of cisplatin or carboplatin to form covalent intra-strand and inter-strand 
cross-links with the genomic DNA is thought to cause its cytotoxic effects. Besides 
their effect on lung cancer, the platinum drugs are extremely effective when used on 
most testicular cancers, head and neck and on a subset of ovarian and bladder tumours.
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However, almost half the women with ovarian cancers present with tumours that are 
intrinsically resistant to the platinum compounds Moreover, a significant number of the 
tumours that respond well initially eventually acquire resistance As a result, the cells’ 
ability to limit these DNA lesions or its ability to repair or tolerate these lesions once 
formed, should influence its survival Therefore resistance to platinum based therapy 
poses a major problem (Wemyj and Monn, 2004) Cisplatin treatment is severely 
limited by neurotoxicity side effects which can cause peripheral neuropathy, tinnitus 
and hearing loss Carboplatm (Figure 1 6) is less potent than cisplatin and its side 
effects are different in that it has less renal and gastrointestinal toxicity but it has more 
hematological toxicity (Wang and Lippard, 2005)
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Mechanisms of cellular platinum resistance identified to date include, decreased 
cisplatin accumulation via increased drug inactivation by protein and non-protein thiols, 
enhanced DNA adduct repair, alteration in the sorts of platinum-DNA adducts formed 
and increased tolerance to platinum-DNA damage However, the underlying molecular 
bases for these chemoresistance mechanisms are still poorly understood (Johnson et a l , 
1996) Chemoresistance to cisplatin remains one of the major obstacles to the successful 
treatment of NSCLC
1 2 4 5-fluorouracil (5-FU)
The drug 5-fluorouracil (an antimetabolite) and its derivatives are among the most 
useful drugs m the treatment of solid tumours but not traditionally used in lung cancer 
First designed and synthesised by Heidelberger and co-workers in 1957, its chemistry 
and mechanism of action has been studied extensively (Longley et a l , 2003) It is
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widely used to treat colorectal, breast, head and neck, non-small-cell lung cancer, 
pancreatic cancer and leukaemias (Manng et a l , 2005) However, as it is unusual to 
observe complete remission when 5-FU is used alone, it is therefore more used as a 
combinational drug For example the combination of 5-FU with oxahplatm and 
îrinotecan which act on targets distinct from 5-FU have improved the response rates of 
advanced colorectal cancer to 40-50% (Longley et a l , 2003)
Targeting rapidly dividing cells, the mam side effects of 5-FU are on the bone marrow 
and intestinal and oral mucosa The result is a decrease in platelet and leukocyte 
production Other side effects include diarrhoea and neurological problems such as 
somnolence and ataxia
Resistance is still a significant limitation to its clinical use Understanding the 
mechanisms involved is vital to overcoming resistance
H
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Figure 1 7 Structure of 5-FU
An analogue of uracil, 5-FU has a fluorine atom at its C-5 position instead of hydrogen 
(Figure 1 7) On entering the cell, it is converted to several active antimetabohtes 5 
fluoro-2-deoxyundine monophosphate (5dUMP), 5 fluoro-2-deoxyundine triphosphate 
(5dUTP) and 5-fluorouridine triphosphate (5FUTP) 5FUTP is incorporated into the 
RNA causing errors in transcription and translation and alters mRNA stability 
5dFUMP inhibits the action of the enzyme essential in DNA synthesis, thymidylate 
synthase (TS) (Pmedo and Peters, 1988, Grem, 2000)
These mechanisms may vary in importance and differ between cell lines Intrinsic or 
acquired resistance to 5-FU is usually caused by aberration in its metabolism
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amplification or alteration of TS, deficiency anabolism or transport or increased 
catabolism Any of the above can result in resistance (Pmedo and Peters, 1988)
TS expression effectively predicts resistance to 5-FU There is an approximate 50% 
failure rate among patients with low TS mRNA Aschele et al (2002) reported that the 
correlation between intratumoral TS levels and clinical response to 5-FU depended 
strongly on the schedule of administration/biochemical modulators that is used in 
different 5-FU regimens This data strengthens the notion that different 5-FU schedules 
have different mechanisms of cytotoxicity Cascinu et al (1999) confirmed the ability of 
TS protein expression to predict for response to 5-FU The study provided further 
evidence for the existence of different patterns of TS expression among different 
metastatic sites, which may have a significant impact on the choice of drugs and the 
design of new treatments in advanced colon cancer
12 5 Adnamycin
Adnamycin is an anthracyclme antibiotic, isolated from Streptomyces peucetus It was 
recognised to have antineoplastic activity over four decades ago but it was not until 
1984 that the anthracyclmes were discovered to be inhibitors of topoisomerases II It is 
this ability that appears to be the primary mechanism of action for tumour cytotoxicity 
(Tewey et a l , 1984)
The drug has a broad spectrum of antitumour activity and is used to treat solid tumours 
including breast, bladder, endometrium, lung, ovarian, stomach and thyroid carcinomas 
It is also effective against soft tissue sarcomas and many cancers of the blood 
(Hortobagyi, 1997) However, adnamycin treatment often causes nausea vomiting, 
anorexia, diarrhoea and in some cases cardiotoxicity (Nielsen et a l , 1996, Monneret, 
2001) Adnamycin is composed of four nngs linked via a glycosidic bond to 
daunosamme - an amino sugar (Figure 1 8)
Figure 1 8 Structure of adnamycin
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The planar moiety of the drug permits intercalation between the bases of the double 
helix resulting in the DNA extending and unwinding It also modifies the ability of the 
nuclear hehcases to dissociate the duplex DNA into single DNA strands therefore 
hindenng the process of DNA strand separation Moreover, all active anthracyclines are 
anthraquinones Quinones can undergo one and two electron reductions producing 
reactive compounds that damage macromolecules and lipid membranes (Myers et a l , 
1977) It is this free radical formation that causes damage to heart tissues 
The main mechanisms of resistance to adnamycin are -
(1) The classic MDR phenotype 1 e increased drug efflux, due to overexpression of P- 
glycoprotein, MRP family members and LRP (Clynes et a l , 1998, Borst et a l , 
1999)
(2) Increased glutathione transferases content and detoxification mechanisms
(3) Alteration in topoisomerase II activity due to decreased cellular expression of the 
enzyme or changes in activity such as decreased drug-induced DNA cleavage, 
differential expression of topoisomerase isoforms, altered subcellular distribution of 
topoisomerase II and changes in extrinsic factors modulating topoisomerase II 
activity (Skovsgaard et a l , 1994)
1.2.6 Etoposide (VP-16)
Etoposide, also commonly known as VP-16 (Figure 1 9) is a semi-synthetic derivative 
of podophyllotoxin and is used in the treatment of certain neoplastic diseases 
Podophylhn-contammg materials have been used as medications by various cultures for 
over 1000 years In the 19th century, podophyllin was found to be topically effective in 
the treatment of skin cancer and in 1946 its antimitotic properties were discovered In 
the 1950s, researchers at Sandoz Pharmaceuticals developed several derivatives, which 
were found to have antitumour activity against LI210 leukaemia The most effective of 
these denvatives was 4,-demethylepipodophyllin benzylidene glucoside (DEPBG) 
Further development of DEPBG resulted in two analogues being synthesised (Hande,
1998) They were named VP-16 and teniposide
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oFigure 1 9 Structure of etoposide
VP-16 has shown activity against testicular cancers, acute myeloid leukaemia, 
Hodgkin’s disease, non-Hodgkin’s lymphoma, lung, gastric, breast and ovarian cancers 
as well as Kaposi’s sarcoma The major toxicities attributable to VP-16 are bone 
marrow depression, nausea, diarrhoea, mucositis and hypotension (Hande, 1998)
VP-16’s mechanism of action involves the poisoning of topoisomerase II enzymes 
whose function is to temporarily break DNA strands and reseal the breaks This results 
in the DNA being sufficiently untangled to allow transcription and replication to occur 
VP-16 poisons topoisomerase II by increasing the steady state concentration of their 
covalent DNA cleavage complexes This converts the topoisomerases into toxins that 
introduce high levels of transient protein-associated breaks in the genome of the treated 
cells
The replication machinery (hehcases), which attempts to traverse the covalently bound 
topoisomerase roadblock, does not function properly This results in disruption of the 
cleavage complex and conversion of the transient DNA breakage into permanent 
double-stranded helices, which are no longer held together by the protemaceous bridges 
It is these breaks that become targets for recombination, sister chromatid exchange, the 
generation of large deletions or insertions and the production of chromosomal 
aberrations ultimately leading to apoptosis and cell death (Hande, 1998)
Development of resistance to VP-16 can be due to reduced levels of topoisomerase II 
within the target cells Moreover, mutations or alterations in drug binding sites on 
topoisomerase II are associated with resistance to VP-16 Increased expression of 
MDR-1 also confers resistance to VP-16
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12 7 Vinca alkaloids - vincristine
Vincristine and vinblastine are naturally occurring alkaloids found m minute quantities 
m the leaves of the Madagascar periwinkle plant Catharanthus roseus The plant was 
initially used by a variety of cultures for the treatment of diabetes However, while it 
was under investigation as a source of oral hypoglycaemic agents, it was noted that 
extracts could reduce white blood cell counts Subsequently it was found to be active 
against lymphocytic leukaemia in mice, which led to the isolation of vincristine (Pratt et 
a l , 1994, Cragg and Newman, 2005) Both drugs are members of a general class of 
drugs that function as mitotic inhibitors which interfere with the function of 
microtubules, a class of long, tube-like cellular organelles approximately 250nm in 
diameter (Pratt et a l , 1994) Microtubules and microfilaments play an important role in 
the movement of cells relative to each other and in the movement of organelles within 
the cytoplasm of a single cell
Vincristine is an asymmetrical and dimeric molecule composed of a dihyrdoindole 
nucleus, vmdoline, linked by a carbon-carbon bond to an indole nucleus, catharanthine 
(Figure 1 10)
Vincristine arrests the cell cycle in G2/M phase by blocking mitotic spindle formation 
High concentrations of vincristine result in a depolymensation of the microtubules This 
prevents the binding of tubulin to microtubule proteins - this mechanism contrasts to 
that of the taxanes which stabilise the tubules In turn this induces apoptosis in vitro or 
tumour necrosis in vivo, triggers Raf-1 activation, phosphorylation of Bcl-2 family 
proteins and induction of p53 expression Low concentrations of vincristine stabilise the 
spindle apparatus resulting in the failure of chromosomes to segregate, leading to
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metaphase arrest and inhibition of mitosis (Bruchovsky et a l , 1965, Gidding et a l ,
1999)
Vincristine is most frequently used in paediatric oncology and is also used to treat acute 
lymhoblastic leukaemia Wilms’ tumour, Hodgkin’s disease and non-Hodgkin’s 
lymphoma Vincristine is also very commonly used in combination with other 
chemotherapeutics (Lofgren et a l , 2004)
Mechanisms of vincristine resistance include the amplification of P-gp, MRP1 and LRP 
Decreased binding affinity of tubulin for vincristine also plays a role in vincristine 
resistance This may be due to changes in the tubulin isoforms expressed or different 
tubulin levels Altered stability of microtubules may also result in changes in the 
equilibrium between free and polymerised tubulin in cells (Gidding et a l , 1999)
12 8 Mitoxantrone
Mitoxantrone, an aminoalkylamino-disubstituted anthraquinone with anti-cancer 
activity was developed in the 1980s as a doxorubicin analogue in a program to find a 
cytotoxic agent with decreased cardiotoxicity compared with doxorubicin (Figure 111) 
(Fox et a l , 2004, Gutierrez et a l , 2000) The drug was developed from a rational design 
of screening of anthranquinone-based intercalating agents (Alderden et a l , 2006)
It has a broad spectrum of antitumour activity and is used to treat acute leukaemia, 
malignant lymphoma, non-small cell lung cancer, melanoma, lymphoma symptomatic 
hormone-refractory prostate cancer, breast and colon cancers (Parker et a l , 2004, Fox, 
2004, Tow ataneia/, 1998)
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Figure 1.11 Structure of mitoxantrone
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The drug binds with high affinity to DNA m a sequence specific manner and unwinds 
the closed circular complex It inhibits nucleic acid synthesis and causes strands of 
DNA to break in vivo (Twentyman et a l , 2004) The intercalation with the DNA leads 
to cytotoxicity via inhibition of topoisomerase II The interaction with DNA is thought 
to be stabilised by two cationic alkylamino side chains, which form electrostatic 
interactions and hydrogen bonds with the strand of DNA Investigations have identified 
that the cationic alkylamino group in mitoxantrone derivatives are important in the 
nuclear localisation, DNA binding and the inhibition of DNA synthesis (Alderden et a l ,
2006) Mitoxantrone is a substrate for P-gp mediated efflux however, when used as a 
selecting agent it frequently selects for non-P-glycoprotein-mediated multidrug 
resistance in in vitro models (Futscher et a l , 1994)
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1 . 3  C a n c e r  a n d  p r o t e o m ic s
Cancer is a multi-faceted disease that presents many challenges to clinicians and cancer- 
researchers alike who search for more effective ways to combat this devastating disease. 
Tumour development is a complex process, requiring the co-ordinated interactions o f 
many proteins, signal pathways and cell types (Negm et a l , 2002) and as such is an 
ideal candidate for proteomic analysis.
Proteomics analysis attempts to identify the protein complement expressed by the 
genome (W ilkins and Williams, 1993) and is the systematic separation, identification 
and characterisation o f  proteins present in a biological sample (Kennedy, 2000). 
Proteomics includes not only the identification o f proteins but also the determination o f 
their locations, modifications, interactions, activities and ultimately their functions. 
Proteomics is regarded as the sister technology to genomics (Kennedy, 2000) 
complementing the knowledge derived from genomic analysis. The ultimate goals o f 
proteomics go beyond a catalogue o f proteins expressed by healthy and diseased cells. 
The eventual objective is to elucidate the organisation and dynamics o f the metabolic, 
signalling and regulatory networks through which the life o f the cell is transacted. 
Cancer proteomics seeks to understand how networks become dysfunctional, predict 
how their function can be manipulated through interventions by drugs or genetic 
manipulations (Anderson et a l , 2000) and enables the identification o f  disease-specific 
proteins, drug targets and markers o f  drug efficacy and toxicity. Furthermore, cancer 
proteomics seeks to identify markers to improve diagnosis, classification o f tumours 
and also to define targets for more effective therapeutic measures (Simpson and Dorow, 
2001). Given the late stage at which cancers often present, the identification o f early 
detection biomarkers by proteomic analysis will offer better prognosis and aid in 
individualizing treatments for certain cancers.
Analysis o f the proteome has added layers o f  complexity compared to the genome. A 
simple gene can encode multiple different proteins by alternative splicing o f the mRNA 
transcript, by varying translation start or stop sites, by frameshifting during which a 
different set o f triplet codons in the mRNA is translated or by posttranslational 
modifications (Anderson and Seilhamer, 1997). A single protein may be multifunctional 
and conversely similar functions may be performed by different proteins (Fields, 2001). 
The result is a proteome estimated to be an order o f magnitude more complex than the 
genome.
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For the past 26 years, high-resolution two-dimensional gel electrophoresis (2-DE) using 
isoelectric focusing/sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(IEF/SDS-PAGE) has been the technology of choice for analysing the protein content of 
tissues and fluids followed by mass spectrometry It has also been used to study changes 
in global patterns of gene expression elicited by a wide range of gene effectors (Cells 
and Gromov, 1999) Originally introduced in 1975, Farrell and Klose demonstrated the 
ability to separate proteins based on their isoelectric points and molecular weights by 2- 
DE on polyacrylamide gels In the first dimension, proteins were separated according to 
their isoelectric point (pi) along a pH gradient using earner ampholyte (CA) containing 
polyacrylamide gels cast in narrow tubes In the second dimension proteins were 
separated according to their molecular weights in SDS-PAGE
1 4 The development of immobilised pH gradient-based 2-DE
For many years 2-DE technology relied on the use of carrier ampholite to establish a pH 
gradient This technique proved to be difficult, labour intensive and a major contributor 
to the variability of 2-DE patterns (Cells and Gromov, 1999) The problems associated 
with CA-based separations included gaps and drift in the gel patterns resulting from 
discontinuities in the pH gradient (Hanash et a l , 1991) These difficulties prompted the 
development of immobilised pH gradients (IPG) for first dimension separation IPGs 
are formed by the co-polymenzation of buffering groups of acrylamide derivatives into 
a polyacrylamide gel matrix They contain chemically immobilised buffering and titrant 
groups that cannot migrate in the electric field This allows steady state focussing and 
eliminates the problem of cathodic drift (Molloy, 2000) Their development meant that 
2-DE became more reproducible, allowing inter-laboratory comparison of results 
(Bjellquist et a l , 1982) Narrow-range strips, suitable for focussing proteins over wide 
pH units (3-10) or single pH range (11-12) (Cordwell et a l , 2000) became available 
(Gorg et a l , 1999) Loading capacity increased (up to 5 milligrams) on wide pH ranges 
(Hanash et a l , 1991) enhancing the detection of less abundant proteins and 
subsequently providing enough amounts for protein sequencing Rabilloud et al (1994) 
improved the resolution by applying the sample dunng the rehydration step thus 
eliminating its precipitation More acidic and basic proteins could be separated with 
increased resolution (Gorg et a l , 1988) It also enabled exact control of protein amounts 
and sample volumes loaded Sanchez et al (1997) developed a simple and inexpensive
2 0
methacrylate rehydration chamber, which could accommodate 10 immobilised IPG 
strips
Two-dimensional electrophoresis continues to deliver high quality protein resolution 
and dynamic range for the proteomics researcher However, in order to remain the 
preferred method for protein separation and charactenzation, several key steps needed 
to be implemented to ensure high quality sample preparation and speed of analysis The 
following describes the progress made towards establishing 2-DE as an optimal 
separation tool for proteomics research
1  5 Sample preparation
A suitable sample preparation is critical for high quality accurate and reliable 2-DE 
results The method involves preparation/purification of cells, cell lysis and 
solubilisation However, there is no unique way to prepare samples, therefore each 
protocol differs depending on the type of sample used Similarly, sample selection and 
handling are of utmost importance, for example, the use of fresh tumour tissue for 2-DE 
analysis was reported to be superior to a frozen sample (Alaiya et a l , 2002) An 
effective sample preparation will solubilise all proteins, prevent protein aggregation 
during focusing, prevent chemical modification of the protein, may remove abundant 
proteins or non-relevant classes, remove contaminating nucleic acids and other 
interfering molecules and yield proteins of interest at detectable levels Solubilisation is 
achieved by the use of chaotropes, detergents and reducing agents
151  Chaotropes
Chaotropes disrupt hydrogen bonding thereby leading to protein unfolding and 
denaturing Urea is a popular uncharged chaotrope used in 2-DE It is typically used at 
the highest possible concentration (usually 5-9 8 M) with an accompanying surfactant 
Rabilloud et al (1997) utilised the high loading capacity of IPGs to resolve 
hydrophobic proteins In the process they improved their solubility by using a 
combination of detergents and chaotropes They showed for example, that addition of 
thiourea, CHAPS and sulphobetain surfactants (SB3-8, SB3-10 and ASB14) to the lysis 
solution which contained urea resulted in much improved solubilisation as well as 
transfer to the SDS gel
The use of thiourea is recommended for use with IPGs, which are prone to absorptive 
losses of hydrophobic and isoelectncally neutral proteins Thiourea (at 2M) when used
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in conjunction with high concentrations of urea, adds to the power of the solubilisation 
solution This was dramatically illustrated with high recoveries seen on 2-DE gels from 
separations of nuclear proteins and integral membrane proteins when compared to 
classical solubilisation solutions (Rabilloud et a l , 1997)
15 2 Surfactants
Surfactants must be included in the solubilisation solution as they act synergistically 
with chaotropes They prevent hydrophobic interactions, which might occur via 
chaotrope-generated exposure of hydrophobic domains These hydrophobic stretches 
must be protected or protein loss can occur through aggregation and adsorption This is 
therefore essential for proteins that have one or more such domains One of the most 
commonly used surfactant, SDS, needs dilution to 0 3% or less so as not to interfere 
with the first dimension The preferred option is to avoid SDS and include a nomomc or 
zwittenonic surfactant in the sample solubilisation solution A zwittenomc surfactant 
such as CHAPS shows superior efficiency over non-ionic detergents such as Nomdet P- 
40 (NP-40) and TntonX-100 (Molloy, 2000) However, 0 5 % of TntonX-100 is often 
used in conjunction with a zwittenomc surfactant to aid in the solubilisation of 
membrane proteins Moreover, typically less than 1 % of carrier ampholytes are added 
to help reduce the problem of protein-matrix interactions and to overcome the 
detrimental effects caused by salt boundanes The salt concentration must be below 10 
mM by dilution as it interferes with the IEF, otherwise the samples must be desalted by 
dialysis
15 3 Reducing agents
Thiol reducing agents break mtra- and inter-molecular disulphide bonds and are critical 
for protein solubilisation The most common agents are cyclic reducing agents such as 
dithiothreitol (DTT) and dithioerythntol (DTE) These reagents work through an 
equilibration reaction However, loss of the agent through migration m the pH gradient 
(DTT and DTE are mildly acidic) can contnbute to horizontal streaking therefore IEF 
should not be earned out for excessively long focussing times Iodoacetamide is 
subsequently used to remove excess DTT, which is responsible for causing “point 
streaking” in silver stained gels (Gorg et a l , 2000) Phosphines are an alternative to 
thiol reducing agents Tnbutylphosphine (TBP) is uncharged and maintains reducing 
conditions throughout the IEF process This minimises the problem of aggregation
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(Molloy, 2000) TBP has been successfully applied to hydrophobic proteins (Gorg et 
a l , 2000)
15 4 Tissue heterogeneity
Tissue heterogeneity is another key problem It is important that a cell population be 
“pure and relevant” (l e free from stroma, blood, serum e tc ) In this context, the impact 
of cancer cell lines derived from tissue samples cannot be overstated Many different 
methods have been developed to minimise or eliminate “non relevant” cell types in 
tissue samples Using Dynabeads, Reymond et al (1997) isolated human colorectal 
tissue from normal tissue to look at the contribution of the normal cells surrounding the 
cancer to the cancer growth and development Proteolytic enzymes are a prime example 
of this as they are often expressed by tumour surrounding fibroblasts but not by tumour 
cells (Okada et a l , 1995) Banks et al (1999) used laser capture microdissection on 
cervix tissue to cleanly remove the epithelium from underlying stroma
15 5 Subcellular fractionation
The problem of limited dynamic range exists as low copy number proteins are rarely 
visualised and successfully identified from 2-DE gels In mRNA-based approaches the 
dynamic range spans five orders of magnitude This is a severe limiting factor as the 
dynamic range of some proteins may be as great as seven to eight orders of magnitude 
coupled with limited dynamic ranges of staining techniques such as silver versus 
coomassie It is therefore more practical to think of the dynamic range of 2-DE/MS in 
terms of what can be observed on a gel -  typically three orders of magnitude for silver 
staining However, the dynamic range of a method is only limited to the number of 
enrichment or prefractionatmg steps performed (Ho et a l , 2006)
Subcellular fractionation of cellular organelles can enrich cells for analysis and reduce 
the complexity of the protein mixture Prefractionation of proteins can be achieved 
either by
(1) Isolating the cell compartments and/or organelles (ribosomes, mitochondria or 
plasma membrane) by high-speed centrifugation
(2) Sequential extraction procedures with increasingly stronger solubilising buffers 
(e g aqueous buffers, ethanol or chloroform/methanol and detergent based 
extraction solutions)
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(3) Precipitation e g TCA/acetone precipitation is a very successful method for (a) 
inactivating proteases, (b) enriching alkaline proteins such as ribosomes in a total 
cell lysate and (c) removing interfering compounds
(4) Chromatography, free flow electrophoresis and/or affinity purification
(5) Commercially available kits such as PlusOne 2-DE clean up kit (Amersham 
Biosciences, UK) which can be bought to remove substance that may interfere with 
the IEF such as salts, nucleic acids lipids or polysacchandes (Shaw and Riederer, 
2003)
This subsequently enhances resolution and a higher number of spots can therefore be 
separated The technique also increases the success rate of protein identification thereby 
decreasing the ambiguity of the protein mixtures Subcellular fractionation requires 
large quantities of biopsy material which can therefore only be applicable to some 
tumour groups (Alaiya, 2002b)
1 6 Limitations associated with 2-DE
While IPG strips revolutionised IEF, some limitations still remain All limitations are 
linked to the enormous chemical diversity of proteins and to their divergent expression 
m cells and tissues In order to achieve the goal of visualising a near-to-total proteome 
using 2-DE, it has become essential to improve existing techniques in each of the areas 
defined as causmg limitations including resolution and protein binding capability, low 
abundance proteins, hydrophobic and membrane proteins, staimng sensitivity, streaking, 
gel matching and automation
161  Resolution and protein loading capacity
Resolution (i e the distance between spots on a 2-DE gel) and protein loading capacity 
(l e the amount of protein per spot) can limit proteome analysis by 2-DE as it restricts 
detection to only a minute fraction of the proteins present This can be overcome by 
using 18 cm narrow-range IPG strips (1 pH unit) Moreover this can avoid the presence 
of multiple proteins per spot and/or cross contamination of spots These new strips have 
a higher protein loading capacity and higher resolving power compared to the medium- 
to wide-pH range IPG strips As the resolution increases, image analysis becomes easier 
and complex protein patterns can be compared in a more efficient and reproducible way 
(Langen and Roder, 2000)
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Low abundance proteins are rarely visualised on traditional 2-DE gels due to 
overwhelming quantities of abundant soluble proteins obscuring their detection or due 
to low solubility (Herbert et a l , 2001) Although 2-DE is the highest resolution 
technique currently available for resolving protein mixtures, low abundance proteins 
can be problematic to detect in a whole cell lysate or in treated body fluids Currently, 
proteins present at a copy number of 1000-3000 per cell are visible with silver staining 
whereas only the significantly more abundant proteins can be seen with standard 
coomassie-type stains Complete recovery and enrichment of selective fractions permit 
global and targeted proteomics Low abundance proteins and biomarkers are often 
masked and therefore require unique tools to observe and compare genuinely 
representative data sets
16 3 Hydrophobic membrane proteins
The under-representation of membrane proteins on 2-DE gels is caused by their being 
poorly soluble in the aqueous media used in standard IEF (Santom et a l , 2000) There 
has been a gradual improvement in detecting highly hydrophobic membrane proteins 
using 2-DE Heat is applied to the protein sample along with SDS (an amomc detergent) 
in denaturing zone electrophoresis to disrupt noncovalent interactions However, an 
intrinsic surface charge on the protein is required when separating via pi Continued 
improvements are seen with novel reagents for solubilisation and separation of 
hydrophobic proteins including chaotropes, surfactants and reducing agents (Molloy, 
2000)
1.6 4 Streaking
Streaks are a major problem for both beginners and experts alike They are also the most 
time-consuming trouble-shooting problem There are a variety of reasons for this 
problem and the following are some of the causes and remedies
1.6.4 1 Protein solubility
Protein solubility is a major bottleneck in proteomics It leads to streaky 2-DE gel 
patterns and/or protein smears To ensure optimum results, special attention must be
16 2 Low abundance proteins
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paid to the following cell lysis conditions, inactivation of proteases, choice and 
concentration of detergents, chaotropes and reducing agents New approaches have 
considerably improved the solubilisation, but much progress remains to be made 
Such improvement will also allow for higher protein loading onto narrow gradients, 
which should, in turn, allow the visualization of the less abundant proteins of the 
proteome and further increase the scope of proteomics
1.6.4.2 Horizontal and vertical streaks
Another problem in proteomics is that of horizontal streaking, which can be 
localised to different areas of the gel They can be caused by protein overloading, 
protein interactions with contaminants (DNA, RNA, lipids etc) and poor solubility 
near the pi Streaking localised to the basic region is caused by over focussing or 
depletion of DTT during IEF However, increasing the concentration of DTT used 
causes distorted patterns To diminish these streaks IPG strips in the range of 6-12 
should be used instead of 6-10 (Gorg et a l , 2000) In contrast, vertical streaks are 
caused by salt fronts, protein aggregates and/or insufficient focussing in the first 
dimension (Gorg et a l , 2000) However, dialysis of the sample can eliminate salt 
fronts (Rabilloud, 1996) Slow sample entry can also avoid salt fronts and use of 
lodoacetamide avoids the problems associated with DTT migration
1 6 4.3 Detergent/chaotrope smear
The traditional detergents such as TntonX-100 and NP-40 cause background smears 
when silver stain is used CHAPS eliminates this problem (Gorg et a l , 2000)
1.6 5 Automation and high-throughput analysis
Despite improvements in the field of proteomics such as the ability to run 10 or even 20 
second dimension SDS gels in parallel, 2-DE is a time consuming, labour intensive, 
poorly reproducible and poorly automated technology Recent improvements include, 
the production of ready-made gels (IPG DryStnps and Excel Gel SDS, GE Healthcare) 
on stable plastic supports, the introduction of IPGphor, the automation of silver staining 
devices and the development of fluorescent labelling which is less labour intensive 
Currently, IPGphor, in conjunction with the ready-made IPG strips, has enabled sample 
m-gel rehydration IEF which can be performed unattended overnight This is an 
important step in the automation of the 2-DE process
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W hilst automating the transfer from the first to the second dimension gels in itself 
would be convenient, in reality it is not the running o f  the 2-DE gels but their 
subsequent analysis that is the bottleneck in most proteomic projects. Automation o f 
many o f the individual steps in the process could increase throughput. For example, 
matching 2-DE gels, picking the polypeptide spots, digestion and processing for mass 
spectrometry (MS) and database searches could all be automated using robotic and 
software technology currently available or being developed (Lopez, 1999).
1 . 7  F lu o r e s c e n c e  2 D  d if f e r e n c e  g e l e le c t r o p h o r e s is
Traditional 2-DE is a well-established high-resolution technique for the simultaneous 
separation and display up to thousands o f proteins. However it is both time-consuming 
and labour intensive as many gels must be run, analysed and compared in order to 
generate statistically significant differences between two or more proteomes. Moreover, 
reproducibility between gels (technical variations in sample preparation and gel running 
conditions) hinders efficient matching. This matching is critical to establish proteins 
with altered expression levels (Tannu and Hemby, 2006).
Two dimensional difference gel electrophoresis (2D-DIGE) introduced by Unlu et al. 
(1997), has made it possible to detect and quantify differences between experimental 
pairs o f samples resolved on one gel system. The technique involves prelabelling the 
protein samples with different spectrally-resolvable fluorescent dyes so they can be 
mixed together, co-separated and visualised on a single 2-DE gel. Such dye triplets 
include the three mass- and charge-matched N-hydroxyl succinimidyl ester derivatives 
o f the fluorescent cyanine dyes (Cy2, Cy3 and Cy5 - GE Healthcare) which are 
covalently bound or the three stains LUCY-506, LUCY-565 and LUCY-569 from 
Sigma which possess distinct excitation and emission spectra. The Cy dyes are used to 
differentially label the lysine residues o f the protein samples.
During labelling, the dyes undergo a nucleophilic substitution reaction with the s-amino 
group o f lysine residues on protein resulting in the formation o f  an amide bond. The 
dye: protein ratio is optimised so that only 5% o f the protein sample is labelled (where 
the protein is abundant). This method ensures that only proteins with a single dye 
molecule are visualised and those containing multiple dye molecules are minimised. 
Where the protein concentration is low, saturation labelling can be used. The result o f 
this labelling system is co-migration o f proteins originating from separate samples. For 
example, healthy and tumour cells can be labelled with different fluorochromes,
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combined and run on the same gel. The advantage o f this method over conventional 2- 
DE is that the samples are exposed to the same chemical environments and 
electrophoretic conditions. Gel-to-gel variation is reduced as co-migration is guaranteed 
for identical proteins from separate samples. The result is higher throughput o f 
experiment and data analysis (Tonge et a l , 2001). The remaining Cy2 is used as an 
internal control for a number o f  gels, to allow more accurate statistical analysis o f 
protein expression differences across many gels can be made (Gharbi et a l , 2002). 
Gharbi et a l  (2002) evaluated the 2D-DIGE technique using a model breast cancer cell 
system. They investigated an ErbB-2-mediated transformation in a cell line system, 
which comprised an immortalised luminal epithelial cell line and a derivative that stably 
overexpressed ErbB-2 at a similar level to that seen in breast carcinomas. They 
determined that 2D-DIGE is a sensitive and reproducible technique for differential 
expression analysis when compared with data from subsequent matrix assisted laser 
desorption ionisation mass spectrometry-compatible silver staining. Results revealed 
that Cy dye labelling is in fact more sensitive than silver staining (less than one 
nanogram o f protein could be detected versus five nanograms with silver staining). It 
was also discovered that the fluorescent protein stain (SyproRuby) is much more 
sensitive than silver staining and produces more uniform staining from gel-to-gel. 
Staining with SyproRuby (or SyproOrange or SyproRed) involves a noncovalent 
reaction whereby the fluorescent compounds bind to the SDS surrounding the proteins. 
The staining shows little to no protein variability and is usually completed after 2-3 
hours (although staining overnight produces better results) with little or no destaining 
required.
Gharbi et a l  (2002) were able to detect 35 distinct protein spots, which showed 
consistent differences in expression levels between the two cell lines. The spots were 
present in all gel images and were detectable by SyproRuby. The numerous proteins 
detected by 2D-DIGE are now implicated in ErbB-2-mediated transformation and may 
represent future targets for breast cancer therapies.
In summary, this proteomic approach is sensitive, MS compatible, reproducible and can 
be used for the rapid identification o f differences in the protein content o f two separate 
cell lysate samples. It provides the basis for detecting proteins associated with a 
diseased state via their altered levels of expression when compared to a control. The 
ability to detect low levels o f  protein is important for proteomics research and 2D-DIGE 
technology supports this by detecting proteins, which are less abundant. This technique
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can detect changes in protein abundance as low as 10% with a 95% confidence (p<0 05) 
for proteins
1.8 Fluorescent staining versus silver staining
Silver staining or fluorescent compounds can detect, with high sensitivity, proteins 
separated by 2-DE An advantage of both is that they are compatible with MS (used for 
subsequent protein analysis) Silver staining methods are ideal for (i) the detection of 
trace components within a protein sample and (11) the analysis of protein samples that 
are present in only limited amounts The detection limit is as low as 0 1 ng protein per 
spot However, despite the many advantages, silver staimng has several limitations such 
as (i) the poor reproducibility of several stains, (11) limited dynamic range, (111) the fact 
that some specific spots stain poorly, negatively or not at all and (iv) the labour 
intensive nature of the staining process (Gorg et a I ,2000)
In contrast, fluorescent staining is more reproducible, easier to perform and can be more 
sensitive than silver staining which is routinely used to study differential expression 
This approach is expected to be more amenable to automation However, this technique 
also has limitations l e (i) photography or electronic image acquisition is required to 
document results and (a) there are still only a limited number of fluorescent cyanin dyes 
available including (Cy3, Cy5, and Cy2), the post-electrophoretic fluorescent dyes, 
ruthenium and SyproRuby The latter is more sensitive than both SyproRed and 
SyproOrange (Gorg et a l , 2000)
1 9 Evolution of mass spectrometry
As proteomics research evolves, so too does the technology used in this field In the last 
decade, explosive progress m the areas of protein science, bioinformatics and m cell and 
molecular biology has resulted in an increased demand for the development of 
instrument technology Mass spectrometry permits the identification of proteins to be 
automatically carried out at high speeds and with high sensitivity Currently it is not 
possible to use nucleotide sequence data to gain insights into how different basic 
biological processes (such as cell differentiation, receptor activation, signal transduction 
and malignant transformation) work in biological systems Consequently, studies of 
protein expression, interaction, post-translational modifications and the resulting 
repercussions in living organisms have to be made at the protein level (Ekstrom et a l ,
2000) Since gel electrophoresis is the most common method for separation of proteins
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it has became desirable to combine gel electrophoresis with a sensitive detection method 
(Neubauer and Mann, 1999)
For protein identification, the traditional, slow system of Edman sequencing has mostly 
given way to mass spectrometry MS now dnves the progress of proteomics and has 
become a powerful, rapid and sensitive tool for the analysis of proteins Proteomics is 
now utterly dependent on new generations of mass spectrometers produced by 
companies such as Finmgan, Micromass and others
Traditional protein techniques rely on digestion of gel-separated proteins into peptides 
by a sequence specific protease such as trypsin Peptides are analysed and not the 
proteins because gel-separated proteins are difficult to elute and analyse via MS In 
contrast, peptides are easily eluted and even small sets of peptides are sufficient to 
identify a particular protein, a procedure referred to as peptide mass fingerprinting 
(PMF) Mass spectrometnc study of gel-separated proteins is leading to a renaissance in 
biochemical approaches to protein function Mass spectrometers have also been 
connected to liquid chromatography systems to identify proteins and study proteomics 
Protein characterisation will continue to improve in throughput, sensitivity and 
completeness with continual developments in MS and 2-DE technology
191 Mass spectrometers
A mass spectrometer measures the mass-to-charge ratio of ions This is achieved by 
ionizing the sample and separating ions of differing masses and recording their relative 
time of flight by measuring intensities of ion flux A typical mass spectrometer 
comprises three parts an ion source, a mass analyzer, and a detector system (Figure 
1 12)
Figure 1 12 Schematic of a mass spectrometer
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The first step is an ionisation source such as matrix-assisted laser desorption ionisation 
(MALDI) or electrospray ionisation (ESI) In MALDI, peptides are embedded m a 
matrix and excited by a laser to allow them to fly In ESI, charged droplets enter a gas 
phase and are ionised The flexibility to combine ionisation sources with mass analysers 
has brought forward numerous types of MS instruments with varying mass accuracy, 
sensitivity and most importantly, applications The sample is introduced into the 
ionisation source then ionised, as ions are easier to manipulate than neutral molecules 
The ions are then extracted into the analyser region of the mass spectrometer where they 
are separated according to their mass (m)-to-charge-(z) ratios {m/z) (Wasinger and 
Corthals, 2002) Examples of mass analysers include quadrupole, ion trap or time-of- 
flight (TOF) tubes A quadrupole consists of four parallel metal rods that have fixed DC 
and alternating RF potentials applied to them Generated ions pass along the middle of 
the quadrupole Their motion depends on the electric fields so only ions of a ceretain 
m/z will be in resonance and pass through to the detector The RF is altered to bring 
ions of differing m/z into focus on the detector and generate a mass spectrum
The separated ions are detected (examples include an electron multiplier, 
photomultiplier or conversion dynode) and this signal is sent to a data system where the 
m/z ratios are stored together with their relative abundance for presentation in the format 
of a m/z spectrum (Yates, 2000) The analyser, detector and often the ionisation source, 
are maintained under high vacuum to give the ions a reasonable chance of travelling 
from one end of the instrument to the other without any hindrance from air molecules
For proteomics, gel spots on a 2D gel are usually attributable to one protein To identify 
the protein, the gel spot is excised and digested proteolytically The peptide masses 
resulting from the digestion can be determined by mass spectrometry using peptide 
mass fingerprinting (PMF) This uses the masses of the proteolytic peptides as input to a 
search of a database of predicted masses that would arise from digestion of a list of 
known proteins If a protein sequence in the reference list gives rise to a significant 
number of predicted masses that match the experimental values, the protein is identified 
as present in the original sample PMF servers on the internet include, Mascot, Aldente 
(Phenyx), MassSearch, Mowse, MS-Fit (Protein Prospector), PepMAPPER, 
PeptideSearch, Profound (Prowl) and XProteo
The performance of existing mass spectrometers for proteomics research has gradually 
improved with technology developments The instruments can be grouped into two
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categories single stage mass spectrometers for peptide analysis (for example MALDI 
and MALDI-TOF) and tandem MS-based systems for sequencing (for example triple 
quadropole lon-trap and hybnd quadropole-TOF) (Gygi and Aebersold, 2000)
1,9 2 MALDI mass spectrometry
To identify a protein/peptides by mass spectrometry, the sample must first be ionised 
MALDI involves the bombardment of sample molecules with a laser light to bnng 
about sample ionisation Typical MALDI mass spectrometers have a pulsed nitrogen 
laser of wavelength 337 nm or an Er-YAG laser operating in the infrared wavelength 
range of 2 94 \xm The sample is dissolved in a volatile solvent, usually with traces of 
tnfluoroacetic acid An aliquot of this removed and mixed with an equal volume of a 
solution containing a vast excess of the matnx The matrix is a highly absorbing 
compound, examples of which include sinapimc acid, which is typically used for 
protein analysis and alpha-cyano-4-hydroxycinnamic acid (CHCA), often used for 
peptide analysis The choice of matnx is important for the control of fragmentation The 
final solution is applied to the sample target, dned and inserted into the high vacuum of 
the mass spectrometer The laser is fired, the energy amving at the sample/matrix 
surface is optimised and data accumulated until a m/z spectrum of reasonable intensity 
has been amassed The time-of-flight analyser separates ions according to their m/z 
ratios by measuring the time it takes for ions to travel through a field free region known 
as the flight or drift tube (Figure 113) The heavier ions are slower than the lighter 
ones The m/z scale is calibrated with known samples that can either be analysed 
independently (external calibration) and/or pre-mixed with the sample and matrix 
(internal calibration)
MALDI MS has numerous advantages over other ionisation methods for peptide 
mapping Sample preparation is simple and when combined with a TOF analyser, it is a 
sensitive and fast method for peptide mass mapping (Jensen et a l , 1997) However, the 
main drawback of MALDI is that it is difficult to analyse low molecular weight 
compounds (<1,000 m/z) because the matnx that allows MALDI to work interferes in 
this mass range (Peterson, 2006) Moreover, a visible coomassie stained spot (100 
femtomoles) of matenal is required for peptide fingerpnnting analysis
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An initial problem with this technology occurred when the energy spread among the 
ions and led to broad peaks. This was therefore limiting in both resolution and mass 
assignment accuracy. In order to counteract this, TOF instruments now use delayed 
extraction i.e. they allow equilibration o f the energy distribution until it reaches a 
narrow range before ion acceleration. These TOF analysers have the advantage o f  being 
relatively inexpensive and simple to operate (Costello, 1999).
1 . 9 . 3  E le c t r o s p r a y  io n is a t io n
ESI utilises the potential difference between a capillary and the inlet o f the mass 
spectrometers to cause charged droplets to be released from the tip o f  a capillary. As the 
droplets evaporate, gas phase charged ionisation is desorbed from the droplets. ESI 
permits a constant ionisation and monitoring. However, it is more sensitive to 
contaminating buffers and detergents than MALDI (McDonald and Yates, 2000).
The technique involves generating a very fine liquid aerosol through electrostatic 
charging, rather than the more familiar gas (pneumatic) methods. Electrospray uses 
electricity instead o f gas to form the droplets. In electrospray, a liquid is passed through 
a nozzle. A plume o f  droplets is generated by electrically charging the liquid to a very 
high voltage. The charged liquid in the nozzle becomes unstable as it is forced to hold 
more and more charge. Soon the liquid reaches a critical point, at which it can hold no 
more electrical charge and at the tip o f the nozzle it blows apart into a cloud o f  tiny,
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highly charged droplets. These droplets are repelled from the needle towards the source- 
sampling cone on the counter electrode (shown in blue in Figure 1.14).
Figure 1.14 A diagram o f an ESI source (http://www.chm.bris.ac.uk/ms/theory/esi- 
ionisation.html)
The solvent evaporates as the droplets travel the distance between the needle tip and the 
cone (circled in black Figure 1.14). This evaporation causes the droplet to shrink until it 
reaches the point where the surface tension cannot sustain the charge any longer (the 
Rayleigh limit, Figure 1.15). At this point a "Coulombic explosion" occurs and the 
droplet is ripped apart. Smaller droplets are formed, which can repeat the process as 
well as naked charged analyte molecules, which can be single or multiple charged. This 
method o f ionisation is very soft i.e. little residual energy is retained by the analyte upon 
ionisation. ESI-M S is therefore an important technique in biological studies where the 
analyst often requires that non-covalent molecule-protein or protein-protein interactions 
are representatively transferred into the gas-phase. The major disadvantage is that very 
little (typically zero) fragmentation is produced. For structural elucidation studies, this 
leads to the requirement for tandem mass spectrometry where the analyte molecules can 
be fragmented.
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Figure 1.15 A schematic o f the mechanism o f  ion formation in ESI.
1.9.4 Other mass spectrometers
Tandem mass spectrometers are built out o f two mass spectrometers. The first one 
selects the peptides by mass one by one and the second mass spectrometer reads out the 
intensities o f  the fragment ions o f each peptide. Many different combinations o f mass 
spectrometers have been tried. A popular configuration today is a quadrupole linked to a 
time-of-flight (called a Q-TOF) or one time-of-flight linked to another time-of-flight 
(called a TOF-TOF).
Liquid chromatography/MS is a hyphenated technique, which combines the separation 
power o f high performance liquid chromatography (HPLC) with the detection power o f  
mass spectrometry. Even with a very sophisticated MS instrument, HPLC is still useful 
to remove the interferences from the sample that would impact the ionisation. An 
interface eliminates the solvent and generates gas phase ions, which are then transferred 
to the optics o f the mass spectrometer. Most instruments use an atmospheric pressure 
ionisation technique, which combine the solvent elimination and ionisation steps. This 
is achieved through a particle beam, which separates the sample from the solvent 
allowing the introduction o f the sample in the form o f dry particles into the high 
vacuum region.
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Recent advances in proteomics, especially technologies that allow rapid “fingerprint” 
profiling o f  multiple biomarkers (e g SELDI technology) have improved the discovery, 
identification and characterisation o f  potential cancer-associated biomarkers The 
proteomic approach is likely to discover many biomarkers and it is predicted that in 
future, high-throughput proteomics will be integrated into a clinical setting to identify 
those patients who are at risk (Negm et a l , 2002)
Any experiment that involves a limited number o f  proteins, for example, those used in a 
purified protein complex are not amenable to 2D-gel separation, which is tedious and 
difficult Methods such as high performance liquid chromatography, gel filtration or 
one-dimensional chromatography are alternatives These techniques separate and 
concentrate proteins sufficiently well to be identified by MS However, they do not 
allow quantification Various strategies have been developed to overcome problems o f 
limited sample volume
The advent o f  M S-based protein biochip technology enabled complex biological 
systems to be routinely analysed under non-denatunng conditions and their protein 
contents purified The technology also enabled studies for the purpose o f  biomarker 
discovery, toxicological investigation and also basic research to be performed 
(M erchant and W einberger, 2000, W einberger et a l , 2000) M S-protein biochip 
technology was based upon the principles o f surface enhanced laser 
desorption/ionisation This is commercially embodied in the ProteinChip systems 
offered by Ciphergen Biosystems (Fremont, CA, USA) In 1993, Hutchens and Yip 
introduced the idea o f  SELDI This novel strategy for MS analysis o f  macromolecules 
simplified sample extraction and facilitated on-probe investigation o f  biopolymers when 
compared to conventional approaches like MALDI
SELDI is an affinity-based mass spectrom etnc method in which proteins o f interest are 
selectively adsorbed onto a chemically modified surface on the biochip Impurities are 
then removed by washing with a suitable buffer The technology allows sensitive and 
high throughput profiling o f  complex biological specimens
1 10 Surface enhanced laser desorption/ionisation (SELDI)
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Crude biological samples, for example serum or cell lysates, can be applied directly to 
the ProteinChip Arrays. After a short incubation period, the unbound proteins are 
washed off the surface retaining only proteins interacting with the chemistry o f  the array 
surface. After washing, energy-absorbing molecules are applied to the array as a final 
step. They are then analyzed in the ProteinChip Reader, a TOF mass spectrometer. The 
mass values and signal intensities for the detected proteins and peptides are viewed and 
then transferred to software in-depth analysis (Figure 1.16).
SELDI ProteinChip™ Technology Process
• S a m p le  g o e s  d ire c tly  o n to  th e  P r o te in C h ip ™  A rra y
• P r o te in s #  a re  c a p tu re d  a n d  re ta in e d  o n  th e  c h ip  ( a f f in i ty  S u t u r e  )
♦ H A M A  is  a d d e d  to  th e  c h ip
♦ R e ta l ia te  m a p  is  “r e a d "  b v  S u r fa c e -E n h a n c e d  L a s e r  D e s o r p t io n  I o n iz a t io n  
(S E L D I)
Sample
Figure 1.16 A schematic o f the mechanism o f  SELDI.
1.10.1 Advantages of SELDI technology
ProteinChip technology has several advantages over the conventional proteomic 
technologies (2-DE and MS). These advantages include speed o f  detection (hours 
versus days), coverage o f a broader region o f the proteome, small sample requirement 
and combination o f  discovery o f  biomarkers and diagnostic assays in one system 
compared to MS, which is limited to the discovery o f  biomarkers only. Another 
advantage o f  the system is that it is automated for high throughput compatibility (Zhang 
et al., 2004). The development o f SELDI and subsequent ProteinChip technology 
enabled the exploitation o f protein separation and detection strategies that were not 
previously possible with existing techniques.
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The potential o f biomarker discovery in proteomics research is enormous It is therefore 
becoming increasingly important that high throughput automated systems are 
developed Ciphergen’s novel technology satisfies this growing need for powerful, 
mechanised bench-top systems for clinical proteomic applications Recent 
developments have boosted system throughput by automated sample preparation and 
loading This eliminates the need for tedious sample preparation allows for greater 
precision and most importantly speeds up the entire process
Reproducibility is a major problem o f the SELDI/MS method especially if  the identities 
o f the peaks are unknown Irreproducibility between laboratones is exemplified in 
ovarian cancer studies, one o f which was published by Petncom ’s group All three 
papers report different key discriminatory peaks, which still have not been identified 
Moreover, re-analysis o f the raw data identified bioinformatic artifacts, which could 
invalidate the original conclusions More recently, careful evaluation o f  methods o f 
sample collection and processing for proteomic analysis by SELDI-TOF revealed that 
preanalytic variables such as sample handling could markedly influence results The 
original data published by Petncoin et al (2002) have never been reproduced A recent 
study further attempted to validate three previously identified breast cancer biomarkers 
by SELDI-TOF using patients from another institution (Li et a l , 2005) Among the 
three previously identified candidate biomarkers, one was not reproduced
111 The application of proteomics to cancer research
As cancer is a multifaceted disease with alterations in protein expression across a 
diverse range o f cellular pathways, proteomics offers an unrivalled opportunity to 
investigate and view the global changes that mark cancer In view o f the current state o f 
the technology in genetic cancer research, clinicians are still faced with difficulty in the 
early detection and diagnosis o f pre-chmcal lesions In addition, it is difficult to predict 
disease-specific biological behaviour, 1 e whether or not a tumour will metastasise or 
resist cytostatic or radiation therapies The ultimate goals o f  cancer proteomics are to 
enhance and improve molecular classification o f  tumours and to develop more sensitive 
biomarkers for disease prognosis and treatment sensitivity There is an increasing 
interest in both academia and the biopharmaceutical industry in the proteomic approach 
to the discovery o f  drug development (Alaiya et a l , 2002)
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The following sections with tables 1 1 and 1 2 are overviews o f  the potential approaches 
o f  proteomics to study different human cancers
1.111 Molecular markers
Markers constitute major targets for the early detection o f cancer and identification o f 
cancer risk (Negm et a l , 2002) Important properties o f  a marker are sensitivity, 
selectivity and specificity irrespective o f the source o f measurement (e g tissue or body 
fluids) The specificity o f  many currently used markers is questionable and only 
detecting late stage malignancies Traditionally, prostatic carcinoma is diagnosed via 
biopsy after discovery o f  elevated blood levels o f  prostatic specific antigen (PSA) In 
normal males, PSA is present at 1 ng/ml However, for both prostatic carcinoma and 
benign prostatic hyperplasia PSA levels can be elevated to 4-10 ng/ml (Merchant and 
Weinberger, 2000) M oreover, PSA shows wide variations in both specificity and 
sensitivity when used to analyse prostate cancer The serum marker a-fetoprotein is 
used to diagnose hepatocellular carcinoma However, high levels o f this marker are also 
detected in patients suffering from ovarian or testicular cancers and also in patients with 
liver cirrhosis Cancer antigen 125 (CA125) is used m screening ovarian cancer While 
increased levels o f  CA125 are detected in 50% o f patients with stage I and in >90% o f 
women with more advanced stages the marker is also elevated in benign cases (e g 
uterine fibroids, endometriosis, tubo-ovanan abscess etc) and ectopic pregnancy 
(Ahmed et a l , 2005) resulting in predictive value o f less than 10% as" a single marker 
(Cohen et a l , 2001) When combined with transvaginal ultrasound, sensitivity and 
specificity are increased
Diagnostic markers are used to aid histopathological classification o f  tumours Lung 
cancer for example, can be classified into squamous, small and large cell carcinomas as 
well as adenocarcinomas In addition, lung malignancies are divided into primary 
carcinomas and metastases originating from extrapulmonary malignancies Markers 
must be developed to classify all these tumours Recently TA02 was discovered to be 
expressed in primary lung adenocarcinomas but not in metastases from colo-rectal 
malignancies allowing for diagnosis and treatment (Alaiya et a l , 2002) In general, 
where a fairly large number o f markers have been described, there are only a few which 
can predict the treatment outcome in each individual patient The general consensus is 
that a panel o f  markers should be used, thereby identifying targets with greater 
sensitivity, specificity and selectivity Cancer proteomics can be used to enhance and
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improve molecular classification o f tumours and develop more sensitive biomarkers for 
disease prognosis and treatment sensitivity.
1.11.2 Lung cancer
The lung is a very common site for metastasis from tumours growing at other sites in 
the body. Lung cancer has a propensity for early spread and usually presents at a very 
late stage (Danesi et a l , 2003). Phenotypic and genotypic heterogeneity o f  lung cancer 
likely precludes the identification o f a single predictive marker and suggests the 
importance o f identifying and measuring multiple markers. To date no satisfactory 
biomarkers are available to screen for lung cancer. Numerous proteomic analyses o f 
lung cancer tissues have been carried out and results are summarized in Table 1.1. 
Analysing these reports together, we can assume that the common identified proteins 
such as a-enolase and triosephosphate isomerase appear to be increased in lung cancer 
tissues.
Seike et a l  (2005) performed proteomic analysis on 30 lung cancer cells lines with 
three different histological backgrounds (squamous cell carcinoma, small cell lung 
carcinoma and adenocarcinoma) to elucidate the mechanisms that determine 
histological phenotypes. Hierarchical clustering and principal component analysis 
divided the cell lines according to their histology. Spot ranking analysis identified 32 
protein spots essential for the classification. Following this, lung cancer cells, isolated 
from tumour specimens by laser capture microdissection were successfully classified on 
the basis o f the expression pattern o f the protein spots
Liu et a l  (2004) reported that the expressions o f T E Fld , vimentin, cytokeratin 8, YB-1, 
PCNA, Nm23, hnRNP A2/B1, pyruvate kinase M2 and HSP90b increased, while those 
o f  14-3-3d and pyruvate kinase M l decreased in four NSCLC cell lines (H1299, H23, 
H226, SW-1573) compared with those in normal human bronchial epithelial cells 
(HBE4-E6/E7 and NHBE-8917).
Tyan et a l  (2005) analyzed pleural effusion from lung adenocarcinoma patients for 
early detection o f lung adenocarcinoma. They identified 44 o f 472 proteins which 
included, retinoblastoma binding protein 7, synaptic vesicle membrane protein, 
corticosteroid binding globulin precursor, PR-domain containing protein 11, envelope
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glycoprotein, MSIP043 protein and titin Many o f  these have not been previously 
reported in plasma and may represent proteins specifically present in pleural effusion 
Retinoblastoma binding protein 7 is o f  interest as it may play a role in the regulation o f 
cell proliferation and differentiation
At present, a-enolase and tnosephosphate isomerase have been identified as the two 
proteins that commonly increase in lung cancer tissues and are expected to be used as 
biomarkers However, further proteomic studies using sputum and pleural effusion from 
lung cancer patients are necessary
There is a need therefore for markers, which can distinguish primary lung 
adenocarcinomas from distant metastases (Alaiya et a l , 2000a) such as surfactant 
proteins Surfactants TA O l and T A 02 (35 kDa markers) were found by 2-DE to be 
significantly overexpressed m approximately 90% o f all primary lung adenocarcinomas 
but were absent in secondary adenocarcinomas metastasised from colo-rectum and 
mammary glands (Hirano et a l , 1997) Chuman et al (1999) determined that T A 02 
was identical to Napsin A, a member o f  the aspartic protease family It is thought to be 
involved in the cleavage o f  pro-surfactant proteins that are produced by the type II 
pneumocystis
The SELDI-TOF-MS ProteinChip system is currently used try to identify biomarkers 
for cancers Yang et al (2005) used SELDI profiling to distinguish between NSCLC 
and normal subjects with relatively high sensitivity and specificity Both NSCLC and 
SCLC patients were chosen for the study to develop a broad biomarker panel for 
screening a diverse, high-risk population
A total o f  208 serum samples, including 158 lung cancer patients and 50 healthy 
individuals, were randomly divided into a training set and a blinded test set Five 
protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a 
biomarker pattern in the training set This SELDI pattern yielded a sensitivity o f 86 9%, 
a specificity o f  80 0% and a positive predictive value o f  92 4% They identified 
Cyfra21-1 and NSE in the 208 serum samples Based on the results o f the test set, they 
found that the SELDI marker pattern showed a sensitivity o f  91 4% in the detection o f 
NSCLC The pattern also had a sensitivity o f  79 1% in the detection o f  lung cancers in 
stages I/II NSCLC
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Zhukov et al (2003) identified specific protein peak patterns in malignant lung tumours 
and pre-malignant airway epithelium showing neoplastic transformation using lung 
tumour specimens The study could detect "malignant" protein signatures, which could 
lend themselves to identification o f populations at high-risk o f  lung cancer and for 
monitoring response to lung cancer chemo-preventative agents The samples were laser 
capture microdissected to obtain pure cell populations from frozen sections o f normal 
lung, atypical adenomatous hyperplasia and malignant tumours SELDI mass 
spectrometry generated protein profiles in each epithelial cell type Three peaks at 17-23 
kDa mass range from tum our cells were markedly increased compared with normal 
cells The peak at 17250 Da was not detected in any o f  the normal cells This peak 
appeared to be present at low levels in the atypical cell samples
Bnchory et al (2001) identified circulating tum our antigens or their related 
autoantibodies Their study provides a means for early cancer diagnosis as well as leads 
for therapy The aim o f the study was to identify proteins that commonly induce a 
humoral response in lung cancer using a proteomic approach and to investigate 
biological processes associated with the development o f autoantibodies Solubilized 
proteins from the lung adenocarcinoma cell line, A549 and from lung tumours were 
subjected to two-dimensional PAGE W estern blot analyses o f 54 sera from newly 
diagnosed patients with lung cancer, 60 patients with other cancers and from 61 non­
cancer controls were tested for primary antibodies Sera from 60% o f patients with lung 
adenocarcinoma and 33% o f patients with squamous cell lung carcinoma but none o f  the 
controls exhibited IgG-based reactivity against proteins identified as glycosylated 
annexins I and/or II Immunohistochemistry revealed that annexm I was expressed 
diffusely in neoplastic cells in lung tumour tissues, whereas annexin II was predominant 
at the cell surface IL-6 levels were significantly higher in the sera o f antibody-positive 
patients compared to antibody-negative patients and controls An immune response due 
to annexm I and II autoantibodies is commonly found in lung cancer It is associated 
with high circulating levels o f an inflammatory cytokine
Bnchory et al (2001b) using 2-DE identified proteins that commonly induce an 
antibody response in lung cancer Sera from 64 newly diagnosed patients with lung 
cancer, 99 patients with other types o f cancer, and 71 non-cancer controls were analysed 
for antibody-based reactivity against lung adenocarcinoma proteins Autoantibodies
against a protein identified by MS as protein gene product 9 5 (PGP 9 5) were detected 
in sera from 9 o f  64 patients with lung cancer and not m the controls Circulating PGP 
9 5 antigen was found in sera from two additional patients with lung cancer, without 
detectable PGP 9 5 autoantibodies It is a neurospecific polypeptide previously 
proposed as a marker for non-small cell lung cancer, based on its expression m tumour 
tissue The PGP 9 5 was present at the cell surface and secreted by o f the A549 cell line 
PGP 9 5 may therefore have utility m lung cancer screening and diagnosis
Zhong et al (2005) used a fluorescent protein microarray to identify and measure 
multiple non-small cell lung cancer-associated antibodies They show how 
simultaneous measurements can be combined into a single diagnostic assay T7 phage 
cDNA libraries o f NSCLC were first biopanned with plasm a samples from normal 
patients and patients with NSCLC to enrich the component o f  tumor-associated 
proteins They were then applied to microarray slides Two hundred and twelve 
immunogenic phage-expressed proteins were identified from roughly 4,000 clones, 
using high-throughput screening with patient plasmas and assayed with 40 cancer and 
41 normal plasma samples Twenty patient and 21 normal plasma samples were 
randomly chosen and used for statistical determination o f the predictive value o f each 
putative marker M easurements o f the 5 m ost predictive phage proteins were 
combined m a logistic regression model that achieved 90% sensitivity and 95% 
specificity in prediction o f patient samples
1.11 3 Ovarian cancer
Ovarian cancer is an example o f a disease with numerous diagnostic difficulties (Alaiya 
et a l , 2000b) It is often very difficult to distinguish between benign, borderline and 
malignant ovanan cancer The application o f  new  emerging genomic and proteomic 
technologies to the early detection o f  ovanan cancer provides a direct approach to 
understanding the role o f  proteins in the biology o f the disease, m om tonng its 
progression and also evaluating the therapeutic and side effects o f drugs (Lafky and 
Maihle, 2002) However, analysis o f  a panel o f markers is a possible approach to the 
diagnostic problems Alaiya et al (1999) showed (via 2-DE) that the expression o f  a 
number o f  proteins, namely the proliferating cell nuclear antigen, oncoprotein 18, 
phosphorylated heat shock protein 60 (pHSP 60), HSP 90 and elongation factor 2 were 
high in ovarian carcinomas In contrast, expression o f  tropomyosin 1 and 2 was
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decreased in the same carcinomas compared to the benign tumours They were able to 
use a set o f 9 proteins to discriminate between benign and malignant ovarian tumours
Petncoin et al (2002) combined SELDI-TOF mass spectrometry and bioinformatics to 
analyse proteomic sera patterns The result was a “fingerprint” that is capable o f 
distinguishing the serum profiles o f  ovarian cancer patients from those o f a control 
group Proteomic spectra were generated from serum samples (50 samples from a 
control group and 50 from patients with ovarian cancer) A “training set” o f  spectra, 
derived from the samples were subsequently analysed by an iterative searching 
algorithm This identified a  proteomic pattern that distinguished cancer from non­
cancer This fingerprint consisted o f  5 distinguishing mass/charge spectra values The 
pattern was used to classify an independent set o f 116 masked serum samples They 
were able to identify 50 out o f  50 malignant ovarian cancer tumours, 18 o f  which had 
stage I ovarian cancer (100% sensitivity) and 63 out o f 66 unaffected individuals (95% 
specificity) Generation o f  the mass spectra only required a small serum sample and the 
results were obtained in under 30 minutes Cost-effective and high-throughput screening 
is therefore possible It could be argued that complex serum patterns may neglect the 
underlying pathological state o f  an organ like the ovary The technology could also 
reveal new insights into the biology o f the ovarian cancer
1114 Breast cancer
Early attempts to resolve proteins from breast material by 2-DE were impeded due to 
the lack o f reproducibility, low sensitivity and use o f biopsy material which contained a 
mixed cell population However, several technological advances now enable systematic 
proteomic analysis o f normal, luminal and myoepithelial breast cells (Page et a l , 1999) 
Differential analysis identified 170 proteins that were elevated between two breast cell 
types M uscle-specific enzyme isoforms and contractile intermediate filaments 
including tropomyosin and smooth muscle a-protein were detected in the myoepithelial 
cells Furthermore, a large number o f cytokeratin subclasses and isoforms characteristic 
o f  luminal cells were detected in this cell type (Page et a l , 1999)
M olecular events leading to breast epithelial cell carcinogenesis involve modification in 
the structure and expression o f  both oncogenic (ras) and suppressive genes (p53) This 
leads to unbalanced growth characterised by high rates o f  proliferation and eventually
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migration There is also a tendency to survive environmental stress better, which would 
under normal circumstances lead to apoptosis
Growth factors, such as the fibroblast growth factor (FGF), are involved in control o f 
cell proliferation, differentiation and survival A dnaenssens et al (2002) used 
proteomic methods to study both rapid (occurring in the first minutes) changes in 
protein tyrosine phosphorlyation and the modifications in protein synthesis that are 
induced by FGF-2 They discovered several proteins as being the FGF receptor 
substrates, namely the oncogenic protein Src, the M AP kinases (p42/p44) and the FGF 
receptor substrate Further work enabled them to identify 14-3-3 and oncogenic mRNA 
H19 gene, which regulates cancer cell growth via 2-DE
Li et al (2002) have utilised SELDI MS technology in conjunction with bioinformatics 
tools to facilitate the discovery o f  new and better tumour biomarkers to detect breast 
cancer They screened for potential biomarkers in 169 serum samples This included 
samples from 103 breast cancer patients at three different clinical stages o f  the disease 
The samples were diluted and applied to immobilised metal affinity capture Ciphergen 
ProtemChip Arrays which had previously been activated with N i2+ The proteins that 
bound to the chelated metal were then analysed on a ProtemChip Reader Model PBS III 
and the complex protein profiles were compared and analysed Zhang and his 
colleagues selected three biomarkers based on their collective contribution to the 
optimal separation between stages 0-III breast cancer patients and controls There was a 
93% sensitivity for all cancer patients and a specificity o f 91% for all controls
1115 Prostate cancer
Qu et al (2002) evaluated and developed a proteomic approach to enable the 
simultaneous detection and analysis o f  proteins for the differentiation o f  prostate cancer 
from non-cancer patients Serum samples from 197 prostate cancer patients, 92 samples 
from men with benign prostatic hyperplasia and 96 from healthy individuals (396 in 
total) were randomly divided into test (n=60) and training sets (n=326) They were then 
analysed by SELDI mass spectrometry Computer analysis detected 124 peaks m the 
training set The peaks were subsequently analysed by an algorithm in order to develop 
a profile for separating prostate cancer from non-cancer groups The classifier was 
challenged with the test set, following which two classifiers were developed The 
AdaBoost classifier, which achieved a 100% sensitivity and specificity, thus separated
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the cancer from the non-cancer patients The second classifier, namely Boosted 
Decision Feature Selection Classifier, achieved a specificity o f  97 9 and sensitivity o f 
98 5% for the test set
Levner (2005) reran the boosted feature extraction algorithm on the same prostate 
samples but used an updated cross-validation scheme on the same data set They 
compared their results to those o f  Qu et al (2002) Their algorithm attained 100% 
specificity and 96 25% sensitivity
Table 1 1 summarises a range o f  proteomically analysed reported proteins from human 
cancers
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Cancer Up-regulated Down-regulated Reference
Oral Tongue
Myosin heavy chain 1, 
Galectm 1, haemoglobin 
HSP 60 and 27, calgranulm B 
nuclear fragile X mental 
retardartion protein
myosin light chains 
tropomyosin 
ATP-synthase ß chain 
crystalline aB
He et al 
(2004)
Neuroblastoma
peptidyl-propyl cis-trans 
isomerase A, nucleophosmin 
stathmin
Adrenodoxin, carbonic 
anhydrase III, aldose 
reductase related 
protein 1
Cam postnm  
et al (2004)
Esophageal
PCNA, eIF-1 A, RNA binding 
m otif protein 8A, Keratin 1 
Transmembrane protein 4 
Ubiquitin C-terminal esterase 
Fascin, Thioredoxin 
peroxidase, AKR family 1, 
GST M2, gp96, 
Reticulocalbin, Proteasome 
subunit b type 4, Prosomal 
protein p30-33k
Galectin-7, Fatty acid- 
binding protein, S I00 
A9, TGase 3, Annexm 
I, Transgelin, 
Tropomyosin, SCCA1 
Proteinase, 
inhibitor,Clade B, 
HSP27, Desmin, 
Proteasome subunit b 
type 9, Keratin 8 and 
13
Zhou et al 
(2005)
Colorectal
Adenosyl homocysteinase, 
Leukocyte elastase inhibitor 
Macrophage capping protein 
Biliverdin reductase A, 
pndoxal kinase, Annexm 1 
fragment, alpha tubulin, 
elongation factor 1-d, 
tropomyosin alpha & alpha 
chain, Actin fragment, 
annexm 3, 4, 5, microtuble- 
associated protein RP/EB, 
GST-P, cathepsin fragment, 
14-3-3 proteins, proteasome 
subunit a type 6, 
Tnosephosphate isomerase, 
P I 3693 translationally 
controlled tum or protein, 
nucleoside diphosphate 
kinase A, Calgranulm 
B ,S100A 9
Puromycin-sensitive
aminopeptidase
NADH-ubiquinone
oxidoreductase
Succinate
dehydrogenase subumt 
A
Aldehyde 
dehydrogenase 
M yosin regulatory light 
chain 2
Selenium-binding
protein
Creatin kinase B chain 
Placental thrombin 
inhibitor
Vimentin, Desmin 
Carbonic anhydrase I 
Tubulin b 5 chain
Friedman et 
al (2004)
HCC PCNA, eIF-5a, E-FABP, 
Lactoylglutathione lyase 
APC-binding protein EB1
G alectm -1 Fujn et al 
(2005)
Table 11 Summary of proteormcally analysed reported proteins (in a range) of human cancers
HCC - Hepatocellular carcinoma.
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1.12 Proteomics and the study of chemoresistance
Resistance to chemotherapy is m ultifactonal and may be affected by the cell cycle stage 
and proliferation status, biochemical mechanisms such as detoxification, cellular drug 
transport or DNA replication and repair mechanisms
Chemotherapy o f cancer can fail for a variety o f reasons, as many factors can conspire 
to limit its effectiveness, including problems o f delivery and penetration Some cancers, 
such as prostate tumours and melanomas are intrinsically resistant to m ost anti-tumour 
drugs (section 11 ) However, ovarian cancer or small cell lung cancer respond to 
chemotherapy and appear to disappear altogether, only to return later as drug resistant 
tumours It is thought that 30% of all cancer patients undergoing chemotherapy 
encounter acquired drug resistance (Kerbel, 1997)
Proteomic technology has been applied to the problem o f chemoresistance to 
successfully determine alterations in protein expressions after exposure o f  the cells to a 
cytotoxic agent However the technology has been unable to accurately detect the 
classic proteins involved in multi-drug resistance, for example P-gp and MRP These 
proteins are extremely basic and hydrophobic and are therefore problematic to detect by 
traditional proteomic gel based methods
It appears that exposure o f  cells to chemotherapy drugs results in the activation o f 
different mechanisms o f resistance that a specific drug-resistant phenotype consists o f 
several molecular mechanisms that are simultaneously active and that hypothesis that 
many metabolic pathways are affected during the resistance process Even though the 
differential expression levels o f such proteins is not clear p roof o f their role in drug 
resistance per se , some are very likely to be involved in the resistance phenotype, and 
therefore may be potential targets for new drugs
1 12 1 Ovarian cancer
Cisplatin is the most common therapeutic agent used for chemotherapy in ovarian 
carcinoma Despite a good response to surgery and initial chemotherapy essentially 
based on cisplatin compounds, late tumour detection and frequent recurrences with 
chemoresistance acquisition are responsible for poor prognosis Several mechanisms 
have been implicated in cisplatin resistance but they are not sufficient to explain this 
resistance emergence Few mechanistic proteomic studies have been applied to describe 
chemoresistance emergence in ovarian cancers
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Le Moguen et a l  (2006) applied proteomics coupled with MS to identify proteins 
associated the development o f chemoresistance using carboplatin sensitive and resistant 
ovarian cell lines IGROV1 and IGROVI-RIO respectively. O f the 40 identified 
proteins, cytokeratins 8 and 18 and aldehyde dehydrogenase 1 were overexpressed in 
IGROVI-RIO, whereas annexin IV was down-regulated. Other differentially regulated 
proteins included: HSP 27, 60 and 70, actin, stathmin, GST, peroxiredoxin, aldolase, 
alpha enolase, GAPDH, Triosephosphate isomerase 1, inorganic pyrophosphatase, 
chloride intracellular channel I, hnRPC, Translation elongation factor 1, Proliferation- 
associated protein 2G4, 14-3-3 Sigma (stratifin), Nucleoside-diphosphate kinase 1 
isoform b and ATPase synthase.
1 . 1 2 . 2  B r e a s t  c a n c e r
The estrogen receptor has proven to be an extraordinarily successful target for breast 
cancer treatment and prevention. Tumours positive for the receptor are commonly 
treated with antagonists o f estrogen, as their growth depends on the presence o f this 
hormone. The non-steroidal drug tamoxifen is the first line treatment even though only 
60% o f the patients are estrogen-receptor positive and one-third o f them initially fails to 
respond or develops resistance during treatment. Besada et a l  (2006) established a pair 
o f  xenograft breast tumours, sensitive and resistant to tamoxifen, 3366 and 3366/TAM 
respectively. They compared the protein expression profiles using 2-DE. Twelve 
proteins were found up-regulated in the tamoxifen-resistant line, while nine were down- 
regulated. Biological functions o f these proteins are related to cell-cell adhesion and 
interaction, signal transduction, DNA and protein synthesis machinery, mitochondrial 
respiratory chain, oxidative stress processes and apoptosis. Three o f the identified 
proteins (ALG-2 interacting protein and two GDP-dissociation inhibitors) could be 
directly involved in the resistance phenomenon. The proteins identified were 
Endothelial actin-binding protein filamin A, vinculin, protein disulfide isomerase 
A3,actin, cytoplasmic 1, beta actin, 40S ribosomal protein SA (precursor), 34-kDa 
laminin receptor, VDAC protein 1, Peroxiredoxin 4, ubiquinol-cytochrome c reductase, 
lysophospholipase I, acyl-protein, thioesterase 1, peroxiredoxin 1 11 SPFH domain 
family member 40S ribosomal protein SA, 67-kDa laminin receptor GMP synthase, 60S 
acidic ribosomal protein, Heat-shock 27 kDa protein, DJ-1 protein Parkinson disease, 
cyclophilin A, peptidylproly, isomerase A, Inorganic pyrophosphatase, translationally-
controlled tumor Rho GDP dissociation inhibitor (GDI) alpha protein 1, glyoxalase I, 
lactoylglutathione lyase
Gregory et al (2004) used SELDI to study the proteomic changes m response to taxol, 
5-FU, adnam ycin and cyclophosphamide chemotherapy in the plasma o f sixty-nine 
patients with stage I- III breast carcinoma They also profiled 15 healthy plasm a 
samples and plasma from patients with cancer to identify breast carcinoma-associated 
protein markers Plasma was sampled on day 0 before chemotherapy and on day 3 post­
treatment in the 69 patients or 3 days apart in the 15 healthy women Twenty-nine 
patients received preoperative and 40 received postoperative treatment 
A single protein peak, induced by taxol (and to a lesser extent by FAC) was identified at 
2790 m/z in 80% o f patients treated preoperatively It was also detected with lesser 
intensity in approximately 40% o f  patients treated postoperatively However no direct 
correlation between the induction o f m/z 2790 during a single dose o f  treatment and the 
final response o f the tumour to preoperative treatment was found The group found five 
other peaks that distinguished between normal and breast cancer patients The peaks 
were also found in patients that had tumours removed surgically These peaks represent 
candidate markers o f micrometastatic disease after surgery
112 3 Prostate cancer
Temporarily effective agents against prostate cancer include chemotherapy and 
androgen therapy Studies are ongoing to test agents that target proteins responsible for 
autocrine and paracrine stimulated growth However, there are limitations on current 
laboratory models to test the effect o f these agents on cell growth and protein targets 
D vorzhinskily et a l (2004) developed a coculture model that can distinguish paracrine 
stimulated growth and effects on proteins
They observed that LNCaP prostate cancer cells and an immortalized rat prostate cell 
line transfected to overexpress the antiapoptotic resistance protein Bcl-2 were 
stimulated to grow via autocrine effects from extra cells in an upper chamber o f  their 
system Two-dimensional differential in gel electrophoresis found four proteins 
(Tnosephosphate isomerase 1, Phosphoglycerate Kinase, enolase and aldolase), which 
increased after autocrine-induced growth stimulation
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1 12.4 Cervical cancer
Lee et al (2005) exposed the HPV-16 positive CaSKi, HPV-18 positive HeLa and the 
HPV-negative C33A cervical carcinoma cell lines to taxol to determine the cytotoxic 
effects Two-dimensional electrophoresis and M ALDI-ToF-MS identified several 
cellular proteins that are responsive to taxol treatment in HeLa cells Exposure to taxol 
elevated mainly apoptosis-related, immune response-related and cell cycle checkpoint 
proteins Growth factors, oncogene-related proteins and transcription regulated-related 
proteins were mamly down-regulated Taxol showed anti-profilerative activity via the 
membrane death receptor-mediated apoptotic pathway with the activation o f caspase-8 
in a TRAIL-dependant fashion as well as the mitochondrial apoptotic pathway with 
down-regulation o f bcl-2 by cytosolic cytochrome c release Two-dimensional 
electrophoresis identified 47 proteins, which exhibited significant changes in taxol- 
treated cells compared to control cells with 24 o f  these proteins being down-regulated 
and 23 up-regulated
Castagna et al (2004) applied proteomics to study the effects o f  cisplatin on the cervix 
squamous cell carcinoma cell line A431 that was resistant to the drug (A431Pt) A four 
way comparison was applied as follows 1) A431 versus A431/Pt cells, 2) A431 versus 
A431 cisplatin exposed cells, 3) A431/Pt versus ^4431/Pt cisplatin exposed cells and 4) 
A431 cisplatin exposed cells versus A431/Pt cisplatin exposed cells Proteins found to 
be differentially regulated included the chaperones (heat-shock proteins HSP60, HSP90, 
HSC71, heat-shock cognate 71 kDa protein), the calcium-bindmg proteins (calmodulin, 
calumenm), proteins involved in drug detoxification (peroxiredoxins PRX 2 and PRX 6 
and glutathione-S -transferase, GST), anti-apoptotic proteins (Bcl-3 and 14-3-3) and 
finally ion channels (such as VDAC-1, voltage-dependent anion-selective channel) 
switched on as a result o f cisplatin exposure
For example, there was up-regulation o f HSC71, HSP60, 14-3-3 and GST in A431/Pt 
cells compared to the parent The results are consistent with the expression o f defence 
factors to protect the cells from drug-induced damage
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Cancer (Drug) Up-regulated Down-regulated Reference
Gastric (D)/(M) Annexin I Sinha et al 
(1998)
Gastric (M) Thioredoxin
Gastric (C) Pyruvate Kinase M2 Yoo et al 
(2004)
Pancreatic (D) Cofilin Sinha et al 
(1999)
Pancreatic (M)
Cofihn
Epidermal Fatty Acid bp 
Stratifin
Fibrosarcoma (M) Rho-GDP Dissociation inhibitor Sinha et al 
(1999)
Colon (M) Adenine Phosphoribosyl 
Transferase
Sinha et al 
(1999)
Breast Cancer Specific Gene 1
Colon (5-FU) Metabotropic Glutamate 
Receptor 4
Yoo et al 
(2004)
Colon (5-FU) Fl FO -ATP Synthase Shin et al 
(2005)
Melanoma (V) Translationally Controlled 
Tumor Protein
Sinha et al 
(2000)
Melanoma (C) Human Elongation Factor 1-5
Melanoma (F) Tetratricopeptide Repeat Protein
Melanoma (VP) 14-3-3-y
Neuroblastoma (VP)
Peroxiredoxin I 
p-Galactoside
Soluble Lectin Binding Protein 
Vimentin
Heat Shock Protein 27 
HnRPK
dUTP
Pyrophosphatase
Urbani et al 
(2005)
Breast (MEL)
Retmoic Acid Binding Protein II 
Macrophage Migration Inhibition 
Factor
Calreticulin 
Cyclophin A 
Heat Shock Protein 27
Hathout et al 
(2002)
Breast (A)
Annexin I
Neuronal Ubiquitin Carboxyl
Hydrolase
Isoenzyme LI
Glutathione-S-Transferase pi 
Nicotinamide N- 
Methyltransferase 
Interleukin-18 Precursor
Catechol-0 - 
Methyltransferase
Gehrmann et 
al (2004)
Table 1 2 Summary of studies using 2-DE and MS for analysis of chemotherapy resistance in
cell lines Drugs D -  daunorubicin, M -  mitoxantrone, C -  cisplatin, F -  fotemustine, V -  
vindesine, VP -  etoposide, MEL, melphalan and A -  adnamycin
113 Conclusion
Proteomic technologies including high resolution 2-DE, protein arrays and advances in 
mass spectrometry are providing the tools needed to discover and identify disease- 
associated biomarkers Recent advances in MS, especially platforms that permit rapid 
“fingerprint” profiling, will m ost assuredly enhance the discovery, identification and 
characterisation o f  potential cancer associated biomarkers Furthermore, improvements 
in preparation o f  cancer samples particularly laser capture microdissection has provided 
a reproducible approach to procure pure populations o f  cells This technology coupled 
with 2-DE and MS has significantly aided the elucidation o f the differential expression 
profiles between malignant, bemgn and normal cell populations Moreover, the 
development and application o f  learning algorithms and bioinformatics to the data 
generated by these proteomic technologies will be essential in determining the clinical 
potential o f  protein biomarkers
The ability to discover and subsequently routinely monitor multiple changes in protein 
composition simultaneously from only a small sample (e g o f blood) will enable the 
realisation o f  three important goals in medicine Firstly, it will enable the earliest 
possible detection o f  disease onset Secondly, it will provide the ability to accurately 
assess disease type and level o f disease progression Finally, it will also provide the 
ability to routinely monitor how a patient is responding to a chosen therapy 
Two-dimensional electrophoresis remains a major component o f proteomics and its 
high-resolution power makes it a challenge to other existing separation techniques 
However, it is still labour intensive and requires skill to generate highly reproducible 
results Despite the interesting results derived from 2-DE technology, especially in the 
area o f cancer research, the many drawbacks o f  this technology preclude its wide 
acceptance in routine clinical use There is an obvious need to further develop and 
generate equally sensitive separation methods that unify both high sample throughput 
and reproducibility ProteinChips will ultimately permit researchers to scan thousands 
o f proteins in a variety o f proteomic experiments including differential expression, 
response to drugs and importantly m the identification o f  disease specific markers
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1.14 Aims of Thesis
The central aim o f this work was to investigate the mechanisms o f  drug resistance in
lung cancer using proteomic technologies through the following approaches
Establishment of clinically relevant drug-resistant variants
>  Many cell lines used as models for studying drug resistance are established with 
clinically unachievable concentrations or do not reflect the patients treatment 
regime To establish drug resistant variants o f two squamous (SKMES and DLRP) 
and two small cell lung carcinoma (DMS-53 and NCI-H69) cell lines, 
chemotherapy-naive cell lines were chosen and pulse-selected (rather than 
continuously) with climcally-relevant concentrations The aim o f carrying out this 
procedure was three-fold Firstly, it was designed to establish variants to reflect the 
clinical scenario Secondly, it facilitated analysis o f the role o f MDR proteins P-gp 
and MRP1 in cells with clinically relevant resistance Finally, these studies would 
contnbute to an understanding o f the relationship between drug resistance and
j
invasive phenotypes
Increased understanding of adnamycin resistance
>  The second aim was to gain further understanding o f  drug resistance in adnam ycin- 
resistant variants o f DLKP by studying differential protein expression using 
proteomic technologies The use o f  variants with high resistance profiles will help 
to select those changes involved in resistance specifically DLKP, a poorly 
differentiated squamous lung cell line, was previously exposed continuously to 
increasing concentrations o f adriamycin resulting in the cell line, DLKP-A This cell 
line was further selected by continuous exposure to adriamycin creating DLKP-A 10 
Two clonal sub-populations were also isolated from DLKP-A by clonal dilution, 
DLKP-A5F and DLKP-A2B Each o f  the above four cell lines has differing levels 
o f resistance to adriamycin and also exhibits cross-resistance profiles to a number o f 
chemotherapeutic drugs While the main mechanism o f resistance m these cell lines 
is associated with P-gp (no detectable levels o f MRP), little information on 
cytoplasmic changes is available This work set out to investigate such changes The 
objective is to increase our understanding o f the mechanisms involved m adriamycin
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resistance and to identify putative markers with possible prognostic/diagnostic 
value.
I n c r e a s e d  u n d e r s t a n d in g  o f  m it o x a n t r o n e  r e s is t a n c e
>  Mitoxantrone, an analogue o f adriamycin with lower levels o f toxicity provides a 
useful means o f  studying resistance further. A proteomic investigation was carried 
out to study the differential protein expression caused by mitoxantrone resistance in 
the already established DLKP-Mitox cell line. While the main mechanism o f 
resistance in this cell line may be associated with BCRP (increased expression o f 
BCRP at the mRNA levels, no detectable levels o f  P-gp and MRP1), little 
information on cytoplasmic changes is available. This work set out to investigate 
such changes to increase our understanding o f the mechanisms involved in 
mitoxantrone resistance to identify putative markers with possible 
prognostic/diagnostic value. It was also o f  interest to compare proteins altered in 
DLKP versus DLKP-A with DLKP versus DLKP-M itox as both adriamycin and 
mitoxantrone are alkylating agents and mitoxantrone is an analogue o f  adriamycin 
with less cardiotoxicity.
I n v e s t ig a t io n  o f  c l i n i c a l l y  r e le v a n t  t a x a n e  r e s is t a n c e
>  The fourth aim is to determine the cellular components that are involved in taxol 
and taxotere resistance in the squamous lung cancer cell lines, SKMES-Txl and 
SKM ES-Txt respectively. The parental cell line, not previously documented to be 
exposed to drug was selected with clinically relevant concentrations o f  the taxanes 
(taxol and separately taxotere), drugs traditionally used in the treatment o f  lung 
cancer. Proteomic analysis o f these cell lines was used to generate a list o f 
differentially expressed proteins that should provide insights into common 
mechanisms o f taxane resistance as well as differences between the taxol and the 
more potent taxotere. Taxol and taxotere have similar mechanisms o f action even 
though taxotere is approximately twice as potent an inhibitor o f  microtubule 
depolymerisation relative to taxol (Gelman, 1994). Moreover, there is a 
geographical bias with taxol predominately used in America and taxotere in Europe. 
Currently, while there is much known about the mechanism of action o f  the taxanes, 
little is known about the differences induced by taxol and taxotere. It is
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hypothesised that proteomic investigation o f  taxol- and taxotere-selected variants 
will yield differential protein expression profiles that may contribute to 
understanding the differences in action o f  taxol and taxotere
Investigation into unstable resistance
>  An unforeseen but fortunate result o f taxane selection with SKMES was the 
observed loss o f  resistance in both taxane-resistant variants o f  SKMES By 
monitoring the differential protein expression over time, the proteins specifically 
involved m the loss o f  resistance may be identified
Investigation into common markers for resistance
>  Do proteins involved m taxane resistance show cross-over with other 
chemotherapeutic drugs (namely adriamycin or mitoxantrone)9 Multi-drug 
resistance is classified as resistance not only to the selecting drug but also to a range 
o f structurally distinct chemotherapeutics As multidrug resistance is a major 
problem in lung cancer, there is a need to understand the common mechanisms 
involved A further aim o f this work was to identify common pathways or 
intermediaries from the proteomic analysis that may provide targets that may act to 
reduce resistance and cross-resistance
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Section 2.0: Materials and Methods
2.1 Preparation of cell culture media
Ultrapure water (UHP) was purified to a standard o f 12-18 M Q/cm  resistance by a 
reverse osmosis system (M illipore M illI-RO 10 Plus, Elgastat UHP) Glassware 
required for cell culture related applications were soaked in a 2% RBS-25 (AGB 
Scientific) for 1 hour, washed in an industrial dishwasher, using Neodisher detergent 
and rinsed twice with UHP All thermostable solutions, water and glassware were 
sterilised by autoclavmg at 121 °C for 20 minutes at 15 bar (Thermolabile solutions were 
filtered through 0 22 Jim sterile filters (M illipore, M illex-GV SLGV025BS))
All IX  basal media were prepared in-house as follows 10X media was 'added to stenle 
UHP water, buffered with HEPES (N-(2-Hydroxyethyl) piperazme-N-(2-ethanesulfomc 
acid) and NaHC0 3  as required and adjusted to pH 7 5 using stenle 1 5 N NaOH or 1 5 
N HC1 The m edia was then filtered through stenle 0 22|am bell filters (Gelman, 12158) 
and stored m stenle 500ml bottles at 4°C Stenlity checks on all media bottles for 
bactenal, yeast and fungal contamination were made using Colombia blood agar 
(Oxoid, CM217), Sabauraud dextrose (Oxoid, CM217) and Thioglycolate broths 
(Oxoid, CM 173) respectively All stenlity checks were then incubated at both 25°C and . 
37°C
Basal m edia were stored at 4°C for up to three months in the dark Complete m edia was 
then prepared as follows supplements o f  2mM  L-glutamine (Gibco, 11140-0350)!for all 
basal media and 1ml 100X non-essential ammo acids (Gibco, 11140-035) and lOOmM 
sodium pyruvate (Gibco, 11360-035) were added to M EM  Other components were 
added as descnbed in Table 2 1 Complete media was stored at 4°C for a maximum o f  
one month in the dark
Cell Lm e B asal
M edia
FCS (% ) A dditions
i/ ■>
DLKP ATCC 5 -
DLRP ATCC 5
i i
DMS-53 R P M I1640 10 Sodium pyruvate
NCI-H69 R P M I1640 10 Sodium pyruvate
SKMES MEM 10 Sodium pyruvate, non-essential amino 
acids
T ab le  2 1 Ad ditional components in mec îa
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2.2 Cells and cell culture
All cell culture work was earned out in a class II laminar air-flow cabinet (Holten) All 
experiments involving cytotoxic compounds were conducted in a cytotoxic laminar air­
flow (LF) cabinet (Gelman Sciences, CG series or Holten Maxisafe) Beforehand after,j 
use the LF cabinet was cleaned with 70% industrial methylated spirits (IMS) Any, items 
brought into the cabinet were also swabbed down with IMS At any time, only,one cell 
line was used in the LF cabinet and upon completion of work with any given cell line, ,a 
15 minutes clearance was given to eliminate any possibilities of cross-contamination i 
between the various cell lines The cabinet was cleaned weekly with Virkon (Antech 
International, P0550) and IMS Details pertaining to the cell lines used „for {the , 
experiments are provided in Tables 2 2 and 2 3 All cells were incubated at 37°C and , 
where required, in an atmosphere of 5% CO2 Cells were fed with fresh media^ or 
subcultured (see section 2 5 1) every 2-3 days or as required in order to maintain active 
cell growth
Cell line Cell type Source Developer
DLKP Poorly differentiated 
squamous cell lung carcinoma
NCTCC* Law et al 1
(1992)
DLKP-A Adnamycin resistant variant of 
DLKP
NCTCC Redmond et al 
(1992)
DLKP-A10 Adnamycin resistant van ant of 
DLKP-A
NCTCC Cleary et al 
(1997) 1 ,
DLKP-A5F Clonal subpopulation of 
DLKP-A
NCTCC Heenan et al 
(1997) t
DLKP-A2B Clonal subpopulation of 
DLKP-A
NCTCC Heenan et al 
(1997)
1 1 >
Table 2 2 Description of DLKP and variants described in this thesis * NCTCC, National cell 
and tissue culture centre
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Cell line Cell type Source
t
DLRP
Poorly differentiated squamous cell lung 
carcinoma
1
NCTCC
DLRP-Cpt Carboplatm resistant variant of DLRP NCTCC*
DLRP-Txt Taxotere resistant van ant of DLRP NCTCC*
DMS-53 Small cell lung cancer
i
EC ACC** ‘
t 1 I I I  t
DMS-Cpt Carboplatm resistant variant of DMS-53 NCTCC*
DMS-Txt Taxotere resistant variant of DMS-53 ! 11 NCTCC*
DMS-Txl Taxol resistant variant of DMS-53 NCTCC*
\
NCI-H69**** Small cell lung cancer ATCC***
H69-Cpt5 & 
H69 Cpt-10
Carboplatm resistant variants of NCI-H69 NCTCC*
H69-VP480 VP-16 resistant van ants of NCI-H69 NCTCC*
1
SKMES Squamous cell lung carcinoma ATCC
SKMES-Cpt30
SKMES-CptlOO
Carboplatm resistant variant of SKMES NCTCC*
SKMES-Txl Taxol resistant variant of SKMES ,NCTCC*
SKMES-Txt Taxotere resistant van ant of SKMES NCTCC*
1
Table 2 3 Description of other cell lines described m this thesis
* - developed during the course of these studies
** EC ACC - European collection of cell cultures *
*** ATCC - American Tissue Culture Collection
**** Morphology resembles floating aggregates, characteristic of SCC - ’
2 21  Subculturmg of adherent cell lines
Waste cell culture medium was removed from the tissue culture flask and discarded mto a 
sterile bottle The flask was then nnsed out with 1ml of trypsin/EDTA solution (0 25% 
trypsin (Gibco, 043-05090), 0.01% EDTA (Sigma, E9884) solution in PBS (Oxoid, 
BRI4a)) to ensure the removal of any residual media Dependmg on the size of the flask,
59
2-5ml o f trypsin was then added to the flask, which was then incubated at 37°C, for 
approximately 5 minutes, until all of the cells detached from the inside surface of the flask 
monitored by microscopic observation Adding an equal volume of complete media to the 
flask deactivated the trypsin The cell suspension was removed from the flask and placed 
m a sterile universal container (Stenlin, 128a) and centnfuged at lOOOipm for 5 minutes 
The supernatant was then discarded from the universal and the pellet was suspended 
gently in complete medium A cell count was performed and an aliquot of cells was used 
to seed a flask at the required density All cell waste and media exposed to cells were 
autoclaved before disposal
2 2.2 Subcultunng of floating aggregate cell lines ^
The cell suspension was removed from the flask and placed in a sterile universal container 
and centrifuged at lOOOg for 5 mmutes The supernatant was then discarded from the 
universal and the pellet was suspended m complete medium The aggregates were broken 
up by gently pipetting the suspension up and down using a 10 ml pipette A cell aliquot 
was used to seed a flask
2.3 Assessment of cell number and viability
Prior to cell counts, cells were prepared for subcultunng as detailed in 2 2 1 or 2 2 2 
depending on adherent or floating aggregates An aliquot of the cell suspension was 
then added to trypan blue (Gibco, 525) at a ratio of 5 1 The mixture was incubated for 3 
minutes at room temperature An aliquot (lOjal) was then applied to the chamber of a 
glass coverslip-enclosed haemocytometer For each of the four gnds, cells in the 16 
squares were counted The average of the four gnds were multiplied by a factor of 104 
volume of the gnd) and the relevant dilution factor to determine the average cell number 
per ml in the onginal cell suspension Non-viable cells stained blue, while viable cells 
excluded the trypan blue dye as their membrane remained intact and remained 
unstained On this basis, percentage viability could be calculated
N . .
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Cells for cryopreservation were harvested in the log phase o f growth and counted as 
descnbed in Section 2 2 1 or 2 2 2 Cell pellets were resuspended in a suitable volume of 
serum An equal volume of a 10 - 20 % DMSO/serum solution was added dropwise with 
mixing, to the cell suspension The suspension was then aliqoted m 1 ml volumes to 
cryovials (Greiner, 122278) and immediately placed m the vapour phase of a liquid 
nitrogen container After four hours, vials were transferred to the liquid phase for long 
term storage (-196°C)
2 4.1 Thawing of cryopreserved cells
A volume of 5ml of fresh growth medium was added to a sterile universal The 
cryopreserved cells were removed from the liquid nitrogen and thawed at 37°C quickly 
The cells were removed from the vials and transferred to the aliquoted media The 
resulting cell suspension was centrifuged at 1,000 rpm for 5 minutes The supernatant was 
removed and the pellet resuspended m fresh culture medium An assessment of cell 
viability on thawing was then earned out (Section 2 3) Thawed cells were then added to 
an appropriately sized tissue culture flask with a suitable volume of growth medium and 
allowed to attach overnight The following day, flasks were refed with fresh media to 
remove any non-viable cells
2 5 Monitoring of sterility of cell culture solutions
Sterility testing was performed in the case of all cell culture media and cell culture 
related solutions Samples of prepared basal media were incubated at 37°C for a period 
of seven days This ensured that no bacterial or fungal contamination was present in the 
media or the solutions
♦
2 6 Serum batch testing
To prevent batch to batch variation (a common problem in foetal calf serum (FCS) in 
cell culture), a range of FCS batches were screened and the most suitable was chosen 
for a block of work (Sigma, F7524) Screening involved growing cells m 96-well plates 
and growth was recorded as a percentage of growth of a serum with known acceptable 
growth rate as described in section 2 8 4
2 4 Cryopreservation of cells ’
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2.7 Mycoplasma analysis of cell lines
Mycoplasma testing was earned out in house by Ms Aine Adams and Mr Michael 
Henry at the NCTCC Both direct and indirect methods were used In the indirect 
method, Mycoplasma negative NRK (Normal rat kidney fibroblast) cells were exposed 
to conditioned media of the test sample Hoechst staining specific fornDNA < shows 
positive for Mycoplasma when viewed in the extracellular spaces In the direct method, 
conditioned media were incubated on cells specifically to encourage Mycoplasma 
growth
2.8 Miniaturised in vitro toxicity assays
2.8.1 In vitro toxicity assay for anchorage dependant cell lines
Cells in the exponential phase of growth were harvested by trypsmisation (section 
2 2 1) Cell suspensions containing lx l0 4 cells/ml in the appropriate culture medium, 
were aliquotted at lOOjul/well in 96-well plates (Costar, 3599) using a multichannel 
pipette Plates were agitated gently in order to ensure even dispersion of cells over a 
given surface Cells were then incubated overnight at 37°C and 5% CO2 Cytotoxic drug 
dilutions were prepared at 2X their final concentration in cell culture medium Volumes 
of the drug dilutions (lOOjxl) were then added to each well using a multichannel pipette 
Plates were then mixed gently as above Cells were incubated for a further 6-7 days at 
37°C and 5% C 02 until the control wells had reached approximately 80-90% 
confluency Assessment of cell survival in the presence of drug was determined by the 
acid phosphatase assay (section 2 8 4) The concentration of drug which caused 50% 
cell kill (IC50 of the drug) was determined from a plot of the % survival (relative to the 
control cells) versus cytotoxic drug concentration
/
2.8 2 In vitro toxicity assay for floating aggregate cell lines
Cells in the exponential growth phase were harvested as m section 2 2 2 However, the 
cell pellet was suspended in 500 |il of Cell Dissociation solution (Sigma, C5914) The 
suspension was then incubated at 37°C for approximately 10 minutes after which afp200 
gilson was used to aid in the disruption of the clumps The assay was set up as described 
in 28  1 except 3 5x10s cells/ml was prepared in RPMI medium and’ aliquotted' at 
lOOjil/well Cells were incubated for a further 9-10 days
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2.8.3 Combination toxicity assays
As described in section 22  1 or 2 2 2, plates were seeded at lxlO4 cells/ml and 
incubated overnight Cytotoxic drug dilutions and non-steroidal anti-inflammatory drug 
(NSAID) dilutions were prepared at 4X their final concentration m media Volumes of 
50jj,1 of the drug dilution and 50jil of the NSAID dilution were then added to each 
relevant well and the final volume in all wells was brought up to 200^1 * with1 media 
where necessary All potential toxicity-enhancing agents were dissolved in DMSO, 
ethanol or media Stock solutions were prepared at approximately 15mg/10ml media, 
filter sterilised with a 0 22jnm low protein binding filter (Millex-GV, SLGV025BS) and 
then used to prepare all subsequent dilutions Cells were incubated for a further 6-7 days 
at 37°C in an atmosphere containing 5% CO2 At this point the control wells would have 
reached approximately 80-90% confluency Cell number was assessed using the acid 
phosphatase assay (section 2 8 4)
2.8.4 Assessment of cell number - acid phosphatase assay for anchorage dependant 
cell lines
Following the mcubation period of 6-7 days, the media with the chemotherapy drug was 
removed from the plates and disposed (Table 2 5) Each well on the plate was washed 
twice with lOOfil PBS and to each well, 100|il of freshly prepared phosphatase substrate 
(lOmM /7-mtrophenol phosphate (Sigma 104-0) in 0 1M sodium acetate (Sigma, 
S8625), 0 1% tnton X-100 (BDH, 30632), pH 5 5) was added The plates were then 
incubated in the dark at 37°C for about 2 hours, monitoring colour development The 
enzymatic reaction was stopped by the addition of 50|il of IN NaOH The plate was 
read m a dual beam plate reader at 405nm with a reference wavelength of 620nm
2 8 5  Assessment of cell number - modified acid phosphatase assayt/o r tfloating
aggregate cell lines
For the anchorage-independent cell lines (NCI-H69 and variants), the same iprocedure 
was followed as described above with the following exceptions Washing involved 
centrifuging the plates and aspirating off the supernatant The plates were incubated for 
a period of approximately 5 hours before the assay was stopped
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2.9 Safe handling of cytotoxic drugs
Cytotoxic drugs were handled with extreme caution at all times in the laboratory, due to 
the potential risks m handling these drugs Disposable mtnle gloves were worn at all 
times and all work was earned out in cytotoxic cabinets All drugs were stored in a 
safety cabinet at room temperature or m designated areas at 4°C or -20°C »The storage * 
and means of disposal of the cytotoxic drugs used in this work are outlined in Table 2 5
t M 'I ilj I
T m  u m M  T O  p i  t O n
/ *• l i »  l i t  I
I t  \1 i t  1 i i n
♦Platinum and non-platmum waste were stored separately pnor to incineration
i >
2.10 Pulse selection of parent cell lines
* ,
Taxanes and carboplatm are the drugs of choice for treatment of NSCLC while VP- 16 
and carboplatm are the drugs of choice for SCLC SKMES-1, DLRP (squamous) and 
DMS-53 (SCLC) were all selected with carboplatm, taxotere SKMES-1 and DMS-53 
were treated with taxol NCI-H69 (SCLC) was pulsed with VP-16 or carboplatm
t \
2 1 0 1  Assay to determine drug concentration for pulse selection
Cells were seeded mto 25cm2 flasks at 3 x 105 cells per flask and as per mimatunzed , 
assay After overnight incubation (37°C), media was removed and a range of drug 
concentrations added for 4 hours Cells were washed and allowed to grow for 5-7 days 
until the control was 80% confluent The end point was determined by cell counting 
(2 2 1) Concentrations chosen for pulse selection of DMS-53, NCI-H69 and SKMES-1 
gave an 80-90% kill, i e IC8o - IC9o. DLRP was pulsed with taxotere and carboplatm at
Cytotoxic Agent Storage Disposal*
Adnamycin 4°C in dark Incineration
Taxol Room temperature in dark Incineration
Carboplatm Room temperature in dark Incineration
Vincnstine 4°C in dark Incineration
Taxotere Room temperature in dark Incineration
VP-16 Room temperature in dark Incineration
5-fluorouracil Room temperature in dark Incineration
Cisplatin Room temperature in dark Incineration
Table 2 5 Storage and disposal details for chemotherapeutic agents
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a concentration that gave a much lower kill, since these cells were found to recover 
poorly when pulsed at higher doses. (Table 2.6).
Cell Line
Taxol
(ng/ml)
Taxotere
(ng/ml)
VP-16
(ng/ml)
Carboplatin
(Hg/ml)
DLRP Not Treated 5 Not Treated 15
DMS-53 60 40 Not Treated 5
SKMES-1 120 60 Not Treated 100 and 30
NCI-H69 Not Treated Not Treated 480 10 and 5
Table 2.6 Concentrations used for pulse-selection
2.10.2 Pulse selection
Cells at 70-80% confluency in 75cm2 flasks were exposed to the chosen concentration 
o f  taxol, taxotere, V P-16 or carboplatin for 4 hours. After this period, the drug was 
removed and the flasks were rinsed and fed with fresh complete media. The cells were 
then grown in drug-free media for 6 days, refeeding every 2-3 days. This was repeated 
once a week for ten weeks. W here cells did not recover sufficiently from the previous 
pulse, more time was required to complete the pulses. Invasive potential (see section 
2.11) and sensitivity to the selecting drug and a variety o f  cytotoxic drugs was the 
determined using miniaturised toxicity assays (see section 2.8.1 and 2.8.2).
2.11 Invasion techniques
2.11.1 In vitro invasion assays
Invasion assays were performed using the method o f  Albini (1998). Matrigel (Sigma E- 
1270) (11 mg/ml) was diluted to 1 mg/ml in serum-free culture media. Matrigel was kept 
ice-cold at all times. Into each insert (Falcon 3097) (8.0jim pore size, 24-well format), 
which stands on 24-well plate (Costar) 1 OOjal o f  1 mg/ml Matrigel was placed. The insert 
and the plate were incubated for one hour at 37°C to allow the gel to polymerise. Cells 
were harvested and resuspended in culture media containing 5% FCS at the 
concentration o f  1 x 106 cells/ml. Excess media was removed from the inserts, and they 
were rinsed in culture media. To each insert, 100|il o f  the suspension cells were added. 
A further 1 OOjil o f  culture media was added to each insert and 500jj1 o f  culture media
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containing 5% FCS was added to the well underneath the insert (no serum gradient was 
used) Cells were incubated at 37°C for 24 hours After this time period, the inner side 
o f  the insert was wiped with a cotton swab dampened with PBS, while the outer side o f  
the insert was stained with 0 25% crystal violet for 10 minutes and then nnsed in UHP 
and allowed to dry The inserts were then viewed and photographed under the 
microscope at 10X The invasion assays were quantified by counting cells within a 
graticule at 40X magnification, use o f positive and negative control confirmed the assay 
procedure
i
2.11.2 Motility assays
The procedure for carrying out m otility assays was identical to the procedure used for 
invasion assays (section 2 111)  with the exception that the inserts were not coated with 
ECM The procedure for quantitative analysis was identical to that o f  the invasion 
assays » > ,
t
2.11.3 Adhesion assays
i * > ‘ ■ » * _
The ECM protein m atngel was diluted to lm g/m l with PBS A volume o f  250^1 was 
placed into wells o f a 24-well plate The plates were gently tapped to ensure that the 
base o f each well was completely covered with the solution The plates were then left 
overnight at 4°C The ECM  solutions were then removed from the wells and the wells 
nnsed twice with stenle PBS To each well, 0 5ml o f  a stenle 0 1% BSA/PBS solution 
was dispensed to reduce non-specific binding The plates were mcubated at 37°C for 20 
minutes and nnsed twice with PBS
Cells were set up in 75cm2 flasks, grown to about 80% confluency, harvested and 
resuspended in serum-free medium A 1ml volum e o f  cells was then plated at „a 
concentration o f  2 5 x 104 cells per well in tnplicate and mcubated at 37°C ¡for , 6 0 , 
minutes Control wells were those which had firstly been coated but contained, no cells, 
and secondly not been coated After 60 minutes, the medium was remoyed from > the 
wells and nnsed gently with PBS This was then removed and 200jal o f  freshly prepared 
phosphatase substrate (lOmM ;?-nitrophenol phosphate (Sigma 104-0) in 0 1M sodium 
acetate (Sigma, S8625), 0 1% tn ton  X-100 (BDH, 30632), pH 5 5) was added to each 
well The plates were then incubated in the dark at 37°C for 2 hours The enzymatic
> ¡ l i t
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reaction was stopped by the addition o f  lOOjil o f  1M NaOH The plate as read in a dual 
beam  plate reader at 405nm with a reference wavelength o f  620nm
211.4 Zymography - t
Zym ography was used to assess the level o f proteolytic activity o f  different proteinases- 
in cell culture supernatants The choice o f  substrate incorporated into the resolving gel 
depends on substrate specificity o f  the species o f  enzyme to be detected1 (Johansson et - 
a l , 1986) Gelatin as a substrate for m atrix metalloproteinases (MMPs), senne and 
cysteine protemases, was used in these experiments
The 10% acrylannde gels were prepared by incorporating gelatin within the 
polymerized acrylamide m atrix The quantities for one gel are given m  Table 2 7
 ^ \ i
C om ponents Resolving gel S tack ing  gel
Acrylamide 3 3 mis 0 5 mis
3mg/ml Gelatm (Sigma, G-8150) 2 5 ml -
1 875M -Tns/HCl, pH 8 8 2 5 ml $ n
1 25M -Tns/HCl, pH 6 8 - 0 8 m l  '
Ultrapure water 1 7 ml 2 ml
10% Ammonium persulphate (Sigma, A- 
1433)
33 pi 33 jj.1 1
TEMED (Sigma, T-8133) 5 \i\ 5 Ml
Table 2 7 Preparation o f resolving and stacking gel for zymography
Cells were grown m  T75 flasks Once cells were about 80% confluent, they were rinsed 
twice with sterile PBS, followed by 2-hour incubation with serum-free medium The { 
cells were then grown in fresh serum-free medium for another 24-72 hours (dependmg 
on their growth rate) After the relevant time penod, supernatants were collected and 
concentrated in centrifugal concentrators (Vivascience, VS2012) Protein was quantifieds 
using a Bio-Rad protein assay kit (Bio-Rad, 500-0006) Samples were mixed 3 1 with 
4X sample buffer (20% glycerol, 0 25M  Tns-H Cl, pH 6 8, 0 1% (w/v) bromophenol
i - i
blue) and were loaded onto the gel A 5\x\ aliquot o f  boiled broad size range protein 
m arker (New England Biolabs, 7708S) was also loaded onto the gel The gels were run
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at 30 mA per gel in IX running buffer (14 4g Glycine, 3 03g Tns and lg  SDS in 1L 
UHP) until the dye front reached the bottom of the gel Following electophoresis, the 
gels were soaked in 2 5% Tnton-X-100 with gentle shaking for 30 minutes at room 
temperature The gels were then rinsed in substrate buffer (50mM Tns-HCl, pH8 0, 
5mM CaCl2) and incubated for 24 hours in substrate buffer at 37°C The gels were then 
stained with Coomassie blue (2 5mg/ml) for 2 hours by shaking and destained in 25% 
acetic acid until clear bands were visible The gels were then scanned To identify the 
different classes of proteinases that were being secreted, inhibitors of protemases were 
added to 2 5% Tnton-X-100 m substrate buffer The inhibitors used in this study are 
listed in Table 2 8 , v. . ){l.
Inhibitor Enzyme inhibited Concentration used
EDTA MMPs 30 mM
PMSF Senne protemases 1 mM
Enhancer Enzyme enhanced Concentration used
Cysteine Cysteine protemases 10 mM
Table 2 8 Inhibitors and enhancers of different classes of proteinases used in gelatin 
zymography
2.11.5 3D-in vitro invasion assays
The hanging drop method was performed using an adapted method from Robinson et 
a l , (2004) Cells were harvested and resuspended at a concentration of lx l0 6 cells/ml in 
complete media Volumes of 20}iL aliquots were deposited onto the underside lid of 
10mm tissue culture dish The lid was then inverted over 10ml stenle UHP or complete 
media to create hanging drops on the upper lid Drops were incubated under tissue 
culture conditions for 24 hours Aggregates were added to a tissue culture dish 
precoated with Agar (5%) and overlaid with 10ml complete media to prevent 
attachment and allow dense spheroid profile formation for 24hrs After' ]this time,*'the 
spheroids were transferred to a 24-well plate coated with matngel or collagen'type I fdr 
the 3-D in vitro invasion assay
A volume of 250jiL of matngel (1 mg/ml) was added 24 well plates and allowed to settle 
overnight at 4°C The excess media was removed and washed twice witfci PBS The
spheroid was carefully placed into matrigel ensuring only one spheroid was implanted. 
The spheroid was then incubated for 2hrs at 37°C in 5% C 0 2. After this time, the well 
was overlaid with 500|iL o f  media. The implanted spheroid was monitored at 24hrs, 
48hrs, 72hrs and up to 7 days. The rate o f  invasion was measured by the distance (|am) 
o f  invasion o f  the cells from the original spheroid with a graticule in the microscope at 
4x magnification.
. \
2.12 Western blotting
2.12.1 Whole cell extract preparation
Cells were grown to 80-90% confluency in 75cm2 flasks. Cells were trypsinised (section 
2.2.1) and washed tw ice with ice-cold PBS. All procedures from this point forward 
were performed on ice. Cells were resuspended in 100-200|nl o f  NP-40 complete lysis 
buffer (50mM Tris-HCl (pH 7.5), 150 mM  NaCl, 0.5%, NP-40 and UHP) and incubated 
on ice for 30 minutes. Immediately before use, lOjal o f  the 100X stocks listed in Table
2.7 were added to 1ml o f  lysis buffer.
100X stock Preparation instructions
lOOmM DTT 154 m g in 10ml UHP
lOOmM PMSF 174 mg in 10ml 100% ethanol (Lennox, 608)
100X Protease inhibitors 2.5 mg/ml leupeptin, 2.5 mg/ml aprotinin, 15 mg/ml 
benzamidine and 1 mg/ml trypsin inhibitor in UHP water
Table 2.7 NP-40 lysis buffer 100X stocks
After incubation on ice, lysates were centrifuged on a bench centrifuge at 14,000rpm for 
15 minutes at 4°C. Supernatant containing extracted protein was transferred to a fresh 
chilled eppendorf tube. Protein concentration was quantified using the Biorad assay as 
detailed in section 2.12.2. Samples were then stored in aliquots at -80°C.
2.12.2 Protein quantification
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 500-0006) 
as follows. A 2mg/ml bovine serum albumin (BSA) solution (Sigma, A9543) was 
prepared freshly in lysis buffer. A protein standard curve (0, 0.2, 0.4, 0.6, 0.8 and 
1.0mg/ml) was prepared from the BSA stock with dilutions made in lysis buffer. The
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Bio-Rad reagent was diluted 1 5 in UHP water A  20jal volume o f protein standard 
dilution or sample (diluted 1 10) was added to 980^1 o f  diluted dye reagent and the 
mixture vortexed All samples were assayed in triplicate After 5 minutes incubation, * 
absorbance was assessed at 570nm The concentration o f  the protein samples wasi ' 
determined from the plot o f  the absorbance at 570nm versus the concentration o f  the 
protein standard
2 12.3 Gel electrophoresis
Protems for analysis by  W estern blotting were resolved using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) Using the Atto dual mim slab kit (AE 6450) the stacking 
and resolving gels were prepared as illustrated in Table 2 8 The gels were set in clean ] 
9cm x 8cm gel cassettes, which consisted o f  2 glass plates separated by a rubber gasket 
to a width o f  1mm The resolvm g gel was added to the gel cassette and allowed to set 
Once the resolving gel had set, stacking gel was poured on top A comb was placed into
i i
the stacking gel after pounng, in order to create wells for sample loading (maximum 
sample loading volume o f  15-20|il)
C om ponents 10%  Resolving Gel 5%  S tacking Gel
Acrylamide stock 4 6 ml 670jal
UHP water 5 6ml 2 7ml
1 875 M Tns-H Cl pH 8 8 3 5 ml -
1 25 M  Tns-H Cl pH 6 8 - 500|il
10% SDS 140|aL 40nL
10% NH4- persulfate* 140|iL 40^L
TEMED* 5 6|iL 4^L
Table 2 8 Preparation protocol:for SDS-PAGE gels ( 2 x 0  75mm gels)
* Added immediately before pounng
i » i
The acrylamide stock m Table 2 8 consists o f  a 30% (29 1) ratio o f  acrylamide bis- 
acrylamide (Sigma, A2792) In advance o f  samples being loaded in to the relevant 
sample wells, 20 |ig  o f  protein was diluted m  10X loading buffer M olecular weight 
markers (Sigma, C4105) were loaded alongside samples The gels were run at 250V and
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45mA until the bromophenol blue dye front was found to have reached the end o f  the 
gel, at which time sufficient resolution o f  the molecular weight m arkers was achieved
11 i i \ i
2.12.4 Western blotting
W estern Blotting was performed by  the method o f  Towbm et al (1979) O nce, 
electrophoresis had been completed, the SDS-PAGE gel was equilibrated in transfer 
buffer (25mM T ns (Sigma, T8404), 192mM glycine (Sigma, G7126), pH 8 3-8 5) for 
approximately 30 minutes Five sheets o f W hatman 3mm filter paper were soaked in 
freshly prepared transfer buffer These were then placed on the cathode plate o f  a sem i­
dry blotting apparatus (Bio-rad) A ir pockets were then removed from between the filter 
paper PVDF membrane (Boehnnger M annheim 1722026) or nitrocellulose membrane 
(Amersham Pharmacia Biotech, RPN 303D), which had been equilibrated in the same 
transfer buffer, was placed over the filter paper on the cathode plate A ir pockets were 
once again removed The gels were then aligned onto the membrane Five additional 
sheets o f  transfer buffer-soaked filter paper were placed on top o f  the gel;'all air pockets 
removed and excess transfer buffer removed from the cathode plate The proteins were 
transferred from the gel to the membrane at a current o f 34mA at 15V for 30-40 
minutes, until all colour markers had transferred !
Following protein transfer, membranes were stained using Ponceau (Sigma, P7170) to 
ensure efficient protein transfer The membranes were then blocked overnight using 5% 
m ilk powder (Cadburys, Marvel skimmed milk) in PBS at 4°C The membranes were 
washed with PBS pnor to addition o f  the prim ary antibody
Membranes were treated with primary antibody for 2-3 hours at room temperature (or 
overnight at 4°C) and a negative control where the membrane was exposed to antibody 
diluent was also performed Antibodies were prepared in 1% M arvel in PBS Primary 
antibody was removed after this period and the membranes rinsed 3 times with PBS 
contaimng 0 5% Tween 20 (Sigma P1379) for a total o f  15-30 mmutes The primary 
antibody dilutions are illustrated in Table 2 9
Secondary antibody (1 in 1,000 dilution o f anti-mouse IgG peroxidase conjugate 
(Sigma, A4914) in PBS, was added for 1 5 hour at room temperature The membranes 
were washed three times thoroughly m PBS contaimng 0 5% Tween for *15 ^minutes 
each time
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Primary Antibody Dilution
p-actin (Sigma, A5441) 1:10,000
P-gp (Santa Cruz, SC-13131) 1:200
Table 2.9 List o f  primary antibodies and dilutions
2.12.5 Enhanced chemiluminescence (ECL) detection
Immunoblots were developed using an Enhanced Chemiluminescence kit (Amersham, 
RPN2109), which facilitated the detection o f  bound peroxidase-conjugated secondary 
antibody. Following the final washing, membranes were subjected to ECL. A layer o f  
parafilm was flattened over a glass plate and the membrane placed gently upon the 
plate. A volume o f 3ml o f  a freshly prepared 50:50 mixture o f  ECL reagents was used 
to cover the membrane. The ECL reagent mixture was completely removed after a 
period o f  one minute and the membrane wrapped in clingfilm. All excess air bubbles 
were removed. The membrane was then exposed to autoradiographic film (Kodak, X- 
OMATS) for various times (from 10 seconds to 30 minutes depending on the intensity 
o f  the signal). The exposed autoradiographic film was developed for 3 minutes in 
developer (Kodak, LX-24). The film was then washed in water for 15 seconds and 
transferred to a fixative (Kodak, FX-40) for 5 minutes. The film was washed with water 
for 5-10 minutes and left to dry at room temperature.
2.13 Proteomic protocols: sample preparation - total protein extraction
In order to obtain between 5-10 mg o f  protein, at least 3x107 cells were required. Cells 
were therefore grown to 70-80% confluency in 175cm2 flasks, trypsinised and counted 
(section 2.2.1), washed three times with 50 ml ice cold PBS or sucrose solution and the 
resulting pellet was left on ice for up to 30 minutes. After 30 minutes, 1ml o f  either o f  
the following complete lysis buffers: (8M urea (Sigma, U6504), 30mM, Tris Base 
(Sigma, T1378) (1M not pH ’d), 4 % (w/v) CHAPS (Sigma, C5070), pH to 8.5 with 
dilute HC1) or ((5 M urea (Sigma, U6504), 2M thiourea (Sigma 88810) 30mM, Tris 
Base (Sigma, T1378) (1M not pH ’d), 4 % (w/v) CHAPS (Sigma, C5070), pH to 8.5 
with dilute HC1) was added to the pellet. Immediately before use, lOjil o f  the 100X 
stocks o f  DNase and RNase were added to 1ml o f  lysis buffer.
The lysate was then put through a 1 ml syringe with a 21 gauge needle 5 times. The cell 
lysate was placed on an orbital shaker and shaken for 1 hour at room temperature. The 
protein lysate was then transferred to an eppendorf and centrifuged at 13,000 rpm for 15
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minutes The resulting supernatant was transferred to a fresh m icrocentnfuge tube and 
its pH was checked to ensure it was between pH 8 0-9 0 by spotting 3 |il onto a pH 
indicator strip The sample was then divided into smaller aliquots and stored at -80°C  
The protein concentration was quantified usm g the Biorad method outlined in section 
2 12 2 At least 6 biological replicates o f  each cell line were prepared
* i
Different protein loadings for isoelectnc focussing were used for 2-DE These volumes 
were dependent on whether or not the samples were to be used for screening, DIGE 1 
analysis or for the identification o f  proteins o f  interest by mass spectrometry (see 
section 2 17 2)
2.14 Labeling of cell lysates for DIGE
2.14.1 Preparation of CyDye DIGE fluor minimal dyes for protem Labelling
2.14 1.1 Preparation of dye stock solution (1 nmol/pl)
The three CyDye DIGE Fluor M immal dyes (Cy3, Cy5 and Cy2 (Amersham, 25-8010- 
65) were thawed from -2 0  °C to room temperature for 5 minutes To each microfuge 
tube dimethylformamide (DMF) (A ldnch, 22,705-6) was added to a concentration o f  1 
nmol/ jxl Each microfuge tube was vortexed vigorously for 30 seconds to dissolve the 
dye The tubes were then centrifuged for 30 seconds at 14,000rpm in a microcentnfuge 
The reconstituted dyes were stored at -2 0  °C for up to two months ■ > > ,, u v., «
2.14.2 Preparation of 10 \il working dye solution (200 pmol/fil)
On thawing, the dye stock solutions were centrifuged in a m icrocentnfuge for 30 
seconds To make 10 |il o f  the three working dye solutions, 8 \i\ o f  DMF was added to 
three fresh eppendorfs labelled Cy2, Cy3 and Cy5 A 0 2 nmol/jil volume o f each o f the 
reconstituted dye stock solutions was added to their respective tubes The dyes were 
stored at -20 °C m tinfoil in the dark for 3 months t ■ > > >
!
2.14.3 Protem sample labelling , i i * i ,
A volume o f  the 6 control samples and 6 treated protein samples equivalent to 50 |ig 
was placed into twelve eppendorf tubes (6 for Cy3 and the other 6 for Cy5) They were 
labelled with the minimal dyes as follows, Control 1-3 and Treated 1-3 were labelled 
with 1 pi each o f  Cy3 and Control 4-6 and Treated 4-6 were labelled with 1 jul each with
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Cy5 Each tube was mixed by  vortexing, centrifuged and then left on ice for 30 minutes «< - 
in the dark To stop the reaction, 1 fil o f  10 mM  lysine was added, the tubes were 
vortexed, centrifuged briefly and left on ice for 10 minutes in the dark The labelled 
samples were stored at -8 0  °C The Cy2 pool for each gel (50 jig) contained a 4*1*7 |ig 
aliquot o f  each o f the 12 protein samples (6 control and 6 treated) To this tube 1 |il o f 
working dye solution was added
2.14 4 Preparing the labelled samples for the first dimension
The protein samples labelled with Cy2 (pooled internal standard), Cy3 and Cy5 were 
thawed on ice (in the dark), combined by placing into a single eppendorf tube and 
mixed An equal volume o f  2X sample buffer (2 5 ml rehydration buffer stock solution
(8M urea, 4 % CHAPS), pharmalyte broad range pH4-7 (2%) (Amersham, 17-6000-86),
<■
DTT (2%) (Sigma, D9163)) was added to the labelled protein samples The mixture was 
left on ice for at least 10 minutes then applied to Immobilme DryStnps for'isoelectric 
focussing
2.15 First dimension separation - isoelectric focussing methodologies
Isoelectric focussing o f  all samples were earned out using immobilme pH gradient 
(IPG) stnps
2.15.1 Strip rehydration using Immobiline DryStnp reswellmg tray
The protective lid was removed from the Immobilme Dry Stnp Reswellmg tray The 
tray was levelled using the spint level A  350(xl volume o f  rehydration buffer solution 
(with 2 % pharmalyte broad range pH4-7 and 2 % DTT) was slowly pipetted into the 
centre o f  each slot, all air bubbles generated were removed The cover film from the 
IPG stnp (Amersham, 17-1233-01) was removed and positioned with the gel side down 
and lowered To ensure the entire stnp was evenly coated the stnp was gently lifted and 
lowered onto the entire surface o f  the solution avoiding trapping air bubbles 
Each stnp was overlaid with about 3 ml IPG Cover Fluid (Amersham, 17-1335-01) 
starting on both ends o f  the stnp, moving to the centre The protective lid was then
1 '  * i i T  t '
replaced and the stnps were left at room temperature to rehydrate overnight (or at least 
12 hours)
t i
74
2 15 2 Isoelectric focussing using the IPGphor manifold t > • -
Following the rehydration procedure, the M anifold (Amersham) was placed onto the 
IPGphor unit by  inserting the “T” shape into the hollow provided A  9 ml volum e o f  
Cover Fluid was placed into each o f  the twelve lanes in the tray m order to cover the 
surface Two wicks (Amersham, 80-6499-14) per strip were placed on tinfoil and 150 pi 
o f  UHP was pipetted onto each one to rehydrate them The rehydrated stnps were 
placed in the correct orientation (+ to anode) and aligned just below the indented mark, 
to allow for the wicks to overlap the strip The rehydrated wicks were then placed over 
both the cathodic and anodic ends o f  all the strips The wicks were checked'to ensure 
they were positioned over the gel portion o f the stnp and avoiding the indent in the lane' 
so as to guarantee a good contact with the electrodes The sample cups (Amersham,-80- * 
6498-95) were then positioned approximately 1 cm from the cathodic end? o f  the stnp 
and an insertion tool was used to securely “click” the cups into place ‘The electrodes 
were then fitted with their “Cam s” open and in direct contact with the wicks •
The amount o f  protein loaded per stnp was 75ug for screemng, 150ug for DIGE or 
400ug for spot picking The protein samples were prepared by  centnfuging to remove 
any insoluble m atenal and the appropnate volum e was loaded with a pipette tip placed 
just beneath the surface o f the cover fluid The cover o f the IPGphor unit was closed 
and the desired programm e selected The temperature was set for 20°C with 50jjtA/stnp 
The IEF parameters are as follows step 1 300 volts for 3 hours (step-and-hold), step 2 
600 volts for 3 hours (gradient), step 3 1000 volts for 3 hours (gradient), step 4 8000 
volts for 3 hours (gradient) The IEF was left at 8000 volts (step-and -ho ld ) until ready 
for SDS-PAGE step On completion o f the IEF run, the stnps were drained o f  the cover 
fluid and stored in glass tubes at -80°C  or used directly in the second dimension 1 1
l I i H ( >1
2.16 Second Dimension -  SDS polyacrylamide gel electrophoresis 1 1 ' ’
2.16.1 Casting gels m the ETTAN Dalt-12 gel caster
The 12 5 % acrylamide gel solution was prepared in a glass beaker (acrylamide/bis 40 
%, 1 5 M  T ns pH 8 8, 10 % SDS) Pnor to pounng, 10 % ammonium persulfate and1 
neat TEMED were added ‘
Two types o f  plates were used, low fluorescent for DIGE expenm ents and hinged for 
preparative and screemng silver stained gels All plates (both normal hmged and low
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fluorescent) and casting equipment were inspected to ensure they were clean The gel 
caster frame was placed on a level bench leaning on its “legs” so that the back o f  the 
caster was open and facing the operator The plates were assembled so that the front and 
back plates were evenly aligned and all seals and hinges m place A thin spacer was 
placed in the gel caster unit followed by an assembled plate followed by  a thm spacer 
then another plate The plates were positioned m the caster unit so that the lower, front 
plate was the furthest away from the operator and the spacers packed with theirt curved t 
edges to the top This layering was repeated until all 14 plates and spacers) were in place 
All plates and spacers were checked to ensure they were packed tightly together so as to  ^
m inimise any gaps and air pockets If  all 14 gels were not required, up to 4 dummy 
plates could be substituted instead o f  the glass plates When the desired amount o f  
plates had been added, the thicker spacers were placed next to bnng  the level marginally 
over the edge o f  the back o f  the caster The backing plate was then added to the caster 
frame and screwed into place with the 6 screws provided The silicone tubing was added 
to the outlet o f  the glass beaker and the glass tube was inserted to the other end o f  the 
silicone tubing The glass tube was inserted into the mlet o f  the reservoir and the glass 
beaker contaimng the gel solution was then clamped to a retort stand The gel solution 
was held in place using arterial clamps on the top tube and the tube running down from 
the reservoir to the caster chamber The top tube was unclamped and the gel solution 
was allowed to fill the tubing and the reservoir dram Air bubbles that had been 
generated were dislodged by  flicking the tube W hen all air bubbles had been removed 
the bottom clamp was released allowing the gel solution into the gel caster W hen the 
gel solution reached the indicator line across the top o f  the caster, the bottom and top 
tubes were reclamped The displacement solution (0 375M Tns-C l 1 5M pH8 8, 30% 
glycerol, UHP and bromophenol blue) was added to the reservoir and the glass tubmg 
was slowly removed from the reservoir mlet The clamp was removed from the bottom 
tube allowing the displacement solution into the tube and forcing the remaining, g e l, 
solution into the gel caster The gels were overlaid with 1 ml saturated butanol or 
sprayed with 0 1 % SDS solution The gels were left to set for at least three hours at 
room temperature Following this, the caster was gently unlocked and the gels removed 
and rinsed with distilled water I f  the gels were not used immediately they were stored 
for up to four days m  1X running buffer at 4 °C , r •
I f  gels were to be used for “spot picking” the plates were silamsed to stick the 
acrylamide mixture to the plates A volume o f 2ml o f  (8ml ethanol, 200jil glacial acetic
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acid, lOpl bind-silane and 1 8ml UHP) was pipetted over the glass plate and wiped over 
with a lint free cloth This was left to air dry for 15 minutes, after which 2ml ethanol 
and 2 ml UHP were each pipetted over the plate and wiped o ff  respectively The plate 
was left to air dry for approximately 1 hour 30 minutes
2 16.2 Preparing the ETTAN DALT 12 electrophoresis unit
The electrophoresis chamber was prepared by addmg 6 48 litres o f  UHP and 720 ml o f  
10X SDS running buffer The pump was then turned on to cool the system to 10 °C
2 16.3 Equilibration of focussed Immobiline DryStrips
The SDS equilibration buffer (30% glycerol, 6M urea, 50nm 1 5M Tns-C l pH 8 8, 2% 
SDS, bromophenol blue and UHP) which had been prepared, aliquotted into 30 ml 
volumes and frozen at -20°C  was allowed to thaw to room temperature Two SDS 
equilibration buffer solutions with DTT (65 mM) or lodoacetamide (240 mM ) (Sigma, 
11149) were then prepared Using a forceps, the IPG strips* were removed from the 
IPGphor unit, the cover fluid was drained o ff by holding the strips at an angle and they 
were placed into individual glass tubes with the support film toward the wall 
Equilibration buffer (10 mis contaimng DTT) was added to each tube and incubated for 
15 minutes with gentle agitation using an orbital shaker D unng this equilibration step, 
the gel cassettes were nnsed with UHP and then the tops rinsed with IX  running buffer 
After the first equilibration, DTT containing equilibration solution was removed and 5 
mis o f  the lodoacetamide containing equilibration buffer added The strips were 
incubated for 10 minutes with gentle agitation During this equilibration step, the 
agarose overlay solution (0 5% agarose in running buffer) was prepared and 50 ml o f 
IX  running buffer was placed in a glass tube
*If the strips had been frozen at this stage they were left at room temperature to thaw 
before the DTT-containmg equilibration solution was added
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2.16.4 Loading the focussed Immobilme DryStrips
Using a forceps and holding the anode end, the IPG strips were nnsed m IX SDS 
electrophoresis running buffer and placed between the two glass plates o f the gel The 
strip was pushed down gently using a thin plastic spacer until it came in contact with the 
surface o f the gel Any air bubbles trapped between the gel surface and the stnp were 
gently removed Approximately 1 ml o f the 0 5 % agarose overlay solution was applied 
over the IPG stnp to seal it in place
1 X .
2.16.5 Inserting the gels mto the Ettan DALT 12 electrophoresis buffer tank
When the running buffer reached the desired temperature (10°C) the loaded gel cassettes 
were wetted with UHP and inserted mto the tank through the slots provided in the same * 
onentation When all 12 slots were filled the upper chamber was filled, 2X running 
buffer was added to the upper chamber until the mark on the side of the chamber was 
reached The cover o f the unit was replaced and the required running conditions 
selected The unit was run for 18-24 hours at 1 5 Watts per gel at 10°C or until the 
bromophenol blue dye front reached the bottom of the gel When the run was 
completed, the gel cassettes were removed from the tank one at a time usmg the DALT 
cassette removal tool and nnsed with UHP to remove the running buffer -
2.17 Method for scannmg DIGE labelled samples
The Typhoon Vanable Mode Imager (GE Healthcare) was turned on and left to warm 
up for 30 minutes pnor to scanning The scannmg control software was opened and the 
fluorescence mode was selected The appropnate emission filters and lasers were then 
selected for the separate dyes (Cy2 520 BP40 Blue (488), Cy3 580 BP30 Green (532) 
and Cy5 670 BP 30 Red (633)) The first gel was placed in the scanner and pre-scanned 
at a 1000 pixel resolution in order to obtain the correct photo multiplier tube (PMT) 1 
value (to prevent saturation o f the signal from high abundant spots) Once the correct 
PMT value was found, the gel was scanned at 100 pixel resolution, resulting in the 
generation o f three images, one each for Cy2, Cy3 and Cy5 Once the scanning was 
completed, the gel images were imported mto the ImageQuant software All gels were 
cropped identically to facilitate spot matching in the Decyder BVA module
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2.18 Analysis of gel images
2.18.1 Differential m-gel analysis (DIA)
The DIA module processes a triplet o f images from a single gel The internal standard is 
loaded as the primary image followed by the secondary and tertiary image, derived, 
from, for example, a control and treated sample Spot detection and calculation o f spots 
properties were performed for each image from the same gel The software determined 
the margins o f the spots, quantified the spot intensities and calculated the relative spot 
intensity as the ratio between the total intensity o f the gel and the intensity o f each 
individual spot The protein spots were then normalised using the m-gel linked internal 
standard The data from the first gel was XML formatted and exported into the . 
Biological Variation Analysis (BVA) software for further analysis This procedure was 
repeated for each gel in the experiment
2.18.2 Biological variation analysis (BVA)
Once all gels from the experiment were loaded into the BVA module, the experiment 
design was set up and the images were assigned into three groups (standard, control and 
treated) The spots on the gels were then matched across all gels in the experiment 
This module detects the consistency o f the differences between samples across all the 
gels The software standardises the relative spot intensity o f the Cy5 image to that o f the 
Cy3 image in the same gel The standardised spot intensity was then averaged across the 
triplicate gels The BVA module detected the consistency o f the differences between 
samples across all the gels and applied statistics to associate a level o f confidence for 
each o f the differences The protein spots with statistically significant protein 
expression changes were designated “proteins o f interest” and placed in a pick list 
Preparative gels for spot picking with 400 ug of protein/gel were focussed and run out 
on SDS-PAGE gels The gels were then stained with colloidal coomassie (section 
2 212) Spots that showed differential protein expression were picked with the ETTAN , 
Spot Picker (section 2 22)
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2 20 Staining methods
2 20.1 Sriver staining 2-D electrophoresis gels (used to screen samples)
This method is used to screen protein samples pnor to labelling with the Cy Dyes After , 
2-DE, the gels were removed from the plates by very carefully placing a ruler between,. 
the two plates at the top nght hand comer and the top plate removed gradually Using 
the ruler, the side borders o f the gel were cut away in line with the ends o f the IPG strip 
at the top of the gel The strip and agarose were then removed and the gel was lifted ^
' gently and placed in a gel box containing fixing solution (50ml ethanol, 12 5 ml acetic 
acid (Lennox, 351) and 62 5 ml UHP) The gel boxes were placed on an orbital shaker - 
and fixed for at least 30 minutes (usually overnight) After fixing, solution was'drained 
from the gels The gels were then washed three times with 150 ml of UHP for 5 mmutes 
each time and drained The gels were next sensitised (60ml ethanol, 13 6g sodium 
acetate, 0 4g sodium thiosulfate and UHP in 200ml) for 30 mmutes on the orbital 
shaker
Using the method outlined above the gels were washed three times (for 10 minutes) 
Following the washes, 200 ml o f silver staining solution was added and the boxes 
returned to the orbital shaker After 20 mmutes the silver solution (0 5g silver nitrate, 
80ul formaldehyde and 200ml UHP) was drained and the gels were washed twice for 5 
minutes each with UHP After the last wash, 200 ml o f developer (5g sodium carbonate, 
40ul formaldehyde and 200ml UHP) was added to each o f the boxes The gels were 
placed on the orbital shaker and allowed to develop When the desired amount o f spots 
appeared the developer was drained into the silver containing 5 L drum (this 
precipitated out the silver) and 200 ml o f stopping solution (2 92g EDTA and 200ml 
UHP) was added The gels were left on the belly dancer for at least 10 mmutes The gels 
were then scanned at > 300 resolution
v i
2.20.2 Brilliant blue G Colloidal coomassie stammg of preparative gels for spot
_ * i
picking
After electrophoresis, the smaller lower plates with the gels attached were placed in the 
gel boxes containing fixing solution (7% glacial acetic acid in 40% (v/v) methanol 
(Aldnch, 200-659-6)) for at least one hour During this step a IX working solution o f  
Brilliant Blue G colloidal coomassie (Sigma, B2025) was prepared by addmg 800ml 
UHP to the stock bottle When the fixing step had nearly elapsed a solution containing 4 
parts o f IX working colloidal coomassie solution and 1 part methanol was made, mixed
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by vortexing for 30 seconds and then placed on top o f the gels The gels were left to 
stain for 2 hours To destam, a solution containing 10% acetic acid in 25% methanol 
was poured over the shaking gels for 60 seconds The gels were then rinsed with 25% 
methanol for 30 seconds and then destained with 25% methanol for 24 hours The glass 
surface was dried and two reference markers (Amersham) attached to the underside o f ’ 
the glass plate before scanning The resulting image was imported into the ImageMaster 
software (Amersham) and the spots were detected, normalised and ■ the reference 
markers selected While keeping the shift key depressed, all spots o f interest» were 
manually selected The resulting image was saved and exported into the Ettan Spot 
Picker software * t * « . »
2.21 Spot picking ) <
The stained gel was placed in the tray o f the Ettan Spot Picker (Amersham, 18-1145-28) 
with reference markers (Amersham, 18-1143-34) aligned appropriately and covered 
with UHP The imported pick list was opened, the syringe primed and the system was 
set up for picking the spots from the pick list The spots were robotically picked and 
placed in 96-well plates, which were stored at 4°C until spot digestion
2.22 Spot digestion and identification with MALDI-TOF
The 96-well plate was placed in the Ettan Digester (Amersham, 18-1142-68) to digest 
the protein as follows Step 1 -  the gel plugs were washed three times for 20 minutes 
each with 50pl 50mM ammonium bicarbonate (Sigma, A6141) m 50% methanol Step 2 
-  the gel plugs were washed twice for 15 minutes with 50pl 70% acetomtnle (Sigma, 
34967) The gel plugs were left to dry for at least 60 minutes After drying, the 
individual gel pieces were rehydrated in 10pl digestion buffer (12 5ng trypsin 
(Promega, V5111) per pi o f 10% acetomtnle, 40mM ammonium bicarbonate)
» X I 1 £
Exhaustive digestion was earned out overnight at 37°C After digestion, the samples 
were transferred as follows Step 1 -  A volume of 40pl o f 0 1% tnfluoroacetic acid
r
(Sigma, 302031) m 50% acetomtnle was added to the wells, mixed and left for 20 
minutes A volume of 60pl o f this solution was transferred to a fresh 96-well plate Step
/  ^ W *
2 - A volume of 30pl o f 0 1% tnfluoroacetic acid m 50% acetomtnle was added to the 
wells, mixed and left for 20 minutes A volume o f 50pl o f this solution was transferred 
to the fresh 96-well plate The liquid in the plate was vacuum-dned m a maxi dry plus 
After drying, the 96-well plate was placed in the Ettan Spotter (Amersham, 18-1142-67)
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for spotting onto the target plates A volume of 3 pi o f 0 5% tnfluoroacetic acid in 50%, 
acetomtnle was added to the desiccated peptides and mixed 5 times A volume o f 0 3 pi 
o f this mixture was spotted onto the target plate after which a volume o f 0 3 pi matrix 
solution [7 5mg/ml a-cyano-4-hydroxycinnamic acid (LaserBio labs, 28166-41-8) in 
0 1% tnfluoroacetic acid in 50% acetomtnle]
The target plate was placed in the MADLI-ToF (Amersham, 11-0010-87) instrument 
The system was set up as follows the target plate was disengaged from the machine A 
new empty run list was opened In the acquisition mode o f the “favontesucon, the < 
“spectrum processes”, specifically PepMix 4 (LaserBio labs, C l04) was picked, and » 
“protein digest optimised” were successively selected and dragged to positions 1 and 2- 
24 respectively on the target slide Within the identification section o f favontes, 
“protein digest Homo sapiens IAA” was selected and dragged to positions 2-24 on the 
target slide The run list for slide 1 was saved and associated to position 1 on the 
previously disengaged tray Selecting process and play then started the MALDI 
Mass spectra were recorded operating in the positive reflector mode at the following  ^
parameters accelerating voltage 20 kV, and pulsed extraction on (focus mass 2500) 
Internal and external calibration was performed usmg trypsin autolysis peaks at 842 509 
m/z, 2211 104 m/z and PepMix 4 respectively Calibration usmg Pep4 was performed as 
follows Once two spectra were generated for the PepMix 4 mix (position 1 on the 
slide), the acquisition of spectra was stopped The first spectrum o f sample one was 
selected and the calibrant peaks readjusted for accuracy The five individual peaks cover 
the 500-3500 Da mass range and include bradykmin fragment 1-5 (573 315), 
angiotensin II human (1046 5424), neurotensin (1672 9176) and insulin B chain 
oxidised (3494 6514) Once calibration was completed it was saved as the new “system 
calibration” The MALDI was then restarted The mass spectra generated for each o f the 
proteins were analyzed usmg MALDI evaluation software (Amersham Biosciences) 
Protein identification was achieved with the PMF Pro-Found search engine for peptide 
mass fingerpnnts '
An example of a mass spectra generated for annexin A1 is seen in Figure 2 1, whereby» 
the sequence coverage is 26 4% with seven of the 15 peptides used 907 419,4261 623, 
1549 833, 1677 909, 1701 891, 1738 722 and 1904 004 The sequence coverage with 
peptide information and p value for each of identified proteins m the thesis is presented 
m the appendices
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Figure 2.1 Mass spectra for the annexin 1 protein with sequence coverage of 2614% ' 1
2.23 PathwayAssist of identified proteins * 1 v '
PathwayAssist is a product aimed at the visualisation and analysis of biological 
pathways, gene regulation networks and protein interaction maps The 
PathwayAssist automated software is comprised of two tools, namely MedScan and 
ResNet The Medscan algorithm is a text-mimng tool that extracts biological interaction 
information by reading digital text documents (e g  biomedical journal articles and
i
abstracts) It efficiently scans sentences searching for co-occurrences o f biological terms 
to locate connecting verbs such as binds, inhibits, modulates or phosphorylates - 
between the co-occumng terms The ResNet database is a repository o f over 500,000 
biological mteractions for more than 50,000 proteins including human, mouse, rat, 
yeast, drosophila, and C ehgans, which are extracted from the current literature 
PathwayAssist permits the identification o f biological interactions among genes and 
protems of interest from the published literature, and provides links to the supporting 
sentences in the matching journal article citations (for articles available online in 
PubMed) The software can also connect two genes/proteins with the shortest possible 
path, import a list o f genes/protems, which can then be arranged mto a pathway and 
finally find common upstream and downstream regulators o f a gene/protein
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Section 3.0: Results
3 1 Development of multidrug resistant variants by pulse selection
Two squamous and two small cell lung carcinoma cell lines were chosen for drug 
treatment on the basis o f no previous exposure to chemotherapeutic drugs Each 
parental cell line was pulsed with two clinically relevant drugs namely a taxane 
(taxotere and/or taxol) and a platinum drug (carboplatin), which are commonly used to 
treat lung cancer (Table 3 1 1) The two squamous cell carcinomas cell lines (SKMES-1 
and DLRP) and one small cell carcinoma cell line, DMS-53 were pulsed with a taxane 
and carboplatin, whereas the NCI-H69 cell line was pulsed with carboplatin and VP-16 
Pulse selection of the cell lines with taxol, taxotere, VP-16 and carboplatin resulted in 
the establishment of twelve novel drug resistant variants These were denoted “-Txl”, “- 
Txt”, “-VP” and “-Cpt” for the taxol, taxotere, VP-16 and carboplatin-selected cells 
respectively
Cell Line Taxol
(ng/ml)
Taxotere
(ng/ml)
VP-16
(ng/ml)
Carboplatin
(Hg/ml)
DLRP Not Treated 5 Not Treated 15
DMS-53 60 40 Not Treated 5
SKMES-1 120 60 Not Treated 100 and 30
NCI-H69 Not Treated Not Treated 480 10 and 5
Table 3 11 Lung cancer cell lines and drug concentrations used for pulse selections
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3.1 1 Determination of sensitivity of parental cell lines to chemotherapeutic agents
The parent cell lines were analysed using an m vitro toxicity assay to determine the IC50 
value (drug concentration that kills half o f the cell population) o f the drugs chosen for 
drug selection and the following panel o f drugs adnamycin, cisplatin, 5-fluorouracil 
and vincristine (section 2 8 1)
The parent cell lines examined showed quite marked differences in sensitivity to the 
range of drugs tested (Table 3 1 2) The cell line SKMES-1 is 3-fold more resistant to 
cisplatin compared to DLRP By contrast, DLRP is 14-fold, 5 6-fold, 7 5-fold and 7 3- 
fold more resistant to 5-FU, adnamycin, taxol and VP-16 respectively compared with 
SKMES-1 Interestingly, both squamous cell carcinoma cell lines show similar 
resistance patterns to taxotere and vincristine Within the small cell carcinoma group, 
NCI-H69 is more sensitive to all drugs except adnamycin and taxol in comparison to 
DMS-53 DMS-53 in turn is more resistant to the taxanes and vincristine when 
compared with both squamous cell lines
Drug
SKMES-1
(ng/ml)
DLRP
(ng/ml)
DMS-53
(ng/ml)
NCI-H69
(ng/ml)
Taxotere 0 7 ± 0 06 0 7 ± 0 1 8 2 ± 0 3 0 23 ± 0 03
Taxol 1 2 ± 0  1 9 ± 0 9 129 ± 1 3 13 3 ± 2 3
Adnamycin 7 3 ± 0 4 40 7 ± 3 1 15 ± 1 7 42 3 ± 6 4
Carboplatm 4600 ± 200 3500 ±360 6 1200± 100 740 ± 112 7
Cisplatin 671 7 ± 7 7  5 223 ±21 4 151 7 ± 12 6 110 ± 2 0
5-FU 89 3 ± 6 6 1250 ± 132 3 733 3 ± 57 7 90 ± 10
Vincristine 3 8 ± 0 3 3 3 ± 0 2 . 85  ± 0 9 3 9 ± 0 3
VP-16 60 3 ± 1 9 438 3 ± 4 0  7 295 ± 22 9 72 ± 2
Table 3 1 2  IC50 values for a range of chemotherapeutic drug acting on the cell lines SKMES- 
1, DLRP, DMS-53 and NCI-H69 The values are given as the average IC50 value ± the standard 
deviation on a minimum of three repeats
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3.1.2 Establishment of taxotere-selected variant of SKMES-1
The SKMES-1 cell line was exposed to an IC90 value (determined from a pulse 
exposure in a 25 cm flask) of 60ng/ml taxotere for four hours, once a week for ten 
consecutive weeks. The cell line resulting from this exposure was designated SKMES- 
Txt.
Toxicity assays were carried out at the following time points:
1: after the final pulse - before cells were frozen in liquid nitrogen,
2: after one month in liquid nitrogen
3: after fifteen months storage in liquid nitrogen (Table 3.1.3)
Cell Line Liquid Nitrogen Storage Time
SKMES-Txt
SKMES-Txt
SKMES-Txt
Pre-Storage 
One Month 
Fifteen Months
Table 3.1.3 Summary of SKMES-Txt selections
3.1.2.1 Morphology of the taxotere variant of SKMES-1
The morphology o f SKMES-Txt was found to have changed during the selection 
procedure with taxotere (Figures 3.1.1 and 3.1.2). The cell line (similar to the parent) 
required cell-to-cell contact for growth. Images were taken at 10X magnification.
Figure 3.1.1 SKMES-1 Figure 3.1.2 SKMES-Txt
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3 1.2 2 Resistance and cross-resistance profiles of SKMES-Txt immediately after 
pulse selection
After the final pulse with taxotere, SKMES-Txt was left to recover for one week before 
toxicity assays were carried each week for one month for eight drugs as described in 
section 2 8
SKMES-Txt was 16-fold resistant to taxotere when tested one week after pulsing The 
resistance increased and stabilised in weeks 2, 3 and 4 (26 7-fold, 26 7-fold and 25 3- 
fold respectively) (Table 3 1 4, Figure 3 1 3)
Stable cross-resistance developed to Adnamycin and VP-16 (2 1-fold and 3 7 fold 
respectively) Moreover, as a result of the selection process, the cell line developed 
unusual cross-resistance to 5-FU (13-fold) SKMES-Txt developed no cross-resistance 
to the platinum drugs (Table 3 15, Figure 3 1 4)
Drug SKMES-1 Week 1 Week 2 Week 3 Week 4
Taxotere (ng/ml) 0 71 ± 0  06 11 4 ±  1 7 19 ± 1 8 19 ± 2 9 19 4 ± 1 6
Table 3 1 4  IC50 values for taxotere acting on the cell line SKMES-Txt before freezing 
Toxicity assays were only earned out once at each week and are given as the average
Figure 3 1 3  Fold resistance of SKMES-Txt to taxotere with respect to SKMES-1 over four 
weeks, as determined by comparing IC50 values IC50 value ± standard deviation of the eight 
rows of a 96 well plate
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Drug IC50 SKMES-1 (ng/ml) IC50 SKMES-Txt (ng/ml) Fold Resistance
Carboplatin 3350 ±200 3120 ± 216 0.93
Cisplatin 671.7 ±72.2 682 ±53.7 1
5-FU 85 ±8.75 1115 ± 164 13
VP-16 66.8 ±6.98 250 ± 56 3.7
Adriamycin 7 ±0.74 14.5 ±2 .7 2.1
Table 3.1.5: IC50 values for a range of chemotherapeutic drugs acting on the cell line SKMES- 
Txt before freezing. Toxicity assays were carried out once at each week. Values are given as the 
average of four IC50 values ± standard deviation over the month.
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Figure 3.1.4 The fold increases in resistance in SKMES-Txt with respect to SKMES-1 over 
four weeks, as determined by comparing IC50 values.
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3 1 2  3 Resistance and cross-resistance profiles of SKMES-Txt after one-month 
storage in liquid nitrogen
After a period of one-month storage in liquid nitrogen, SKMES-Txt were thawed and 
the resistance and cross-resistance measured for eight drugs as described in section 2 8 
The toxicity assays were carried out on each of the eight drugs every week for at least 
one month after thawing (Figure 3 15)
The resistance to taxol and taxotere was found to have altered with one-month storage 
in liquid nitrogen
SKMES-Txt was 5 6-fold resistant when tested one week after thawing The resistance 
increased and stabilised in weeks 2 and 3 (29-fold and 30 9-fold respectively) however, 
resistance fell sharply to 16 6-fold by week 4 Unstable cross-resistance to taxol also
f
developed in this cell line The cell line was 63-fold resistant when tested one week 
after thawing (Table 3 16) Interestingly, taxol resistance fell at each of the subsequent 
weeks tested (Figure 3 15)
Similar to results to cells tested immediately after pulse selection, stable cross­
resistance developed to adnamycin, vincristine and VP-16 (7 3-fold, 19 6-fold and 3 8 
fold respectively) Moreover, as a result of the selection process, the cell line developed 
unusual cross-resistance to 5-FU (13 2-fold) SKMES-Txt developed no cross­
resistance to the platinum drugs (Table 3 17, Figure 3 16)
ICso values of SKMES-Txt (ng/ml)
Drug SKMES-1 Week 1 Week 2 Week 3 Week 4
Taxotere 0 71 ± 0  06 4 ± 0 4 21 ± 2 8 22 ± 2  8 11 8 ± 0 3
Taxol 1 2 ± 0 1 63 ± 11 49 9± 5 1 36 2 ± 4 8 30± 2 1
Table 3 1 6  IC50 values for a range of chemotherapeutic drugs acting on the cell line SKMES- 
Txt after one month frozen The values are given as the average IC50 value ± the standard 
deviation on two repeats for taxotere and once for taxol
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Figure 3 1 5  The fold increases in resistance to the taxanes in SKMES-Txt with respect to 
SKMES-1 over four weeks, as determined by comparing IC50 values
Drug IC50 SKMES-1 
(ng/ml) IC50 SKMES-Txt (ng/ml) Fold Resistance
Carboplatin 3350 ±200 3350 ±290 1
Cisplatin 671 7 ± 72  2 687 ± 33 1 02
5-FU 85 ± 8 75 1123 ± 170 13 2
VP-16 66 8 ± 6 98 259 ± 20 7 3 8
Vincristine 1 15 ± 0  07 22 5 ± 3 2 19 6
Adriamycm 7 ± 0 74 51 16 ± 4 3 73
Table 3 17 IC50 values for a range of chemotherapeutic drugs acting on the cell line SKMES- 
Txt after one-month storage in liquid nitrogen The values are given as the average IC50 value ± 
the standard deviation on a minimum of three repeats The fold increases in resistance to 
chemotherapeutic drugs in SKMES-Txt with respect to SKMES-1, as determined by comparing 
IC50 values
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Figure 3.1.6 The fold increases in resistance to chemotherapeutic drugs in SKMES-Txt with 
respect to SKMES-1, as determined by comparing IC50 values
3.1.2.4 Resistance profiles of SKMES-Txt after fifteen-months storage in liquid 
nitrogen
After a period of fifteen-months storage in liquid nitrogen, SKMES-Txt were thawed 
and the resistance and cross-resistance measured for eight drugs as described in section 
2.8 . The toxicity assays were carried out on each of the eight drugs every week for at 
least six weeks after thawing.
Table 3.1.8 and Figures 3.1.7 and 3.1.8 demonstrate that SKMES-Txt has lost further 
resistance to all drugs tested when compared to pre-freezing and after one-month 
storage in liquid nitrogen (Tables 3.1.4 3.1.6). Taxotere and taxol resistance has fallen 
sharply with long-term storage in this cell line. The cell line after fifteen-months 
storage in liquid nitrogen is 5.9-fold and 4.4-fold resistant to taxotere at weeks 2 and 4 
compared to 29-fold and 16.6-fold at the same weeks after one-month storage in liquid 
nitrogen. There is a significant loss o f resistance to taxol, the cell line is now 10.6-fold 
resistant at week 2 (was 41.5-fold). This Figure drops to 5.3-fold at week 4 (was 25- 
fold). Resistance to both taxanes continued to fall at each subsequent week tested.
Stable but lower cross-resistance to 5-FU and vincristine developed (8 ± 0.6 and 3.4 ± 
0.5 fold respectively, values averaged over 6 weeks ± standard deviation). SKMES-Txt
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retained the same cross-resistance to VP-16 and adnamycin but resistance to both drugs 
decreases over the six weeks tested
Fold Resistance of SKMES-Txt
Drug Week 2 Week 3 Week 4 Week 5 Week 6
Taxotere 5 9 ± 0 2 4 6 ± 0 2 4 4 ± 0 1 2 7 ± 0 1 3 7 ± 0 2
Taxol 10 6 ± 0 6 9 4 ± 1 7 8 ± 0 1 5 3 ± 0 7 6 6 ± 0 7
5-FU 9 6 ± 0 4 7 7 ± 0 01 Not done 7 6 ± 0 06 8 7 ± 0 7
Adnamycin 4 3 ± 0 4 2 8 ± 0 1 4 6 ± 0 4 2 5 ± 0 06 2 9 ± 0 4
VCR 4 5 ± 0 6 3 1 ± 0 2 4 0 ± 0 7 3 0 ± 0 09 3 6 ± 0 1
VP-16 11 8 ± 0 9 7 4 5 ± 0 1 5 6 ± 0 2 3 9 ± 0 08 6 3 ± 0 1
Table 3 1 8 ^ fhe fold increase in resistance to chemotherapeutic drugs in SKMES-Txt with
respect to SKMES-1 after fifteen months storage in liquid nitrogen, as determined by comparing 
IC5o values The values are given as the average IC50 value ± the standard deviation on a 
minimum of three repeats
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Figure 3.1.7 Fold Resistance of SKMES-Txt to Taxol and Taxotere over 6 weeks after 15 
months in liquid nitrogen with respect to SKMES-1 as determined by comparing IC5o values.
4
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Figure 3.1.8 Fold Resistance of SKMES-Txt to 5-FU, adriamycin, VCR and VP-16 over 6 
weeks after 15 months in liquid nitrogen with respcct to SKMES-1, as determined by comparing 
IC5o values.
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3.1.2.5 Establishment of SKM ES-Txt(ll)
It was decided to attempt to further increase the resistance o f SKMES-Txt to taxotere. 
The cell line was cultured for seven weeks then exposed to 60ng/ml taxotere for four 
hours. The cell line was left to recover for one week. The cell line resulting from this 
exposure to taxotere was designated SKMES-Txt(l 1).
Table 3.1.9 and Figure 3.1.9 demonstrates the effect of an additional pulse o f taxotere 
on SKMES-Txt after seven weeks in culture. The pulse resulted in a cell line that is now 
169-fold resistant to taxotere and 41-fold cross-resistant to taxol.
Drug Week 4 Week 5 Week 6 Week 7 Week 7 pulse 11
Taxol 7.8 ±0.1 5.3 ±0 .7 6.6 ±0 .7 7.3 ±0.8 41.1 ± 1
Taxotere 4.4 ±0.1 2.7 ±0.1 3.7 ±0.2 3 ± 0 .2 169 ± 0 .0
Table 3.1.9: The fold increase in resistance to the taxanes after a pulse with taxotere at week 7 
in SKMES-Txt with respect to SKMES-1 after fifteen months storage in liquid nitrogen, as 
determined by comparing IC5o values. The values are given as the average IC50 value ± the 
standard deviation on a minimum of three repeats.
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Figure 3.1.9: Fold Resistance of SKMES-Txt(l 1) to taxol and taxotere with respect to SKMES- 
1, as determined by comparing IC5o values.
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3 1 3  Development of the taxol resistant variant of SKMES-1
SKMES-1 was also exposed to an IC90 (determined from a pulse selection in a 25 cm2 
flask) value of 120ng/ml of taxol for four hours, once a week for ten consecutive weeks 
(section 2 10) The cell line resulting from this exposure was designated SKMES-Txl 
Toxicity assays were performed after the cell line was frozen in liquid nitrogen for one- 
month and eight months (Table 3 110)
Toxicity assays were carried out at the following time points 
1 after one month in liquid nitrogen 
3 after eight months storage in liquid nitrogen (Table 3 13)
Cell Line Liquid Nitrogen Storage Time
SKMES-Txl
SKMES-Txl
One Month 
Eight Months
Table 3 1 10 Summary of SKMES-Txl selections
3.1 3 1 Morphology of the Taxol Variant of SKMES-1
The morphology o f SKMES-Txl was found to have changed during the selection 
procedure with taxol (Figures 3 1 10 and 3 111) The cell line (like the parent and 
SKMES-Txt) required cell-to-cell contact for growth Images were taken at 10X 
magnification
Figure 31 10 SKMES-1
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3.1 3.2 Resistance profiles of SKMES-Txl after one-month storage in liquid 
nitrogen
The resistance and cross-resistance profiles o f SKMES-Txl were determined for eight 
drugs using the long-term toxicity assay (section 2 8 1) The toxicity assays were carried 
out on each o f the eight drugs two, three and four weeks after the final 12ng/ml pulse 
with taxol Table 3 112 shows the fold resistance patterns o f SKMES-Txl to each o f the 
drugs after one-month storage in liquid nitrogen
SKMES-Txl developed high but unstable resistance to taxol with 72 9-fold resistance 
on week 2, which dropped to 12 9-fold 4 weeks after thawing (Table 3 112, Figure 
3 111) The results also demonstrate that SKMES-Txl developed unstable cross­
resistance to all other chemotherapy drugs tested Unusual cross-resistance to 5-FU 
(15 1-fold at week 2) developed while little cross-resistance to the platinum drugs is 
seen (Figure 3 113)
ICso values of SKMES-Txl (ng/ml)
Drug SKMES-1 Week 2 Week 3 Week 4
Taxotere 0 7 ± 0 06 21 8 ± 3  1 13 8 ±  1 8 6 9 ± 0  14
Taxol 1 2 ± 0  1 87 5 ± 1 0  6 72 5 ± 3 5 15 5 ± 0  56
Adnamycin 7 3 ± 0 4 29 2 ± 1 1 26 5 ± 2 6 8 95 ± 0 63
Carboplatin 4600 ± 200 6050 ±353 6500± 141 1500± 141
Cisplatin 671 7 ± 7 7  5 680 ± 99 1125 ±247 170 ± 14
5-FU 89 3 ± 6 6 1350 ± 212 730 ± 28 2 700 ± 14
Vincristine 3 8 ± 0 3 56 ± 8 4 52 5 ± 6 3 3 3 ± 0 3
VP-16 60 3 ± 1 9 720 ± 28 2 600± 127 410 ± 2 8  2
Table 3111 IC50 values for a range of chemotherapeutic drugs acting on the cell line SKMES- 
Txl after one-month storage in liquid nitrogen The values are given as the IC50 value from a 96 
well plate at each week Toxicity assays were earned out once for each drug at each week
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Drug SKMES-1 Week 2 Week 3 Week 4
Taxotere 1 31.1 19.7 9.8
Taxol 1 72.9 60.4 12.9
Adriamycin 1 4 3.6 1.2
Carboplatin 1 1.3 1.41 0.3
Cisplatin 1 1 1.67 0.25
5-FU 1 15.1 8.2 7.8
Vincristine 1 17.7 13.8 0.86
VP-16 1 11.9 9.9 6.8
Table 3.1.12: 1fhe fold increase in resistance to chemotherapeutic drugs in SKMES-Txl with
respect to SKMES-1 after one-month storage in liquid nitrogen, as determined by comparing 
IC50 values
2 3
Week Number
Figure 3.1.12 Fold Resistance of SKMES-Txt to taxol and taxotere with respect to SKMES-1, 
as determined by comparing IC50 values
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Week Number
■  Adriamycin
■  Carboplatin
□  Cisplatin
□  5-FU
■  VCR
□  VP-16
Figure 3.1.13 Fold Resistance of SKMES-Txt to adriamycin, carboplatin, cisplatin, 5-FU, VCR 
and VP« 16 s with respect to SKMES-1, as determined by comparing IC50 values
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3 1 3  3 Resistance profiles of SKMES-Txl after eight months storage m liquid 
nitrogen
After eight-months storage in liquid nitrogen the cells were again tested for resistance 
and cross-resistance to a range of chemotherapeutic drugs
Table 3 1 13 and Figures 3 1 14 and 3 115 demonstrate that SKMES-Txl has lost 
resistance to all drugs tested when compared to Tables 3 1 12 Taxotere and taxol 
resistance has fallen sharply with storage in this cell line The cell line is now 4 4-fold 
resistant to taxotere at week 2 (was 28 6-fold) and 3-fold at week 4 (was 9 7-fold) 
There is a significant loss o f resistance to taxol, the cell line is now 8-fold resistant at 
week 2 (was 76 7-fold) and 5 1-fold at week 4 (was 15 2) Resistance to both taxanes 
stabilises at from week 4 onwards
Stable but lower cross-resistance to 5-FU, adnamycin and VP-16 developed (7 8 ± 0 3, 
2 7 ± 0 4 and 4 5 ± 0 6-fold respectively, values averaged over 6 weeks ± standard 
deviation)
Fold Resistance of SKMES-Txl
Drug Week 2 Week 3 Week 4 W eekS Week 6
Taxol 8 ± 0 3 12 5 ± 0 1 5 1 ± 0 4 5 2 ± 0 3 5 8 ± 0 3
Taxotere 4 4 ± 0 2 6 7 ± 0 2 3 ± 0 1 2 3 ± 0 2 2 95 ± 0  14
Adnamycin 2 8 ± 0 1 2 3 ± 0 1 3 3 ± 0 1 2 4 ± 0 05 2 54 ± 0 04
5-FU 8 2 ± 0 1 7 5 ± 0 4
Not
determined 7 5 ± 0 1
7 8 ± 0 1
VCR 3 2 ± 0 1 5 6 ± 0 2 3 ± 0 2 2 8 ± 0 1 3 1 ±0 1
VP-16 5 1 ± 0 3 4 ± 0 1 4 6 ± 0 2 3 8 ± 0 05 4 9 ± 0 5
Table 3 1 13 The fold increase in resistance to chemotherapeutic drugs in SKMES-Txl with 
respect to SKMES-1 after eight-months storage in liquid nitrogen, as determined by comparing 
IC50 values, n=3
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Figure 3.1.14 Fold Resistance of SKMES-Txl to Taxol and Taxotere over 6 weeks with respect 
to SKMES-1, as determined by comparing IC50 values
Figure 3.1.15 Fold Resistance of SKMES-Txl to 5-FU, adriamycin, VCR and VP-16 over 6 
weeks with respect to SKMES-1, as determined by comparing IC50 values.
3.1 3 4 Establishment of SKM ES-Txl(ll)
In an attempt to further increase the resistance of SKMES-Txl to taxol, the cell line was 
cultured for seven weeks then exposed to 120ng/ml taxotere for four hours The cell line 
was left to recover for one week The cell line resulting from this exposure to taxol was 
designated SKMES-Txl(ll)
Table 3 114 demonstrates the effect o f an additional pulse o f taxol on SKMES-Txl after 
seven weeks in culture The pulse resulted in a cell line that is now 14 4-fold resistant 
and 4-fold cross-resistant to taxol and taxotere respectively at week 11 where it was 5- 
fold and 2 5-fold previously
Fold Resistance of SKMES-Txl
Drug Week 4 W eekS Week 6 Week 7 Week 7 pu lsell
Taxol 5 1 ± 0 4 5 2 ± 0 3 5 8 ± 0 3 5 ± 0 38 14 4 ± 1 6
Taxotere 3 ± 0 1 2 3 ± 0 2 2 95 ± 0  14 2 5 ± 0 1 4 ± 0 1
Table 3 1 1 4  The fold increase in resistance to the taxanes after a pulse with taxol at week 7 in 
SKMES-Txl with respect to SKMES-1 after eight months storage in liquid nitrogen, as 
determined by comparing IC50 values, n=3
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3 1 4  Establishment of carboplatm selected variants of SKMES-1
The sensitivity o f SKMES-1 to carboplatm necessitated two approaches to obtain pulse- 
selected variants In the first approach, as with other cell lines in this project, the 
SKMES-1 cell line was exposed to an IC90 value of 100 ng/ml carboplatm for four 
hours, once a week for four consecutive weeks (section 2 10) However, the fourth pulse 
resulted in almost total cell death The cells were left to recover to almost full 
confluency before being pulsed again Each o f the next four pulses resulted in almost 
total cell death so the cells were again left to recover after each pulse The final two 
pulses were consecutive (i e no longer than a week between pulses), as resistance to 
carboplatm had developed The cell line resulting from this exposure was designated 
SKMES-CptlOO
In the second approach, pulse selection was performed at an IC50 concentration 
(30^g/ml) The cell line could then be pulsed for four hours once a week for ten 
consecutive weeks similar to the regime used for other cell lines in this project The cell 
line resulting from this exposure was designated SKMES-Cpt30
3 1 4 1  Morphology of the carboplatm resistant variants of SKMES-1
The morphology o f SKMES-CptlOO was found to have changed during the selection 
procedure with carboplatm, these cells are bigger than the parent In contrast, selection 
with a lower concentration of carboplatm resulted in a cell line with smaller cells It was 
observed that this cell line (like the parent and the taxane-selected variants) also 
required cell-to-cell contact for growth as a high growth rate was seen with high cell 
density (Figures 3 1 16-18)
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Figure 3.1.16 SKMES-1 Figure 3.1.17 SKMES-Cpt30
3.1.4.2 Resistance profiles of platinum variants
The resistance and cross-resistance profiles were determined for eight drugs (Table 
3.1.15). The toxicity assays were carried out on the SKMES-CptlOO and SKMES-Cpt30 
variants to eight drugs each week for one month after the final lOOug/ml and 30ug/ml 
pulses with carboplatin. Table 3.1.16, Figure 3.1.19 show the fold resistance patterns of 
both variants to each of the drugs.
The toxicity profiles demonstrate that the carboplatin resistance o f both carboplatin 
variants was not significantly increased in comparison to the parental cell line, despite 
the fact that high cell kill was observed during selection with both concentrations o f  
carboplatin.
SKMES-CptlOO exhibited no cross-resistance to taxotere whereas SKMES-Cpt30 was 
2.5-fold resistant. SKMES-Cpt30 became sensitised to 5-FU (0.8-fold), vincristine (0.6- 
fold) and adriamycin (0.3-fold). SKMES-CptlOO developed 5.2-fold resistance to 5-FU. 
Both cell lines showed similarly low levels of cross-resistance to cisplatin and VP-16.
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Drug SKMES-1(ng/ml) SKMES-CptlOO (ng/ml) SKMES-Cpt30 (ng/ml)
Taxotere 0 7 ± 0 06 0 6 ± 0 1 1 8 ± 0 2
Taxol 2 ± 0  2 4 ± 0 2 4 4 ± 0 2
Adriamycin 7 3 ± 0 4 6 5 ± 0 9 2 1 ± 0 3
Carboplatin 4596 7 ±150 9233 3 ± 896 3 5333 3 ± 642 9
Cisplatm 671 9 ± 77  5 1165 ± 7 4  7 1036 ±31 6
5-FU 89 3 ± 6 6 466 7 ± 75 7 73 3 ± 11 5
Vincristine 3 8 ± 0 3 1 8 ± 0 2 2 4 ± 0 1
VP-16 60 3 ± 1 9 128 3 ±17 6 141 ± 7  9
Table 3 1 15 IC50 values for a range of chemotherapeutic drugs acting on the squamous lung 
carcinoma cell lines SKMES-1, SKMES-C100 and SKMES-C30 The values are given as the 
average IC5o value ± the standard deviation on a minimum of three repeats
Drug SKMES-CptlOO P value SKMES-Cpt30 P value
Taxotere 0 8 0 001 2 5 0 004
Taxol 3 2 0 06 3 6 0 001
Adriamycin 0 9 0 008 03 0 000
Carboplatin 2 0 005 1 2 0 18
Cisplatm 1 7 0 079 1 5 0 007
5-FU 5 2 0011 0 8 0 124
Vincristine 0 5 0 036 0 6 0 005
VP-16 2 1 0 343 2 3 0 002
Table 3 116 The fold increase in resistance to chemotherapeutic drugs of SKMES-CptlOO and 
SKMES-Cpt30 with respect to SKMES-1, as determined by comparing IC50 values
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3 1.5 Development of the DLRP-Cpt and DLRP-Txt selected variants
The DLRP squamous cell line (developed in this laboratory) proved to be highly 
sensitive to carboplatin drug treatment Pulse selection at an IC90 value o f lOOug/ml 
carboplatin for four hours, once a week for 4 consecutive weeks resulted in total cell 
death (section 2 10) It was therefore decided to reduce the carboplatin pulse 
concentration to an IC50 level (50 fig/ml) The result was total cell death at pulse 4 
Subsequently, the cell line was pulsed with 15 ng/ml (IC10) of carboplatin All pulses at 
this concentration resulted in high cell kill so the cells were allowed to recover after 
each pulse The cell line resulting from this exposure was designated DLRP-Cpt
Similarly to the DLRP carboplatin selections, DLRP proved to be highly sensitive to 
taxotere drug treatment Pulse selection at an IC90 value o f 60ng/ml o f taxotere for four 
hours, once a week for 4 consecutive weeks resulted in total cell death The taxotere 
concentration had to be reduced to 5 ng/ml All pulses at this concentration resulted in 
high cell kill so the cells were allowed to recover after each pulse The cell line resulting 
from this exposure to taxotere was designated DLRP-Txt
3 1 5 1  Morphology of the taxotere and carboplatin selected variants of DLRP
The morphology o f DLRP-Txt and DLRP-Cpt cell lines were found to have changed 
during the selection procedure with both drugs The cells have rounded up and almost 
lost their dendritic-like appearance in both cases The two cell lines required increased 
cell-to-cell contact for growth in comparison to the parent (which also required it) but to 
a lesser degree As a result o f drug treatment both cell lines developed sensitivity to 
trypsin and also required their own conditioned media for growth (Figures 3 1 20-22)
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3 1 5  2 Resistance profiles of DLRP selections
The resistance and cross-resistance profiles were determined in triplicate for eight drugs 
using the long-term toxicity assay
The results demonstrate that no resistance to carboplatin developed in DLRP-Cpt 
despite the fact that high cell kill was observed during selection process (Table 3 117- 
18, Figure 3 1 23) Cross-resistance to VP-16 and taxotere was observed (1 2-fold and
4 6-fold respectively) Interestingly, the cell line became sensitised to adriamycin (0 5- 
fold) and to cisplatin (0 8-fold) and 5-FU (0 9-fold) to a lesser degree
DLRP-Txt developed low but statistically significant resistance to taxotere (4 4-fold) 
This cell line also developed cross-resistance to adriamycin (2 7-fold) and to a lesser 
degree carboplatin, 5-FU, vincristine and VP-16 (1 2-fold, 1 3-fold, 1 5-fold, 1 4-fold 
and 1 2-fold respectively)
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Drug DLRP (ng/ml) DLRP-Cpt (ng/ml) DLRP-Txt (ng/ml)
Taxotere 0 7 ± 0 1 3 2 ± 0 2 3 1 ± 0 4
Taxol 9 ± 0 9 8 7 ± 0 9 11 1 ± 1
Adriamycm 40 7 ± 3 1 21 8 ± 1 8 108 3 ± 7 6
Carboplatm 3500 ± 360 6 3500 ± 300 4633 3 ±152  8
Cisplatin 223 ±21 4 174 7 ± 25 198 3 ± 2  9
5-FU 1250 ± 132 3 1150±50 , 1933 3 ±230  9
Vincristine 3 3 ± 0 2 3 9 ± 0 5 4 7 ± 0 7
VP-16 438 3 ± 40 7 526 7 ± 25 2 533 3 ± 70 2
Table 3 1 1 7  IC50 values for a range of chemotherapeutic drugs acting on the squamous lung 
carcinoma cell lines DLRP, DLRP-Cpt and DLRP-Txt The values are given as the average 
IC50 value ± the standard deviation on a minimum of three repeats
Drug DLRP-Cpt P value DLRP-Txt P value
Taxotere 4 6 0 001 4 4 0 008
Taxol 1 0 0 698 1 2 0 051
Adriamycm 0 5 0 002 2 7 0 001
Carboplatm 1 0 1 00 1 3 0 02
Cisplatin 0 8 0 065 0 9 0 182
5-FU 0 9 0 321 1 5 0 019
Vincristine 1 2 0 147 1 4 0 052
VP-16 1 2 0 043 1 2 0 132
Table 3 1 18 The fold increase in resistance to chemotherapeutic drugs of DLRP-Cpt and 
DLRP-Txt with respect to DLRP, as determined by comparing IC50 values
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Figure 3.1.23 Resistance Profiles of DLRP Selections
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3 1 6  Establishment of taxane and carboplatin selected variants of the small cell 
lung carcinoma cell line DMS-53
The DMS-53 cell line was exposed to an IC90 value of 40 ng/ml o f taxotere and an IC90 
value of 60 ng/ml of taxol respectively The cell line was pulsed for four hours, once a 
week for 10 consecutive weeks with both drugs individually (section 2 10) The cell 
lines resulting from the taxane exposures were designated DMS-Txt and DMS-Txl 
respectively
The DMS-53 cell line was also exposed to an IC90 value o f 5ug/ml o f Carboplatin The 
cell line was pulsed for four hours, once a week for 10 consecutive weeks The cell lines 
resulting from the carboplatin exposure was designated DMS-Cpt
3 1 6  1 Morphology of the taxane and carboplatin resistant variants of DMS-53
The morphologies o f the three MDR variants o f DMS-53 appeared to change during the 
selection procedure with carboplatin, taxotere and taxol When trypsimsed, DMS-53 
forms spheroids if  agitated too severely The three drug selected variants retain this 
ability If these spheroids are broken into single cells and placed in a fresh flask, they 
will attach and grow as a monolayer (Figures 3 1 24-27)
The two taxane-selected variants have gained the ability to overcome contact inhibition, 
1 e they grow on top of each other Cells maintained viability in suspension (if reseeded 
in a new flask, they would re-attach and grow)
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Figure 3.1.26 DMS-Cpt Figure 3.1.27 DMS-Txl
3.1.6.2 Resistance profiles of drug selected variants
The resistance and cross-resistance profiles were determined for eight drugs using the 
long-term toxicity assay (Table 3.1.19). The toxicity assays were carried out on each of  
the eight drugs each week for at least one month after the final pulses with carboplatin, 
taxotere and taxol. Table 3.1.20 shows the fold resistance patterns of both variants to 
each of the drugs.
Table 3.1.20 and Figure 3.1.28 represents the fold increase in resistance of DMS-Cpt, 
DMS-Txt and DMS-Txl with respect to DMS-53. The results demonstrate that DMS- 
Cpt only developed 1.6-fold resistance to carboplatin despite the fact that high cell kill 
was observed during the selection process. The cell line also developed 2.1-fold, 1.4- 
fold and 1.4-fold cross-resistance to cisplatin, adriamycin and taxol respectively. 
However, DMS-Cpt became sensitised to taxotere (0 5-fold) and vincristine (0.8-fold). 
Moreover, cross-resistance to VP-16 and 5-FU was not significantly increased in 
comparison to the parental cell line.
I l l
DMS-Txt developed low but statistically significant stable resistance to taxotere, taxol, 
adriamycin, vincristine and cisplatin (1 8-fold, 5 9-fold, 1 3-fold, 1 6-fold and 1 4-fold 
respectively) No change in resistance to carboplatin, 5-FU or VP-16 was observed
DMS-Txl developed low but statistically significant resistance to taxol, adriamycin, 
vincristine and carboplatin (6 3-fold, 1 6-fold, 3 3-fold and 1 2-fold respectively) No 
change m resistance was observed to 5-FU, cisplatin, taxotere or VP-16
Drug
DMS-53
(ng/ml)
DMS-Cpt
(ng/ml)
DMS-Txt
(ng/ml)
DMS-Txl
(ng/ml)
Taxotere 8 2 ± 0 3 3 8 ± 0 4 14 6 ± 2 2 8 8 ± 1 5
Taxol 129 ± 1 3 187 ± 2 5 75 7 ± 4 81 ± 2 5
Adriamycin 15 ± 1 7 20 3 ± 3 1 19 5 ± 0 9 24 ± 2  5
Carboplatin 1200± 100 1840 ± 5 2  9 1210 ± 17  3 1406 7 ± 100 7
Cisplatin 151 7 ±  126 324 ± 46 8 210 ± 2 6  5 148 3 ± 12 6
5-FU 733 3 ± 57 7 863 ± 118 5 723 3 ± 75 1 7 6 0 ± 121 7
Vincristine 8 5 ± 0 9 6 6  ± 0 8 13 7 ± 1 3 28 3 ± 1 5
VP-16 295 ± 22 9 321 7 ± 4 0  7 334 3 ± 3 4  3 271 1 ± 12 6
Table 3 1 19 IC50 values for a range of chemotherapeutic drugs acting on the small cell lung 
carcinoma cell lines DMS-53, DMS-Cpt, DMS-Txt and DMS-Txl The values are given as the 
average IC5o value ± the standard deviation on a minimum of three repeats
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Drug DMS-Cpt P value DMS-Txt P value DMS-Txl P value
Taxotere 0.5 0.000 1.8 0.034 1.1 0.528
Taxol 1.4 0.04 5.9 0.001 6.3 0.002
Adriamycin 1.4 0.079 1.3 0.029 1.6 0.003
Carboplatin 1.6 0.000 1.0 0.323 1.2 0.034
Cisplatin 2.1 0.018 1.4 0.034 1.0 0.762
5-FU 1.2 0.189 1.0 0.864 1.0 0.755
Vincristine 0.8 0.49 1.6 0.005 3.3 0.000
VP-16 1.1 0.393 1.1 0.184 0.9 0.217
Table 3.1.20: The fold increase in resistance to chemotherapeutic drugs of DMS-Cpt, DMS-Txt 
and DMS-Txl with respect to DMS-53, as determined by comparing IC50 values.
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Figure 3.1.28 Resistance profiles of DMS-53 selections
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3.1.7 Development of the NCI-H69 VP-16 and carboplatin selected variants
The NCI-H69 cell line was exposed to IC90 concentration o f 480 ng/ml o f VP-16. The 
cell line was also exposed to IC90 and IC50 values of 10 ug/ml and 5 ug/ml of carboplatin 
respectively. The cell line was pulsed for four hours, once a week for 10 consecutive 
weeks with all concentrations of both drugs individually (section 2.10). The cell line 
resulting from the VP-16 exposures was designated H69-VP480. The cell lines resulting 
from the carboplatin exposures were designated H69-Cptl0 and H69-Cpt5.
3.1.7.1 Morphology of the VP-16 and carboplatin resistant variants of NCI-H69
The morphology o f NCI-H69 variants was not found to have changed during the 
selection procedure with carboplatin and VP-16 (Figure 3 .1.29).
Figure 3.1.29 Morphology of NCI-H69
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3 1 7  2 Resistance profiles of drug selected variants
The resistance and cross-resistance profiles were determined for eight drugs using the 
long-term toxicity assay (Table 3 121 and 3 1 22) The toxicity assays were carried out 
on each o f the eight drugs each week for one month after the final pulses with 
carboplatin and VP-16 (section 2 8 2)
Table 3 1 23 and Figure 3 131 represent the fold resistance values o f each of the 
chemotherapeutic agents for the parental NCI-H69 cell line and its VP-16 and 
carboplatin selected variants H69-VP480, H69-Cptl0 and H69-Cpt5 The results 
demonstrate that the VP-16 resistant variant developed 2 9-fold resistance to VP-16 and 
exhibited cross resistance to carboplatin (1 6-fold), cisplatin (1 2-fold), taxotere (2 4- 
fold) and 5-FU (3 9-fold) The cell line became sensitised to taxol (0 3-fold resistant), 
adriamycin (0 4-fold resistant) and vincristine (0 8-fold resistant)
The results also reveal that although pulsed with half the concentration of carboplatin, 
the H69-Cpt5 variant developed higher resistance and cross-resistance to carboplatin 
(2 2-fold), 5-FU (8 6-fold) and VP-16 (2 fold) In contrast, H69-Cptl0 developed higher 
cross-resistance to taxotere (5 4-fold) and cisplatin (3-fold) Interestingly both platinum- 
resistant variants became sensitised to the same drugs namely, taxol, adriamycin and 
vincristine
Drug NCI-H69 (ng/ml) H69-VP480 (ng/ml)
Taxotere 0 23 ± 0 03 0 6 ± 0 1
Taxol 13 3 ± 2 3 4 3 ± 0 7
Adriamycin 42 3 ± 6 4 17 ± 1 8
Carboplatin 740 ± 112 7 1206 7 ± 11 5
Cisplatin 110 ± 20 138 7 ± 5  5
5-FU 90 ± 10 353 3 ± 2 0  8
Vincristine 3 9 ± 0 3 3 3 ± 0 4
VP-16 72 ± 2 306 7 ± 38  8
Table 3 1 21 IC50 values for a range of chemotherapeutic acting on the small cell lung 
carcinoma cell line NCI-H69 and the VP-16 resistant variant The values are given as the 
average IC50 value ± the standard deviation on a minimum of three repeats
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Drug NCI-H69 (ng/ml) H69-Cptl0 (ng/ml) H69-Cpt5 (ng/ml)
Taxotere 0 23 ± 0 03 1 3 ± 0 2 0 6 ± 0 1
Taxol 13 3 ± 2  3 4 2 ± 0 5 5 9 ± 1 7
Adriamycin 42 3 ± 6 4 19 1 ± 0 8 20 7 ± 2 4
Carboplatin 740± 112 7 1166 7 ± 57 7 1600 ± 173 2
Cisplatin 110 ± 20 355 ± 4 7  7 259 7 ± 31
5-FU 90 ± 10 760 ± 36 1 773 3 ± 97 1
Vincristine 3 9 ± 0 3 0 7 ± 0 1 3 6 ± 0 2
VP-16 72 ± 2 75 7 ± 7 5 144 ± 12 3
carcinoma cell line NCI-H69 and the carboplatin resistant variants The values are given as the 
average IC50 value ± the standard deviation on a minimum of three repeats
Drug H69-VP480 P value H69-Cptl0 P value H69-Cpt5 P value
Taxotere 2 4 0 022 5 4 0 006 2 4 0 004
Taxol 03 0 014 03 0 016 0 4 0 012
Adriamycin 0 4 0 016 0 5 0 023 0 5 0 018
Carboplatin 1 6 0 18 1 6 0 01 2 2 0 003
Cisplatin 1 2 0 243 3 0 0 006 22 0 005
5-FU 3 9 0 000 8 4 0 000 86 0 006
Vincristine 0 8 0 114 0 2 0 001 0 9 0 189
VP-16 2 9 0 026 1 1 0 49 20 0 008
Table 3 1 23 The fold increase in resistance to chemotherapeutic drugs in H69-VP480, H69- 
CptlO and H60-Cpt5 with respect to NC1-H69, as determined by comparing IC50 values
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Invasion assays were performed, as described in Section 2 11, to assess the ability o f  
each of the following four cell lines SKMES-1, DLRP, NCI-H69 and DMS-53 and their 
drug selected variants to invade through matngel Cell culture inserts were coated with 
matngel and placed in medium containing 24-well plates prior to cell addition Cells 
were considered invasive if  they migrated through the matngel and the 8 |iM porous 
membrane and attached to the underside o f the membrane within 24 hours The nasal 
carcinoma cell lines RPMI-2650 and its melphalan-selected variant RPMI-Melphalan 
were used as negative and positive controls respectively The images presented are 
representative o f at least three separate experiments, are at a magnification of 10X and 
are stained with crystal violet
3 2 1 Invasion potential of SKMES-1 and MDR variants
The ability o f SKMES-1, both the taxane and the carboplatin-selected variants to invade 
through matngel was assessed in a 24-hour invasion assay The SKMES-1 parental cell 
line is highly invasive (Figure 3 2 1) Increased invasion was observed in the taxane- 
selected variants, SKMES-Txt (Figure 3 2 2) and SKMES-Txl (Figure 3 2 3) compared 
with the parent SKMES-CptlOO is more invasive than the parent (Figure 3 2 5) By 
contrast, SKMES-Cpt30 is less invasive i e fewer cells attached to the underside of the 
membrane, compared with the parental cell line (Figure 3 2 4) A change in morphology 
as a result o f the selection process is seen in SKMES-Txt and SKMES-CptlOO 
compared to the parent (Figures 3 2 2 and 3 2 5)
3 2 Analysis of multidrug resistant variants using in vitro invasion assays
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Figure 3.2.1
Figure 3.2.2
Figure 3.2.3
Invasion of SKMES-1
Invasion of SKMES-Txt
Invasion of SKMES-Txl
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Figure 3.2.4
Figure 3.2.5
Invasion of SKMES-Cpt30
Invasion of SKMES-CptlOO
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3.2.2 Quantification of invasion
The invasion assays were quantified by counting cells with a graticule at 40X 
magnification (Table 3.2.1, Figure 3.2.6). The data shows that selection o f SKMES-1 
with lower levels o f carboplatin results in a less invasive cell line. By contrast, the 
taxane drugs and the higher carboplatin pulse produces more invasive cell lines. Table
3.2.2 and Figure 3.2.7 demonstrates that both taxane variants become more invasive 
with time.
Cell Line Average cell count/area/view P value
SKMES-1 8.2 ± 1.03 -
SKMES-C30 2.5 ±0.25 0.008
SKMES-C100 11.5 ± 1.5 0.04
SKMES-Txt 17.8 ±0.58 0.0005
SKMES-Txl 11 ±0.64 0.015
Table 3.2.1 Quantification of SKMES-1 and pulse-selected variants
The values are given as the average cell counts/area/view ± the standard deviation on a 
minimum of three repeats.
SKMES-1
Cell Line
Figure 3.2.6 Quantification of SKMES-1 and pulse selected variants
1 2 1
Due to the unstable nature of both SKMES-Txt and SKMES-Txl variants, their invasiveness 
was assessed at both weeks 2 and 7 where decreasing drug resistance was observed.
Drug selection with taxotere and taxol appears to induce invasion compared to the 
control (2.17-fold and 1.34-fold respectively). However, at week 7 when drug resistance 
has fallen by 2.2-fold in both cell lines (to their selecting drug), the taxol-selected 
variant was 5-fold more invasive than the control whereas the invasive potential o f the 
selected variant has only increased by 3.3-fold (Table 3.2.2 and Figure 3.2.7).
Average cell count/area/view P value
Cell Line Week 2 Week 7 Week 7
SKMES-1 8.2 ± 1.03* -
SKMES-Txt 17.8 ±0.58 27 ± 1.4 1 * lO-4
SKMES-Txl 11 ±0.64 41.3 ± 2.17 0.0002
Table 3.2.2 Quantification of SKMES-1 and taxane-selected variants
The values are given as the average cell counts/area/view ± the standard deviation on a 
minimum of three repeats. # The invasiveness of the SKMES-1 cell line was assessed over one- 
month; the value given is the average cell counts/area/view ± the standard deviation over this 
time on a minimum of four repeats.
SKMES-1 SKMES-Txt SKMES-Txl
Cell Line
■ Week 2
■ Week 7
Figure 3.2.7 Quantification of invasion in SKMES-1 and taxane-selected variants
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3.2.3 Invasion potential of SKMES-1 and SKMES-TaxoI in collagen Type I
Invasion assays were also carried out whereby cells were induced to grow as spheroids 
using the hanging droplet technique with subsequent growing in a petri dish o f media 
for a total four days (section 2.11.1). The spheroids were then transferred to a well o f a 
24-well plate coated in collagen type I. The invasion through the collagen was measured 
using a graticule at 20X magnification. Images were taken at 4X magnification.
The results reveal that both SKMES-1 and the taxane variants are invasive after 24 
hours in collagen type I (Figures 3.2.8-13). However, the taxol and taxotere variants are 
less invasive than the parent over seven days (Table 3.2.3 and Figure 3.2.14).
Figure 3.2.8 SKMES-1 day 1 Figure 3.2.9 SKMES-1 day 3
Figure 3.2.10 SKMES-Txl day 1 Figure 3.2.11 SKMES-Txl day 3
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Figure 3.2.12 SKMES-Txt day 1 Figure 3.2.13 SKMES-Txt day 3
Invasion Through Collagen Type I (^Meters)
Day SKMES-1 SKMES-Txt SKMES-Txl
2 113 ± 8 64 ± 4 45 ± 6
3 139± 15 75 ±  11 60 ± 8
4 159 ± 11 79 ±  10 68 ± 3
5 186 ± 8 105 ± 8 83 ± 4
7 246 ± 16 126 ± 3 109 ± 8
Table 3.2.3 Quantification of invasion of SKMES-1 and taxane variants in collagen type I. 
Values are given as the average invasion (at 20X magnification) in micrometers ± the standard 
deviation on four repeats.
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Figure 3.2.14 Quantification of invasion of SKMES-1 and taxane variants in collagen type I 
3.2.4 Invasion potential of DLRP and MDR variants
The ability o f DLRP and its taxotere and carboplatin selected variants to invade through 
matrigel was assessed in a 24-hour assay. DLRP, DLRP-Cpt and DLRP-Txt display 
varying levels of invasion at 10X magnification (Figure 3.2.15, 3.2.16 and 3.2.17). Both 
drug-selected variants (DLRP-Cpt and DLRP-Txt) are highly invasive. The invasion 
assays were quantified by counting at 40X magnification. The data shows that selection 
with carboplatin had no effect on invasion. However, selection with taxotere resulted in 
a slightly more invasive cell line (1.3-fold compared to the control) (Figure 3.2.18 and 
Table 3.2.4).
Figure 3.2.15 Invasion of DLRP
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Figure 3.2.16 Invasion of DLRP-Cpt
Figure 3.2.17 Invasion of DLRP-Txt
Cell Line Average cell count/area/view P value
DLRJP 11.7 d= 1.2 -
DLRP-Cpt 11.4 ± 1.2 0.47
DLRP-Txt 15.4 ±0.2 0.007
Table 3.2.4 Quantification o1f invasion of DLRP and pulse selected variants
The values are given as the average cell counts/area/view ± the standard deviation on a 
minimum of three repeats.
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Figure 3.2.18 Quantification of invasion of DLRP and pulse selected variants
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3.2.6 Invasion potential of DMS-53 and MDR variants
The DMS-53 small cell lung cell line is non-invasive after 24 hours (Figure 3.2.19). 
Pulse selection of DMS-53 with taxotere, taxol and carboplatin, showed no change in 
invasion potential at 24 hours. DMS-53 and variants were also non-invasive after 48 
and 72 hours. Invasion assays were carried out in triplicate at each time point.
Figure 3.2.19 DMS-53
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3.2.7 Invasion potential of DMS-53 and drug selected variants in collagen Type I
To assess this lack o f invasion further, additional invasion assays were carried out as 
described in section 2.11.1 whereby cells were induced to grow as spheroids and placed 
in collagen type I. In all cases no invasion was observed after 10 days in collagen type I 
(Figures 3.2.20 -  3.2.23). Invasion assays were carried out in triplicate.
Figure 3.2.20 DMS-53 Figure 3.2.21 DMS-Txl
Figure 3.2.22 DMS-Txt Figure 3.2.23 DMS-Cpt
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3.2.8 Invasion potential of DMS-53 and drug selected variants in matrigel
To assess this further, additional invasion assays were carried out as described in 
section 2.11.1 whereby cells were induced to grow as spheroids and placed in matrigel. 
In all cases no invasion was observed after 10 days in matrigel (Figures 3.2.24 -
3.2.27). Invasion assays were carried out in triplicate.
Figure 3.2.24 DMS-53 Figure 3.2.25 DMS-Txl
Figure 3.2.26 DMS-Txt Figure 3.2.27 DMS-Cpt
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3.2.9 Invasion potential of NCI-H69 and MDR variants
NCI-H69 small cell lung cell line is non-invasive after 24 hours in matrigel (Figure
3.2.28). Pulse selection o f H69 with VP-16 and carboplatin, showed no change in 
invasion potential after 24 hours and 48 hours. Invasion assays were carried out in 
triplicate at each time point.
Figure 3.2.28 NCI-H69
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3.2.10 Invasion potential of NCI-H69 and drug selected variants in collagen Type I
Invasion assays were also carried out whereby cells were induced to grow as spheroids 
using the hanging droplet technique with subsequent growing in a petri dish o f media 
for a total four days (section 2.11.1). The spheroids were then transferred to a 24-well 
plate coated in collagen type I. Results revealed that the NCI-H69 cell line and all the 
pulse selected variants are non-invasive after 10 days in collagen type I (Figures 3.2.29- 
3.2.32). Invasion assays were carried out in triplicate.
Figure 3.2.29 NCI-H69 Figure 3.2.30 H69-Cptl00
Figure 3.2.31 H69-Cpt5 Figure 3.2.32 H69-VP480
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3.2.11 Invasion potential of NCI-H69 and drug selected variants in matrigel
Spheroids were also transferred to a 24-well plate coated in matrigel. Results revealed 
that the NCI-H69 cell line and all the MDR variants are also non-invasive after 10 days 
in matrigel (Figures 3.2.33-3.2.36). Invasion assays were carried out in triplicate.
Figure 3.2.35 H69-Cpt5 Figure 3.2.36 H69-VP480
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3.2.12 Analysis of drug resistant variants using in vitro motility assays
Motility assays were carried out as described in section 2.12 to compare the locomotive 
ability o f the four parental cell lines (SKMES-1, DLRP, NCI-H69 and DMS-53) and 
their drug selected variants. The procedure used to demonstrate cell motility was similar 
to that used for the invasion assays except that the inserts were not coated with ECM 
prior to the addition o f the cells. Cells were considered motile if they migrated through 
the 8 (iM porous membrane and attached to the underside within 24 hours. The images 
presented are representative of at least three separate experiments, are at a magnification 
at 10X and stained with crystal violet.
3.2.13 Motility of SKMES-1 and MDR variants
The motility o f SKMES-1 and SKMES-CptlOO was assessed in a 24-hour motility 
assay. The results obtained demonstrate that the highly invasive cell line SKMES- 
CptlOO is more motile that SKMES-1 (Figures 3.2.37 and 3.2.38).
Figure 3.2.37 Motility of SKMES-1
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Figure 3.2.39 Motility o f SKMES-Cpt30
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3.2.14 Quantification of motility assays
The motility assays were quantified by counting cells using a graticule at 40X 
magnification (Table 3.2.5, Figure 3.2.40). The data shows that selection o f SKMES-1 
with higher levels o f carboplatin has no significant effect on motility whereas pulse 
selection with lower levels o f carboplatin results in a less motile cell line.
Cell Line Average cell count/area/view P Value
SKMES-1 26.2 ± 1.1 -
SKMES-C30 17.33 ±1.73 0.0006
SKMES-C100 28.2 ±1.1 0.09
Table 3.2.5 Quantification of motility of SKMES-1 and pulse selected variants
The values are given as the average cell counts/area/view ± the standard deviation on a
minimum of three repeats.
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Figure 3.2.40 Quantification of motility of SKMES-1 and pulse selected variants
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3.2.15 Motility of DLRP and MDR variants
The motility of DLRP and both drug selected variants DLRP-Cpt and DLRP-Txt were 
assessed in a 24-hour motility assay. The results obtained demonstrate that there is little 
change in the motility of the three cell lines (Figures 3.2.41 - 3.2.43).
Figure 3.2.41 Motility of DLRP
Figure 3.2.42 Motility of DLRP-Cpt
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Figure
3.2.16 Quantification of motility assays
The motility assays were quantified by counting cells using a graticule at 40X 
magnification (Table 3.2.6, Figure 3.2.44). The data shows that selection of DLRP with 
taxotere and carboplatin had no significant effect on motility.
Cell Line Average cell count/area/view P value
DLRP 18.1 ± 1.3 -
DLRP-Cpt 19.1 ± 1.0 0.005
DLRP-Txt 17 ± 0.5 0.31
Table 3.2.6 Quantification of motility of DLRP and pulse se ected variants
The values are given as the average cell counts/area/view ± the standard deviation on a 
minimum of three repeats.
3.2.43 Motility of DLRP-Txt
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DLRP-Cpt 
Cell Line
DLRP-TxtDLRP
Figure 3.2.44 Quantification of motility of DLRP and pulse selected variants
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To analyse the adhesiveness of the four parental cell lines to matngel (SKMES-1, 
DLRP, NCI-H69 and DMS-53) and their drug selected variants to matngel adhesion 
assays were carried out as described in section 2 113 The adhesion assays presented are 
representative of three separate experiments
3.2 18 Adhesion of SKMES-1 and MDR variants
Table 3 2 7, Figures 3 2 45 and 3 2 46 show the levels of adhesion of SKMES-1 and the 
taxane- and carboplatin-selected variants (after two and seven weeks culture) to
j
matngel after 1 hour SKMES-Txt is more adhesive to matngel than either the parent or 
taxol-selected variant The taxol-selected variant is less adhesive than the parent Loss 
of adhesion is seen in both taxane cell lines with respect to time SKMES-Txt is 2 45- 
fold less adhesive at week 7 compared to week 2 SKMES-Txl is also less adhesive at 
week 7 compared to week 2, revealing that loss of adhesion to matngel is greater in the 
taxotere-selected variant than in taxol-selected variant
3 2 17 Analysis of drug resistant variants using in vitro adhesion assays
Fold Adhesion
Cell Line Week 2 P value Week 7 P value
SKMES-1 1 ± 0  09
SKMES-Txt 3 85 ± 0 29 0 001 1 4 ± 0  13 0 01
SKMES-Txl 0 83 ± 0 08 0 1 0 44 ± 0 05 0 002
SKMES-CptlOO 2 51 ± 0  14 0 0002 - -
SKMES-Cpt30 1 21 ± 0  35 0 4 - -
Table 3 2 7 Quantification of adhesion of SKMES-1 anc drug selected vanants
The values are given as the fold adhesion compared to the parental cell line ± the standard 
deviation on a minimum of three repeats
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SKMES-1 SKMES-Txt SKMES-Txl
Cell Line
Figure 3.2.45 Quantification of adhesiveness of SKMES-1 and taxane selected variants to 
matrigel
SKMES-1 SKMES-Cpt100 SKMES-Cpt30
C e ll L in e
Figure 3.2.46 Quantification of adhesiveness of SKMES-1 and carboplatin selected variants to 
matrigel
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Table 3.2.8 and Figure 3.2.47 show the adhesiveness of DLRP and pulse-selected 
variants to matrigei after 1 hour. Both DLRP-Cpt and DLRP-Txt are less adhesive to 
matrigel in comparison to the parent with DLRP-Cpt being statistically the least 
adhesive of the three.
3.2.19 Adhesion of DLRP and MDR variants
Cell Line Fold Adhesion P value
DLRP 1 ± 0.023 -
DLRP-Txt 0.91 ±0.125 0.006
DLRP-Cpt 0.62 ±0.05 0.02
Table 3.2.8 Quantification of adhesion of DLRP and selected variants to matrigel
The values are given as the fold adhesion to matrigel relative to the parental cell line ± the
standard deviation on a minimum of three repeats.
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Figure 3.2.47 Quantification of adhesiveness of DLRP and pulse selected variants
DLRP DLRP-Txt DLRP-Cpt
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Table 3.2.9 and Figure 3.2.48 show no change in the adhesiveness of the non-invasive 
cell line DMS-53 and pulse selected variants to matrigel after 1 hour.
3.2.20 Adhesion of DMS-53 and MDR variants
Cell Line Fold Adhesion P value
DMS-53 1± 0.092 -
DMS-Cpt 0.95 ± 0.15 0.7
DMS-Txl 1.03 ±0.12 0.8
DMS-Txt 0.99 ± 0.09 0.3
Table 3.2.9 Quantification of adhesion of DMS-53 and selected variants to matrigel 
The values are given as the fold adhesion to matrigel relative to the parental cell line ± the 
standard deviation on a minimum of three repeats.
D M S-53 DM S-Cpt DMS-Txl DM S-Txt
C e ll L ine
Figure 3.2.48 Quantification of adhesiveness of DMS-53 and pulse selected variants
143
3.2.21 Expression of gelatin degrading proteases from SKMES-1, DLRP and their 
MDR variants
Matrix metalloproteinases (MMPs), cysteine proteinases and serine proteineases are 
secreted by cells. They play an important role in degrading the extracellular matrix. To 
investigate the mechanism underlying the invasive phenotype of the two squamous cell 
lines and their drug-selected variants, studies of the proteineases were carried out as 
described in section 2.11.4.
The RPMI-Melphalan, DLKP and RPMI-2650 cell lines, which secrete MMP-2 
(66kDa), MMP-9 (86kDa), and serine proteinases respectively, were used as positive 
controls in these studies. A band corresponding to MMP-9 is visible in all cell lines 
tested. A band corresponding to MMP-2 is apparent in all cell lines except DLRP-Cpt. 
SKMES-1 and both carboplatin-selected variants secrete proteinases, which are not 
MMPs (Figure 3.2.49).
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Figure 3.2.49 Zymograph of the proteinases in SKMES-1, DLRP and corresponding drug 
resistant variants. Lanes 1-12 = markers, SKMES-1, SKMES-Txt, SKMES-Txl, SKMES-Cpt30, 
SKMES-CptlOO, DLRP, DLRP-Cpt, DLRP-Txt, RPMI-2650, RPMI-melphalan and DLKP. 
Zympgraphy was carried out in triplicate and results were consistent.
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3.2.22 Investigation with type of gelatin degrading protease from SKMES-I, DLRP 
and MDR variants
To confirm that the bands detected in Figure 3.2.50 were MMP-2 and MMP-9 and also 
to determine if the bands secreted by SKMES-1, SKMES-Cpt30 and SKMES-100 were 
MMPs, the inhibitor EDTA was added.
3.2.22.1 The effect of EDTA
EDTA is a chelating agent, which can bind zinc and calcium needed for the activation 
of MMPs. To confirm that the bands are MMPs, proteinase inhibitors were added to 
inactivate their corresponding substrates. After the gel was incubated with EDTA, the 
bands corresponding to MMP-2 and MMP-9 disappeared in all the cell lines. This 
indicates that the three bands are MMPs. Bands at ~90kDa in SKMES-Cpt30 and 
SKMEs-CptlOO also disappeared indicating that they are MMPs. However, EDTA had 
no effect on the expression of the other bands in SKMES-1 and carboplatin selected 
variants (Figure 3.2.50).
Figure 3.2.50 Zymograph of the proteinases in SKMES-1, DLRP and corresponding drug 
resistant variants with EDTA. Lanes 2-12 = markers, SKMES-1, SKMES-Txt, SKMES-Txl, 
SKMES-Cpt30, SKMES-CptlOO, DLRP, DLRP-Cpt, DLRP-Txt, RPMI-2650, RPMI-melphalan 
and DLKP. Zymography was carried out in triplicate and results were consistent.
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3.2.22.2 The effect of PMSF
PMSF is a serine protease inhibitor, which does not inhibit MMP secretion. PMSF was 
used to establish that the bands observed were due to MMP secretion, not serine 
protease secretion. After the gel was incubated with PMSF, it was shown that all 
previously observed bands were MMP bands (Figure 3.2.51). The addition of PMSF to 
the substrate buffer did not suppress or reduce the expression of the protease bands of 
SKMES-1, SKMES-Cpt30 and SKMES-CptlOO, suggesting the proteases are not serine 
proteases.
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Figure 3.2.51 Zymograph of the proteinases in SKMES-1, DLRP and corresponding drug 
resistant variants with PMSF. Lanes 2-12 = markers, SKMES-1, SKMES-Txt, SKMES-Txl, 
SKMES-Cpt30, SKMES-CptlOO, DLRP, DLRP-Cpt, DLRP-Txt, RPMI-2650, RPMI-melphalan 
and DLKP. Zympgraphy was carried out in triplicate and results were consistent.
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3.2.23 Expression of gelatine-degrading proteases from DMS-53, DMS-Txt, DMS- 
Cpt and DMS-Txl
Zymography gels were carried out on concentrated supernatants collected from the non- 
invasive cell lines DMS-53, DMS-Txt, DMS-Cpt and DMS-Txl. Figure 3.2.52 shows 
that DMS-53 has a band at ~66kDa corresponding to MMP-2. This band is not present 
in the two variants. Another band corresponding to pro-MMP-9 (92kDa) is also visible 
in this cell line and absent in the others. There are also bands expressed at 
approximately 50-60kDa in the three cell lines.
Figure 3.2.52 Zymograph of the proteinases in DMS-53, DMS-Txt, DMS-Cpt and DMS-Txl 
and. Lanes 1-6 - Markers, DMS-53, DMS-Txt, DMS-Cpt and DMS-Txl, DLKP. Zymography 
was carried out in triplicate and results were consistent.
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3.2.23.1 The effect of cysteine
Cysteine keeps cysteine proteases in their reduced form thus making them more active. 
If the bands visible in Figure 3.2.52 were cysteine proteases, they would become 
stronger after incubating the gel with cysteine. Figure 3.2.53 suggests that the bands 
originally thought to be MMP-9 could be cysteine proteases in DMS-53 and DMS-Cpt.
kDa
120
90
65
40
30
■"
Figure 3.2.53 Zymograph of the cysteine proteinases in DMS-53, DMS-Txt, DMS-Cpt and 
DMS-Txl. Lanes 1-6 - Markers, DMS-53, DMS-Txt, DMS-Cpt and DMS-Txl, DLKP. 
Zympgraphy was carried out in triplicate and results were consistent.
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3.2.23.2 The effect of EDTA
To determine if the bands at -65 kDa are MMPs, or cysteine proteases, EDTA was 
included in the substrate buffer. After the gel was incubated with EDTA, the three bands 
did not disappear, indicating that they are probably not MMPs (Figure 3.2.54)
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Figure 3.2.54 Zymograph of the proteinases in DMS-53, DMS-Txt, DMS-Cpt and DMS-Txl 
with the MMP inhibitor EDTA Lanes 1-6 - Markers, DMS-53, DMS-Txt, DMS-Cpt and DMS- 
Txl, DLKP. Zymography was carried out in triplicate and results were consistent.
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3.2.23.3 The effect of PMSF
PMSF was used to establish that the bands observed were due to MMP secretion, not 
serine protease secretion. After the gel was incubated with PMSF, all previously 
observed bands were MMP bands. The addition of PMSF did not suppress or reduce the 
expression of the protease bands in the four cell lines suggesting the proteases are not 
serine proteases (Figure 3.2.55).
Figure 3.2.55 Zymograph of the proteinases in DMS-53, DMS-Txt, DMS-Cpt and DMS-Txl 
with the inhibitor PMSF. Lanes 1-6 - Markers, DMS-53, DMS-Txt, DMS-Cpt and DMS-Txl, 
DLKP. Zymography was carried out in triplicate and results were consistent.
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Gelatine zymography of the taxane selected variants and corresponding parental cell 
lines in these studies revealed the presence of MMP-9 in all invasive cell lines tested A 
band corresponding to MMP-2 was also detected in all invasive taxane-selected 
variants A loss of secreted proteinases, which are not MMPs or serine proteinases was 
observed in the SKMES-Txt and SKMES-Txl compared to the parental cell line 
Gelatine zymography of the carboplatin-selected variants in these studies, revealed the 
presence of MMP-9 in all invasive cell lines tested A band corresponding to MMP-2 
was also detected in the selected variants, except DLRP-Cpt SKMES-1 and both 
carboplatin-selected variants secrete proteinases which are not MMPs or sernne 
proteinases
3.2 24 Summary of zymography
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3.3.1 Circumvention of adriamycin and taxotere resistance
Toxicity assays were carried out on cell lines with (1) a combination of adriamycin, an 
MRP1 substrate, and the non steroidal anti-inflammatory drug sulindac, an MRP1 
inhibitor or (2) a combination of taxotere, a P-gp substrate, with GF120918, a P-gp 
inhibitor (section 2.8.3). A summary of the results observed in all combination assays 
can be seen in Table 3.3.1. Western blotting revealed that P-gp levels, though expressed 
in DMS-53 and absent in SKMES-1 were overexpressed in all taxane-resistant variants 
of these cell lines as well as the carboplatin resistant variant of DMS-53. Combinations 
assays with GF 12098 revealed a greater than 20% and 40% enhanced effect of taxotere 
toxicity in DMS-53 and SKMES-1 respectively. However, GF12098/taxotere resulted in 
a greater than 60% enhanced effect in DMS-Txl, DMS-Txt and SKMES-Txt. These 
results suggest that P-gp plays a major role in taxane resistance in these cell line. No P- 
gp was detected in DLRP or DLRP-Txt. Combinations assays with sulindac and 
adriamycin had a greater than 20% enhanced effect of adriamycin toxicity in both 
carboplatin selected variants of SKMES-1. The MRP1 status of these cell lines has not 
been fully completed due to problems with the primary antibody.
3.3 Combination assay summary
Cell line Sulindac and 
adriamycin
MRP1
Expression
GF120918 and 
taxotere
P-gp
ExpressionSKMES-1 - UK ++ Y
SKMES-Txt - UK +++ Y
SKMES-CptlOO + UK - N
SKMES-Cpt30 + UK - N
DLRP - UK - N
DLRP-Txt + UK + N
DLRP-Cpt - UK - N
DMS-53 + UK + Y
DMS-Txt - UK +++ Y
DMS-Txl - UK +-H - Y
DMS-Cpt - UK ++ Y
Table 3.3.1 Summary of effects observed in combination assays. + Indicates >20% enhanced 
effect, ++ indicates >40% enhanced effect, +++ indicates >60% enhanced effect, - indicates no 
cffect. Y indicates expression, N indicates no expression, UK indicates unknown.
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The combinations of three concentrations of sulindac were tested with 1.56ng/ml 
adriamycin for SKMES-1. The combination of sulindac with adriamycin did not 
enhance adriamycin cell kill indicating the possible absence of MRP1 in this cell line 
(Figure 3.3.1).
3.3.2 Adriamycin in combination with sulindac for SKMES-1
F ig u re  3.3.1 Adriamycin in Combination with Sulindac in SKMES-1. The values are given as 
the average % survival values ± the standard deviation on a minimum of three repeats. Adr = 
adriamycin, Sul = sulindac.
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The combinations of three concentrations of sulindac were tested with 3ng/ml 
adriamycin for SKMES-CptlOO. The combination of adriamycin with the NSAID 
sulindac enhanced adriamycin toxicity in this cell line indicating the possible up- 
regulation of MRP1 (Figure 3 .3 .2).
3.3.3 Adriamycin in combination with sulindac for SKMES-CptlOO
F ig u re  3 .3 .2  Adriamycin in Combination with Sulindac in SKMES-CptlOO. The values are 
given as the average & survival values ± the standard deviation on a minimum of three repeats. 
Adr = adriamycin, Sul = sulindac.
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The combinations of three concentrations of sulindac were tested with 7.8ng/ml 
adriamycin for SKMES-Txt. The combination of sulindac with adriamycin did not 
enhance adriamycin toxicity indicating that MRP1 is probably absent in this cell line 
(Figure 3.3.3).
3.3.4 Adriamycin in combination with sulindac for SKMES-Txt
(0>£DCO
120
100
u
Control
Adr
7.8ng/ml
Sulindac
20ug/ml
Adr + Sul 
20ug/ml
Sulindac
10ug/ml
Adr + Sul 
10ug/ml
Sulindac
5ug/ml
Adr + Sul 
5ug/ml
□  SKMES-Txt 100 94.45831 89.82472 72.52706 97.50806 75.77663 97.8743 78.2243
F ig u re  3 .3 .3  Adriamycin in Combination with Sulindac in SKMES-Txt. The values are given as 
the average % survival values ± the standard deviation on a minimum of three repeats. Adr = 
adriamycin, Sul = sulindac.
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The combinations of three concentrations of sulindac were tested with 1.9ng/ml 
adriamycin for SKMES-Cpt30. The combination of sulindac with adriamycin enhanced 
adriamycin toxicity indicating the possible presence of MRP 1 in this cell line (Figure
3.3.4).
3.3.5 Adriamycin in combination with sulindac for SKMES-Cpt30
<o>
'EDCO
Control
Adr
1.9ng/ml
Sulindac
20ug/ml
Adr + Sul 
20ug/ml
Sulindac
10ug/ml
Adr + Sul 
10ug/ml
Sulindac
5ug/ml
Adr + Sul 
5ug/ml
□  SKMES-Cpt30 100 93.7465 134.667 57.4208 147.333 61.274 151.333 62.3807
F ig u re  3 .3 .4  Adriamycin in Combination with Sulindac in SKMES-Cpt30. The values are given 
as the average IC value ± the standard deviation in duplicate. Adr = adriamycin, Sul = sulindac.
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3.3.6 Adriamycin in combination with sulindac for DLRP and DLRP-Txt
The combinations of three concentrations of sulindac were tested with 0.3ng/ml 
adriamycin for DLRP and DLRP-Txt. The combination of sulindac with adriamycin had 
no effect on adriamycin toxicity in the parent cell line, DLRP indicating the absence of 
MRP1. However, the same combination in DLRP-Txt resulted in >20% enhanced 
toxicity indicating that MRP1 is most likely up-regulated (Figure 3.3.5).
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10ug/m l
Sulindac
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□  D L R P 10 0 94.8186 9 6 .14 7 9 1 9 7 .13 2 6 7 8 7 .2 3 7 2 7 7 0 .3 7 8 14 7 3 .6 4 13 9 60.4 79 35
■  DLRP-Txt 10 0 9 0 .4 5 13 7 1 1 1 .1 0 9 2 81.84634 99.70973 7 5 .18 0 9 7 10 0 .0 74 3 8 5 .4 5 2 14
Figure 3.3.5 Adriamycin in Combination with Sulindac in DLRP and DLRP-Txt. The values 
are given as the average % survival values ± the standard deviation on a minimum of three 
repeats. Adr = adriamycin, Sul = sulindac.
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The combinations of three concentrations of sulindac were tested with 0.3ng/ml 
adriamycin for DLRP. The combination of sulindac with adriamycin had no effect on 
adriamycin toxicity indicating the possible absence of MRP 1 in this cell line (Figure
3.3.6).
3.3.7 Adriamycin in combination with sulindac for DLRP-Cpt
Figure 3.3.6 Adriamycin in Combination with Sulindac in DLRP-Cpt. The values are given as 
the average % survival values ± the standard deviation on a minimum of three repeats. Adr = 
adriamycin, Sul = sulindac.
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The combinations of three concentrations of sulindac were tested with 3.1ng/ml 
adriamycin for DMS-53 and drug resistant variants. The combination of sulindac with 
adriamycin in the parental cell line DMS-53 resulted in > 20% enhanced toxicity. 
However, in each of the variants no effect on adriamycin toxicity was observed 
indicating the probable absence of MRP1 (Figure 3.3.7).
3.3.8 Adriamycin in combination with sulindac for DMS-53 and variants
Figure 3.3.7 Adriamycin in Combination with Sulindac in DLRP-Cpt. The values are given as 
the average IC value ± the standard deviation on a minimum of three repeats. Adr = adriamycin, 
Sul = sulindac.
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The combinations of three concentrations of GF120918 were tested with 0.45ng/ml 
taxotere for SKMES-1. The combination of GF120918 with taxotere in the parental cell 
line resulted in > 40% enhanced toxicity confirming the expression of P-gp (Figure
3.3.8).
3.3.9 Taxotere in combination with GF120918 for SKMES-1
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140
120
100(0>
E3</)
U -
Contol
T axotere 
0.45ng/ml
G F  75  
ug/ml
Tax + G F  
75ug/ml
G F
150ug/ml
Tax + 
G F 15 0 u g / 
ml
G F
300ug/ml
Tax + G F  
300ug/ml
□  SKM ES 100 73.4 9 373 1 1 1 .2 7 0 7 32 .2 8 19 3 102.9724 29.36253 10 7.34 9 1 31.0894 3
Figure 3.3.8 Taxotere in Combination with GF 120918 in SKMES-1. The values are given as 
the average % survival value ± the standard deviation on a minimum of three repeats. Tax = 
taxotere, GF = GF 120918.
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The combinations of three concentrations of GF120918 were tested with 1.87ng/ml 
taxotere for SKMES-Txt. The combination of GF 120918 with taxotere in the parental 
cell line resulted in > 60% enhanced toxicity indicating the expression of P-gp (Figure
3.3.9).
3.3.10 Taxotere in combination with GF120918 for SKMES-Txt
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Taxotere 
1 .87ng/ml
GF 75 
ug/ml
Tax + GF 
75ug/ml
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1 50ug/ml
Tax + 
GF150ug/ 
ml
GF
300ug/ml
Tax + GF 
300ug/ml
□  SKMES-Txt 100 101.22649 108.4697 13.570563 106.42838 14.188589 106.9504 23.736188
F ig u re  3.3.9 GF 120918 in Combination with taxotere in the SKMES-Txt MDR resistant 
variant. The values are given as the average % survival values ± the standard deviation on a 
minimum of three repeats. Tax = taxotere, GF = GF120918.
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A concentration of 1.8ng/ml taxotere on the parent cell line SKMES-1 results in ~ 30% 
survival. However, the same concentration of taxotere on SKMES-Txt with the lowest 
concentration of GF120918 (75|ag/ml) results in 23.7 % survival (Figure 3.3.10).
3.3.11 Taxotere in combination with GF120918 for SKMES-1 and SKMES-Txt
a>£3
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1S6f ' V
u
Control
Taxotere
1.8ng/ml
G F75 u g /m l
T a x + G F
75ug/m l
Parent 
Taxotere 1.8
□  SKM ES-Txt 10 0 10 1.2 2 6 4 9 4 2 10 6 .9 5039 6 3 2 3 .7 3 6 18 7 5 9 30 .6 237374 4
Figure 3.3.10 GF120918 in Combination with taxotere in the SKMES-Txt MDR resistant 
variant. The values are given as the average % survival values ± the standard deviation on a 
minimum of three repeats. Tax = taxotere, GF = GF 120918.
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The combinations of three concentrations of GF120918 were tested with 0.25ng/ml 
taxotere for DLRP. The combination of GF120918 with taxotere in the parental cell line 
did not enhance taxotere resistance at each concentration tested indicating the possible 
absence of P-gp in this cell line (Figure 3.3.11).
3.3.12 Taxotere in combination with GF120918 for DLRP
120
Figure 3.3.11 GF 120918 in Combination with taxotere in the parental cell line DLRP. The 
values are given as the average % survival values ± the standard deviation on a minimum of 
three repeats. Tax = taxotere, GF = GF 120918.
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3.3.13 Taxotere in combination with GF120918 for DLRP-Cpt
The combinations of three concentrations of GF120918 were tested with O.llng/ml 
taxotere for DLRP-Cpt. The combination of GF 120918 with taxotere in the parental cell 
line had no effect on taxotere resistance indicating that P-gp is most likely absent in this 
cell line (Figure 3.3.12).
VJ
Contol
Taxotere 
0.11 ng/ml
GF 75 
ug/ml
Tax + G F  
75ug/ml
GF 
1 50ug/ml
Tax + 
GF150ug/ 
ml
GF
300ug/ml
Tax + GF 
300ug/ml
■  DLRP-Cpt 100.00 112.28 103.46 95.37 99.76 90.40 89.63 88.47
Figure 3.3.12 GF 120918 in Combination with taxotere in DLRP-Cpt. The values are given as 
the average % survival values ± the standard deviation on a minimum of three repeats. Tax = 
taxotere, GF = GF 120918.
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3.3.14 Taxotere in combination with GF120918 for DLRP-Txt
The combinations of three concentrations of GF120918 were tested with 0.38ng/ml 
taxotere for DLRP-Txt. The combination of GF120918 with taxotere in the parental cell 
line had greater than 20% enhanced toxicity indicating the possible presence of P-gp 
(Figure 3.3.13).
Figure 3.3.13 GF120918 in Combination with taxotere in DLRP-Txt. The values are given as 
the average % survival values ± the standard deviation on a minimum of three repeats. Tax = 
taxotere, GF = GF 120918.
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3.3.15 Taxotere in combination with GF120918 for DMS-53 and variants
The combinations of three concentrations of GF120918 were tested with 0.75ng/ml 
taxotere for DMS-53 and drug resistant variants. The combination of GF120918 with 
taxotere in the parental cell line DMS-53 and DMS-Cpt resulted in > 20% and 40% 
enhanced toxicity. However, in the taxane variants, greater than 60% enhanced toxicity 
was observed indicating the presence of P-gp in the parental cell line and its up- 
regulation in the variants (Figure 3.3.14)
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u
Contol
Taxotere
0.75ng/ml
G F  75  
ug/ml
T a x + G F
75ug/m l
G F
150ug/m l
Tax + 
G F 15 0 u g /  
ml
G F
300ug/ml
T a x + G F
300ug/ml
□  DM S-53 100.00 78.23 97.72 42.76 96.41 34.44 85.70 33.0 7
m DMS-Txt 100.00 99.88 10 8 .01 32.58 9 9.19 31.0 6 99.45 37.84
□  DMS-Txl 100.00 99.99 108.34 47.81 1 1 1 .0 8 43.74 9 1.6 0 45.79
□  DM S-Cpt 100.00 8 3.18 91.60 2 3 .7 1 9 1.0 7 24.73 82.33 34.58
Figure 3.3.14 GF120918 in Combination with taxotere in DMS-53 and MDR resistant variants. 
The values are given as the average IC value ± the standard deviation on a minimum of three 
repeats. Tax = Taxotere, GF = GF120918.
166
3 3 16 P-gp Expression in SKMES-1 and taxane-selected variants
Western blots were earned out to determine P-gp expression in the SKMES-1 taxane- 
selected cell lines There was up-regulation of P-gp in both taxane-selected variants of 
SKMES-1 Taxotere exposure resulted in a higher expression of P-gp compared to taxol 
exposure Protein samples were prepared at weeks 34, 36 and 38 from SKMES-Txl (see 
Figure 4 1) and at weeks 61, 63 and 65 from SKMES-Txt (see Figure 4 2) to determine 
if a correlation existed between fall of drug resistance with P-gp expression Results 
revealed no correlation P-actin is differentially expressed in SKMES-Txl (Wk3) 
according to proteomic results (see Table 3 6 7)
Figure 3 3 15 P-gp expression in SKMES-1 and taxane-selected variants Lane 1 SKMES-1, 2 
SKMES-Txt (Wk2), 3 SKMES-Txt (W5), 4 SKMES-Txt (Wk6), 5 SKMES-Txl (Wk2), 6 
SKMES-Txl (W5), 7 SKMES-Txl (Wk6) Western blots comparing parent with SKMES-Txt 
and SKMES-Txl (week 2) have been earned out m tnplicate However, the companson of 
taxane-selected vanants at weeks 3 and 5 have only been earned out once
3 3 17 P-gp Expression in DMS-53 and drug selected variants
Western blots were earned out to determine P-gp expression in the carboplatin and 
taxane-selected vanants of DMS-53 There was slight up-regulation of P-gp in the 
vanants \ a
P'gp
fr-Actin
Figure 3 3 16 P-gp expression in DMS-53 and drug-selected vanants Lane 1 DMS-53, 2 
DMS-Txt, 3 DMS-Txl, 4 DMS-Cpt Western blots were only earned out once and need to be
i
repeated
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Two-dimensional-difFerence gel electrophoresis (2D-DIGE), a new development in 
proteomics has made it possible to detect and quantify the differences between 
experimental pairs of samples on one gel. Protein samples are prelabelled with different 
fluorescent dyes (Cy2, Cy3 and Cy5) so they can be mixed together, co-separated and 
visualised distinctly on a single 2D gel. Pooling an aliquot of all biological samples in 
the experiment and labelling it with the Cy2 fluor creates the internal standard. The 
internal standard is then run on every gel along with each individual sample. Each 
protein from all samples is therefore represented in the internal standard, which is 
present on all gels resulting in co-migration of proteins originating from separate 
samples (Figure 3.4.1). For example, a control cell line and a corresponding drug- 
resistant variant can be labelled with the different dyes, combined and run on the same 
gel. The advantage of this method over conventional 2-DE is that the samples are 
exposed to the same chemical environments and electrophoretic conditions. Gel-to-gel 
variation is reduced as co-migration is guaranteed for identical proteins from separate 
samples.
3.4 Two-dimensional-difference gel electrophoresis
Pooled internal 
standard 
label with Cy™2
Protein extract 1 
label with Cy3
Protein extract 2 
label with Cy5
Mix labelled 
extracts
2-DE
separation
Typhoon™ 
Variable Mode 
Imager
DeCyder™
Differential
Analysis
Software
Figure 3.4.1 The 2D-DIGE system.
The two-dimensional DIGE system has greatly reduced inherent system variation to a 
level that allows detection of minor protein expression changes of as little as 20%. The 
result is new levels of statistical reliability in electrophoresis results. Each protein has
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its own internal standard, which ensures high accuracy enabling even the smallest 
possible real differences in protein abundance to be detected The technique was used to 
look at differential protein expression in cancer and drug-resistant variants by labelling 
control and resistant variants with spectrally-resolvable fluorophores and as DIGE is 
multiplexed, an internal control was run to allow improved matching between gels
3 4 1 Outline of proteomic analysis of adnamycin resistant variants of DLKP
Investigations were carried out to establish differential protein expression caused by 
adnamycin resistance in DLKP, a squamous lung cell line displaying varying levels of 
resistance to adnamycin (Table 3 4 1) The adnamycin-resistant cell lines (produced by 
a number of researchers at the NCTCC (section 2 2)) were developed from the DLKP 
cell line DLKP was established from a lymph node biopsy of a 52-year-old male 
identified as a poorly differentiated squamous cell lung carcinoma (Law et a l , 1992)
Fold Resistance
Cell Line Adnamycin Cisplatin Vincristine VP-16 5-FU
DLKP 1 1 1 1 1
DLKP-A 10 765 3 0 8* 3000 63 3 0 9
DLKP-A5F 235 4 1 4 1275 50 6 0 98
DLKP-A 122 6 1 5 1504 60 7 1 8
DLKP-A2B 7 0 6 228 3 182 1 3
’able 3 4 1 Drug resistance profiles of adnamycin resistant vanants of DLK *Carboplatin
Table was compiled from Cleary et a l, 1997 and Heenan et a l, 1997 Resistance to adnamycin 
was reconfirmed by toxicity assay Fold resistance was calculated with respect to DLKP
The DLKP-A variant was developed from DLKP by continuous exposure to increasing 
concentrations of adnamycin to a final concentration of 2 |xg/ml (Clynes et a l , 1992) 
The DLKP-A10 cell line was selected by continuous exposure of the DLKP-A cell line 
to further increasing concentrations of adnamycin to a final concentration of lO^g/ml 
(Cleary et a l , 1997) Two clonal sub-populations were also established from DLKP-A 
by clonal dilution, and named DLKP-ASF and DLKP-A2B (Heenan e ta l , 1997) All of  
the above four resultant variants have varying levels of resistance to adnamycin and 
also exhibit cross-resistance profiles to a number of other chemotherapeutic drugs 
(Table 3 4 1)
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The DLKP-A10 cell line is 765 3-fold resistant to adriamycin when compared to DLKP 
The cell line is also 3 2-fold, 6 2-fold and 109 3-fold times more resistant to adriamycin 
when compared to DLKP-A5F, DLKP-A and DLKP-A2B respectively All cell lines 
exhibited very high levels of cross resistance to vincristine with DLKP-A10 being 
3000-fold resistant when compared to the parent and 2 3-fold, 1 99-fold and 13-fold 
resistant when compared to DLKP-A5F, DLKP-A and DLKP-A2B respectively Cross­
resistance to cisplatin did not correspond to adriamycin resistance, DLKP-A10 and 
DLKP-A2B are lower than the parent while DLKP-A and DLKP-A5F are marginally 
higher Some small cross-resistance is seen for DLKP-A and DLKP-A2B but the more 
resistant variants (DLKP-A5F and DLKP-A10) show sensitivity in comparison to 
DLKP-A, almost back to the same levels as DLKP
DLKP, DLKP-A, DLKLP-A2B and DLKP-A5F have stable expression and toxicity 
assays confirmed the fold resistance to adriamycin (Table 3 4 1) The DLKP-A10 
variant requires exposure to drug every four passages in order to maintain resistance 
levels This was also confirmed by toxicity assays (data not shown)
3 4 11 Invasive status of the adriamycin resistant variants of DLKP
Invasion assays were performed, as described in Section 2 11, to assess the ability of 
each of the five DKLP cell lines to invade through matngel Cell culture inserts were 
coated with matngel and placed in medium containing 24-well plates prior to cell 
addition Cells were considered invasive if they migrated through the matngel and the 8 
faM porous membrane and attached to the underside of the membrane within 24 hours 
The images presented are representative of at least three separate experiments, are at a 
magnification of 10X and are stained with crystal violet
The DLKP parental cell line is invasive (Figure 3 4 2) Increased invasion was observed 
in DLKP-A (Figure 3 4 3) when compared to the parent Further exposure of DLKP-A 
to adnamycin resulted in a less invasive variant, DLKP-A10 (Figure 3 4 4) Similarly, 
the least resistant subclone of DLKP-A, namely DLKP-A2B is less invasive than 
DLKP-A In contrast, DLKP-A5F which is more resistant than DLKP-A is also more 
invasive (Figure 3 4 5)
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Figure 3.4.4 DLKP-A10 Figure 3.4.5 DLKP-A2B
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Figure 3.4.4 DLKP-A5F
3.4.1.2 Quantification of invasion
The invasion assays were quantified by counting cells with a graticule at 40X 
magnification (Table 4.2.2, Figure 3.4.5). Proteomic analysis was carried out on these 
cell lines. The data shows that DLKP, an invasive cell line was compared to the slightly 
more invasive DLKP-A. DLKP-A was compared to a more invasive cell line, DLKP- 
A5F and two less invasive cell lines, DLKP-A2B and DLKP-A10 respectively.
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Cell Line Average cell count/area/view P value
DLKP 11.35 ± 1.09 -
DLKP-A2B 1.36 ±0.35 0.002
DLKP-A 14.85 ± 1.41 0.029
DLKP-A5F 33.13 ± 2.15 0.0006
DLKP-A10 5.56 ±0.68 0.001
T ab le  3.4.2 Quantification of DLKP and adriamycin-resistant variants. The values are given 
as the average cell counts/area/view ± the standard deviation. (n=3).
DLKP DLKP-A2B DLKP-A DLKP-A5F DLKP-A10
Cell Line
Figure 3.4.5 Quantification of adriamycin resistant variants of DLKP.
3.4.2 The overview of proteomic analyses
Initially DLKP was used as the control and compared only to DLKP-A (Table 3.4.3). So 
as not to confuse the lengthy proteomic procedure, when confidence had been built the 
remaining variants, A2B, A5F and A10 were compared to DLKP-A.
Experiment No. Control Treated
1 DLKP DLKP-A
2 DLKP-A DLKP-A2B
3 DLKP-A DLKP-A5F
4 DLKP-A DLKP-A10
Table 3.4.3 Overview of 2D-DIGE experiments carried out in this thesis
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3.4 2 1 Screening of DLKP and variants protein samples
The DIGE system required six high quality protein samples per cell line per experiment 
(section 2 15) Many sample preparations were earned out to refine the procedure to 
generate good gels with many distinct protein spots and to ensure low levels of 
contaminating factors such as DNA, RNA, lipids and salts The gels were silver-stained 
and scanned at 300 resolution to ensure the quality of protein samples The best six 
samples showing most solubilised, well-defined protein spots free of streaking and salt 
fronts were selected
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Figure 3 4 6a DLKP
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figure 3 4 6b DLKP-A
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Figure 3 4 6c DLKP-A10 Figure 3 4 6d DLKP-A5F
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Figure 3 4 6e DLKP-A2B
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The experimental design for DIGE analysis of DLKP versus DLKP-A is outlined as 
follows: Six biological replicates of each cell line were reverse labelled with 200pmol 
of the Cy dyes (section 2.16.1.3) to allow for statistical analysis of protein expression 
using DeCyder™ software. Three replicates of DLKP and DLKP-A were labelled with 
Cy3 for gels 1-3 and 4-6 respectively. Three replicates of DLKP-A and DLKP were 
labelled with Cy5 for gels 1-3 and 4-6 respectively. Each replicate was also labelled 
with Cy2. A volume of 50|ig protein was labelled with each Cy dye resulting in a total 
of 150}ig/gel (50|ig Cy2 internal standard, 50|ug Cy3 and 50jng Cy5).
Once labelling was completed, six 2D gels were generated (sections 2.17 and 2.18) and 
scanned using the Typhoon scanner. All images generated were initially analysed in the 
DIA mode of the DeCyder™ software (section 2.20.1). In-depth analysis to identify 
spots with differential protein expression was carried out with the BVA module of the 
software (section 2.20.2). To identify these proteins, preparative 2D gels were generated 
and stained with colloidal blue coomassie, excised with the ETTAN spot picker and 
digested to be identified with a MALDI-TOF mass spectrometer (sections 2.22, 2.23 
and 2.24 respectively).
3.4.3.1 DeCyder analysis of DLKP versus DLKP-A
Differential protein expression between the lung cell line DLKP and its adriamycin 
resistant variant DLKP-A was observed using 2D-DIGE. Difference In-gel Analysis 
using Decyder™ revealed a total of 3454 ± 303 protein spots between DLKP and 
DKLP-A. Biological variation analysis of these spots revealed a total of 282 spots 
showing a greater then 1.2-fold change in expression with a t-test score of 0.05 or less 
(Figure 3.4.7). Of these 282 spots, 38 have been identified using MALDI-TOF mass 
spectrometry.
A total of 244 of the differentially regulated spots were not identified (102 down- 
regulated and 142 up-regulated) as: (1) many failed to appear on a colloidal coomassie 
gel due to their relatively low abundance; (2) highly abundant proteins on the gel 
sometimes masked those proteins in low abundance and (3) some proteins, especially 
high molecular weight hydrophobic proteins do not fly well in the mass spectrometer.
3.4.3 Experimental outline of labelling of DLKP and DLKP-A protein samples
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Figure 3.4.7 Representative Cy5 labelled DLKP-A gel showing completed BVA analysis of 
DLKP versus DLKP-A between pH4-7. Spots circled in blue are the 282 statistically significant 
differentially regulated proteins (p< 0.05, protein fold >1.2).
3.4.3.2 Identification of differentially regulated proteins
Matrix assisted laser desorption ionisation (MALDI) time of flight (TOF) mass 
spectrometry successfully identified 38 differentially regulated proteins between DLKP 
and DLKP-A (Figure 3 .4.8). Of these 38 spots, 23 were found to be up-regulated and 15 
down-regulated (Table 3.4.4). For visual clarity, the proteins were numbered as outlined 
in Table 3.4.4. Spots are numbered according to their relative molecular weight, from 
highest to lowest.
Over 65% of the proteins listed in Table 3 .4.4a and 3 .4.4b have been shown to be either 
increased or decreased in response to chemotherapy drug exposure. Proteins such as the 
heat shock proteins and the apoptotic response proteins are typically differentially 
regulated.
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Above approximately 70kDa, out of 84 differentially expressed proteins only 4 were 
identified due to reasons (1) to (3) mentioned in section 3.4.3.1. Moreover, below 
approximately 17kDa, out of 53 differentially expressed proteins only 4 were identified. 
Therefore in the central part of the gel, out of 108 spots, 30 were identified.
Figure 3.4.8a-b A colloidal 
coomassie stained preparative 
DLKP-A gel (400^g protein/gel) 
which marks the 38 identified 
protein spots exhibiting differential 
expression identified via MALDI- 
TOF ms analysis as listed in table 
3.4.4a and 3.4.4b.
176
Spot
No
Protein Name gi Number
Gene
Symbol
Fold pi M w
1 Valosin containing Protein gi|48257098| VCP 2 32 49 71 56
2 HSP70 kDa 9B (MTHsp75) gi|292059| HSPA9B 1 97 6 74 12
3 Lamin B1 gi|576840| LMNB1 3 07 53 67 79
4 HSP 70 protein 8 isoform 2 gi|62896815| HSPA8 3 21 56 53 6
5
Chaperonin containing TCP1 
subunit 3
gi|58761484| CCT3 2 58 6 57 78
6 hnRPK gi|55958547| HNRPK 1 93 54 42 02
7 Aldehyde dehydrogenase A1 gi|2183299| ALDH1A1 165 63 55 44
8 Aldehyde dehydrogenase A1 gi|2183299| ALDH1A1 1 52 63 55 44
9
Succinyl-CoA 3 ketoacid 
CoA transferase gi| 10280560| OXCT1 23 72 56 6
10 Aldehyde dehydrogenase A1 gi|2183299| ALDH1A1 147 63 55 44
11 CCT2 gi|48I46259| CCT2 2 58 6 57 78
12 hnRPHl gi|48145673| HNRPH1 1 52 59 49 5
13 Rab dissociation inhibitor 
beta
gi|4960030| GDI2 1 69 59 41
14 Cham C, OAT Mutant Y85i gi|78101704) OATL1 -3 45 66 48 81
15 HSPC108 (stomatin) gi|6841440| STOML2 2 03 5 8 37 3
16 elF 2b gi| 19353009) EIF2 142 65 58 17
17 HSP 70 protein 8 isoform 2 gi|62896815| HSPA8 -2 15 56 53 6
18 K alpha 1 protein gi|62897609| K-
ALPHA-1
-1 55 5 50 49
19 Stress induced phosphoprotein gi|54696884| STIPI -1 43 64 63 25
Table 3 4 4a Identified proteins from DLKP versus DLKP-A Gene symbol determined from 
“gi number5’ conversion software package “DAVID” and Entrez gene (OAT Ornithine 
Aminotransferase)
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Spot
No Protein Name gi Number
Gene
Symbol Fold Pi M w
20 Annexin A1 gi|442631| ANXA1 2 29 79 35 25
21 Annexin A1 gi|442631| ANXA1 251 79 35 25
22 Annexin A1 gi|442631| ANXA1 1 63 79 35 25
23 Replication A2 32, kDa gi|56204165| RPA2 1 5 64 30 25
24 Protein disulphide isomerase protein 5 gi| 1710248| p5 -2 18 5 46 52
25 HSP 27 kDa gi|54696638| HSPB1 1 47 6 22 82
26 Actm G protein gi| 178045| ACTG1 -145 56 26 15
27 HSP 70 kDa protein 8 isoform 2 gi|62896815| HSPA8 -1 25 56 53 6
28 Tnosephosphate isomerase gi|66360366| TPI1 1 89 65 26 95
29 Tnosephosphate isomerase gi|66360366| TPI1 -1 46 65 26 95
30 Thioredoxin peroxidase B chain J gi|9955016| PRDX5 -2 33 57 21 68
31 K130r mutant of human DJ-1 gi|33358056| PARK7 1 54 65 21 14
32 Thioredoxin peroxidase B gi| 1617118| PRDX2 -1 95 52 18 48
33 Sorcin isoform b gi|38679884| SRI 1 51 5 1 20 61
34 Nucleoside diphosphate kinase 1 gi|38045913| NME1 1 54 54 19 86
35 elF 5a gi|33383425| EIF5A -2 63 5 1 16 98
36 Human tubulin chaperone cofactor A gi|21730330| TBCA -126 53 12 29
37 Galectin-1 gi|42542977| Galectin-1 -1 55 5 3 14 75
38 Thioredoxin delta 3 gi| 1827674| TXN -1 17 48 11 86
Table 3 4 4b Identified proteins form D ,KP versus DLKP-A continued
178
3.4.3.3 Ontology analysis of identified proteins
Ontology information was obtained through PubMed literature searches. Of the 
identified proteins, the majority have functions in the stress response (26%), glycolysis 
(16%), ion binding/transport (11%), apoptosis (11%) and cytoskeletal functions (8%). 
Cell signalling, translation, metabolism and transcription accounts for 5% each. Finally, 
3% of the proteins are involved in protein turnover (Table 3.4.5, Figure 3.4.9).
The stress response proteins, which account for 26% of all differentially regulated 
proteins, were expected to be differentially regulated, as they are known to increase 
resistance to cell death induced by a variety of stimuli. The majority of these proteins 
are all up-regulated in DLKP-A. The apoptosis/redox regulation proteins have also been 
linked to overcoming drug-resistance through evading apoptosis. They are both up- and 
down-regulated in DLKP-A. Glycolysis was also regulated quite significantly in DLKP- 
A versus DLKP. This could be anticipated as drug-resistant variants may need energy 
for actively pumping out drugs.
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Reported Function Protein Name
Apoptosis/Redox regulation
Galectin 1, chain a 
Thioredoxin delta 3 
Thioredoxin peroxidase B chain J 
K13 Or mutant of human DJ-1
Glycolysis
Aldehyde dehydrogenase A1 
Peroxiredoxin 2 
Tnosephosphate isomerase
T ranscnption/T ranscnption Regulation
Nucleoside diphosphate kinase 1 
Replication A2, 32kDa
Stress Response
HSP 27 kDa
HSP 70 kDa protein 8 isoform 2 
Human tubulin chaperone cofactor A 
HSPC108 (stomatin)
Stress induced phosphoprotein 
HSP70 kDa 9B (MTHsp75) 
Chaperonm containing TCP1 subunit 3 
CCT2
Ion Binding/Transport
Annexin A1 
Sorcin isoform b
Translation
elF 2b 
elF 5a
Cytoskeletal ,
LammBl
K alpha 1 protein / TNF alpha 
Actin gl protein
Protein Turnover Protein disulphide isomerase protein 5
Cell Signalling
VCP protein
Rab dissociation inhibitor beta
RNA Processing
hnRPK
hnRPHl
Metabolism
Succinyl-CoA 3 ketoacid CoA transferase 
Ornithine mutant amine transferase Y85 chain c
Table 3 4 5 Ontology analysis of identifiec proteins from DLKP versus DLKP-A
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PathwayAssist literature mining software permits the identification of biological 
interactions among genes and proteins of interest from the published literature. This 
analysis was carried out on the 38 identified proteins in Table 3.4.4. The gene symbol 
list was imported into the software and from this both direct- and common-interacting 
pathways were built. Figure 3.4.10 shows only the direct links between differentially 
regulated proteins. Only the differentially regulated proteins were submitted for 
PathwayAssist analysis. These proteins are involved in stress response and redox 
reactions. Thioredoxin and thioredoxin peroxidase are linked components in a redox 
chain that couples peroxide reduction to NADPH oxidation. Thioredoxin peroxidase is 
also increased in Thioredoxin-1 transfected cells which results in enhanced protection 
against apoptosis caused by hydrogen peroxide but not by other agents including 
dexamethasone, etoposide and doxorubicin. Both of these proteins are decreased in 
DLKP-A. The stress induced phosphoprotein, VCP and HSPB1 have each been shown 
to interact with HSPA8.
3.4.3.4 PathwayAssist analysis of identified proteins
Figure 3.4.10 PathwayAssist analysis of direct interactions between proteins. This identifies 
only direct links between the proteins. This finds proteins that are regulated by all selected 
nodes. Green and purple lines mark regulatory and binding effects respectively. Grey lines 
indicate effect on expression.
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Figure 3.4.11 shows the pathways built based on common targets for selected nodes (i.e. 
differentially regulated proteins). Pathway analysis found that processes of apoptosis, 
differentiation and proliferation are important in the development of adriamycin 
resistance in DLKP, reflecting ontology analysis to some extent.
Stimulators of apoptosis include STIP1, PARK7, LMNB1, ANAX1, NME, and 
LGALS1. The majority of these are up-regulated in response to adriamycin exposure. 
Inhibitors of apoptosis include HSPA9B, PRDX1, HSPB1, HSPA8 and ALDH1A1. 
Expression of all other proteins are increased in DLKP-A. Six proteins were observed to 
interact with the differentiation cell process. The single inhibitory protein of 
differentiation, NME1 was found to be increased in DLKP-A by 1.54-fold. The 
remaining stimulators of differentiation were both increased and decreased in DLKP-A. 
No proteins were found to have an inhibitory effect on proliferation in DLKP-A. The 
proteins that stimulated proliferation were predominantly down-regulated in DLKP-A
orange. Green and red lines mark positive and negative regulatory effects respectively. Grey 
lines indicate an unknown regulatory effect.
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3.4.4 DeCyder analysis of DLKP-A versus DLKP-A2B
This experiment was designed to compare DLKP-A to a less resistant subpopulation, 
DLKP-A2B in order to examine the protein expression changes resulting from a loss of 
resistance. DLKP was 254.14-fold resistant to adriamycin compared to DLKP while 
DLKP-A2B was only 36.8-fold resistant. The experimental design for DIGE analysis of 
DLKP-A compared to DLKP-A2B is identical to that of DLKP versus DLKP-A with 
DLKP-A as the control and 5 biological replicates.
Difference In-gel Analysis of DLKP-A (the control) compared to DLKP-A2B using 
Decyder™ revealed a total of 3483 ± 493 protein spots between DLKP-A and DKLP- 
A2B. Biological variation analysis revealed a total of 80 spots showing a greater than 
1.2-fold change in expression with a t-test score of 0.05 or less (Figure 3.4.12). Of these 
80 spots, 26 have been identified by MALDI-TOF mass spectrometry. A total of 54 
differentially regulated spots were not identified (33 down-regulated and 21 up- 
regulated).
Figure 3.4.12 A representative Cy5 labelled DLKP-A2B gel showing completed BVA analysis 
of DLKP versus DLKP-A2B between pH 4-7. Spots circled in blue are the 80 statistically 
significant differentially regulated proteins (p< 0.05, protein fold >1.2).
183
pi 4-7
Figure 3.4.13a-d Colloidal coomassie stained preparative DLKP-A gel, which marks the 
proteins in common with DLKP versus DLKP-A - white spots (Figure 3.4.8). Yellow spots 
indicate the overlapping proteins from DLKP-A vs -A5F and -A 10. Green proteins are unique to 
DLKP-A2B
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Comparisons between DLKP-A versus DLKP-A2B and DLKP versus DLKP-A 
revealed that 8 proteins were shared (white spots in Figure 3 4 13) Of the commonly 
shared proteins, many show a positive correlation with resistance when taking DLKP 
versus DLKP-A into account The transcription/transcription regulation proteins, 
replication A2 (RPA2) and nucleoside diphosphate kinase 1 (NDPK1) showed a 
decrease in protein expression as resistance fell This reflects a positive correlation with 
a fall of drug resistance In contrast, two proteins involved in apoptosis/redox 
regulation, namely galectin-1 and thioredoxin delta 3 are both decreased in DLKP 
versus DLKP-A, by 1 55 and 1 17-fold respectively However, in the less resistant cell 
line, DLKP-A2B, both proteins show an increase in expression, 1 71-fold and 1 6-fold 
respectively The same trend is seen for the cytoskeletal protein actin G1 and the stress 
response protein, HSP 70 kDa protein 8 isoform 2 The protein expression of human 
tubulin chaperone cofactor A protein was reduced from -1 26-fold to -1 88-fold 
whereas the expression of tnosephosphate isomerase increased a further 1 87-fold from 
1 89-fold in DLKP-A2B (Table 3 4 6)
PathwayAssist analysis of RPA2 and NDPK1 in DLKP versus DLKP-A revealed that 
RPA2 is involved in G1 and S phase, mitogenesis, mitosis chromosomal DNA 
replication and DNA damage recognition yet is only connected to s phase in DLKP- 
A2B (Figure 3 4 16) NDPK1 (labelled NME1 in PathwayAssist) functions in 
differentiation and apoptosis in DLKP versus DLKP-A (Figure 3 3 11) but is linked to 
recognition of signal transduction, shape, contraction and assemble in DLKP-A2B
Spot
No
Protein Name Fold Pi M w.
DLKP vs 
DLKP-A
23 Replication A2, 32 kDa -1 29 6 4 30 25 1 5
26 Actin G1 protein 2 95 5 5 26 68 -1 45
27 HSP 70 kDa protein 8 isoform 2 2 87 5 6 53 6 -1 25
28 Tnosephosphate isomerase 1 87 65 26 95 1 89
34 Nucleoside diphosphate kinase 1 -1 28 5 4 19 86 1 54
36 Human tubulin chaperone cofactor A -1 88 53 12 29 -1 26
37 Galectin-1 1 71 53 14 75 -1 55
38 Thioredoxin delta 3 1 6 4 8 11 86 -1 17
Table 3 4.6 Fold difference of overlapping protein spots between the comparisons DLKP versus
DLKP-A and DLKP-A versus DLKP-A2B
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Eight proteins that were found to be differentially regulated in DLKP-A versus DLKP- 
A2B were also seen in the comparison of DLKP-A versus DLKP-A5F or DLKP-A 
versus DLKP-A10 (Table 3 4 7)
Spot
No
Protein Name gi Number
Gene
Symbol
Fold Pi M W .
39 Actin G1 protein gi|40226101| ACTG1 6 5 5 26 68
40 Annexin 1 gi|442631| ANXA1 -1 6 54 35 25
41 Chloride intracellular 
channel 1 variant gi|62898319| CSTD -1 66 5 1 27 34
42 HSP 70 kDa protein 8 
isoform 2 gi|62896815| HSPA8 79 5 6 53 6
43 Cham B, Horf 6 a novel 
human peroxidase enzyme gi|3318842| - -1 61 6
24 9
44
Eukaryotic translation 
elongation factor 1 delta 
isoform
gi| 152154511 EEF1D -2 48 4 9 31 22
45 Vimentin gi|37852| VIM -1 64 5 1 53 72
46 HPRT gi|6730253 HPRT1 , -1 71 5 5 39 3
Table 3 4 7 The 8 overlapping protein spots between the comparisons DLKP versus DLKP- 
A2B and/or DLKP-A versus DLKP-A5F, DLKP-A10 (Spots marked yellow in Figure 3 4 13)
Of the eight proteins shared with the two more resistant variants, DLKP-A5F and 
DLKP-A10 Three are shared with DLKP-A5F and five with DLKP-A10 Actin G1 
shows an inverse relation between DLKP-A, DLKP-ASF and DLKP-A2B HPRT and 
the peroxidase enzyme do not correlate with resistance Between DLKP-A and DLKP- 
A2B, HSP 70 kDa protein 8 isoform 2 correlates inversely while vimentin correlates 
directly with resistance
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Eleven proteins were determined to be unique to DLKP-A versus DLKP-A2B, the 
majority of which are involved in protein turnover and have both increased and 
decreased proteins expression HSP 70 kDa protein 8 isoform 2 and annexin 1 elicited 
the highest protein fold changes, 3 42 and 2 42 respectively Both of these proteins have 
previously been linked to the development of drug resistance (Table 3 4 8)
Spot
No
Protein Name gi Number
Gene
Symbol
Fold pi M W
41 Chloride intracellular 
channel 1 variant gi|62898319| CSTD -1 66 5 1 27 34
52 alpha tubulin 6 variant gi|62897609| TUBA6 1 81 5 50 49
53 Annexin 1 gi|442631| ANXA1 2 42 79 35 25
54 Beta Actm gi|15277503| ACTB -1 8 56 40 54
55 Chain D, Cathepsin B 
(E C 3 4 22 1) gi|999911| CSTB -1 87 52 22 97
56 Chain H Cathepsin D at 
pH 7 5 gi|5822091| CSTD 1 54 53 26 46
57 HSP 70 kDa protein 8 
isoform 2 gi|62896815| HSPA8 3 42 5 6 53 6
58 KIAA0002 gi|l 136741| KIAA0002 -2 02 5 8 59 06
59 Peroxiredoxin gi|62896877| PRDX3 1 72 7 1 27 95
60 Prolyl 4-hydrolase, beta 
subunit gi|48735337| P4HB -1 89 4 8 57 5
61
Proteasome (prosome, 
macropain) subunit, alpha
type 5
gi|54696300| PSMA5 1 6 4 7 26 58
Table 3 4 8 Proteins unique to DLKP-A versus DLK5-A2B (Spots marked green in Figure
3 4 13)
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3.4.4.1 Proteins identified between DLKP-A versus DLKP-A2B
Ontology analysis shows proteins with decreased protein expression are involved in 
translation, cytoskeleton, protein turnover, ion binding/transport, apoptosis/redox 
regulation and the stress response. Proteins showing increased expression have 
functions involving stress response, ion binding and transport, cytoskeleton, 
apoptosis/redox reactions glycolysis and protein turnover (Table 3.4.9, Figure 3.4.14). 
Interestingly, protein turnover and cytoskeletal proteins appear to be more important in 
the DLKP-A2B variant, 19% each in comparison to DLKP versus DLKP-A.
A decrease in glycolysis and stress response proteins is seen in DLKP-A2B, only 4% 
and 19% in comparison to 16% and 26% respectively in DLKP versus DLKP-A. In 
comparison to DLKP versus DLKP-A, no cell signalling, metabolic or RNA processing 
proteins were differentially regulated. Similar percentages of apoptosis/redox 
regulation, ion binding/transport, transcription/ transcription regulation and translation 
accounts were seen in DLKP versus DLKP-A and DLKP-A versus DLKP-A2B (Figure 
3 .4.14 and Figures 3.4.9).
Translation
4 %
Transcription/Tran­
scription
Regulation
8%
Protein Turnover 
1 9 %
Apoptosis/Redox
regulation
1 5 %
Ion
Binding/Transport
12%
Figure 3.4.14 Ontology analysis of differentially regulated proteins
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Reported Function Protein Name
Apoptosis/Redox regulation Galectin 1, chain a Thioredoxin delta 3 
Peroxiredoxm
Chain B, Horf 6 A Novel Human Peroxidase Enzyme
Glycolysis Tnosephosphate isomerase
T ranscription/T ranscription 
Regulation
JSiucleoside diphosphate kinase 1 
Replication A2, 32kDa
Stress Response
Human tubulin chaperone cofactor A 
KIAA0002
HSP 70 kDa protein 8 isoform 2
Ion Binding/Transport Annexin A1 variant 3 Chloride intracellular channel 1
Cytoskeletal ACTG1 Protein Alpha tubulm 
Beta Actm 
Vimentin
Protein Turnover
Chain D, Cathepsin B (E C 3 4 22 1)
Chain H Cathepsin D at pH 7 5 
HPRT
Prolyl 4-hydrolase, beta subunit
Proteasome (prosome, macropain) subunit, alpha type,
5
Translation
Eukaryotic translation elongation factor 1 delta 
isoform
Table 3 4 9 Ontology analysis of identified proteins from DLKP-A versus DLKP-A2B
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3 4 4.2 Pathway Assist analysis of identified proteins between DLKP-A and DLKP- 
A2B
Pathway Assist analysis was earned out on the identified differentially regulated spots in 
DLKP-A versus DLKP-A2B to identify both direct and common pathways between the 
proteins Figure 3 4 15 shows only direct links between the list of differentially 
regulated proteins submitted to pathway analysis As with DLKP-A, proteins involved 
in stress response and apoptosis are shown Cathepsin D has been show to activate 
cathepsin B and that cathepsin B influences dephosphorlyation of cathepsin D
Figure 3 4 15 PathwayAssist analysis of direct interactions between proteins This identifies 
only direct links between the proteins This finds proteins that are regulated by all selected 
nodes The proteins with direct links are shown in grey Red line indicates an inhibitory effect 
Grey dashed lines indicate effect on expression
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Figure 3.4.16 shows the pathways built based on common targets for selected nodes (i.e. 
differentially regulated proteins). Pathway analysis found that processes of regulation of 
signal transduction and assembly and that the proteins HPRT1 and galectin-1 are 
important in the loss of adriamycin resistance in DLKP-A2B compared to DLKP-A. 
Stimulators of signal transduction include NME1, HPRT1, PRDX3, HSPA8, ANAX1, 
TXN and LGALS1. The majority of these are up-regulated as resistance fell in DLKP- 
A2B. There are no inhibitors of signal transduction. The stimulators of assembly 
include NME1, TXN, HSPA8, ACTB and EEF1D
Figure 3.4.16 Pathway Assist analysis of common interactions between proteins. Selected 
protein nodes are shown in grey the picture with the cellular processes in yellow and functional 
classes in orange. Green and red lines mark positive and negative regulatory effects 
respectively. Grey lines indicate an unknown regulatory effect.
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3.4.5 DeCyder analysis of DLKP-A versus DLKP-A5F
This experiment was designed to compare DLKP-A to a more resistant subpopulation, 
DLKP-A5F in order to examine the protein expression changes resulting from an 
increase in drug resistance. The experimental design for DIGE analysis of DLKP-A 
compared to DLKP-A5F is identical to that of DLKP versus DLKP-A.
Difference In-gel Analysis of DLKP-A (the control) compared to DLKP-A5F using 
Decyder™ revealed a total of 3323 ± 233 protein spots. Biological variation analysis 
revealed a total of 106 spots showing a greater than 1.2-fold change in expression with a 
t-test score of 0.05 or less. Of these 106 spots, 21 have been identified by MALDI-TOF 
mass spectrometry. A total of 85 differentially regulated spots were not identified (72 
down-regulated and 13 up-regulated).
O  ^  i f
Figure 3.4.17 A representative Cy5 labelled DLKP-A5F gel showing completed BVA analysis 
of DLKP versus DLKP-A5F. Spots circled in blue are the 106 statistically significant 
differentially regulated proteins (p< 0.05, protein fold >1.2).
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Figure 3.4.18a-b Colloidal coomassie stained preparative DLKP-A gel, which marks the 
proteins in common with DLKP versus DLKP-A - white spots (Figure 3.4.8). Yellow spots 
indicate the overlapping proteins from DLKP-A vs -A2B and/or -A 10. Blue proteins are unique 
to DLKP-A5F
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Comparisons between DLKP-A versus DLKP-A5F and DLKP versus DLKP-A 
revealed that ten proteins were shared (white spots in Figure 3.4.8 Table 3.4.10). Of the 
commonly shared proteins, many show a positive correlation with an increase of 
resistance when taking DLKP versus DLKP-A into account. Heat shock protein 27 kDa 
developed a further increase in protein expression as resistance increased. 
Pathway Assist analysis of HSP 27 kDa reveals it to be involved in the regulation of 
signal transduction, contraction, assemble, differentiation and maturation. In DLKP vs 
DLKP-A it is also involved in the regulation of contraction, differentiation and is also 
involved in apoptosis, mitogenesis, cell survival, proliferation and drug resistance.
The protein expression of both apoptosis/redox regulation proteins increased with a rise 
in drug resistance, they include thioredoxin peroxidase B and galectin-1. Both of these 
proteins were previously down-regulated in DLKP versus DLKP-A but became 
increased in DLKP-A versus DLKP-A5F.
In contrast, the protein expression of elF 2b and triosephosphate isomerase decreased in 
DLKP-A versus DLKP-A5F. A further decrease in expression is observed in two stress 
response proteins, (stress induced phosphoprotein and HSP 70 kDa protein 8 isoform 2) 
and the translation protein, elF 5a.
Spot
No.
Protein Name
A vs. 
A5F Pi
Mw
DLKP vs. 
DLKP-A
16 elF 2b -1.38 6.5 58.17 1.42
19 Stress induced phosphoprotein -1.35 6.4 63.25 -1.43
25 HSP 27 kDa protein 1.55 6 22.82 1.47
27 HSP 70 kDa protein 8 isoform 2 -2.15 5.6 53.6 -1.25
28 Triosephosphate isomerase -2.26 6.5 26.95 1.89
29 Triosephosphate isomerase 6.5 26.95 -1.46
30 Thioredoxin peroxidase B 1.44 5.7 21.68 -2.33
33 Sorcin 1.47 5.1 20.61 1.51
35 elF 5a -2.04 5.1 16.98 -2.63
37 Galectin-1 1.65 5.3 14.75 -1.55
Table 3.4.10 Overlapping protein spots between the comparisons DLKP versus DLKP-A and 
DLKP-A versus DLKP-A5F Comparisons between both experiments revealed that 9 proteins 
were shared (white spots in Figure 3.4.18).
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Comparisons between DLKP-A versus DLKP-A2B and DLKP-A versus DLKP-A5F 
revealed that three proteins overlapped namely, actin G, chain B, Horf 6 a novel human 
peroxidase enzyme and HRPT (Table 3 4 11) In the less resistant variant the protein 
expression of the apoptotic/redox regulation proteins, chain B, Horf 6 a novel human 
peroxidase enzyme, decreased from 1 34-fold in DLKP-A5F to -1 61-fold in DLKP- 
A2B In contrast, increased protein expression was observed in the cytoskeletal proteins 
actin G that was 4 07-fold decreased in DLKP-A5F but became 6-fold increased in 
DLKP-A2B Protein expression of the RNA processing protein HPRT was increased 
from -1 71 in DLKP-A2B to -1 33 in DLKP-A5F
Spot
No
Protein Name gi Number
Gene
Symbol
Fold pi Mw
39 Actin G1 protein gi|40226101| ACTG1 -4 07 55 26 68
43 Chain B, Horf 6 a novel 
human peroxidase enzyme gi|3318842| - 1 34 6
24 9
46 HPRT gi|6730253 HPRT1 -1 33 5 5 39 3
47 Synovial sarcoma 
breakpoint 3 gi|57162655| SSX3 -1 73 6 1
11 37
48 BlP gi|6470150| GBP -2 04 5 72 21
49 Prohibitin gi|76879893| PPA1 -2 13 56 29 87
50 Heat shock 27kDa protein gi|54696638| HSPB1 1 48 6 22 82
51 Beta tubulin gi| 18088719] TUBB -1 93 4 7 50 11
Table 3 4 11 Overlapping protein spots between the comparisons DLKP versus DLKP-A5F and 
DLKP-A versus DLKP-A2B, A10 (spots marked yellow in Figure 3 4 18)
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Three proteins were determined to be unique to DLKP-A versus DLKP-A5F with 
functions including proteins turnover, cytoskeletal and RNA processing The 
Pathway Assi st analysis software failed to find any common or direct interactions 
between the putative protein of Nbla 10058 and Alpha tubulin 6 variant proteins (Table 
3 4 12) ER-60 is involved in the following cellular processes regulation of signal 
transduction, s phase, contraction and synthesis (Figure 3 4 21)
Spot
No
Protein Name gi Number
Gene
Symbol
Fold Pi Mw
62 Putative protein of Nbla 
10058 gi|76879893| PPA1 -1 76 5 9 49
63 Alpha tubulin 6 variant gi|62897609| TUBA6 -1 38 5 50 49
64 ER-60 gi|2245365| PDIA3 1 45 6 57 18
Table 3 4 12 Protein spots unique to DL £P-A5F (spots marked blue in Figure 3 4 18)
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3.4.5.1 Proteins identified between DLKP-A versus DLKP-A5F
Proteins with decreased protein expression are involved in all reported functions except 
ion binding/transport. Proteins showing increased expression have functions involving 
stress response, ion binding/transport, apoptosis/redox regulation and RNA processing 
(Table 3.4.16). Stress response, cytoskeletal and apoptosis/redox regulation proteins 
account for 25%, 15% and 15% respectively. Transcription/transcription regulation, 
glycolysis and RNA processing each accounts for 10%. The remainder of the proteins 
account for 5% each (Figure 3.4.19). A similar level of apoptosis/redox regulation, 
protein turnover and stress response proteins was observed in both DLKP versus 
DLKP-A and DLKP-A versus DLKP-A5F. There are approximately twice as many 
RNA processing, transcription, cytoskeletal and translation/translation regulation 
proteins regulated in DLKP-A versus DLKP-A5F compared to DLKP versus DLKP-A. 
In contrast, ion binding/transport accounts for 11% of the differentially regulated in 
DLKP versus DLKP-A, which is double that in DLKP-A5F. Glycolytic proteins are 
more differentially regulated in DLKP versus DLKP-A in comparison to DLKP versus 
DLKP-A5F (Table 3.4.13, Figure 3.4.19).
iin Turnover 
5%
Translation
10%
Apoptos is/Redox 
Regulation 
14%
Ion Binding/ 
Transport 
5%
Glycolysis
10%
Stress Response 
23%
Transcription/
Transcription
Regulation
10%
Processing
10%
Cytoskeletal
13%
Figure 3.4.19 Ontology analysis of differentially regulated proteins.
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Reported Function Protein Name
Apoptosis/Redox regulation
Galectin 1, chain a
Thioredoxin peroxidase B chain J
Peroxidase
Glycolysis Tnosephosphate isomerase
Transcription/Transcription Regulation Prohibitin
Synovial sarcoma breakpoint 3
Stress Response
BiP
HSP 27 kDa
HSP 70 kDa protein 8 isoform 2 
Stress induced phosphoprotein
Cytoskeletal Actin G 
Alpha tubulin 6 
Beta tubulin
Translation EIF 2b 
EIF 5a
Ion Binding/Transport Sorcin isoform b
RNA Processing ER-60
HPRT
Protein Turnover Putative protein ofNblal0058
Table 3 4 13 Ontology analysis of identified proteins from DLKP versus DLKP-A5F
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3.4.5.2 Pathway Assist analysis of identified proteins between DLKP-A and DLKP- 
A5F
PathwayAssist analysis was carried out on identified differentially regulated spots in 
DLKP-A versus DLKP-A5F to identify both direct and common pathways between the 
proteins. Figure 3.4.20 shows only direct links between the list of differentially 
regulated proteins submitted to pathway analysis.
HSP 70 kDa protein 8 isoform 2, HSP 27 kDa and HSP 1 lOkDa have been reported to 
spontaneously form a large complex and to directly interact with one another in vitro in 
mammalian culture systems. The stress-induced-phosphoprotein, STIP1 is also known 
as the Hsp70/Hsp90-organising protein as it binds to the HSPA8 proteins. The GRP58 
proteins (also known as PDIA3 and ER-60) interact with high mobility group box 
proteins 1 and 2, HSPA8 and 3-phosphate dehydrogenase complex. It results after the 
incorporation of unnatural nucleosides into the DNA structure and is a determinant of 
cell sensitivity to DNA modifying chemotherapy. (3-tubulin has also been shown to 
bind the HSP27 kDA protein.
Figure 3.4.20 PathwayAssist analysis of direct interactions between proteins. The proteins 
involved in expression are shown in grey. Purple line indicates protein binding.
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Figure 3.4.21 shows the pathways built based on common targets for selected nodes (i.e. 
differentially regulated proteins). Pathway analysis found that processes of 
differentiation, synthesis and regulation of signal transduction are important in the gain 
of adriamycin resistance in DLKP-A5F compared to DLKP-A. Important proteins 
include HSPB1, PHB and HPRT1.
The stimulators of differentiation include LGALS1, TUBB, HSPB1 and HPRT1, which 
are both increased and decreased in DLKP-A5F.
The two stimulators of synthesis include GRP58 and TUBB both of which are down- 
regulated in DLKP-A5F. PHB negatively affected synthesis and is down-regulated in 
DLKP-A5F
Figure 3.4.21 Pathway Assist analysis of common interactions between proteins. The selected 
proteins are shown in grey the picture with the cellular processes in yellow, small molecule in 
green and functional classes in orange. Green and red lines mark positive and negative 
regulatory effects respectively. Grey lines indicate an unknown regulatory effect.
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3.4.6 DeCyder analysis of DLKP-A versus DLKP-A10
This experiment was designed to compare DLKP-A to a more drug-resistant variant, 
DLKP-A10 in order to examine the protein expression changes resulting from this 
increase in resistance. The experimental design for DIGE analysis is identical to that of 
DLKP versus DLKP-A as outlined in Table 3.4.3 with DLKP-A as the control and 6 
biological replicates included.
Difference In-gel Analysis revealed a total of 3118 ± 524 protein spots between DLKP- 
A and DKLP-A10. Biological variation analysis revealed a total of 149 spots showing a 
greater thanl.2-fold change in expression with a t-test p-value score of 0.05 or less 
(Figure 3.4.22). Of these 149 spots, 34 have been identified by MALDI-TOF mass 
spectrometry (Figure 3.4.23). A total of 34 differentially regulated spots 115 were not 
identified (76 down regulated and 39 up regulated).
Figure 3.4.22 A representative Cy5 labelled DLKP-A 10 gel showing completed BVA analysis 
of DLKP versus DLKP-A 10. Spots circled in blue are the 149 statistically significant 
differentially regulated proteins (p< 0.05, protein fold >1.2).
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Figure 3.4.23a-d Colloidal coomassie stained preparative DLKP-A gel which marks identified 
differentially regulated protein spots between DLKP-A and DLKP-A 10. Spots in white are 
overlapping with DLKP-versus DLKP-A. Spots in yellow overlap with A5F and/or A2B. Spots 
in red are unique to A10. Due to problems with the ImageMaster software spots 35, 39 and 29 
had to added separately and are not on the main picture.
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Comparisons between DLKP-A versus DLKP-A10 and DLKP versus DLKP-A revealed 
that twelve proteins were shared (white spots in figure 3 4 13)
The K alpha 1 protein, 1 55-fold decreased in DLKP versus DLKP-A is now 1 81-fold 
increased in DLKP-A10, which correlates with an increase in drug resistance 
The ion binding/transport proteins annexin and sorcin have lower levels of resistance in 
DLKP-A10 compared to DLKP versus DLKP-A A loss of protein expression was also 
observed with all other shared proteins
Spot
No
Protein Name Fold Pi Mw
DLKP vs 
DLKP-A
4 HSP 70 protein 8 isoform 2 1 44 56 53 6 3 21
11 CCT2 1 8 6 57 78 2 58
16 elF 2b -1 63 65 58 17 1 42
18 K alpha 1 protein 1 81 5 50 49 -1 55
20 Annexin A1 2 06 7 9 35 25 2 29
21 Annexin A1 2 19 7 9 35 25 251
27 HSP 70 kDa protein 8 isoform 2 -6 5 56 53 6 -1 25
29 Tnosephosphate isomerase -3 21 65 26 95 -1 46
31 K130r mutant 1 54 65 21 14 1 54
33 Sorcin -2 33 5 1 20 61 1 51
34 Nucleoside diphosphate kinase 1 1 27 54 19 86 1 54
35 eIF5a -2 85 5 1 16 98 -2 63
Table 3 4 18 Overlapping protein spots between the comparisons DLKP-A versus DLKP-A 10
and DLKP versus DLKP-A (spots marked white in Figure 3 4 23)
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Comparisons between DLKP-A versus DLKP-A10 and DLKP-A versus DLKP-A2B 
revealed that four proteins overlapped namely, annexin 1, HSP 70 kDa protein 8 
isoform 2, eukaryotic translation elongation factor 1 delta isoform and vimentin 
Annexin 1 was 1 6-fold decreased in the DLKP-A2B cell line, proteins expression 
decreased further in DLKP-A10 The heat shock protein while increased m DLKP-A2B 
(7 9-fold) is now 1 51-fold decreased in DLKP-A10 In contrast and in correlation wth 
drug resistance, vimentin is 1 64-fold decreased in DLKP-A2B but increased in DLKP- 
A10
A comparison between DLKP-A versus DLKP-A10 and DLKP-A versus DLKP-A5F 
again revealed that four proteins overlapped These included synovial sarcoma 
breakpoint 3, BiP, prohibitin and beta tubulin These proteins are further decreased in 
DLKP-A10 in comparison to DLKP-A2B (Table 3 4 19)
Spot
No
Protein Name gi Number
Gene
Symbol
Fold pi M.W
39 Actin G gi|40226101| ACTG1 -4 69 5 5 26 68
40 Annexin 1 gi|442631| ANXA1 -2 27 54 35 25
42 HSP 70 kDa protein 8 
isoform 2 gi|62896815| HSPA8 -1 51 5 6 53 6
44
Eukaryotic translation 
elongation factor 1 delta 
isoform
gi| 152154511 EEF1D -1 67 4 9 31 22
45 Vimentin gi|37852| VIM 3 88 5 1 53 72
47 Synovial sarcoma 
breakpoint 3 gi|57162655| SSX3 -1 9 6 1
11 37
48 BiP gi|6470150| GBP -3 5 72 21
49 Prohibitin gi|76879893| PHB -2 28 56 29 87
51 Beta tubulin gi| 18088719| TUBB -5 23 4 7 50 11
Table 3 4 19 Overlapping protein spots between the comparisons DLKP versus DLKP-A 10 
and/or DLKP-A versus DLKP-A5F, -A2B (spots marked yellow in Figure 3 4 23)
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Sixteen proteins were determined to be unique to DLKP-A versus DLKP-A10, the 
majority of which are involved in the cytoskeleton and are predominantly down- 
regulated The remaining proteins also predominantly down-regulated have functions 
involving proteins turnover, cell signalling, glycolysis, stress, ion binding/transport, 
transcription regulation and RNA processing (Table 3 4 20)
Spot
No
Protein Name gi Number
Gene
Symbol
Fold Pi M W
65
26S proteasome- 
associated padl homolog 
variant
gi|62088020| PSMD14 -1 54 65 18 99
66 Beta Actin gi| 15277503 ACTB 1 64 58 40 83
67 Beta Actin gi| 15277503 ACTB 1 63 56 40 54
68 Beta Actin gi| 15277503 ACTB -2 03. 5 6 40 54
69 Aldehyde Dehydrogenase 
A1 gi|2183299| ALDH1A1 1 45 63 55 4
70 Actin G1 gi|178045| ACTG -2 85 5 5 29 68
71 Chloride intracellular 
channel 4 gi|55666469| CLIC4 -4 69 5 5 28 98
72 hnRPF gi|16876910| HNRPF 1 92 54 46 02
73 HSP 60 kDa gi|77702086| HSPD1 1 33 5 7 61 37
74 HSPC124 gi|6841470| PPA2 -2 48 56 36 96
75 LASP 1 gi|2135552| Lasp-1 -1 48 6 1 30 19
76 Peroxiredixm 3 isoform a 
precursor variant gi|62896877| PRDX3 -145 8 27 95
77 Retinoblastoma binding 
protein 7 gi|57209889| RBBP7 -2 43 4 9 47 6
78 Rho GDP dissociation 
inhibitor (GDI) alpha gi|30582607| ARHGDIA -1 83 5 23 25
79 Peroxiredoxin 2 gi| 1617118| PRDX2 -1 86 5 2 18 48
80 Vimentin gi|57471646| VIM -2 24 5 47 53
Table 3 4 20 Proteins unique to DLKP-A versus DLKP-A 10 (spots marked m red in Figure
3 4 23)
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3.4.6.1 Proteins identified between DLKP-A versus DLKP-A10
Proteins with decreased protein expression have all reported functions in Table 3.4.22 
except RNA processing and glycolysis. In contrast, proteins with increased protein 
expression are involved in RNA processing, glycolysis, cytoskeleton, stress, 
apoptosis/redox regulation and ion binding/transport. The majority of protein changes 
are involved in cytoskeleton, stress response, ion binding/transport and transcription/ 
transcription regulation account for 25%, 21%, 15 and 12% respectively.
Apoptosis/redox regulation proteins, proteins involved in glycolysis and translation 
each accounts for 6%. The remainder of the proteins account for 3% each (Figure 
3.4.19). A similar level of protein turnover, translation/translation regulation, RNA 
processing, ion binding/transport, stress response and cell signalling proteins were 
observed in both DLKP versus DLKP-A and DLKP-A versus DLKP-A10. There are 
approximately twice as many transcription proteins in DLKP-A10 compared to DLKP 
versus DLKP-A and three times more cytoskeletal. In contrast, there are approximately 
twice as many glycolytic and apoptosis/redox regulation proteins in DLKP versus 
DLKP-A compared to DLKP-A versus DLKP-A10 (Table 3.4.21, Figure 3.4.24 and 
Figures 3.4.9).
Translation
8%
RNA Processing
Stress Response 
19%
Cell Signalling
3%
Cytoskeletal
26%
Transcription/Tran­
scription 
Regulation 
11%
Apoptosis/Redox
Regulation
5% Glycolysis 
8%
Protein Turnover
3%
Figure 3.4.24 Ontology analysis of differentially regulated proteins.
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Reported Function Protein Name
Apoptosis/Redox regulation fC130r mutant of human DJ-1 
Peroxiredoxin variant 2
Glycolysis Peroxiredoxin 2 
Aldehyde dehydrogenase 1
Stress Response HSPC 124
HSP 70 kDa protein 8 isoform 2 
HSP 60 
BlP Protein 
CCT2
Ion Binding/Transport Annexin A1
Chloride intreacellular channel 4 
Sorcin isoform b
Translation
elF 5a 
eEF 2b
Eukaryotic translation elongation factor 1 delta, 
isoform 2
Cytoskeletal ACTB Protein 
ACTG1 
Beta tubulin 
Tubulin alpha 6 
Vimentin 
LASP 1
Protein Turnover 26S proteasome-associated padl homolog variant
Cell Signalling Rho GDP dissociation inhibitor alpha
T ranscri ption/T ranscr lpt ion 
Regulation Prohibitin
Retinoblastoma binding protein 7 
Synovial sarcoma, X breakpoint 3 
Nucleoside diphosphate kinase 1
RNA Processing hnRPF
Table 3 4 21 Ontology analysis of DLKP-A10
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3.4.6.2 PathwayAssist analysis of identified proteins between DLKP-A and DLKP- 
A10
PathwayAssist analysis was carried out on differentially regulated spots in DLKP-A 
versus DLKP-A10 to identify both direct and common pathways between the proteins. 
Figure 3 .4.25 shows only direct links between the list of differentially regulated proteins 
submitted to pathway analysis.
The RhoGD protein inhibits the eukaryotic translation elongation factor 1 delta proteins 
which is a guanine nucleotide exchange protein. The CLIC4 protein has been shown to 
bind beta actin in vivo. NME1 forms molecular complexes with beta tubulin and that the 
number of complexes increases during the differentiation process of murine cells.
inhibitory effect.
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Figure 3.4.26 shows the pathways built based on common targets for selected nodes (i.e. 
differentially regulated proteins). Pathway analysis found that processes of apoptosis 
and differentiation are important in the development of increased adriamycin resistance 
in DLKP-A. Stimulators of apoptosis include ARHGD1 A, PHP, ANAX1, NME, EEF2, 
CLIC4, HSPD1, VIM, and RBBP7. The majority of these are down-regulated in DLKP- 
A10. Inhibitors of apoptosis include PRDX3 and PRDX2, HSPA8 and ALDH1A1. 
With the exception of ALDH1A1 the expression of all other proteins is decreased in 
DLKP-A10.
Eight proteins were observed to interact with the differentiation cell process. The single 
inhibitory protein of differentiation, NME1 was found to be increased in DLKP-A10 by 
1.27-fold. The remaining stimulators of differentiation were all decreased except for 
ALDH1A1.
Figure 3.4.26 Pathway Assist analysis of common interactions between proteins. The selected 
protein nodes are shown in grey the picture with the cellular processes in yellow and functional 
classes in orange. Green and red lines mark positive and negative regulatory effects 
respectively. Grey lines indicate an unknown regulatory effect.
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3 4 7 Correlation with drug resistance
Figure 3 4 27 and Table 3 4 22 shows differentially expressed proteins that correlate 
with drug resistance across the panel of adnamycin cell lines These proteins are all up- 
regulated in DLKP versus DLKP-A and are further increased in other cell lines in the 
panel Proteins involved in transcription/transcription namely nucleoside diphosphate 
kinase and replication A2 are similarly changed in DLKP-A2B with NME1 being 
further up-regulated in the most resistant cell line, DLKP-A 10 The three stress 
response proteins especially CCT2 and HSPA8 are markedly increased in DLKP-A10 
Similar results are seen for the apoptosis/redox regulation protein K130r mutant of 
human Dj-1 (PARK7) The two isoforms of the ion binding protein, annexin A1 are also 
strongly up-regulated in DLKP-A 10
Spot
No
Gene Name DLKP DLKP-
A2B
DLKP-
A
DLKP-
A5F
DLKP-
A10
34 NME1 -1 54 -1 28 1 1 1 27
22 RPA2 -1 5 -1 29 1 1 1
25 HSPB1 -1 47 1 1 1 48 1
11 CCT2 -2 58 1 1 1 1 8
31 PARK7 -1 54 1 1 1 1 26
4 HSPA8 -3 21 1 1 1 1 44
20 ANXA1 -2 29 1 1 1 2 06
21 ANXA1 -2 51 1 1 1 2 19
Table 3 4 22 Proteins correlating with drug resistance across the adnamycin-resistant panel
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NDPK
Replication A1 
HSP 27 
CCT2
K130r mutant of human DJ-1 
HSP70kDa protein 8 isoform 2 (4) 
Annexin 1 (20) 
annexin 1(21)
DLKPA
2.5 -r
DLKP DLKP-A2B DLKP-A 
Cell Line
DLKP-A5F DLKP-A10
Figure 3.4.27 Proteins correlating with drug resistance across the adriamycin-resistant panel. 
Numbers in brackets indicate spot numbers.
Figure 3.4.28 and Table 3.4.23 shows differentially expressed proteins that inversely 
correlate with drug resistance across the panel. The stress response proteins stress 
induced phosphoprotein and HSP 70kDa protein 8 isoform 2 are further decreased in 
A5F and/or A10. BiP is unchanged in DLKP versus DLKP-A but decreased in A5F and 
A10. The transcription/transcription regulation proteins, prohibitin and synovial 
sarcoma breakpoint 3 though unchanged in DLKP versus DLKP-A but decreased in the 
more adriamycin-resistant variants. The glycolytic protein triosephosphate isomerase 
and the cytoskeletal protein, gamma actin are both decreased in DLKP versus DLKP-A, 
increased in A2B and decreased in both A5F and A10. The translation protein, eIF5a is 
decreased in DLKP-A and further decreased in DLKP-A5F and DLKP-A10.
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Spot
No.
Gene Name DLKP DLKP-
A2B
DLKP-
A
DLKP-
A5F
DLKP-
A10
19 STIPI 1.43 1 1 -1.35 1
27 HSPA8 1.25 2.87 1 -2.15 -6.5
49 PPAI 1 1 1 -2.13 -2.28
48 GPB 1 1 1 -2.04 -3.00
47 SSX3 1 1 1 -1.73 -1.9
35 EEF5A 2.63 1 1 -2.04 -2.85
39 ACTG 1 6 1 -4.07 -4.69
29 TPI 1.46 1.87 1 -2.06 -3.21
Table 3.4.23 Proteins inversely correlating with drug resistance across the adriamycin-resistant 
panel
— ♦ — stress induced phosphoprotein HSP70kDa protein 8 isoform 2 (27)
prohibitin - x- Bip
- x  synovial sarcoma Xbreakpoint 3 •  EIF5a
Cell Line
Figure 3.4.28 Proteins inversely correlating with increasing resistance (Brackets indicate spot 
number where isoforms are present).
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Figure 3.4.29 and Table 2.4.24 shows the proteins increased in DLKP versus DLKP-A
but show no change in the other adriamycin-resistant variants.
Spot
No.
Gene Name DLKP DLKP-
A2B
DLKP-
A
DLKP-
A5F
DLKP-
A10
1 VCP -2.32 1 1 1 1
2 HSPA9B -1.97 1 1 1 1
3 LMNB1 -3.07 1 1 1 1
5 CCT3 -1.89 1 1 1 1
6 HNRPK -1.93 1 1 1 1
7 ALDH1A1 -1.65 1 1 1 1
8 ALDH1A1 -1.52 1 1 1 1
9 OXCT1 -2.3 1 1 1 1
10 ALDH1A1 -1.47 1 1 1 1
12 HNRPH1 -1.52 1 1 1 1
13 GDI2 -1.69 1 1 1 1
15 STOML2 -2.03 1 1 1 1
22 ANXA1 -1.63 1 1 1 1
28 TPI -1.89 1 1 1 1
Table 3.4.24 Proteins only increased in DLKP-A versus DLKP. There is no change across the 
rest of the panel.
DLKP A
VCP protein 
lamin 61 
HNRPK
- t -  Aldehyde dehydrogenase 1 (8) 
—  Aldehyde dehydrogenase 1(10) 
Rab dissociation inhibitor beta 
Annexin 1 (22)
HSP70 KDa 9B
Chaperonin containing TCP1 subunit 3 
Aldehyde dehydrogenase 1 (7) 
Succinyl-CoA 3 ketoacid CoA transferase 
HNRPH1
HSPC108 (stomatin)
Triosephosphate isomerase (28)
2
o
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Ö
ok_
CL
0.80
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0.40
DLKP DLKP A DLKP A2B DLKP A5F DLKPA10
Cell Line
Figure 3.4.29 Proteins correlating with a baseline increase in resistance (Brackets indicate spot 
number where isoforms are present),
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Figure 3.4.30 and Table 2.4.25 shows the proteins decreased in DLKP versus DLKP-A
but show no change in the other adriamycin-resistant variants.
Spot
No.
Protein Name DLKP DLKP-
A2B
DLKP-
A
DLKP-
A5F
DLKP-
A10
14 OATL1 3.45 1 1 1 1
17 HSPA8 2.15 1 1 1 1
24 P_5 2.18 1 1 1 1
32 PRDX2 1.95 1 1 1 1
Table 3.4.24 Proteins decreased in DLKP versus DLKP-A only. There is no change across the 
rest of the panel
DLKP A
4
3.5
3
<D
o 2.5
Cl
CO
o 1.5u.
1
DLKP DLKP A DLKPA2B DLKP A5F DLKPA10
Cell Line
Figure 3.4.30 Proteins inversely correlating with a baseline resistance (Brackets indicate spot 
number where isoforms are present).
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3 5 Proteomic analysis of DLKP-Mitox
Resistance to the chemotherapy drug mitoxantrone has been associated with several 
mechanisms such as drug accumulation defects, a decrease in its target proteins 
topoisomerase II a and P 4 and overexpression of the breast cancer resistance half 
transporter protein (BCRP1) While the main mechanism of resistance in DLKP-Mitox 
is associated with BCRP1, little information on cytoplasmic changes is available This 
work set out to investigate differential protein expression resulting from mitoxantrone 
resistance in DLKP Previously, the DLKP cell line was pulsed 5 times with 60ng/ml 
mitoxantrone to establish resistance (Liang et a l , 2004) The resulting cell line, DLKP- 
Mitox was 5 8-fold stably resistant to mitoxantrone No cross-resistance developed to 
adriamycin or taxotere The cell line became sensitised to carboplatin (0 4-fold) Low 
cross-resistance developed to vincristine (1 6-fold) and methotrexate (1 4-fold) The 
mitoxantrone resistance was confirmed by toxicity assays (section 2 8 1) In this section 
of the thesis, DLKP was used as the control and compared to DLKP-Mitox It is also of 
interest to compare proteins altered in DLKP versus DLKP-A with DLKP versus 
DLKP-Mitox as both adriamycin and mitoxantrone are alkylating agents Mitoxantrone 
is an analogue of adriamycin and has less cardiotoxicity
3 5 1 Screening of DLKP and DLKP-Mitox protein samples
As previously mentioned, the DIGE system required six high quality protein samples of 
each cell line (section 2 15) The gels were silver-stained to ensure the quality of protein 
samples The best six samples showing most solubilised, well-defined protein spots, 
free of streaking and salt fronts were selected
♦ * I
Figure 3 5 la-b Silver 
stained images of 
DLKP and DLKP- 
Mitox A volume of 
75 \x% protein of all 
cell lysates for 2D- 
DIGE analysis were 
run on pH 4-7 IPG
Figure 3 51a DLKP Figure 3 5 lb  DLKP-Mitox stnps
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3.5.2 The invasive status of the mitoxantrone-resistant variant of DLKP
Invasion assays were performed, as described in Section 2.11, to assess the ability 
DKLP and DLKP-Mitox to invade through matrigel. Cell culture inserts were coated 
with matrigel and placed in medium containing 24-well plates prior to cell addition. 
Cells were considered invasive if they migrated through the matrigel and the 8 |aM 
porous membrane and attached to the underside of the membrane within 24 hours. The 
images presented are representative of at least three separate experiments, are at a 
magnification of 10X and are stained with crystal violet.
The DLKP parental cell line is invasive (Figure 3.5.2). Decreased invasion was 
observed in DLKP-Mitox (Figure 3.5.3) when compared to the parent.
Figure 3.5.2 DLKP Figure 3.5.3 DLKP-Mitox
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3.5.2.1 Quantification of invasion
The invasion assays were quantified by counting cells with a graticule at 40X 
magnification (Table 5.2.1, Figure 3.5.4). Proteomic analysis was carried out on these 
cell lines. The data shows that DLKP-Mitox is less invasive than DLKP.
Cell Line Average cell count/area/view P value
DLKP 11.35± 1.09 -
DLKP-Mitox 0.85 ± 0.05 0.003
Table 3.5.1 Quantification of DLKP and DLKP-Mitox. The values are given as the average cell 
counts/area/view ± the standard deviation. (n=3).
DLKP DLKP-Mitox
Cell Line
Figure 3.5.4 Quantification of mitoxantrone resistant variant of DLKP
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3.5.3 Experimental outline of labelling of DLKP and DLKP-Mitox
The experimental design for DIGE analysis of DLKP versus DLKP-Mitox is outlined as 
follows: Six biological replicates of DLKP and DLKP-Mitox were labelled with 
200pmol of Cy3 and Cy5 respectively (section 2.16.1.3). Each replicate was also 
labelled with Cy2 for the internal control. This generated a total of 150|ug lysate/gel 
(50|ig Cy2 internal standard, 50jng Cy3 and 50|ig Cy5).
Difference In-gel Analysis of DLKP compared to DLKP-Mitox using Decyder™ 
revealed a total of 2221 ± 140 protein spots. BVA revealed a total of 343 spots showing 
a greater than 1.2-fold change in expression with a t-test score of 0.05 or less of which 
147 had a p value less than 0.01 (Figure 3.5.5). Of these 343 spots, 60 have been 
identified by MALDI-TOF mass spectrometry. A total of 283 differentially regulated 
spots were not identified.
Figure 3.5.5 Representative Cy5 labelled DLKP-Mitox gel showing completed BVA analysis 
of DLKP versus DLKP-Mitox between pH4-7. Spots circled in red are the 343 statistically 
significant differentially regulated proteins (p< 0.05, protein fold >1.2).
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3.5.4 Identification of differentially regulated proteins
MALDI-TOF mass spectrometry successfully identified 60 differentially regulated 
proteins between DLKP and DLKP-Mitox (Figure 3.5.6). Of these 60 spots, 31 were 
found to be up-regulated and 30 down-regulated (Table 3.5.2). For visual clarity, the 
proteins were numbered and the identification outlined in Table 3.5.2, 3.5.3 and 3.5.4. 
Table 3.5.2 shows the protein spots, which show shared expression between DLKP-A 
and DLKP-Mitox and are numbered to be consistent with those of DLKP versus DLKP- 
A. Table 3.5.3 shows the protein spots, which show shared expression between DLKP- 
Mitox and the DLKP-A variants A2B and A5F. Table 3.5.5 shows the differentially 
expressed protein spots, which are unique to DLKP-Mitox.
Figure 3.5.6 Colloidal coomassie stained preparative DLKP-A gel with the 60 identified protein 
spots exhibiting differential expression identified via MALDI-TOF MS analysis as listed in 
Tables 3.5.2, 3.5.3 and 3.5.5.
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3 5 5 Shared differentially expressed proteins between DLKP-A and DLKP-Mitox
Spot
No Protein Name gi Number
Gene
Symbol Fold Pi Mw
1 Valosin containing Protein gi|48257098| VCP -2 0 49 71 56
2 HSP70 kDa 9B (MTHsp75) gi|292059| HSPA9B -2 53 6 74 12
3 Lamin B1 gi|576840| LMNB1 -2 1 53 67 79
4 HSP 70 protein 8 isoform 2 gi|62896815| HSPA8 -2 99 56 53 6
5 Chaperomn containing TCP1 subunit 3 gi|58761484| CCT3 -2 02 6 57 78
6 hnRPK gi|55958547| HNRPK -2 69 54 42 02
8 Aldehyde dehydrogenase A1 gi|2183299| ALDH1A1 164 63 55 44
10 Aldehyde dehydrogenase A1 gi|2183299| ALDH1A1 1 61 63 55 44
14 Chain C, OAT Mutant Y85i gi|78101704| OATL1 196 66 48 81
16 elF 2b gi| 19353009) EIF2B -132 65 58 17
21 Annexin A1 gi|442631| ANXA1 1 89 79 35 25
22 Annexin A1 gi|442631| ANXA1 1 2 79 35 25
24 Protein disulphide isomerase protein 5 gi]1710248| p5 2 82 5 46 52
26 Actin G protein gi| 178045] ACTG1 -2 45 56 26 15
29 Tnosephosphate isomerase gi|66360366| TPI1 -1 25 65 26 95
31 K130r mutant of human DJ-1 gi|33358056| PARK7 1 25 65 21 14
33 Sorcin isoform b gi|38679884| SRI 3 85 5 1 20 61
34 Nucleoside diphosphate kinase 1 gi|38045913| NME1 -145 54 19 86
37 Galectm-1 gi|42542977| Galectm-1 -14 53 14 75
38 Thioredoxin delta 3 gi|l 827674| TXN 198 48 11 86
Table 3 5 2 Overlapping proteins form DLKP versus DLKP-Mitox and DLKP versus DLKP-A 
Gene symbol determined from DAVID software and PubMed Entrez gene (section 2 24) Where 
the same protein has two separate numbers this indicates the presence of isoforms e g annexin 
A1 Spots marked white in Figure 3 5 6
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Spot
No Protein Name gi Number
Gene
Symbol Fold Pi Mw
39 Actin G protein gi|l 78045| ACTG1 3 19 56 26 15
40 Annexin A1 gi|442631| ANXA1 2 21 79 35 25
49 Prohibitin gi|46360168| PHB -136 56 29 86
43 Chain B, Horf 6 a novel human 
peroxidase enzyme
gi|3318842| - -162 6 24 9
44 Eukaryotic translation elongation factor delta isoform 2 gi| 152154511 EEF1D 2 04 49 31 22
57 HSP 70 kDa protein 8 isoform 2 gi|62896815| HSPA8 179 56 53 646 Human Hprt gi|47115227| HPRT 2 25 55 39 359 Peroxiredoxin gi|62896877| PRDX3 22 7 1 27 95
60 prolyl 4-hydrolase beta subunit gi|48735337| P4HB 1 28 48 57 5
61 Proteasome subunit alpha type 5 gi|54696300| PSMA5 -128 47 26 58
65 26S Proteasome- associated Padl homologue variant gi|62088020| PSMD14 144 65 : 18 9968 Beta Actin gij 15277503| ACTB 2 01 40 54 56
69 Aldehydedehydrogenase 1A1 gi|2183299| ALDH1A1 157 63 55 4441 Chloride intracellular channel 1 gi|62898319| CLIC1 -1 34 5 1 27 3472 HNRPF gi| 16876910| HNRPF -1 71 54 46 02
76 Peroxiredixin 3 isoform a precursor variant 2 gi|62896877| PRDX3 1 61 8 27 9562 putative protein of Nbla10058 gi|76879893| PSMC2 -1 25 59 4963 Alpha tubulin 6 gi|62897609| TUBA6 139 5 50 4964 ER-60 protease gi| 1208427| PDIA3 -1 57 6 57 1851 Beta Tubulin gi| 18088719| TUBB -1 48 47 50 11
Table 353 Overlapping proteins form DLKP versus DLKP-Mitox, and DLKP-A versus 
DLKP-A2B, -A5F and -A 10 Gene symbol determined from “gi number” conversion software 
package “DAVID” and PubMed Entrez gene (section 2 24) (spots marked yellow, blue, green in 
Figure 3 5 6)
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Table 3 5 4 and Figure 3 5 7 shows differentially expressed proteins that are shared 
between DLKP and the adriamycin and mitoxantrone resistant variants Taking the 
cellular functions of these cells into account a number of observations can be made 
Proteins involved in glycolytic activities such as aldehyde dehydrogenase and 
triosephosphate isomerase are similarly up- or down-regulated respectively Ion binding 
protein annexin A1 while up-regulated in both variants are more strongly so in DLKP- 
A Conversely, sorcin appears more important to the DLKP-Mitox cell line Of interest 
are the opposite changes in stress-related proteins, in DLKP-Mitox these are down- 
regulated while in DLKP-A, they are up-regulated Apoptosis/redox-related proteins 
galectin-1 and K130r mutant of human DJ-1 are similarly regulated in the two cell lines
while thioredoxin delta 3 is more important in DLKP-Mitox than in DLKP-A
Spot
No
Gene
Symbol
DLKP vs 
DLKP-Mitox
DLKP vs 
DLKP-A Function
26 ACTG1 2 45 -145 Cytoskeleton3 LMNB1 -2 1 3 07
10 ALDH1A1 1 61 1 47
Glycolysis8 ALDH1A1 1 64 1 52
29 TPI -1 25 -1 46
22 ANXA1 1 2 1 63
Ion binding21 ANXA1 1 89 251
33 SRI 3 85 1 51
5 CCT3 -2 02 1 89
Stress Response2 HSPA9B -2 53 1 97
4 HSPA8 -2 99 3 21
37 Galectin-1 -1 4 -1 55
Apopto si s/Redox31 PARK7 1 25 1 54
38 TRX 1 98 -1 17
16 EIF2 -1 32 142 Translation
6 HNRPK -2 69 1 93 RNA processing
14 OAT 1 96 -3 45 Metabolism
34 NDPK -1 45 1 54 Transcription
24 PDI 2 82 -2 18 Protein turnover
Table 3 5 4 Interesting overlapping proteins form DLKP versus DLKP-Mitox, and DLKP 
versus DLKP-A
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Figure 3.5.7 Shared differentially expressed proteins between DLKP versus DLKP-Mitox and 
DLKP versus DLKP-A.
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3 5 6 Unique differentially expressed proteins between DLKP and DLKP-Mitox
Spot
No Protein Name gi Number
Gene
Symbol Fold Pi Mw
81 Aldehydedehydrogenase 1A1 gi|2183299| ALDH1A1 132 63 55 4482 Annexin A4 gi| 1703319| ANXA4 1 51 5 8 36 0983 Beta Actin gi|l 5277503| ACTB 2 97 56 40 54
84 Beta Actin gi|15277503| ACTB 2 53 56 40 5485 Beta Actin gi| 15277503) ACTB -137 56 40 54
86 Tropomyosin gi|825723| TPM1 3 1 48 26 6287 CGI-46 Protein gi|4929561| CGI-46 -1 35 63 48 588 GST-pi chain B gi|23200511| GSTP1 1 8 54 23 43
89 High mobility Group box 1 gi|55958717| HMGB1 24 56 25 1
90 HLA-B associated transcript 1 variant gi|62897383| BAT1 -2 05 55 49 5691 HSP 70kDa protein 8 isoform 2 gi|62896815| HSPA8 -2 3 56 53 692 KIAA0098 gi|58257644| CCT5 -1 73 55 6149
93 Mannose-6-phosphate receptor binding protein gi| 163067891 M6PRBP1 -1 26 53 47 1994 nucleophosmin gi|13536991| NPM1 -137 45 29 62
95 Phosphoglycerate mutase 1 (brain) variant gi|62897753| PGAM1 -3 34 67 28 9396 PKCq-mteractingprotein gi|6840947| TXNL2 -1 58 54 37 797 PP protein gi|33875891 PP -2 88 6 35 97
98 Proteasome activator subunit 3 gi|47523754| PSME3 -1 71 57 29 699 Proteasome beta 3 subunit gi|15278174| PSMB3 145 61 23 22100 Purine nucleoside phosphorlyase gi|387033| PNP 1 38 65 32 23101 Cofilm (non muscle) gi|30582531| CFL1 -3 77 65 24 46
Table 3 5 5 Proteins unique to DLKP versus DLKP-Mitox (spots markecpink in Figure 3
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3.5.7 Ontology analysis of identified proteins
Ontology information was obtained through PubMed searches. Of the identified 
proteins, the majority have functions in cytoskeleton (19%), protein turnover (13%) 
with apoptosis/redox regulation, ion binding/transport and stress response accounting 
for 12% each. Glycolytic and RNA processing proteins account for 10% respectively. 
Transcription accounts for 5% with 3% of the proteins involved in cell signalling and 
metabolism. Finally, 2% are involved in tumour immunity and translation (Table 3.5.6, 
Figure 3.5.8).
Twice the amount of cytoskeletal and RNA processing proteins are found in DLKP- 
Mitox compared to DLKP-A. In contrast, twice the amount of stress response proteins is 
found in DLKP-A compared to DLKP-Mitox. Similar metabolic, translation, 
transcription, cell signalling and ion binding/transport responses are found in both cell 
lines (Figure 3.4.9, Figure 3.5.8).
Mitoxantrone was designed to produce less free radicals in comparison to adriamycin 
however, similar levels of apoptotic/redox response proteins were differentially 
regulated in both cell lines. However, in contrast to DLKP-A, the majority of these 
proteins are up-regulated in DLKP-Mitox.
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Figure 3.5.8 Ontology analysis of differentially regulated proteins.
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Reported Function Protein Name
Apoptosis/Redox regulation
3eroxiredoxin 
5eroxidase 
GST-pi chain B 
Galectin 1,
Thioredoxin delta 3
Cl 3Or mutant of human DJ-1
Peroxiredixin 3 isoform a precursor variant 2
Glycolysis
Aldehyde dehydrogenase A1 
Triosephosphate isomerase chain b 
Phosphoglycerate mutase 1 (brain) variant
T ranscription/T ranscription 
Regulation
Nucleoside diphosphate kinase 1 
5rohibitin
-ligh mobility Group box 1
Stress Response
HSP 70 kDa protein 8 isoform 2 
HSP70 kDa 9B (MTHsp75) 
Chaperonin containing TCP1 subunit 3 
KIAA0098 
CGI-46 Protein
Ion Binding/Transport
Annexin A1
Sorcin isoform b
Chloride intracellular channel 1
Annexin A4
Nucleophosmin
Translation elF 2b
Cytoskeletal
^amin B1 
Alpha tubulin 6 
Tropomyosin 
Actin gl protein 
Beta Actin 
Beta Tubulin 
Cofilin
Cell Signalling VCP protein
5urine nucleoside phosphorlyase
RNA Processing
hnRPK
hnRPF
HPRT
ER-60
Vlannose-6-phosphate receptor binding protein 
EEF2
Metabolism Chain C, OAT Mutant Y85i 
PP protein
Protein Turnover
Putative protein of Nblal0058 
Proteasome subunit alpha type 5 
26S Proteasome-associated Padl homologue 
variant
Prolyl 4-hydrolase beta subunit 
Protein disulphide isomerase protein 5 
Proteasome beta 3 subunit 
Proteasome activator subunit 3 
PKCq-interacting protein
Tumour Immunity HLA-B associated transcript 1
Table 3.5.6 Ontology analysis of identified proteins from DLKP versus DLKP-Mitox
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3.5.8 PathwayAssist analysis of identified proteins
The gene symbol list was imported into the programme and from this both direct and 
common pathways were built. Only the differentially-regulated proteins were submitted 
for PathwayAssist analysis. Figure 3.5.9 shows only the direct links between 
differentially-regulated proteins between DLKP versus DLKP-Mitox. The NME1 
protein forms complexes with beta-tubulin in in vitro tumour cell lines, but not in 
primary tumours. GRP58 and P4HB have been shown to bind in bovine and canine 
systems. These four proteins are decreased in DLKP-Mitox. The high mobility groups 
box proteins 1 and 2 (HMGB1) complexes with heat shock protein (HSPA8). In 
eukaryotic systems, HMGB1 interacts with hnRNP K and GSTP1 binds with prohibitin. 
The VCP protein has been shown to interact with HSPA8 in yeast.
Figure 3.5.9 PathwayAssist analysis of direct interactions, identifying only direct links between 
the proteins. This finds proteins that are regulated by all selected nodes. Purple circles indicate 
binding, blue triangles indicate regulation and orange squares indicate effect on expression.
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Figure 3.5.10 shows the pathways built based on common targets for selected nodes (i.e. 
differentially regulated proteins). Pathway analysis found that processes of apoptosis 
and differentiation are important in the development of increased mitoxantrone in 
DLKP-Mitox. Stimulators of apoptosis include NME1, PARK7, LMNB1, ANAX1, 
GSTP1, LGALS1 and NPM1. The majority o f these are down-regulated in DLKP- 
Mitox. Inhibitors of apoptosis including HSPA9B, HSPA8, PRDX3, P4HB and 
ALDH1A1 are up-regulated in DLKP-Mitox. Stimulators of differentiation include 
BAT1, NP, TUBB, PSMC2, TXN, ALH1A1, HPRT1, PHB, GSTP1, HMGB1 and 
LGALS1. The majority o f these are increased in DLKP-Mitox. NME1 inhibits 
differentiation and is down-regulated.
molecules in green and functional classes in orange. Grey lines mark positive and negative 
regulatory effects.
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3 6 Two-dimensionai-difference gel electrophoresis of taxane-selected variants of 
SKMES-1
Investigations were earned out to establish differential protein expression caused by 
taxotere and taxol resistance in the squamous lung cell line SKMES-1, a cell line 
developed from a pleural effusion from a 65-year old male with squamous cell 
carcinoma of the lung The taxol and taxotere resistant cell lines were established from 
SKMES-1 during the course of this work Briefly, SKMES-1 was exposed to IC 9 0  
concentrations of taxotere (60ng/ml) and taxol (120ng/ml) for four hours, once a week 
for ten consecutive weeks The resulting cell lines were designated SKMES-Txt and 
SKMES-Txl respectively (Table 3 6 1) These resistance levels were the levels observed 
at week 61 for SKMES-Txt and week 34 for SKMES-Txl (Figures 4 1 and 4 2)
Fold Resistance
Cell Line Taxotere Taxol 5-FU Adnamycin VCR VP-16
SKMES-1 1 1 1 1 1 1
SKMES-Txt 
(week 2)
5 9 ± 0 2 10 6 ± 0 6 9 6 ± 0 4 4 3 ± 0 4 4 5 ± 0 6 11 8 ± 0 9 7
SKMES-Txl 
(week 3)
6 7 ± 0 2 12 5 ± 0  1 7 5 ± 0 4 2 3 ± 0 1 5 6 ± 0 2 4 ± 0 1
SKMES-Txl 
(week 6)
2 95 ± 0  14 5 8 ± 0 3 7 8 ± 0 1 2 54 ± 0 04 5 1 ± 0  3 4 9 ± 0 5
Table 3 61 Drug resistance profiles of taxane resistant variants of SKM ÌS-1
3 6 1 Overview of SKMES-Taxane resistance
The SKMES-Txt cell line is 5 9-fold and 10 6-fold resistant to taxotere and taxol 
respectively when compared to SKMES-1 The cell line is also approximately twice and 
three times more cross-resistant to adnamycin and VP-16 respectively when compared 
to SKMES-Txl (week 3 and week 6) The SKMES-Txl (week 3) cell line is 12 5-fold 
and 6 7-fold resistant to taxol and taxotere respectively when compared to SKMES-1 
All cell lines exhibited cross-resistance to 5-FU and vincristine Resistance to taxol and 
taxotere fell in SKMES-Txl (week 6) to 5 8-fold and 2 95-fold respectively in 
comparison to SKMES-Txl (week 3)
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3.6.2 Screening protein samples of SKMES-1 and variants
The DIGE system required six high quality protein samples per cell line per experiment, 
(section 2.15). Many sample preparations were carried out to refine the procedure to 
generate good gels with many distinct protein spots and to ensure low levels o f 
contaminating factors such as DNA, RNA, lipids and salts. These lysates were 
generated from 7M urea/2M thiourea lysis buffer. The gels were silver-stained and 
scanned at 300 resolution to ensure the quality of proteins samples. The best six samples 
showing most solubilised, well-defined protein spots, free o f streaking and salt fronts 
were selected.
. •  • * *
Figure 3.6.1b SKMES-Txt (wk 2)
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Figure 3.6.1c SKMES-Txl (wk 3) c6)
Figures 3.6.1a-d Silver stained images of SKMES-1 and taxanes-resistant variants. A volume of 
75 ¿ig protein of all lysates for 2D-DIGE analysis were run on pH 4-7 IPG strips.
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3.6.3 Experimental outline of SKMES-1 versus and SKMES-Txt (Wk 2)
This experiment was designed to compare SKMES-1 to its taxotere-resistant variant 
(SKMES-Txt) at a time point when resistance was the highest (section 3.1.3.3). The aim 
was to determine the protein expression changes resulting from taxotere resistance.
The experimental design for DIGE analysis is outlined as follows: six biological 
replicates of each cell line were labelled with 150pmol of the Cy dyes. All SKMES and 
SKMES-Txt (Wk2) lysates were labelled with Cy3 and Cy5 respectively. A Cy2 
labelled internal standard comprising of 6 SKMES, 6 SKMES-Txt (Wk2), 6 SKMES- 
Txl (Wk 2) and 5 SKMES-Txl (Wk6) was also included on each gel. A volume of 50|ig 
protein was labelled with each Cy dye resulting in a total o f 150|ig/gel (50|ig Cy2 
internal standard, 50}ig Cy3 and 50|ig Cy5). Once labelling was completed, six 2D gels 
were generated, scanned, analysed and proteins of interest identified as previously 
described in section 3.4.
3.6.3.1 DeCyder analysis of SKMES-1 versus SKMES-Txt (Wk 2)
Differential protein expression between the lung cell line SKMES-1 and SKMES-Txt 
(Wk2) was observed using 2D-DIGE. Difference In-gel Analysis using Decyder™ 
(version 6) revealed a total of 1417 ± 131 protein spots. Biological variation analysis o f 
these spots revealed a total o f 157 spots showing a greater than 1.2-fold change in 
expression with a t-test score of 0.05 or less. O f these 157 spots, 40 have been identified 
using MALDI-TOF mass spectrometry. A total of 116 of the differentially regulated 
spots were not identified. As can be seen from Tables 3.6.3a and 3.6.3b, the fold 
changes are low, ranging from 1.98-fold increased to 1.68-fold decreased.
Figure 3.6.2 Representative Cy5 
labelled SKMES-Txt (week 2) gel 
showing completed BVA analysis 
of SKMES-1 versus SKMES-Txt 
(week 2). Spots circled in red are 
the statistically significant 
differentially-regulated proteins.
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Figure 3.6.3, Table 3.6.3a and 3.6.3b shows the identified differentially regulated 
proteins between SKMES-1 and SKMES-Txt.
Figure 3.6.3a-d Colloidal coomassie stained preparative SKMES-Txt gel, which marks the 
proteins differentially-regulated between SKMES-1 versus SKMES-Txt - blue spots.
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Spot
No
Protein Name gi Number
Gene
Symbol
Fold Pi M w
1 150kDa oxygen-regulated 
precursor gi| 10720185| HYOU 1 33 52 1116
2 Valosin containing Protein gi|55662798| VCP -1 58 49 71 56
3 Valosin containing Protein gi|55662798| VCP -1 87 49 71 56
4 Lamm A/C gi|55957496| LMNA 1 58 6 1 53 23
5
Chaperomn containing TCP1 
subunit 3
gi|58761484| CCT3 1 23 6 57 78
6 HSP 70 protein 8 isoform 2 gi|62896815| HSPA8 1 24 56 53 6
7 Dihydropynmidinase-like 
variant 2 gi|62087970| CRMP-1 1 42 5 8 68 62
8 HSP 60 kDa gi|77702086| HSPD1 145 57 61 37
9 HSP 60 kDa gi|77702086| HSPD1 1 35 5 7 61 37
10 Glucose 6 phosphate 
dehydrogenase gi|26224874 G6PD1 I 22 63 59 53
11 Glucose 6 phosphate 
dehydrogenase gi|26224872| G6PD1 1 55 63 59 53
12 Glucose 6 phosphate 
dehydrogenase gi|26224874 G6PD1 1 2 67 55 21
13 Vimentin gi|37852| VIM -1 63 5 1 53 72
14 hnRPHl gi|48145673| HNRPH1 1 57 59 49 5
15 Keratin 8 gi|62913980| CARD2 -1 51 5 6 55 89
16 PMPCA protein gi|48257293| PMPCA 1 73 66 58 86
17
TATA binding protein 
interacting protein 49 kDa 
variant
gi|62896685| GTF2D 1 32 6 50 54
18 Mannose-6-phosphate 
receptor binding protein gi|16306789| M6PRBP1 -1 22 5 3 47 19
19 Beta tubulin gi|18088719| TUBB 1 21 47 50 11
20 Septin 2 gi|15680208| NEDD5 1 31 6 1 41 69
21 HNRPC protein gi|58476967| HNRPC 1 32 45 27 86
22 Mitochondrial nbosomal s22 gi| 14424546| MRPS22 1 19 78 41 43
23 Annexin A1 gi|442631| ANXA1 143 79 35 25
Table 3 6 3a Identified proteins form SKMES-1 versus SKMES-Txt Gene symbol 
determined from “gi number” conversion software package “DAVID” and Entrez Gene
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Spot
No
Protein Name gi Number
Gene
Symbol
Fold Pi M w
24 LASP 1 ' gi|2135552| Lasp-1 1 61 6 1 30 19
25 Annexin A3 gi|47115233| ANXA3 1 48 56 36 63
26 HSPC124 gi|6841470| PPA2 1 77 56 36 96
27 Proteasome activator subunit 
2 gi|48734793| PSME2 1 62 54 27 51
28 Cham H Cathepsin D at pH 
75 gi|5822091| CTSD 1 98 5 3 26 46
29
Proteasome (prosome, 
macropam) subunit, alpha 
type 5
gi|54696300| PSMA5 -1 26 47 26 58
30
Proteasome (prosome, 
macropam) subunit, alpha 
type 5
gi|54696300| PSMA5 1 27 47 26 58
31 Prohibitin gi|76879893| PPA1 1 43 56 29 87
32 Chlonde intracellular channel 
4 gi|55666469| CLIC4 1 74 55 28 98
33 High mobility Group box 1 gi)55958717| HMGB1 1 46 56 25 1
34 Cham B, Horf 6 a novel 
human peroxidase enzyme gi|3318842| - 1 36 6 24 9
35 Ubiquitin Carboxy Hydrolase 
LI gi|4185720| PGP9 5 1 27 53 23 35
36 K130r mutant of human DJ-1 gi|33358056| PARK7 1 23 65 21 14
37 Peroxiredoxin 2 gi|32483377| PRDX2 1 72 7 1 27 95
38 GST-pi gi|4139460| GSTP1 -1 68 54 23 43
39 GST-pi chain B gi|23200511| GSTP1 -1 37 54 23 43
40
i
Galectin-1 gi|42542977| Galectin-1 -1 55 5 3 14 75
Table 3 6 3b Identified proteins form SKMES-1 versus SKMES-Txt-continued
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3.6.4 Ontology analysis of identified proteins
Ontology information was obtained through PubMed searches. Of the identified 
proteins, the majority have functions in protein turnover, stress response and 
cytoskeletal proteins with 21%, 15% and 12% of the differentially regulated proteins 
respectively. The stress response and protein turnover proteins were expected to be 
differentially regulated, as they are known to increase resistance to cell death induced 
by a variety o f stimuli. The majority of these proteins are all up-regulated in SKMES- 
Txt. There are twice as many transcription/transcription regulation and metabolic 
proteins differentially regulated in contrast to cell signalling proteins in SKMES-Txt. 
The ion binding/transport, apoptosis/apoptosis regulation and RNA processing proteins 
account for 7% each. The apoptosis/redox regulation proteins have also been linked to 
overcoming drug-resistance through evading apoptosis, the majority of which are up- 
regulated in SKMES-Txt. Finally, 2% of the proteins are involved in glycolysis, 
cytokinesis and mitochondrial processing (Table 3.6.4, Figure 3.6.4).
Metabolism
Cytokinesis
Glycolysis Transcription/Trans- 
2% r  cription Regulation
T Regulation
7%
Stress Response Mitochndrial Cytoskeletal
16% Processing 12%
Figure 3.6.4 Ontology analysis of differentially regulated proteins.
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Reported Function Protein Name
Apoptosis/Redox regulation
Galectin-1
Cham B, Horf 6 a novel human peroxidase enzyme 
K130r mutant of human DJ-1
Glycolysis Peroxiredoxin
Transcription/Transcription
Regulation
Prohibitin
TATA binding protein 
High mobility Group box 
Dihydropyrimidinase-like variant 2
Stress Response
HSP 60 kDa
HSP 70 kDa protein 8 isoform 2 
HSPC124
150kDa oxygen-regulated protein 
Chaperonm containing TCP1 subunit 3
Ion Binding/Transport Annexin A1Chloride intracellular channel 4 
Annexin A3
Cytoskeletal
Vimentin 
Beta Tubulin 
Lamm A/C 
LASP 1 
Keratin 8
Protein Turnover
Proteasome activator subunit 2 
Chain H Cathepsin D at pH 7 5 
Proteasome (prosome, macropain) subunit, alpha 
type 5
GST-pi chain B 
Proteasome beta 3 subunit 
GST-pi
Ubiquitin Carboxy Hydrolase LI
Cell Signalling VCP protein
RNA Processing hnRPHlMannose-6-phosphate receptor binding protein 
hnRPC
Metabolism Glucose 6 phosphate dehydrogenase 
Mitochondrial nbosomal s22
Cytokinesis Septin 2
Mitochondrial Processing PMPCA protein
Table 3 6 4 Ontology analysis of identified proteins from SKMES-1 versus SKMES-Txt
236
3 6 5 Pathway Assist analysis of identified proteins
Pathway Assist (version 3 0), which permits the identification of biological interactions 
among genes and proteins of interest from the published literature, was carried out on 
the 40 identified proteins The gene symbol list was imported into the programme and 
from this both direct and common pathways were built Figure 3 6 5 shows only the 
direct lines between differentially regulated proteins They are cytoskeletal, metabolic, 
cell signalling and stress response proteins The cytoskeletal and cell signalling proteins 
are all down-regulated whereas the stress response and metabolic proteins are up- 
regulated It has been shown that there is a specific interaction of the penplakin linker 
domain with keratin 8 and vimentin Glucose-6-phosphate dehydrogenase complexes 
with HSPD1 HSPA8 has a direct effect on the regulation of HSPD1 Finally, VCP has 
been shown to interact with HSPA8 in yeast
Figure 3 6 5 Pathway Assist analysis of direct interactions, identifying only direct links 
between the proteins This finds proteins that are regulated by all selected nodes Purple circles 
indicate binding, blue triangles indicate regulation and orange squares indicate an effect and 
direct effect on expression respectively
/
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Figure 3.6.6 shows the pathways built based on common targets for selected nodes (i.e. 
differentially regulated proteins). Pathway analysis found that cellular processes o f 
apoptosis, differentiation and proliferation and the proteins HSPD1 and G6PD are 
important in the taxotere resistant cell line, SKMES-Txt.
Stimulators of proliferation include HYOU, CRMP1, HSPA8, VCP, G6PD and HSPD1. 
All o f these are up-regulated except VCP in SKMES-Txt versus SKMES-1. The two 
inhibitors of proliferation include TUBB and ANAX1 are both up-regulated. 
Stimulators of differentiation include TUBB, ANAX1, VIM and G6PD are up-regulated 
except VIM. There are no inhibitors of differentiation. The stimulators of apoptosis 
include VIM, G6PD, KRT8, CRMP1 and ANAX1. HSPA8 inhibits apoptosis. The 
majority o f these proteins are up-regulated in SKMES-Txt.
Figure 3.6.6 Pathway Assist analysis of common interactions between proteins. Selected protein 
nodes are shown in red with the cellular processes in yellow, small molecules in green and 
complexes in blue. Green, red and gray lines mark positive, negative and unknown regulatory 
effects respectively.
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3.6.6 Experimental outline of SKMES-1 versus SKMES-Txl (Wk 3)
This experiment was designed to compare SKMES-1 to its taxol-resistant variant 
SKMES-Txl when resistance was the highest (12.5-fold). The aim was to determine the 
protein expression changes resulting from taxol resistance. The experimental design for 
DIGE analysis o f SKMES compared to SKMES-Txl is identical to that of SKMES-1 
versus SKMES-Txt as outlined in Table 3.6.3 with SKMES-1 as the control and 6 
biological replicates.
3.6.6.1 DeCyder analysis of SKMES-1 versus SKMES-Txl (Wk 3)
Differential protein expression between the lung cell line SKMES-1 and SKMES- 
Txl(Wk3) was observed using 2D-DIGE. Difference In-gel Analysis using Decyder™ 
revealed a total o f 1636 ±102  protein spots. Biological variation analysis o f these spots 
revealed a total of 193 spots showing a greater than 1.2-fold change in expression with a 
t-test score of 0.05 or less (Figure 3.6.7). Of these 193 spots, 55 have been identified 
using MALDI-TOF mass spectrometry. A total of 138 of the differentially-regulated 
spots were not identified (Figure 3 .6.8).
Figure 3.6.7 A 
representative Cy5 labelled 
SKMES-Txl (Wk 3) gel 
showing completed BVA 
analysis of SKMES-1 versus 
SKMES-Txl (Wk 3) between 
pH 4-7. Spots circled in red 
are the 193 statistically 
significant differentially 
regulated proteins (p< 0.05, 
protein fold >1.2).
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Figure 3.6.8a-e Colloidal coomassie stained preparative SKMES-Txt gel, which marks the 
proteins in common with SKMES-Txl -  light blue spots. Yellow spots indicate the overlapping 
proteins from SKMES-Txl (Wk3) versus SKMES -Txl (Wk6). Dark blue spots are unique to 
SKMES-Txl (Wk3).
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3 6 6 2 Table 3 6 5 highlights the overlapping proteins from SKMES-1 versus SKMES-TxI 
(wk3) and SKMES-1 versus SKMES-Txt Spots marked light blue in Figure 3 6 8
Spot
No
Protein Name gi Number
Gene
Symbol
Fold Pi M w
1 150kDa oxygen-regulated 
protein gi| 10720185|
ORP150 1 94 52 1116
2 Valosin containing Protein gi|55662798| VCP -1 31 49 71 56
3 Valosm containing Protein gi|55662798| VCP -14 49 71 56
4 Lamm A/C gi|55957496| LMNA 1 71 6 1 53 23
5
Chaperomn containing TCP1 
subunit 3
gi|58761484| CCT3 141 6 57 78
6 HSP 70 protein 8 isoform 2 gi|62896815| HSPA8 -1 55 56 53 6
10 Glucose 6 phosphate 
dehydrogenase gi|26224874
G6PD1 1 23 63 59 53
12 Glucose 6 phosphate 
dehydrogenase gi|26224872|
G6PD1 143 63 59 53
15 Keratin 8 gi|62913980| CARD2 -1 57 5 6 55 89
22 HNRPC protein gi|58476967| HNRPC 14 45 27 86
24 LASP 1 gi|2135552| Lasp-1 1 58 6 1 30 19
26 HSPC124 gi|6841470| PPA2 1 58 5 6 36 96
27 Proteasome activator subunit 
2 gi|48734793| PSME2 -1 43 54 27 51
30
Proteasome (prosome, 
macropain) subunit, alpha 
type 5
gi|54696300| PSMA5 1 21 47 26 58
31 Prohibitin gi|76879893| PPA1 144 5 6 29 87
34 Chain B, Horf 6 a novel 
human peroxidase enzyme gi|3318842| - 1 37 6
24 9
35 Ubiquitin Carboxy Hydrolase 
LI gi|4185720| PGP9 5 1 21 5 3 23 35
36 K130r mutant of human DJ-1 gi]33358056| PARK7 129 65 21 14
37 Peroxiredoxin gi|32483377| PRDX2 1 19 7 1 27 95
38 GST-pi gi|4139460| GSTP1 -1 37 54 23 43
39 GST-pi chain B gi|23200511| GSTP1 -1 92 54 23 43
Table 3 6 5  Overlapping proteins form SKMES-1 versus SKMES-Txl (wk3) and SKMES-1 
versus SKMES-Txt Spots marked light blue in Figure 3 6 8
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Twenty-one proteins were found to be overlapping between SKMES-1 versus SKMES- 
Txt and SKMES-1 versus SKMES-Txl (Wk3). Similar levels of regulation resulted for 
the majority of the proteins with the exception of proteasome activator subunit 2 and 
peroxiredoxin 2, both of which are increased to a greater level in SKMES-Txt (Figure
3.6.9).
2.5 t
Protein
Figure 3.6.9 Review of shared proteins in SKMES-Txt and SKMES-Txl (Wk3)
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Comparisons between SKMES-1 versus SKMES-Txl (Wk3) and SKMES-Txl (Wk3) 
versus SKMES-Txl (Wk6) revealed that 4 proteins were shared ER-60, thioredoxin 
peroxidase B and protein disulfide isomerase protein 5 are increased in SKMES-1 
versus SKMES-Txl (wk3) (Table 3 6 6, Figure 3 6 8)
Spot
No
Protein Name gi Number Gene
Symbol
Fold Pi M w
41 ER-60 protease gi| 1208427| PDIA3 1 35 6 57 18
42 Annexm V gi|809190| ANXA5 1 56 49 35 84
43 Thioredoxin peroxidase B gi|1617118| PRDX2 2 02 48 20 16
44 Protein disulphide isomerase 
protein 5 gi| 1710248| P5 165 5 46 52
Table 3 6 6 The overlapping protein spots between the comparisons SKMES versus SKMES- 
Txl (wk3) with SKMES-Txl (wk3) versus SKMES-Txl (Wk6) Spots marked yellow in Figure 
368
In contrast to the unique proteins differentially regulated in response to taxotere 
exposure, taxol exposure resulted in the differential expression of 23 unique proteins of  
which most were down-regulated The majority of these proteins have function in ion 
binding/transport, protein turnover and the stress response (Table 3 6 7)
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Spot
No.
Protein Name gi Number
Gene
Symbol
Fold Pi M.w.
50 Annexin A1 gi|442631| ANXA1 -1.26 7.9 35.25
51 Annexin A1 gi|442631| ANXA1 -1.29 7.9 35.25
52 Annexin A1 gi|442631| ANXA1 1.25 7.9 35.25
53 Annexin A1 gi|442631| ANXA1 -1.31 7.9 35.25
54 26S Proteasome-associated 
Padl homologue variant gi|62088020| PSMD14 1.22 6.5 18.99
55 Chain D, Cathepsin B 
(E.C.3.4.22.1) gi|999911| CSTB -1.77 5.2 22.97
56
Proteasome (prosome, 
macropain) subunit, alpha 
type 5
gi|54696300| PSMA5 1.2 4.7 26.58
57 Beta tubulin gi| 18088719| TUBB -1.56 4.7 50.11
58 Prolyl 4-hydroxlyase, beta 
subunit gi|48735337| P4HB 1.26 4.8 57.5
59 Beta Actin gi|15277503| ACTB -1.42 5.6 40.54
60 Nucleophosmin gi| 13536991| NPM1 -1.15 4.5 29.62
61 HSP 27 kDa gi|54696638| HSPB1 -1.41 6 22.82
62 HSPC108 gi|7305503| STOML2 1.31 5.8 37.3
63 Annexin A4 gi| 1703319| ANXA4 1.37 5.8 36.09
64 HLA-B associated transcript 
1 variant gi|62897383| BAT1 1.26 5.5
49.56
65 6 phosphogluconolactonase gi|6018458| PGLS 1.22 2.7 27.81
66 ATP Synthase gi| 16741373| ATP5B 1.61 6.6 20.15
67 ATPase beta subunit gi| 179279| ATP5B -1.33 5.0 50.52
68 Actin G1 protein gi|40226101| ACTG1 -1.26 5.5 26.68
69 HSP70 kDa 9B (MTHsp75) gi|292059| HSPA9B -1.33 6 74.12
70 CCT2 gi|48146259| CCT2 1.32 6 57.78
71 Replication A2 32, kDa gi|56204165| RPA2 1.22 6.4 30.25
72 eiF 3 subunit 2 beta 36 kDa gi|47003155| EIF3S2 -1.79 5.4 36.5
Table 3.6.7 Proteins unique to SKMES-1 versus SKMES-Txl(Wk2), Spots marked dark blue 
in Figure 3.6.8.
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3.6.7 Ontology analysis of identified proteins
Ontology information was obtained through PubMed searches. Of the identified 
proteins, the majority have functions in protein turnover, cytoskeletal, the stress 
response and ion binding/transport and account for 21%, 17%, 15% and 13% 
respectively. The levels of stress response, metabolic and protein turnover proteins are 
similar to those obtained for SKMES-1 versus SKMES-Txt. The protein turnover 
proteins and ion binding/transport are both increased and decreased in SKMES-Txl 
(wk3). The majority of the stress response proteins are all up-regulated in SKMES-Txl 
(wk3) whereas the cytoskeletal proteins are predominantly decreased. Metabolic and 
apoptosis/redox regulation accounts for 10% and 6% respectively in SKMES-Txl 
(wk3). There are twice as many cell signalling, transcription/transcription regulation, 
and RNA processing proteins regulated in contrast to translation, tumour immunity and 
glycolysis proteins in SKMES-1 versus SKMES-Txl (wk3). There is a higher 
percentage of cytoskeletal and ion binding/transport proteins differentially regulated in 
SKMES-Txl (wk3) compared to SKMES-Txt. Taxotere exposure resulted in more than 
twice the amount of transcription/transcription regulation proteins being differentially 
regulated in comparison to taxol exposure. There are similar levels o f cell signalling, 
glycolysis and apoptosis/redox regulation proteins in both cell lines whereas there are 
no cytokinesis or mitochondrial processing proteins differentially regulated in SKMES- 
1 versus SKMES-Txl (wk3) (Table 3.6.8, Figure 3.6.10).
Tumour immunity
2%
Metabolism  
10%
Cell Signalling
Protein Turnover 
21%
Cytoskeletal
17%
Translation
2%
Stress Response 
15%
■Y:’;- i ' i W :
T ra nsc r iption/T ra ns - 
cription Regulation 
4%
Figure 3.6.10 Ontology analysis of differentially regulated proteins
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Reported Function Protein Name
Apoptosis/Redox regulation
Thioredoxin peroxidase B
K130r mutant of human DJ-1
Chain B, Horf 6 a novel human peroxidase enzyme
Glycolysis i
Peroxiredoxin
T ranscnption/T ranscnption 
Regulation Prohibitm
Replication A2 32, kDa
Stress Response
HSP 27 kDa
HSP 70 kDa protein 8 isoform 2 
HSPC124
Chaperonin containing TCP1 subunit 3 
HSP70 kDa 9B (MTHsp75)
CCT2
HSPC108
150kDa oxygen-regulated protem
Ion Binding/Transport
Annexin A1 
Annexin A4 
Annexm V 
Nucleophosmin
Translation eiF 3 subunit 2 beta 36 kDa
Cytoskeletal
Beta Actm 
Gamma Actm 
Beta Tubulin 
Lamm A/C 
LASP 1 
Keratin 8
Protein Turnover
Proteasome activator subunit 2 
Cham D, Cathepsin B (E C 3 4 22 1)
Proteasome (prosome, macropain) subunit, alpha type 5
GST-pi chain B
GST-pi
Prolyl 4-hydrolase, beta subunit 
Protein disulphide isomerase protem 5 
Ubiquitin Carboyxy Terminal hydrolase LI 
26S Proteasome-associated Padl homologue variant
Cell Signalling VCP protem
RNA Processing
HnRPC
ER-60 protease
Metabolism
ATPase beta subunit 
ATP Synthase 
6 phosphogluconolactonase 
Glucose 6 phosphate dehydrogenase
Tumour Immunity HLA-B associated transcript 1
Table 3 6 8 Ontology analysis of identified proteins from SKMES versus SKMES-Txl (wk3)
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The gene symbol list was imported into the programme and from this both direct and 
common pathways were built Figure 3 6 11 shows only the direct lines between 
differentially regulated proteins between SKMES-1 versus SKMES-Txl (Wk3) The 
proteins with direct interactions include, cytoskeletal, ion binding, metabolic, protein 
turnover, transcription/transcription regulation and stress response proteins These 
proteins are both up- and down-regulated in SKMES-Txl Both a- and (3-tubulin 
associate with HSPB1, which also associates with GSTP1 Annexm 5 promotes a dose- 
dependent inhibition of annexin 1 phosphorylation GRP58 binds to P4HB, the resultant 
complex inhibits further interactions VCP possesses chaperone-like activities and can 
functionally interact with HSPA8 Finally HSPA8 also binds with HSPB1
3 6 8 Pathway Assist analysis of identified proteins
Figure 3 611 Pathway Assist analysis of direct interactions, identifying only direct links 
between the proteins This finds proteins that are regulated by all selected nodes Purple circles 
indicate binding, blue triangles indicate regulation of expression
\
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Figure 3.6.12 shows the pathways built based on common targets for selected nodes (i.e. 
differentially regulated proteins). Pathway analysis found that cellular processes of 
apoptosis, differentiation and proliferation and the proteins HSPD1 and G6PD are also 
important in the taxol resistant cell line, SKMES-Txl (wk3). Stimulators o f proliferation 
include GSTP1, ANAX5, BATL1, HSPB1, HSPA8, G6PD, HSPA9B, HYOU, UCHL1, 
PRDX2, GRP58, VCP, PRDX3 and PARK7. The three inhibitors o f proliferation 
include NPM1, TUBB and ANAX1 the majority o f these are down-regulated in 
SKMES-Txl whereas in SKMES-Txt both TUBB and ANAX1 are up-regulated. The 
stimulators of differentiation include NPM1, HSPB1, G6PD, ANAX1, ANAX5, 
PRDX2, GSTP1 and TUBB. Similarly to SKMES-Txt, there are no inhibitors of 
differentiation. The majority o f these are decreased in SKMES-Txl (Wk3).
protein nodes are shown in grey, the cellular processes in yellow, a complex in red, a small 
molecule in green and functional classes in orange. Grey lines indicate a negative and positive 
regulatory effect.
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3.6.9 Experimental outline of SKMES-Txl (Wk3) versus SKMES-Txl (Wk 6)
This experiment was designed to compare SKMES-Txl (Wk3) to a less resistant variant, 
SKMES-Txl (Wk6) in order to examine the protein expression changes resulting from a 
loss of taxol resistance. SKMES-Txl (Wk3) was 12.5-fold resistant to taxol compared to 
SKMES-1 while SKMES-Txl (Wk6) was only 5.8-fold resistant. The experimental 
design for DIGE analysis o f SKMES-Txl (Wk3) versus SKMES-Txl (Wk 6) is identical 
to that of SKMES-1 versus SKMES-Txt as outlined in Table 3.6.3 with SKMES-Txl 
(Wk3) as the control and 5 biological replicates.
3.6.9.1 DeCyder analysis of SKMES-Txl (Wk3) versus SKMES-Txl (Wk 6)
Differential protein expression between the lung cell line SKMES-Txl (Wk3) and 
SKMES-Txl (Wk6) was observed using 2D-DIGE. Difference In-gel Analysis using 
Decyder™ revealed a total o f 1553 ± 213 protein spots. Biological variation analysis o f 
these spots revealed a total o f 159 spots showing a greater than 1.2-fold change in 
expression with a t-test score of 0.05 or less (Figure 3.6.13). Of these 159 spots, 28 have 
been identified using MALDI-TOF mass spectrometry (Figure 3.6.14).
Figure 3.6.13 A 
representative Cy5 labelled 
SKMES-Txl (Wk6) gel 
showing completed BVA 
analysis of SKMES-Txl 
(Wk3) versus SKMES-Txl 
(Wk 6) between pH 4-7. 
Spots circled in red are the 
159 statistically significant 
differentially regulated 
proteins (p< 0.05, protein 
fold >1.2).
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Figure 3.6.14a-b Colloidal coomassie stained preparative SKMES-Txt gel, which marks the 
proteins in common with SKMES-Txt -  blue spots. Yellow spots indicate the overlapping 
proteins from SKMES-1 versus SKMES-Txl (Wk3). Purple proteins are unique to SKMES-Txl 
(Wk6).
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Table 3 6 9 shows the 11 differentially expressed proteins that are shared between the 
comparisons SKMES-1 versus SKMES-Txt and SKMES-1 versus SKMES-Txl (Wk3) 
The majority of these proteins are up-regulated in SKMES-1 versus SKMES-Txt but decreased 
in this comparison The exceptions include, GST-pi which is decreased m SKMES-1 versus 
SKMES-Txt and peroxiredoxin 2 which is increased in SKMES-1 versus SKMES-Txt but 
decreased in this comparison
Spot
No
Protein Name gi Number
Gene
Symbol
Fold Pi MW
2 Valosin containing Protein g»|55662798| VCP -1 31 49 71 56
8 HSP 60 kDa gi|77702086| HSPD1 1 6 5 7 61 37
6 HSP 70 protein 8 isoform 2 gi|62896815| HSPA8 1 30 56 53 6
14 hnRPHl gi|48145673| HNRPH1 -1 24 59 49 5
19 Beta tubulin gi|18088719| TUBB -1 94 47 50 11
24 LASP 1 gi|2135552| Lasp-1 -1 49 6 1 30 19
25 Annexin A3 gi|47115233| ANXA3 -139 56 36 63
33 High mobility Group box 1 gi|55958717| HMGB1 1 2 56 25 1
37 Peroxiredoxin 2 gi|32483377| PRDX2 -1 25 7 1 27 95
38 GST-pi gi|23200511| GSTP1 2 29 54 23 43
40 Galectin-1 gi|42542977| Galectin-1 -132 5 3 14 75
Table 3 6 9 Overlapping proteins between SKMES-Txl (Wk3) versus SKMES-Txl (Wk6) and 
SKMES-1 versus SKMES-Txt
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Comparisons between SKMES-1 versus SKMES-Txl (Wk3) and SKMES-Txl (Wk3) 
versus SKMES-Txl (Wk6) revealed that 4 proteins were shared. ER-60, thioredoxin 
peroxidase B and protein disulfide isomerase protein 5 show a decrease in protein 
expression as resistance falls. This reflects a positive correlation with a fall o f drug 
resistance (Figure 3.6.15, Table 3.6.10).
Spot
No.
Protein Name gi Number
Gene
Symbol
Fold Pi M.W.
41 ER-60 protease gi| 1208427| PDIA3 -1.55 6 57.18
42 Annexin V gi|809190| ANXA5 2.10 4.9 35.84
43 Thioredoxin peroxidase B gi| 1617118| PRDX2 -1.33 4.8 20.16
44 Protein disulphide isomerase 
protein 5 gi| 1710248| p5 -1.48 5 46.52
Table 3.6.10 The 4 overlapping protein spots between the comparisons SKMES-1 vs. SKMES- 
Txl (wk3) and SKMES-Txl (wk3) vs SKMES-Txl (Wk6) (Spots marked yellow in Figure
3.6.8).
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Figure 3.6.15 Review of shared proteins in SKMES-1 versus SKMES-Txl (Wk2) and 
SKMES-Txl (Wk3) versus SKMES-Txl (Wk6)
PDIA3
1 I— "
ANXA5 PRDX2 p5
Protein Name
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Ten proteins were found to be unique to SKMES-Txl (Wk6) The majority of these 
proteins are cytoskeletal and stress response proteins (Table 3 6 11)
Spot
No
Protein Name gi Number
Gene
Symbol
Fold pi M w
73 KIAA0098 gi|58257644| CCT5 -1 31 55 61 49
74 HSP 70 protein 8 isoform 2 gi|62896815| HSPA8 -129 56 53 6
75 HSP 70 protein 8 isoform 2 gi|62896815| HSPA8 -1 3 56 53 6
76 Beta Actin gi| 15277503) ACTB 2 38 56 40 54
77 Lamin B1 gi|576840| LMNB1 1 7 5 3 67 79
78 Rab dissociation inhibitor 
beta
gi|4960030| GDI2 1 69 59 41
79 Stathmin gi|57870| STMN1 -1 24 6 17 15
80 hnRPK gi|55958547| HNRPK -1 33 54 42 02
81 Chloride intracellular channel 
1 gi|62898319| CLIC1 -1 21 5 1 27 34
82 RPLPO gi|47123412| RPLPO 1 39 86 27 45
Table 3 611 Proteins unique to SKMES-Txl (Wk3) versus SKMES- 
purple m Figure 3 6 14
xl (Wk6), Spots marked
253
3.6.10 Ontology analysis of identified proteins
Ontology information was obtained through PubMed searches. O f the identified 
proteins, the majority have functions in the stress response, cytoskeletal, RNA 
processing and ion binding/transport and account for 18%, 18%, 12% and 12% 
respectively. There are twice as many cell signalling, apoptosis/redox regulation and 
proteins turnover differentially regulated proteins compared to 
transcription/transcription regulation, glycolysis and translation proteins. The levels o f 
stress response, apoptosis/redox regulation, cytoskeletal, ion binding/transport and 
transcription proteins are similar to those obtained for SKMES-1 versus SKMES-Txl 
(wk3). There are twice as many cell signalling, glycolysis, translation and three times as 
many RNA processing proteins differentially regulated in SKMES-Txl (wk3) versus 
SKMES-Txl (wk6) compared to SKMES-1 versus SKMES-Txl (wk3). In contrast there 
are more proteins turnover proteins differentially regulated in SKMES-1 versus 
SKMES-Txl (wk3). There are no metabolic or tumour immunity proteins regulated in 
SKMES-Txl (wk3) versus SKMES-Txl (wk6) (Table 3.6.12, Figure 3.6.16).
Ion
Binding/Transport
Transcription/Tran­
scription
Regulation 
Other 4%
Cell Signalling 4%
8%
Translation
RISIA Processing 
12%
Protein Turnover 
8%
Apoptosis/Redox 
Regulation 
8%
Cytoskeletal
18%
Stress Response 
18%
Glycolysis
4%
Figure 3.6.16 Ontology analysis of differentially regulated proteins
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Reported Function Protein Name
Apoptosi s/Redox regulation Thioredoxm peroxidase B 
Galectin-1
Glycolysis
Peroxiredoxin
T ranscnption/T ranscnption Regul ation
High mobility Group box 1
Stress Response
HSP 70 kDa protein 8 isoform 2
HSP60 kDa
KIAA0098
Ion Binding/Transport
Chloride intracellular channel 1 
Annexin V 
Annexin A3
Translation
RPLPO
Cytoskeletal/cytoskeletal regulation
Beta Actin
Alpha tubulin 6 variant
Beta Tubulin
LaminBl
LASP 1
Stathmin
Protein Turnover
GST-pi chain B
Protein disulphide isomerase protein 5
Cell Signalling VCP protein
Rab dissociation inhibitor beta
RNA Processing
hnRPK
ER-60 protease 
HnRPHl
Table 3 6 12 Ontology analysis of identified proteins from SKMES-Txl (Wk3) versus SKMES- 
Txl (Wk6)
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3 6 11 Pathway Assist analysis of identified proteins
The gene symbol list was imported into the programme and from this both direct and 
common pathways were built Figure 3 6 17 shows only the direct links between 
differentially regulated proteins High mobility group box protein interacts with HSPA8 
and GRP58 and forms a complex HMGB1 also binds to hnRNP K VCP which 
possesses chaperone-like activities functionally interacts with HSPA8 Stathmin binds 
with HSPA8 This is most likely biologically relevant in their control of numerous 
intracellular signalling and regulatory pathways, and normal cell growth and 
differentiation Stathmin is also an important regulatory protein thought to control the 
dynamics of microtubules through the cell cycle in a phosphorylation-dependent 
manner Stathmin interacts with two molecules of dimeric alpha- beta-tubulin to form a 
tight ternary T2S complex
indicate binding
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Figure 3.6.18 shows the pathways built based on common targets for selected nodes (i.e. 
differentially regulated proteins). Pathway analysis found that cellular processes o f 
apoptosis, differentiation and proliferation and the proteins GSTP1, HMGB1, STMN1, 
HSPD1 and GRP58 are important in the loss of taxol resistance. Important cellular 
processes include apoptosis, proliferation and proliferation.
Figure 3.6.18 Pathway Assist analysis of common interactions between proteins. The selected 
protein nodes are shown in grey, the cellular processes in yellow, a small molecule in green, cell 
objects in pink and functional classes in orange. Grey lines indicate a negative and positive 
regulatory effect.
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Section 4.0: Discussion
Lung cancer is the most prevalent and lethal of malignancies in the world (Akehurst et 
a l, 2002) with deaths exceeding those from breast, colon and prostate combined 
(Danesi et a l , 2003) Lung cancer can be categorised as non-small cell and small cell 
lung cancers which account for approximately 80% and 20% of lung cancer deaths 
respectively Chemotherapy and radiotherapy are important elements in the treatment of 
NSCLC with surgery to a lesser extent However, greater than 70% of patients present 
with advanced or metastatic disease so surgery is rarely an option (Akehurst et a l , 
2002) The use of chemotherapy in the treatment of NSCLC patients has greatly 
increased over the last twenty years, with agents being used in combination more 
effectively than alone The most commonly used drugs for the treatment of NSCLC are 
the taxanes and platinum drugs with platinum-based doublets remaining the preferred 
option (Socinski, 2004) However, the development of resistance to these drugs is 
frequent and a major obstacle in lung cancer treatment
Many in vitro studies have attempted to simulate resistance by continuously exposing 
cells to chemotherapeutics The result is highly resistant cell lines (100-1000-fold) 
which do not reflect the 5-10-fold resistance normally found in situ (Simon and 
Schindler, 1994) In order to satisfy the clinical situation, the following criteria were 
used
(1) use of chemotherapy naive cell lines Each of these cell lines had no previous 
exposure to chemotherapeutic drugs,
(2) pulsing rather than continuous selection This method of pulse-selection, instead of 
continuous exposure (often employed in in vitro studies) was used to try to mimic 
the clinical scenario, where drug is administered to patients every 1-3 weeks for a 
period of 2-3 months, depending on the type of cancer in question (Calderom and 
Cemy 2001) The cell lines were exposed to low levels of the drugs in question for 
four hours once a week for ten weeks
(3) use of low levels l e pharmacologically achievable concentrations
To study the molecular events causing resistance, a panel of NSCLC (two 
adenocarcinomas, two large cell carcinomas and two squamous cell carcinomas) and 
SCLC were selected for developing resistant variants For this body of work, two 
squamous and two SCLC were studied, all of which were chemotherapeutically naive
4 1 Development of MDR variants of squamous and small cell lung cancer cell lines
2 5 8
Each parental cell line was pulsed separately with two or three clinically relevant drugs 
namely a taxane (taxotere and/or taxol) and the platinum drug, carboplatin The two 
squamous cell carcinomas (SKMES-1 and DLRP) and one small cell carcinoma, DMS- 
53 were pulse-selected with a taxane and carboplatin The NCI-H69 cell line was pulsed 
with carboplatin and VP-16 The pulse selections yielded a total of twelve drug-resistant 
variants and allowed for a comparison m the development of drug resistance as well as a 
comparison of two common subclasses of lung cancer
The following sections will outline the selections resulting initially to taxol (SKMES-1, 
DMS-53), taxotere (SKMES-1, DMS-53 and DLRP), VP-16 (NCI-H69) or to 
carboplatin (SKMES, DLRP, DMS-53 and NCI-H69) The process resulted in variants 
exhibiting modest changes in resistance with some cross-resistance As these drug- 
resistant variants were selected at or near sustainable pharmacological levels (Scripture 
et a1, 2005, Ogun et a l , 1988), they provide a suitable model for in vitro investigations
4 1 1  Analysis of SKMES-1 drug selected variants
The squamous cell carcinoma line, SKMES-1, was originally established from a pleural 
effusion from a 65-year-old male with squamous cell carcinoma of the lung (Fogh et a l , 
1977) Initial toxicity assays (section 3 11) indicated that the cell line along with DLRP 
was extremely sensitive to the taxanes, 5-FU and adnamycin m comparison to the other 
NSCLC cell lines in the panel In contrast, the cell line was most resistant to the 
platinum drugs In order to study the phenotypic features related to acquired-drug 
resistance, a taxol-selected variant was established by pulse selection A recent study by 
Scripture et al (2005) showed that the achievable levels of taxol in the plasma of a 
patient ranges from 1 2 - 5  3jxg/ml, depending on the dose The drug concentration 
available in a tumour is only 25ng/ml (Gyorffy et a l , 2006) SKMES-1 was exposed to 
120ng/ml and 60ng/ml of taxol and taxotere rspectively for 4 hours, once a week for 10 
weeks and the resulting cell lines were designated SKMES-Txl and SKMES-Txt
2 5 9
4 1 2 Stability of SKMES-Txl
Taxol, originally extracted from the bark of the Pacific yew, is a potent anticancer 
agent It has demonstrated remarkable antineoplastic effects against a wide range of 
human tumours, including ovarian, breast, head and neck, small-cell and non-small-cell 
lung cancers, as well as metastatic melanomas (Parekh et a l , 1997) Studies of taxol- 
resistant tumour cell lines have shown that the cellular transport of taxol and drug efflux 
is typically associated with increased P-gp expression and its subsequent microtubule- 
binding activity play a major role in the development of resistance to taxol (Pratt et a l ,
1994) Other mechanisms of resistance include increased and changes m expression of 
apoptosis-related proteins such as caspases and the bcl-2 family (Wang et a l , 2000) 
Unstable resistance to taxol resulting from the selection process was revealed over time 
(Figure 4 11) Resistance is lost in culture and with storage in liquid nitrogen when 
tested one month from initial freezing and after eight months storage The cell line was 
frozen one week after the final pulse Following one-month storage and at the second 
week from thawing, SKMES-Txl was 72 9-fold resistant to taxol (section 3 13 2, 
Figure 4 11) After thirty-four weeks storage, taxol resistance had fallen from 72 9-fold 
to 12 9-fold Similar to the SKMES-Txt results, the cells appear more sensitive the first 
week after thawing Taxol resistance levelled out to between 8-fold at week 33 to 5 1- 
fold at week 37
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Figur e  4 1 1  Summary of unstable resistance of SKMES-Txl The broken line indicates storage 
in liquid nitrogen Continuous lines indicate cells in culture
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4.1.3 Stability of SKMES-Txl to other drugs
Cross-resistance to taxotere resistance also fell during storage and with culture. 
SKMES-Txl was 31.1-fold resistant after one month storage. This fell to 9.8-fold after 
one month in culture (Table 3.1.11). Taxotere resistance also fell with time in storage, 
SKMES-Txl was 31.1-fold resistant after one month but only 4.4-fold resistant after 
eight months (Table 3.1.13). Given the similarities of taxol and taxotere, it is not 
surprising that the taxol-resistant variant is also resistant to taxotere or that taxotere is 
twice as effective as taxol, in agreement with the literature. SKMES-Txl was found to 
be 14.7-fold resistant to vincristine (Table 3.1.11), which, like the taxanes, functions by 
disrupting the tubulin/microtubule equilibrium, resulting in cell cycle arrest at 
metaphase (Bruchovsky et al.y 1965; Gidding et al., 1999).
Unstable resistance to most of the other drugs in the panel resulting from the selection 
process was revealed over time (Figure 4.1.2). When tested at week 2, SKMES-Txl is 4- 
fold resistant to adriamycin, an anthracycline with different structural and functional 
properties to the taxanes and the vinca alkaloids and 11.9-fold resistant to VP-16, an 
epipdophyllotoxin. Both these drugs are associated with classical MDR. Interestingly, 
cross-resistance developed to 5-FU (15.1-fold) but very low levels of resistance to the 
platinum drugs was seen.
- ♦ —Adriamycin - * _ 5 -F U  VCR —k— VP-16 _*_Taxotere
Week Number
Figure 4.1.2 Summary o f  unstable fold-resistance o f SKMES-Txl to adriamycin, 5-FU, 
vincristine, V P-16 and taxotere.
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After eight-months storage, resistance to each of the drugs had levelled out in culture 
Unlike testing one month after pulsing, lower but stable cross-resistance developed to 5- 
FU, adnamycin (consistent with P-gp expression) and VP-16
Another pulse-selected cell line also showed unstable resistance, RPMI 2650 cell line 
pulse-selected with a range of chemotherapeutic agents, the initial resistance quickly 
reversed with increasing passage number (Rasha Linehan, PhD, 2003) A study carried 
out by Liang et al (2001) on the nasal carcinoma cell line, RPMI-2650, found that the 
RPMI-2650 taxol-resistant variant was 226-fold resistant to taxol and cross-resistant to 
adnamycin, vincristine, vinblastine and VP-16 There was no significant resistance to 
melphalan, cisplatm or 5-FU However, these were obtained through continuous 
selection starting with 4ng/ml and culminating with 200ng/ml Bhalla et al (1993) 
exposed the human myeloid leukemia cell line, HL-60, cell line to progressively higher 
concentrations of taxol This resulted in the development of two taxol-resistant cell 
lines The cells developed a variable degree of cross-resistance to taxotere, vincristine 
and adnamycin, however, they were sensitive to the antimetabolite, cytosine 
arabmoside (Ara-C) The LCLC cell lines NCI-H1299 and NCI-H460, pulsed at 
clinically relevant concentrations of taxol yielded approximately 2-4-fold increase m 
resistance to taxol and showed a low level of cross-resistance to vincristine and cisplatm 
but not to VP-16 or adnamycin (Laura Breen PhD thesis, 2005)
This loss/mstability of resistance may be resulting from prolonged growth of cells in the 
absence of selection pressure The cell line was therefore cultured for seven weeks then 
exposed to 120ng/ml taxotere for four hours The resulting cell line, SKMES-Txl(l 1), 
was 14 4-fold resistant to taxol and 4-fold cross-resistant to taxotere Future 
experiments will involve testing the stability of this cell line to the panel of drugs It 
may therefore be beneficial to expose cells to their selecting agent occasionally to avoid 
loss of resistance m this cell line
The need to re-expose drug-resistant cell lines to their selection agent occasionally to 
maintain their resistance levels is not unique to pulse selections The DLKP-A10 cell 
line developed through continuous exposure of escalating concentrations of adnamycin- 
established in the NICB (Cleary, PhD, 1995) required periodic exposure to adnamycin 
to maintain resistance The lung large cell carcinoma cell line, CorL23R cell line must 
be exposed to 0 2ug/ml adnamycin after the first passage m culture (Twentyman et a l ,
1986) Chromosome instability with the loss of double minute chromosomes is one
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mechanism of unstable resistance (Curt et a l , 1984) or the presence of clonal variations 
Two subclonal population of DLKP-A are more (DLKP-A5F) and less resistant (DLKP- 
A2B) than DLKP-A
4 1.4 SKMES-Txt
Taxotere resistance has been attributed to a number of changes including increased 
expression of P-gp, alterations in the expression of tubulins and mutations at the taxane 
site of action in microtubules Other studies have demonstrated that resistance to taxol 
can be a independent of P-gp activity The mam target of taxol and taxotere are the 
microtubules which are involved in a wide range of cellular functions, including mitosis 
and maintenance of cell shape The major component of the microtubules is tubulin, a 
protein containing two non-identical (alpha and beta) 50kDa subunits arranged head-to- 
tail in linear protofilaments A single microtubule is composed of 13 protofilaments, 
forming a hollow structure with a “minus” and “plus” end (Jordan, 2002) Microtubules 
exhibit dynamic instability This non-equilibrium behaviour occurs due to the 
association and dissociation of tubulin dimers from the microtubule ends leading to 
rapid growth and shrinkage of the microtubules Microtubule-associated proteins 
(MAPs) and proteins such as stathmin can stabilise microtubules through interaction 
with tubulin dimers and play a role in regulation of microtubule stability Taxol and 
taxotere disrupt the equilibrium and shifts them in the direction of assembly rather than 
disassembly The result is a stabilisation of ordinary cytoplasmic microtubules and the 
formation of abnormal bundles of microtubules (Schiff et a l, 1980) Cells with 
alterations or mutations in microtubules have greater tolerance for taxane-induced 
stabilisation than those of the parental cells (Schibler and Cabral, 1986)
4 1 5  Stability of SKMES-Txt to taxotere
Unstable resistance to taxotere resulting from the selection process was revealed over 
time (Figure 4 1 3) Pnor to storage in liquid nitrogen, SKMES-Txt was determined to 
be 16-fold at week 1 This resistance increased and stabilised at about 26-fold over the 
next three weeks The cells appear more sensitive the first week after freezing 
Following one-month storage in liquid nitrogen, the initial resistance to taxotere at week 
1 had fallen to 5 6-fold but subsequently recovered While Figure 4.1 3 would suggest 
that freezing the cells m liquid nitrogen had a serious effect on loss of resistance, it may 
have been to soon after the thawing to have tested the cells and would suggest that the
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cells are in a more “sensitive” form immediately after thawing so have lower fold 
resistance. However, looking at the drop from weeks 15-16 to week 60 it is clear that 
there is a drop in resistance as a result of the storage as well as a drop during culturing.
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Figure 4.1.3 Summary o f unstable resistance o f SKMES-Txt to taxotere. Broken lines indicate 
storage in liquid nitrogen. Continuous lines indicate cells in culture.
4.1.6 Stability of SKMES-Txt to other drugs
Taxol resistance, 52.5-fold at week 2 was reduced by half at week 4 (Figure 3.1.5). 
Given the similarities of these two taxane drugs, it is not surprising that the taxotere- 
resistant variant is also resistant to taxol and has been well reported in the literature. 
After fifteen months storage, taxol resistance had again fallen significantly, being 10.6- 
fold resistant at week 60 (Table 3.1.8).
After fifteen months storage SKMES-Txt lost further resistance to all drugs tested when 
compared to one-month and fifteen-months storage in liquid nitrogen (Figure 4.1.4). 
Stable cross-resistance developed to 5-FU, VP-16, adriamycin and vincristine when 
tested for four weeks in culture, before freezing, after one month and fifteen months 
storage. No cross-resistance to the platinum drugs was observed at each time point. 
However, resistance to vincristine and 5-FU falls with long-term storage in liquid 
nitrogen (Figure 4.1.4). Interestingly, VP-16-resitance is stable over the fifteen-month 
storage period. The squamous cell lines selected by pulsing at clinically relevant
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concentrations (SKMES-Txl, DLRP) show cross-resistance to 5-FU. This is not 
observed in the DLKP or hepatocellular carcinoma (Zhou el al.t 2001) cell lines as they 
were pulsed by continuous selection.
□  Pre-Freezing iiO n e  Month □  Fifteen Months
Parent Adriamycin 5-FU VP-16 VCR
Drug
Figure 4.1.4 Summary o f fold-resistance o f SKMES-Txt to adriamycin, 5-FU, V P -16 and 
vincristine before freezing, after one and fifteen months storage. Values are given as fold 
increase in resistance with respect to SKMES-1 as determined by comparing IC50 values on a 
minimum o f three repeats.
Similar to results obtained from SKMES-Txl, this loss (and instability) of resistance 
may be resulting from prolonged growth of cells in the absence of selection pressure. 
The cell line was therefore cultured for seven weeks then exposed to 60ng/ml taxotere 
for four hours. The resulting cell line, SKMES-Txt(l 1), was 169-fold resistant to 
taxotere and 41-fold cross-resistant to taxol. Future experiments will involve testing the 
stability of this cell line to the panel of drugs. It may therefore be beneficial to expose 
cells to their selecting agent occasionally to avoid loss of resistance in this cell line.
Western blotting detected low levels of P-gp protein in HI 299 and HI 299-tax with 
combinations of GF120918 and taxol having a potent toxic effect. A small combination 
effect was observed in A549-txl and SKLU-l-txl suggesting a low level of P-gp protein 
in these cell lines, which may be enough to contribute to taxol resistance. Studies have 
shown that even a small increase in P-gp expression can result in an MDR phenotype 
and also explain the cross-resistance pattern of the SKLU-l-tax cell line (Laura Breen, 
PhD thesis 2005). Since only small effects can be seen in the taxol-selected variants
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when P-gp is inhibited with GF120918, it is reasonable to assume these cell lines 
possess alternative mechanisms of taxol resistance
4 1 7  Analysis of carboplatin-selected SKMES-1 variants
Toxicity assays indicated that the parental cell line exhibited high resistance to both 
carboplatin and cisplatin in comparison to the other drugs in the panel (Table 3 1 2) 
However, on a molar basis and consistent with the literature, cisplatm was the most 
potent of the two
In order to study the phenotypic features related to carboplatin-resistance, two 
carboplatin-selected variants of SKMES-1 were established by pulse selection with 
100|ig/ml and 30jug/ml of the drug respectively The resulting cell lines were designated 
SKMES-CptlOO and SKMES-Cpt30 Achievable plasma concentrations in patients for 
carboplatin range from 9-55jag/ml, depending on the dose (Oguri et a l , 1988) while 
0 5 jag/ml was clinically achievable in the tumour (Gyorffy et a!, 2006) The 100|ig/ml 
concentration is very high and is not clinically achievable compared to the taxol pulse 
selections The remaimng carboplatin-resistant cell lines are valuable models for the 
study of carboplatin resistance
Stable, but notably less, resistance to carboplatin developed in both cell lines, SKMES- 
CptlOO and SKMES-Cpt30 The SKMES-Carboplatin cell lines developed cross­
resistance to cisplatin, which was expected since these drugs share a common 
mechanism of action Both SKMES-1 variants developed about 3-fold cross-resistance 
to taxol, however, SKMES-Cpt30 developed cross-resistance to taxotere and VP-16 
SKMES-CptlOO became sensitised to taxotere The SKMES-CptlOO cell line, like the 
SKMES-Txl developed unusual cross-resistance to 5-FU (5 2-fold) This contrasts to 
the SKMES-Cpt30 cell line All variants became sensitised to adnamycin 
Two adenocarcinomas of the lung and two large cell lung carcinomas pulse-selected 
with carboplatin resulted in variants displaying fold resistance in the range of 1 3- to 
2 7-fold (Laura Breen, PhD thesis 2005) There was no common cross-resistance pattern 
observed in the resistant cell lines SKLUl-cpt displayed the most cross-resistance to 
adnamycm and VP-16 (MRP1 was upregulated) The resistance observed in the 
carboplatin-selected cells was unstable
The combination of adnamycin and sulmdac in SKMES-1 had no effect on toxicity 
indicating that MRP-1 is not present m the parent cell line However, this combination
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in SKMES-CptlOO and SKMES-Cpt30 resulted in greater than 20% enhanced toxicity 
in both cases indicating the up-regulation of MRP1 and suggest that carboplatin may 
lead to an increase in MRP-mediated drug resistance for this variant GF120918 failed 
to circumvent the approximately 3-fold taxol resistance m both cell lines, suggesting 
MDR-1 is not expressed Duffy et al (1998) showed, m agreement with our findings, 
that sulmdac circumvented MRP-1 mediated drug resistance in vitro In another study in 
our laboratories, A549 and H460 carboplatin-selected cell lines showed increased 
MRP1 expression (Laura Breen, PhD thesis 2005) Combination assays with adnamycin 
and sulmdac led to enhanced adnamycin toxicity
A study by Ikuta et al (2005) examined the expression of MDR1, MRP1 and LRP in 
NSCLC cells and compared this with sensitivity to cisplatin No correlation between 
expression of these markers and sensitivity to cisplatin in the NSCLC cells was found 
Combination assays were performed to further elucidate mechanisms of resistance to 
taxotere in these cell lines The combination of GF 120918 and taxotere m the three 
parental and three taxotere-selected cell lines resulted in all cell lines (except DLRP and 
DLRP-Txt) becoming sensitised to taxotere The effect was greatest in SKMES-Txt and 
DMS-Txt suggesting that P-gp plays a role in taxotere resistance in these cell lines No 
effect was seen with the combination of sulmdac and adnamycin in all cell lines 
indicating the absence of MRP-1 In a study by Liu et al (2001), intrinsic and acquired 
taxotere-resistant cell lines have shown expression of the mdr-1 gene The group also 
confirmed that taxotere resistance was not mediated by MRP, using RT-PCR and the 
MRP-specific inhibitor mdomethacm
4 1.8 Analysis of DLRP selections
Toxicity assays indicated that DLRP is highly sensitive to taxotere but intrinsically 
resistant to carboplatin, 5-FU and VP-16 (Table 3 1 2) DLRP was pulsed with 5 ng/ml 
of taxotere and 15jag/ml of carboplatin respectively The cell lines resulting from this 
exposure were designated DLRP-Txt and DLRP-Cpt No resistance to carboplatin 
developed in DLRP-Cpt This cell line, in comparison to the others in the panel selected 
with carboplatin, retained sensitivity to carboplatin throughout the selection process and 
took longer to recover from each pulse implying that resistance had not developed 
Interestingly, DLRP-Cpt developed cross-resistance to taxotere and VP-16 and became 
sensitised to adnamycin The combination of sulmdac with adnamycin in both DLRP
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and DLRP-Cpt had no effect on adriamycm toxicity indicating the possible absence of 
MRP1 in these cell lines
DLRP-Txt developed low and stable resistance to taxotere (4 4-fold) and was cross- 
resistant to adriamycm (2 7-fold) and to a lesser degree carboplatin, 5-FU, vincristine 
and VP-16 (1 3-fold, 1 5-fold, 1 4-fold and 1 2-fold respectively)
Western blotting revealed that P-gp levels were increased in SKMES-Txt in comparison 
to the parental cell line, which had very low expression levels of P-gp No P-gp was 
detected in DLRP or DLRP-Txt
4 1 9  Analysis of DMS-53 selections
The small cell lung carcinoma cell line DMS-53, obtained from the EC ACC had been 
established from a mediastinal biopsy of a 54-year-old male prior to treatment Toxicity 
assays indicated that DMS-53 exhibits high intrinsic resistance to taxotere in contrast to 
DLRP and SKMES-1, which are highly sensitive to the drug This cell line is also the 
most sensitive to carboplatin DMS-53 was pulsed with 40ng/ml and 60ng/ml taxotere 
and taxol and designated DMS-Txt and DMS-Txl DMS-53 was selected with 5|ig/ml of 
carboplatin and designated DMS-Cpt
DMS-Txl was 6 3-fold resistant to taxol and stable after six weeks in culture Stable 
cross-resistance also developed to adnamycin (1 6-fold), vincristine (3 3-fold) and 
carboplatin (1 2-fold) No cross-resistance to taxotere, cisplatin, VP-16 or 5-FU 
developed DMS-Txt developed low but stable resistance to taxotere, taxol, adriamycm, 
vincristine and cisplatin (1 8-fold, 5 9-fold, 1 3-fold, 1 6-fold and 1 4-fold respectively) 
No change in resistance to carboplatin, 5-FU or VP-16 was observed DMS-Cpt became 
resistant to taxol and sensitised to taxotere The cell line became sensitised or developed 
no resistance to vincristine and adriamycm respectively
Liang et al (2003), found that the DLKP-taxotere resistant variant was approximately 
36-fold resistant to taxotere, 262-fold and 33-fold cross-resistant to vincristine and 
adriamycm respectively No cross-resistance developed to cisplatin (resistance to 5-FU 
was not determined) These results are m agreement with our findings 
Western blotting revealed that P-gp levels were increased in DMS-Txt and DMS-Txl in 
comparison to the parental cell line, which had high levels of P-gp intrinsically and was 
the most resistant of the parental cell lines to the taxane drugs Combinations assays 
with GF120918 revealed a greater than 20% enhanced effect of taxotere toxicity in the
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parent cell line However, the GF12098/taxotere combination resulted in a greater than 
60% enhanced effect in both DMS-Txl and DMS-Txl and greater than 40% enhanced 
effect in DMS-Cpt (Figure 3 3 14) These results suggest that P-gp plays a major role in 
taxol resistance in this cell line DLKP-Txt, a taxotere resistant variant of the poorly 
differentiated squamous lung cell line, DLKP developed by pulsing also showed an 
increase in P-gp as determined by RT-PCR and Western blotting (Rasha Linehan PhD 
Thesis 2003)
The combination of sulmdac with adriamycin in DMS-53 resulted in greater than 20% 
enhanced toxicity indicating the presence of MRP1 However, m each of the variants, 
no effect on adriamycin toxicity was observed indicating the probable absence of MRP 1 
(Figure 3 3 7)
4.1.10 Analysis of NCI-H69 selections
In contrast to both squamous and the DMS-53 cell lines, the NCI-H69 are more 
sensitive to both platinum drugs, VP-16 and taxotere (Table 3 12) The NCI-H69 
variant was pulsed with lOjag/ml and 5jig/ml of carboplatin The resulting variants were 
designated H69-Cptl0 and H69-Cpt5 respectively The cell line was also pulsed with 
480ng/ml VP-16, resulting in H69-VP480
Similar to results from squamous carboplatin selections, all small cell variants 
developed low carboplatin and cisplatin cross-resistance Both H69-Carboplatm variants 
and H69-VP480 developed cross-resistance to taxotere and became sensitised to taxol, 
adriamycin and vincristine The three variants developed cross-resistance to 5-FU Only 
H69-Cpt5 and H69-VP480 developed resistance to VP-16 No combination assays were 
earned out on NCI-H69 or vanants as the cell line is non-adherent and grows as 
spheroids in culture
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4.1.11 Taxane resistance -  mechanism of action
Resistance to the taxanes has been reported to involve the amplification of the MDR1 
gene for the 170-kDa membrane glycoprotein, P-gp. This protein functions in pumping 
various hydrophobic agents (e.g. the taxanes, adriamycin, vincristine and etoposide) out 
of the cell in an ATP-dependent manner. Cells positive for P-gp expression exhibit 
resistance to taxol but are also cross-resistant to an array of structurally unrelated 
compounds such as adriamycin, vincristine, vinblastine, VP-16 and show little or no 
cross resistance to alkylating agents, platinum drugs and antimetabolites. SKMES-Txl 
displays a MDR profile consistent with classic mdr-1-conferred drug resistance. 
Immunohistochemical analysis of P-gp expression in cell lines and tumour samples 
have revealed a correlation with resistance and P-gp expression (Mechetner et al,. 1998) 
and with taxol-based chemotherapy in NSCLC (Chou et al, 2003).
A number of studies using high taxane concentrations have generated cell lines with 
several mechanisms in addition to P-gp.
A taxol-resistant subline, SKOV-3TR, isolated from the human ovarian cancer cell line 
SKOV-3, was established by increasing the taxol concentration from 0.03 nM to 0.3 
IiM. The resulting subline was 100-fold more resistant to taxol compared to SKOV-3. 
Differential display analysis of the cell lines identified a new gene, TRAG-3 (Taxol 
Resistance Associated Gene-3) whose expression is associated with the chemotherapy- 
resistant and neoplastic phenotype. TRAG-3 mRNA was overexpressed in SKOV-3TR 
as well as MDA 435TR (a taxol-resistant breast cancer cell line). Further analysis 
revealed its overexpression in the adriamycin-resistant myeloma cell lines 8226/00X40 
and 8226/MDR10V (Duan et a l , 1999).
Parekh et al. (1997) established a series of taxol-resistant human ovarian carcinoma 
clones by step-wise sequential exposure starting from 0.05[iM to 0.5 fiM displayed 
resistance to taxol in the range of 250 to greater than 1500-fold. Resistance to taxol 
developed via P-gp-mediated and non-P-gp-mediated mechanisms. Non-P-gp-mediated 
resistance to taxol may be due to alterations in the taxol-binding affinity of the 
microtubules and alterations in tubulins. Giannakakou et al (1997) discovered 
alterations in the (3270 and (3364 regions of the tubulin that abrogated the effect of taxol 
in vitro and conferred resistance in taxol-resistant sublines from a human ovarian 
carcinoma cell line, A2780, in the presence of verapamil, a P-gp antagonist.
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Han et al (2000) developed a taxol-resistant large cell lung cancer variant of the NCI- 
H460 cell line (H460/T800), which is 1000-fold resistant to taxol and showed cross­
resistance to colchicine, vinblastine and doxorubicin Increased expression of P-gp and 
overexpression of a- and P-tubulin are observed in the resistant cell line Down- 
regulation of the a-tubulin expression by antisense resulted in an increased drug 
sensitivity of the cell line
Bums et al (2001) exposed the osteosarcoma cell line, TE-85, to increasing doses of 
taxol or taxotere over a nine-month period Two highly resistant variants were 
developed, TE-85TXL and TE-85TXR The taxol-resistant variant was greater than 
1000-fold resistant to taxol and taxotere and 60-fold resistant to adriamycin The 
taxotere-resistant variant developed greater than 1000-fold resistance to taxol and 800- 
fold and 80-fold resistance to taxotere and adriamycin respectively and not surprisingly 
both taxol- and taxotere-resistant variants overexpress P-gp Little cross-resistance to 
topotecan developed and both cell lines became sensitised to cisplatin Verapamil, a P- 
gp circumventing agent partially reversed taxane and adriamycin resistance and flow 
cytometry analysis revealed reduced accumulation of adriamycin in both variants
4 112 Climcally-relevant taxane selections
Other investigations, using clinically relevant drug concentrations also revealed P-gp
i
and non-P-gp mechanisms Zhou et al (2001) developed a taxol-resistant variant of the 
hepatocellular carcinoma cell line, QGY-7703 through continuous selection by 
increasing the concentrations of taxol from 2nM to 50nM The resulting cell line, QGY- 
TR50, was more than 250-fold resistant to taxol and exhibited cross-resistance to 
adriamycin (6-fold), vincristine (12 4-fold), vinblastine (5 7-fold) and actinomycin D 
(4 5-fold) No cross-resistance to 5-FU developed Western blot analysis revealed P-gp 
over-expression in the taxol-resistant variant RT-PCR analysis of the expression of the 
6 isotypes of p-tubulin revealed no overall change in the levels of expression of p- 
tubulm However, lowly expressed Pn-tubulm was increased and Pm-tubulin was 
decreased Increased expression of pm-tubulin has been shown in taxol-resistant cells 
and is thought to contribute to taxol-resistance by offering the cells a survival 
advantage Overexpression of pn-tubulin and Piya-tubulin has also been linked to cell 
survival
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Martello et al (2003) studied two taxol-resistant variants of the adenocarcinoma cell 
line A549 called A549-T12 and A549-T24 A549-T12 is 9-fold resistant to taxol and 
does not express P-gp A549-T24 is 17-fold resistant to taxol and expresses low levels 
of P-gp Both cell lines are dependent of taxol for normal growth as tubulin 
polymerisation is taxol-dependent There is a mutation in the major a-tubulin iso-type 
Kal This report highlights the complexity of taxol resistance in mammalian cells
4 2 13 Apoptosis and taxane resistance
Padar et al (2004) suggested that-altered intracellular calcium homeostasis could 
contribute to the taxol-resistant phenotype They determined whether intracellular 
calcium levels have a regulatory role in the development of taxol resistance in A549 and 
the resistant subclone A549-T24 Similar basal levels of calcium were found in both cell 
lines However, a decreased response to thapsigargin (a sarcoplasmic/endoplasmic 
reticulum Ca -ATPase inhibitor) in A549-T24 cells compared to the parent cell line 
suggested a lower ER Ca2+ content in these cells An altered calcium influx pathway m 
the taxol-resistant cell line was found Western blot and RT-PCR analysis revealed an 
increase of the anti-apoptotic protein Bcl-2 and sorcin m the resistant variant compared 
to the parent, both of which have previously been implicated in resistance as they can 
modulate calcium levels
Zaffaroni et al (2002) implicated apoptotic factors in taxol resistance in an ovarian 
cancer cell line Stable transfection with survivm cDNA resulted in a 4-fold to 6-fold 
increase in resistance to taxotere and taxol with a concomitant reduction in the apoptotic 
response to taxol There was no effect on sensitivity to cisplatin or oxaliplatm High 
expression of the survivm protein, detected by immunohistochemistry in advanced 
ovarian carcinomas, was significantly associated with clinical resistance to a 
taxol/platinum-based regimen but unrelated to tumour shrinkage following cisplatin- 
mcludmg combinations (non-taxol based)
Ooe et al (2006) investigated the relationship between p53 mutation status and 
response to taxotere in breast cancers Mutational analysis of p53 was carried out in 50 
primary breast cancer samples and 17 locally recurrent breast cancer patients before 
taxotere therapy The response of the p53-mutated tumours was lower (44%) than that 
of the p53-wild tumours (62%) Gene expression profiling of 186 tumour samples 
identified 2412 genes, 13 of which were significantly altered in mRNA expression
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between p53-wild and p53-mutated tumours and three were significantly increased in 
the p53-mutated tumours The expression of CCT5, RGS3, and YKT6 mRNA was up- 
regulated in p53-mutated tumours and was associated with a low response rate to 
taxotere Silencing RNA specific for the chaperone protein, CCT5 the regulatory protein 
RGS3 or the trafficking protein YKT6 in MCF-7 cells resulted in a significant 
enhancement of taxotere-induced apoptosis
4 1.14 Carboplatin resistance
In 1965, Rosenberg and co-workers first reported the inhibition of cell division in 
Eschericia coh by the electrolysis products from a platinum electrode Besides their 
effect on lung cancer, the platinum drugs are extremely effective when used on most 
testicular cancers, head and neck and on a subset of ovarian and bladder tumours The 
mechanisms of resistance to carboplatin are not as well characterised as those to taxol 
The ability of cisplatin or carboplatin to form covalent intra-strand and inter-strand 
cross-links with the genomic DNA is thought to cause its cytotoxic effects Mechanisms 
of cellular platinum resistance include decreased drug accumulation via increased drug 
inactivation by protein and glutathione/thiol conjugates enhanced DNA adduct repair, 
alteration in the sorts of platinum-DNA adducts formed and increased tolerance to 
platinum-DNA damage However, the underlying molecular bases for these 
chemoresistance mechanisms are still poorly understood (Johnson et a l, 1996) 
Chemoresistance to the platinum drugs remains one of the major obstacles to the 
successful treatment of NSCLC In this work, a range of carboplatin concentrations was 
used for pulse-selection of the cell lines
4.115 Cross-resistance to carboplatin
Compared to the literature, SCLC cell lines treated with cisplatin showed no cross­
resistance to the anti-microtubule agents, namely, taxotere and taxol' (Ikubo et a l , 
1999)
Osmak et al (1995) exposed human larynx carcinoma cells to incremental 
concentrations of carboplatin over 5 days to a final clinical level of 9 23 (ig/ml The 
result was the development of three clones, CBP-3, CBP-6 and CBP-7 which were 2 0- 
fold, 2 1-fold and 2 9-fold resistant to carboplatin respectively The CBP-7 and CBP-6 
clones exhibited cross-resistance to cisplatin CBP-7 clone became markedly more
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sensitive and CBP-3 slightly more sensitive to 5-FU CBP-6 became sensitive to VP-16 
and vinblastine CBP-7 developed resistance to vinblastine None of the three clones 
developed resistance to mitomycin C, adnamycin or vincristine A significant increase 
in glutathione levels and glutathione transferase were observed in CBP-7 only There 
was an increase in the expression of the c-los and c-Ha-ras oncogenes in CBP-6 and 
CPB-7 The cross-resistance profiles, GSH and GST biochemistry and oncogene 
expression indicate that the acquired resistance to carboplatin is a complex, 
multifactonal process in these carboplatm-selected cell lines In our studies, all cell lines 
resistant to carboplatin, developed cross-resistance to cisplatin Moreover, no cross­
resistance to adnamycin or vincnstine developed SKMES-Cpt30 became sensitized to 
5-FU None of the cell lines became sensitized to VP-16
Fram et al (1990) have shown that human colon carcinoma cells, resistant to cisplatin 
and cross-resistant to carboplatin, became resistant to adnamycin and VP-16 but 
sensitized to 5-FU Carboplatm-resistant ovarian tumour cells became cross-resistant to 
mitomycin C and depending on the treatment schedule, either retained their sensitivity 
to adnamycin or became resistant to the drug (Kuppen et a l , 1988) In contrast, all cell 
lines in these studies developed no significant resistance or became sensitised to 
adnamycin
From the literature, carboplatin resistant cells are cross-resistant to cisplatin and 
resistance ratios are similar for both drugs However, our resistance ratios were different 
(H69-Cptl0) than those published in the literature, probably due to the drug 
concentrations used in resistance development Our results, as well as the above- 
mentioned experimental data clearly show that induction of carboplatin resistance is a 
very complex, multifactonal process The changes induced in cells dunng resistance 
development depend on the cell line used and on the schedule of resistance 
development Furthermore, with the same cell line and different pulse concentrations, 
the variants produced can have opposite sensitivities to a range of drugs, as is the case 
of SKMES-Carboplatin selections and cross resistance to taxotere and 5-FU
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4 1.16 Other mechanisms of carboplatin resistance
Cytogemc alterations have also been implicated in platinum resistance (Osterberg et a l , 
2005) Comparative genomic hybridization revealed more frequent cytogenetic 
alterations in carboplatin resistant ovarian tumours compared to carboplatin sensitive 
tumours Differences in tumour histology were also found There were gams of lq, 
5ql4~q23, 13q21~q32, and losses of 8p and 9q associated with clinical carboplatin 
resistance Moreover, differences were found between primary resistant and secondary 
resistant tumours
Daubeuf et al (2003) investigated the effect of G-glutamyltransferase (GGT) 
overexpression on cell viability after carboplatin treatment compared to cisplatin 
Carboplatin exposure of HeLa cells induced GGT and glutamate-cysteine ligase (GCL) 
activities by 2-fold and 1 4-fold respectively and increased glutathione levels (1 5-fold) 
HeLa-GGT cells Stable transfection of GGT in the parent to yield HeLa-GGT, 
facilitated a study of the role of GGT Culturing the cell lines with low levels of 
cysteine resulted m a dramatic decrease (90%) of the intracellular GSH level and a 2 5- 
fold increase of carboplatin cytotoxicity A decrease in carboplatin resistance was 
observed with the inclusion of GSH m the media in the HeLa-GGT cells only Using 
partially purified GGT from HeLa-GGT cells, cisplatin forms adducts with 
cysteinylglycme, depending only on GGT activity whereas carboplatin did not 
efficiently react with cysteinylglycme GGT activity can affect platinum cytotoxocity by 
two different ways cisplatin can be detoxified extracellularly after reaction with the -  
SH group of cysteinylglycme, in the case of carboplatin, the supply of GSH precursors, 
initiated by GGT, increases the intracellular level of the tripeptide and provides 
enhanced defensive mechanisms to the cell
Changes in control of apoptosis have been implicated in carboplatin resistance Itoh et 
al (2002) demonstrated that the Bcl-2 family member Bcl-xL provide resistance to 
chemotherapeutic agents including carboplatin Using Morphohno Bcl-xL antisense 
oligonucleotides (oligos) to down-regulate Bcl-xL in carboplatin-resistant (MIT8, 
MIT 16) and carboplatin-sensitive (MIT7) squamous cell carcinoma cell lines resulted m 
a reduction in Bcl-xL levels and substantially prevented cell growth of both carboplatin- 
sensitive and resistant cells This reduction in cell growth was further augmented the 
addition of Bcl-xL oligos
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Ribosomal proteins and elongation factors were found to be a common characteristic of 
cisplatin resistant cell lines (Wu et al., 2005). To survive cisplatin exposure, it was 
hypothesised that cells have to synthesize DNA repair proteins, antiapoptotic proteins 
and growth-stimulating proteins. Therefore, blocking the translation of these proteins 
could restore cisplatin sensitivity. CCI-779, an ester analogue of rapamycin, could 
restore cisplatin sensitivity in SCLC cell lines selected for cisplatin resistance and cell 
lines derived from patients who failed cisplatin treatment. By disabling mTOR, 
translation is inhibited and cisplatin sensitivity was restored. The addition of CCI-779 
decreased the amount of 4E-BP phosphorylation and p-70S6 kinase phosphorylation 
and lowered the amount of elongation factor. The compound is effective at 10 ng/ml. At 
this concentration, it can increase the growth inhibition of cisplatin by 2.5-fold to 6 fold. 
It can also enhance the apoptotic effect of cisplatin in cisplatin-resistant cell lines. 
However, at achievable clinical concentrations CCI-779 had no effect on the growth of 
P-gp or MRP1 overexpressing cells.
4.1.17 Analysis of VP-16 resistance in the NCI-H69 cell line
Etoposide/VP-16 is a semi-synthetic derivative of podophyllotoxin used in the treatment 
of testicular cancers, acute myeloid leukaemia, Hodgkin’s disease, non-Hodgkin’s 
lymphoma, lung, gastric, breast and ovarian cancers as well as Kaposi’s sarcoma 
(Hande, 1998). The major toxicities attributable to VP-16 are bone marrow depression, 
nausea, diarrhoea, mucositis and hypotension.
4.1.18 Mechanism of VP-16 resistance
VP-16 works as a topoisomerase II (topo II) poison whose function is to temporarily 
break DNA strands and reseal the breaks. This results in the DNA being sufficiently 
untangled to allow transcription and replication to occur.
VP-16 increases the steady state concentration of the covalent DNA cleavage 
complexes, converts the topoisomerases into toxins that introduce high levels of 
transient protein-associated breaks in the genome of the treated cells. Development of 
resistance to VP-16 can be due to reduced levels of topoisomerase II within the target 
cells. Moreover, mutations or alterations in drug binding sites on topoisomerase II are 
associated with resistance to VP-16. Increased expression of MDR-1 also confers 
resistance to VP-16.
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Overexpression of P-gp or MRP1 is a mechanism of resistance to VP-16 It results in 
decreased intracellular drug accumulation (Smha et a l , 1998) Minato et al (1990) 
developed a 9 4-fold etoposide-resistant variant of the NCI-H69 cell line The cell line 
was cross-resistant to adnamycin, temposide, vindesine and vincristine as opposed to 
our NCI-H69 VP-16 resistant variant Topoisomerase II levels between the parent and 
variants were almost unchanged The catalytic level of the enzyme was lower in the 
resistant variant Northern blot analysis revealed that P-gp levels were significantly 
increased in H69/VP suggesting that it has a typical MDR phenotype
VP-16 treatment also prevents the activation of p34cdc2 protein kmase, which usually 
becomes activated at the end of the G2 phase of the cell cycle It is believed to have a 
critical role in allowing cells to start mitosis It is possible that the arrest of cells in the 
G2 phase of the cell cycle which is seen with VP-16 is due to interference with p34cdc2 
Ikubo et al (1999) studied the cytotoxicity of anti-microtubule agents in SCLC cell 
lines, including a primary cell line from an untreated patient and cell lines from treated 
patients The panel consisted of representatives of intrinsic drug-resistance and cell lines 
selected by continuous exposure to increasing concentrations of adnamycm, etoposide 
or cisplatin, as representative of acquired drug resistance Results showed that the cell 
lines treated with adnamycin or etoposide were highly resistant to taxol, taxotere, 
vincnstine, vindesine and vinblastine as well being resistant to their selection agents 
(unlike our van ants)
Hill et al (1994) established four epipodophyllotoxm-selected cell lines, which had 
alterations in topoisomerase II No cross-resistance to taxotere developed suggesting 
that taxotere cross-resistance is not automatically expressed by classic MDR tumour 
cells
A phenotype has been identified in which cells that are resistant to VP-16 retain normal 
sensitivity to the vinca alkaloids and normal drug transport charactenstics It anses from 
the expression of different forms of topoisomerase II with altered catalytic activities 
(Glisson et a l , 1986) Another form of resistance has been traced to a mutation that 
resulted in decreased expression of the topoisomerase II protein with otherwise normal 
catalytic activity (Deffie et a l, 1989)
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4.119 Summary
The criteria required to mimic the clinical situation, namely the use of chemotherapy- 
naive cell lines, pulsing rather than continuous selection and the use of 
pharmacologically achievable concentrations were adhered to in the generation of 
clinically relevant drug-resistant variants Resistant tumour cells in situ are usually no 
more than 5 tol0-fold resistant (Simon and Schindler, 1994) Excluding the unstable 
SKMES-Taxane selections, selection with taxol resulted in a variant with a fold 
resistance of 6 3-fold compared to the parent Selection with taxotere resulted in 
variants with fold resistance differences between 1 8-fold and 4 4-fold compared to the 
parent cell lines Unstable resistance developed to both taxane-selected variants of 
SKMES contrasting to the taxane selected variants arising from DLRP and DMS-53 
Carboplatin selection resulted in variants with stable fold resistance differences between 
1-fold and 2 2-fold compared to the parent
The resistance m taxane-selected variants may be due to a number of mechanisms 
including alterations in tubulin dynamics, mutations m tubulin and increased expression 
of P-gp The carboplatin-resistance observed might be due in part to increased MRP-1 
expression
The resulting selected variants displayed relatively low-level resistance to the pulsing 
drug (1-76 7-fold) and therefore provide excellent models for the study of taxotere, 
taxol, VP-16 and carboplatin resistance
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4 1 20 Cell invasion, motility and adhesion
Invasion is one of the most critical steps of metastasis in cancer and is a major cause of 
cancer deaths as approximately 50% of all cancer patients develop metastasis (Fidler et 
a l , 1994) Tumour progression requires the dispersion of epithelial cells from the 
neoplastic cluster and cell invasion into adjacent tissue The development of metastasis 
is a multistep process involving attachment to the basement membrane, local proteolysis 
and migration into surrounding tissues, lymph or bloodstream and re-attach at a 
different site Tumour cells must initiate and successfully complete all of these steps in 
order to enter the circulatory and lymphatic systems to form distant metastases It is 
thought that some tumour cells acquire favoured phenotypes that give them an 
advantage in disseminating from the primary tumour and invading other areas 
Understanding the relationship between cell dispersion and cell invasion represents a 
challenge in elucidating the mechanisms contributing to the acquisition of an invasive 
phenotype A good tumour metastasis model is not yet available to analyse the 
metastatic potential of lung cancer cells It is difficult to correlate in vitro the cellular 
and molecular modifications, which lead to invasion with a precise cell behaviour At 
present, models cannot analyse cell adhesion and the individual ability of each cell to 
disperse and be invasive
Widespread metastasis is common in non-small-cell lung cancer The adenocarcinomas 
typically metastasise at an early stage whereas squamous cell lines occur relatively late 
Small cell lung carcinomas are very malignant tumours, grow aggressively and 
metastasize early Damstrup et al (1998) correlated in vitro mvasiveness with 
expression of epidermal growth factor receptor (EGFR) in a panel of 21 SCLC cell 
lines They determined that only EGFR-positive SCLC cell lines had the in vitro 
invasive phenotype suggesting that the EGFR might play an important role for the 
invasion potential of SCLC cell lines The inclusion of the EGFR-neutralizmg 
monoclonal antibody mAb528 in six EGFR-positive SCLC cell lines resulted in a 
significant reduction in in vitro invasion in three of the cell lines
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4.1.21 MDR and invasion
Studies have begun to focus on a correlation between cancer invasion, metastasis and 
drug resistance There is increasing evidence that drug resistance may induce an 
invasive phenotype m cancer cells and vice versa (Kondo et a l , 1961, Takenaga et a l , 
1986, McMillan et a l , 1987) Previous studies in our laboratories have shown that 
selection with some chemotherapeutic agents can lead to increased in vitro mvasiveness 
(Liang et a l , 2001) The aim of this part of the thesis was to determine whether invasion 
could be induced in non-invasive cells (DMS-53 and NCI-H69) and whether an already 
invasive phenotype be altered as a result of drug selection (SKMES-1 and DLRP)
4.1.22 SKMES-1
Pulse selection of SKMES-1 with taxotere and taxol resulted in more invasive variants, 
with the taxotere variant being the most invasive in comparison to the parent cell line 
(2 17-fold and 1 34-fold respectively) Due to the unstable nature of both SKMES-Txt 
and SKMES-Txl variants, their mvasiveness was also assessed after long-term storage 
at week 7 where drug resistance had fallen by approximately 2 2-fold in both cell lines 
The taxol variant SKMES-Txl, was 5-fold more invasive compared to the control at 
week 7, and 1 3-fold invasive at week 2 The taxotere-selected variant SKMES-Txt was 
3 3-fold more invasive at week 7 compared to the control (2  1-fold invasive at week 2) 
The mvasiveness of the parental cell line remained unchanged over the same period
Selection of SKMES-1 with the high concentration of carboplatin resulted in a more 
invasive (1 4-fold) cell line whereas pulse selection with a lower concentration resulted 
in a less invasive (3-fold) and less motile (1 5-fold) cell line No change in motility was 
observed in SKMES-CptlOO These cell lines provide a model for the future study of 
invasion SKMES-CptlOO is 2 5 times more adhesive than the parent cell line with the 
SKMES-Cpt30 cell line being only 1 2 times more adhesive
The most widely accepted method to measure and quantify in vitro mvasiveness is the 
use of the monolayer Boyden Chamber assay, where cells are placed into a microporous 
membrane insert pre-coated in e g matngel (section 2 111) However, this assay is 
limited and does not fully reflect the in vivo tumour situation Therefore, invasion 
assays were also carried out on SKMES-1, SKMES-Txt and SKMES-Txl, whereby cells
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were induced to grow as spheroids (to try and mimic the in vivo situation), then 
transferred to a well of a 24-well plate coated in collagen type I. Components of the 
extracellular matrix play a fundamental role in the process of tumour invasion and 
metastasis. During metastasis, invasive cells must traverse tissue barriers which are 
mainly comprised of type I collagen. This process is dependent on the ability of tumour 
cells to degrade the surrounding collagen matrix and migrate through. The results 
revealed that both SKMES-1 and the taxane variants are invasive after 24 hours. 
However, the taxol and taxotere variants are approximately half as invasive as the 
parent when tested over the seven days.
Taxotere was found to greatly increase the invasiveness and motility of the DLKP- 
Taxotere cells (Rasha Linehan, PhD thesis 2003). The invasiveness of DLKP-taxotere 
was reversed using MMP inhibitor III which inhibits MMP-1, -2, -3, -7, -13.
Adhesion assays to matrigel compared to a control with no matrigel determined that 
SKMES-Txt (3.85-fold) is more adhesive to matrigel than either the parent or taxol- 
selected variant (0.83-fold) with the taxol-selected variant being less adhesive than the 
parent. Loss of adhesion was seen in both taxane cell lines with respect to time, 
SKMES-Txt and SKMES-Txl being 1.4-fold and 0.44-fold less adhesive at week 7 
compared to week 2 respectively with respect to SKMES-1 (Table 3.2.7). Loss of 
adhesion to matrigel is greater in the taxol-selected variant than in taxotere-selected 
variant, 2.5 times versus 1.5-times respectively. Taxol-mediated stabilisation of 
microtubules and subsequent cell death may be more effective if the tumour is adhered 
to the extracellular matrix. It may be advantageous to a tumour or cell line to become 
less adhesive to extracellular matrix components, in order to lessen the effects of taxol 
or taxotere on microtubules. A study on the invasive breast cancer cell line MDA-MB- 
435S-F found that selection with the agents taxol and adriamycin led to a more 
aggressive invasive phenotype termed “superinvasive” (Glynn et al., 2004). These 
variants were also considerably less adhesive to laminin, fibronectin, collagen type IV 
and matrigel.
Gelatine zymography of the taxane selected variants and corresponding parental cell 
lines in these studies revealed the presence of MMP-9 in all invasive cell lines tested. A 
band corresponding to MMP-2 was also detected in all invasive taxane-selected 
variants. A loss of secreted proteinases* which are not MMPs or serine proteinases was 
observed in the SKMES-Txt and SKMES-Txl compared to the parental cell line.
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4 2 23 DLRP
Exposure to taxotere resulted in the DLRP-taxotere becoming only slightly more 
invasive No change in motility was observed However, DLRP-Txt (0 91-fold) was less 
adhesive than the parent cell line Carboplatin selection had no effect on drug resistance, 
motility or mvasiveness of DLRP-Cpt However, this cell line was considerably less 
adhesive than the parent
4.1 24 DMS-53 and NCI-H69
Exposure of the non-invasive cell line, DMS-53, to taxol and taxotere did not induce an 
invasive or motile phenotype or a change in adhesiveness Previous findings showed 
taxol did not induce a strong invasive phenotype in the non-invasive cell line RPMI- 
2650 (Liang et a l , 2001) The SCLC cell lines (DMS-Cpt, H69-Cptl0 and H69-Cpt5) 
remained non-invasive after pulse selection with carboplatin
However, when cultured in vitro, such as the classic SCLC cell line NCI-H69, grow in 
floating aggregates and express negligible proteolytic activity Sage et al (2004) 
selected for adherent NCI-H69 cells, which expressed tissue factor as well as 
gelatinolytic activity, namely MMP-2 and MMP-9 If this occurs in SCLC patients it 
might increase the understanding of the steps involved in the spreading of this highly 
metastatic type of lung cancer
4 1 25 Taxol and invasion
, Taxol treatment has been linked to decreased invasion and motility Belotti et al (1996) 
determined the effect of taxol on the adhesive and motility properties of human ovarian 
carcinoma cell lines, OVCAR 5, SK-OV-3, and HOC-IOTC Taxol significantly 
inhibited the motility of these cell lines but it did not affect their adhesion to the 
subendothelial matrix Taxol is therefore a potent inhibitor of ovarian carcinoma cell 
motility and this activity is independent of its cytotoxic activity In a different study by 
the same group, results indicated that taxol has a strong antiangiogemc activity, a 
property that might contribute to its antineoplastic activity in vivo (Belotti et a l , 1996)
In another ovarian cancer cell line, Ovcar-3, taxol was also found to suppress invasion, 
motility and cell attachment of ovarian cell line and was accompanied by an increase of 
TIMP-2 protein release (Westerlund et a l, 1997) Motile and invasive cells were 
trypsmised from the invasion chamber and counted These invasion results do not 
correlate with the results obtained from SKMES-Txl which became more invasive after
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pulse selection Similar mcreases in invasion were also seen in taxol-selected H460 and 
SKLU1 cell lines (Laura Breen, PhD thesis 2005)
In the study, RPMI-2650M1 (melphalan-resistant) and RPMI-2650Tx (taxol-resistant) 
cell lines were established through continuous selection with melphalan and taxol, 
respectively The variants exhibited a multiple drug resistant phenotype However, 
RPMI-2650M1 but not RPMI-2650Tx, exhibited a highly invasive phenotype, with 
increased expression of MMP-2 and MMP-9 as well as increased adhesion to collagen 
type IV, laminin, fibronectin and matrigel (Liang et a l , 2001)
Terzis et al (1997) tested taxol for its anti-migrational, anti-invasive and anti­
proliferative effect on two human glioma cell lines, GaMg and D-54Mg, which were 
grown as spheroids Both cell lines showed a dose-dependent growth and migratory 
response to the drug taxol The GaMg cells were 5-10 times more sensitive than the D- 
54Mg cell line It was also highly effective in preventing invasion in a co-culture system 
in which tumour spheroids were confronted with foetal rat brain cell aggregates
Confocal microscopy of both cell lines showed an extensive random organisation of the
\
microtubules in the cytoplasm After exposure, the GaMg and the D-54Mg cells 
displayed a fragmentation of the nuclear material, indicating a possible induction of 
apoptosis Flow cytometric DNA histograms showed an accumulation of cells in the 
G2/M phase of the cell cycle after 24 hours of exposure Forty-eight hours resulted in a 
deterioration of the DNA histograms indicating nuclear fragmentation
4 1 26 Carboplatin and invasion
Carboplatin selection of other lung cell lines namely, H460, HI299, A549 and SKLU1 
in our laboratones resulted in a less invasive phenotype (Laura Breen, PhD thesis 2005) 
In contrast, pulse-selection with cisplatin led to increased in vitro invasiveness in lung 
cancer cell line DLKP (Liang et a l , 2004) This increased invasiveness was associated 
with increased expression of the matnx metalloproteinases MMP-2 and MMP-13
Gelatine zymography of the carboplatin-selected variants in these studies, revealed the 
presence of MMP-9 in all invasive cell lines tested A band corresponding to MMP-2 
was also detected in the selected variants except DLRP-Cpt SKMES-1 and both 
carboplatin-selected variants secrete proteinases which are not MMPs or serine 
proteinases
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It is suggested that tumour growth, angiogenesis and metastasis are dependent on MMP 
activity. They break down matrix barriers, thereby allowing tumour cells to penetrate 
tissues, gain access to blood vessels, exit blood vessels and metastasise to distant sites. 
Koivunen et al (1999) developed a specific MMP-2 and MMP-9 synthetic peptide 
inhibitor, CTTHWGFTLC (CTT1) and CCT2 to prevent the migration of human 
endothelial and tumour cells. It also inhibited tumour growth and invasion in animal 
models and improved the survival of mice with human tumours. CTT1-displaying 
phage could specifically target angiogenic blood vessels in vivo. However, CTT2 did 
not inhibit the type I collagen degradation by human collagenases (MMP-1, MMP-8 and 
MMP-13) in tongue SCC. It reduced the blood vessel density and improved the survival 
of the mice bearing human tongue carcinoma xenografts (Heikkila et al, 2006). The 
development of matrix metalloproteinase inhibitors as an anti-cancer agents, is therefore 
very important and may prove useful in tumour targeting and anticancer therapies.
The tumour microenvironment, which consists of soluble factors, components of the 
extracellular matrix as well as cell-cell interactions is often overlooked when 
considering tumour response to chemotherapeutic agents. Anti-apoptotic pathways 
initiated by cell adhesion are operative in tumour cells and cause resistance to 
mechanistically-distinct cytotoxic drugs. Cell adhesion of hematopoietic cancers (e.g. 
the human myeloma 8226 cell line) to fibronectin is sufficient to inhibit apoptosis 
induced by mechanistically distinct chemotherapy drugs. The results in blocking cell 
cycle progression result in increased p27kipl levels. This correlates with cell cycle 
arrest and drug resistance. A reduction in initial DNA damage induced by topo II 
inhibitors has also been seen in adherent hematopoietic cancer cell lines (Hazelhurst and 
Dalton, 2004).
It has been proposed that extracellular effectors namely, cytokines, matrix components 
and adjacent cells may provide sanctuary to cancer cells and inhibit stress-induced cell 
death. Cell adhesion has been shown to confer a protective advantage to adherent cancer 
cells against classical chemotherapeutic agents and irradiation and prevent cell death 
through a number of mechanisms. Shain and Dalton (2001) observed that fibronectin 
adhesion of K562, the chronic myelogenous leukemia cell line reduced the effectiveness 
of the BCR-Abl kinase inhibitors STI-571 and AG957. The results show that the 
microenvironment of the cancer cell can provide a sanctuary conferring resistance to 
cancer therapy.
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Hikawa et al (2000) used a glioma cell line, IN 157 to study changes in cell adhesion 
and invasion on acquiring drug-resistance to VP-16, vincristine and adriamycin The 
drug-resistant cells had increased expression of mtegnns alpha 2, 3 and 5 and beta 1 
The adhesiveness of the variants increased to laminin, fibronectin and type IV collagen 
Reduced invasion was observed The development of drug-resistance and an increase in 
the expression of mtegnns may have enhanced the adhesion to ECM proteins
Pulse selection of NCI-H69 cells with VP-16 had no effect on the invasive phenotype of 
the cells In solid tumours, cancer cells are exposed to various micro-environmental 
stresses such as hypoxia, nutritional depletion and low pH Cancerous cells adapt to 
these conditions and circumvent cell death by acquiring physiologic functions, such as 
mvasiveness Mutsuko et al (2005) treated rat ascites hepatoma MM1 cells with VP-16 
and hypoxia and acidic conditions Under stress conditions, the cells became invasive 
and changed morphologically This was induced by caspase-3 activation In contrast, 
acid-induced mvasiveness was not activated by caspase-3 inhibition
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Studies have begun to focus on a correlation between cancer invasion, metastasis and 
drug resistance There is increasing evidence that drug resistance may induce an 
invasive phenotype in cancer cells The aim of this part of the thesis was to determine 
whether invasion could be induced in non-invasive cells (DMS-53 and NCI-H69) and 
whether an already invasive phenotype be altered as a result of drug selection (SKMES- 
1 and DLRP)
Invasion was not induced in a non-invasive cell line (NCI-H69 and DMS-53) when 
pulsed with carboplatin and/or taxotere, taxol and VP-16 Pulse selection of an already 
invasive cell line was found to alter the invasiveness Taxane selection resulted in 
increased invasion whereas carboplatin induced different levels of mvasiveness 
depending on the concentration used
Pulse selection of SKMES-1 with both taxanes resulted in more invasive variants, with 
the taxotere variant being the more invasive of the two when checked over two and 
seven weeks A correlation between a fall in drug resistance and adhesiveness with 
increase in the invasive phenotype was observed in both cell lines over this period 
Exposure of DLRP to taxotere resulted in the DLRP-Txt cell line becoming only 
slightly more invasive and as seen in SKMES-Taxane selection a loss of adhesion was 
observed Pulse selection of the non-invasive small cell lung carcinoma cell line, DMS- 
53, to taxol and taxotere did not induce an invasive or motile phenotype or a change in 
adhesiveness Gelatine zymography of the taxane selected variants in these studies 
revealed the presence of MMP-9 and MMP-2 in all invasive cell lines tested A loss of 
secreted protemases, which are not MMPs or serine proteinases was observed in the 
SKMES-Txt and SKMES-Txl compared to the parental cell line
Collagen type I is a major component of the extracellular matrix which plays a 
fundamental role in the process of tumour invasion and metastasis To try and mimic the 
in vivo situation, SKMES-1 and both taxane-selected variants were induced to grow as 
spheroids and transferred to collagen type I The results revealed that both SKMES-1 
and the taxane variants are invasive after 24 hours However, the taxol and taxotere 
variants are approximately half as invasive as the parent when tested over the seven 
days
4 1 27 Summary
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Selection of SKMES-1 with the high concentration of carboplatin resulted in a more 
invasive cell line whereas pulse selection with a lower concentration resulted in a less 
invasive and less motile cell line No change in motility was observed in SKMES- 
CptlOO Both carboplatin selections are more adhesive than the parent cell line 
Carboplatin selection had no effect on drug resistance, motility or mvasiveness of 
DLRP-Cpt However, this cell line was considerably less adhesive than the parent 
Similar results to the taxane selections on the DMS-53 cell line were observed with 
carboplatin selection on NCI-H69 and DMS-53 No change in the invasive and motile 
phenotype was observed Gelatine zymography of the carboplatin-selected variants and 
parental cell lines in these studies, revealed the presence of MMP-9 in all invasive cell 
lines tested A band corresponding to MMP-2 was also detected in the selected variants, 
except DLRP-Cpt SKMES-1 and both carboplatin-selected variants secrete proteinases 
which are not MMPs or senne proteinases This increased invasiveness was associated 
with increased expression of the matrix metalloproteinases MMP-2 These cell lines 
therefore provide a model for the future study of invasion
Pulse selection of NCI-H69 cells with VP-16 had no effect on the invasive phenotype of 
the cells
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Cancer is a multi-faceted disease, presenting many challenges to clinicians and cancer- 
researchers alike who search for more effective ways to combat this devastating disease. 
Tumour development is a complex process, requiring the co-ordinated interactions of 
many proteins, signal pathways and cell types (Negm et al., 2002) and as such, is an 
ideal candidate for proteomic analysis. Cancer proteomics seeks to understand how 
networks become dysfunctional, predict how their function can be altered through 
interventions by drugs or genetic manipulations (Anderson et al, 2000) and enables the 
identification of disease-specific proteins, drug targets and markers of drug efficacy and 
toxicity. Improving diagnosis, classification of tumours and defining targets for more 
effective therapeutic measures are among the central challenges of this disease 
(Simpson and Dorrow, 2001). Proteomic approaches hold the promise of identifying 
specific protein modifications in tumour tissues to aid in individualising treatments for 
certain cancers.
Lung cancer is the most lethal of cancers with 1.2 million cases diagnosed each year and
1.1 million deaths (Seve and Dumontet, 2005). Poor survival rates are due to: the 
propensity for early spread; the lack of effective screening for early diagnosis (75% 
present with advanced stage disease); the inability of systemic therapy to cure metastatic 
disease and the poor understanding of the biology of the tumours and the development 
of resistance to chemotherapeutics (Bunn, 2002; Niklinski and Hirsch, 2002).
4.2.1 Drug resistance and cancer
The development of resistance to drug therapy is one of the major problems in cancer 
treatment and a main cause of limited long-term survival. Intrinsic and acquired drug 
resistance are believed to cause treatment failure in over 90% of patients with metastatic 
cancer (Longley and Johnston, 2005). Tumours can be initially sensitive to a 
chemotherapy drug but through drug selection acquire resistance. In contrast, other 
tumours are intrinsically resistant before treatment. Non-small cell lung carcinomas 
often show intrinsic multidrug resistance (Wilhelm and Kolesar, 2005), whereas small 
cell lung carcinomas usually respond well to various anticancer agents initially and then 
acquire resistance. Treatment with one chemotherapeutic agent can often lead to 
associated resistance to a number of unrelated agents, a phenomenon called multiple 
drug resistance (MDR). MDR is caused by a variety of changes in the cancer cells and
4.2 Proteomic analysis of drug-resistant variants of squamous lung carcinomas
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is almost always multifactonal A better understanding of the mechanisms of drug 
resistance would help to overcome this obstacle Huge advances have been made in 
understanding the biology of lung cancer and the mechanisms of drug resistance 
Mechanisms include drug inactivation (GSTs), alterations in the target, decreased drug 
accumulation, increased drug efflux, enhanced processing of drug-induced damage and 
evasion of apoptosis (Longley and Johnston, 2005) MDR categories based on the 
specific cellular targets include -  classical multidrug resistance (MDR/P-gp), non P-gp 
MDR (MRP) and atypical MDR (mediated through altered expression of 
topoisomerases II) (Scagliotti, et a l , 1999)
Cellular pathways that are mutated in cancer and associated with resistance may provide 
cancer therapy approaches Increased overall survival and resistance to unfavourable 
growth conditions develop as the consequence of several mechanisms such as mutations 
in p53, up-regulation of PI3K-AKT signalling and growth factor receptor associated 
pathways, resistance to hypoxia-induced apoptosis Anticancer therapy should therefore 
be directed against targets that represent weaknesses in the armour of tumour cells and 
not their strong points Some apoptosis mechanisms are unlikely to be mutated during 
tumour progression and are interesting potential therapeutic targets One such potential 
mechanism is the lysosomal apoptotic pathway The high protein turnover in tumour 
cells is another example of a possible weak point to be exploited The protein-folding 
compartment of the endoplasmic reticulum (ER) is particularly sensitive to 
disturbances, which, if severe, could trigger apoptosis (Chen et a l , 2005)
In addition to developing MDR, some cells also become metastatic and migrate to 
distant sites in the body (Lucke-Huhle, 1994) Conversely, metastatic cells may also 
develop drug resistance more readily than their non-invasive counterparts (Cillo et a l ,
1987) A better understanding of the relationship between chemotherapeutic drug 
resistance and invasion in cancer could lead to a more effective treatment for the disease 
(Liang et a l , 2002)
In this work, proteomic tools were used to study the chemoresistance mechanisms in 
cell culture systems derived from squamous lung carcinomas The parental cell lines 
along with the chemoresistant variants were cultured and analysed for differential 
proteins expression using 2D-DIGE Differentially expressed proteins were identified 
by MALDI-TOF mass spectrometry
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4 2 2 Proteomic analysis of adnamycm-resistant variants of DLKP
Proteomics has emerged as a valuable tool for identifying proteins, which play a role in 
chemotherapeutic efficacy In these studies, we used the ETTAN DIGE two- 
dimensional electrophoresis system, where protein samples were labelled with three 
different charge- and size-matched fluorescent cyamne dyes possessing distinct 
excitation and emission spectra Proteomic analysis was earned out to study differential 
protein expression caused by adnamycin resistance in a range of established cell lines 
displaying varying levels of resistance to adnamycin DLKP, a poorly differentiated 
squamous lung cell line, was previously exposed continuously to increasing 
concentrations of adnamycin resulting in the cell line, DLKP-A (Clynes et a l , 1992) 
This cell line was further selected continuously with adnamycin creating DLKP-A10 
(Cleary et a l , 1997) Several clonal sub-populations were also established from DLKP- 
A by clonal dilution including, DLKP-A5F and DLKP-A2B (Heenan et a l , 1997) Each 
of the above four cell lines has diffenng levels of resistance to adnamycin and also 
exhibits cross-resistance profiles to a number of chemotherapeutic drugs (Table 4 2 1) 
While the mam mechanism of resistance in these cell lines is associated with P-gp (no 
detectable levels of MRP), little information on cytoplasmic changes was available 
This work set out to investigate such changes to increase our understanding of the 
mechanisms involved m adnamycin resistance and to identify putative markers with 
possible prognostic/diagnostic value
Fold Resistance
Cell Line Adnamycin Cisplatm Vincristine VP-16 5-FU
DLKP-A10 765 3 0 825* 3000 63 3 0 92
DLKP-A5F 235 4 1 39 1275 04 50 6 0 98
DLKP-A 122 6 1 46 1504 60 67 1 75
DLKP-A2B 7 0 57 228 32 18 17 1 28
Table 4 21 Drug resistance profi es o f adnamycin resistant variants o f DLKP
*Carboplatin Table was compiled from Cleary et a l , 1997 and Heenan et a l , 1997 Resistance 
to adnamycin was reconfirmed by toxicity assay Fold resistance was calculated with respect to 
DLKP
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4.2.3 Summary of identified proteins
Proteomic analysis was carried out whereby DLKP was compared to DLKP-A. DLKP- 
A was then compared to DLKP-A2B, DLKP-A5F and DLKP-A10.
DLKP-A versus the parent yielded a total of 300 proteins of which 38 were identified. 
Of the total number of proteins identified (68) from all the comparisons, the most 
interesting, with respect to drug resistance, were those that increased with resistance (8 
proteins) (Figure 3.4.27; those that decreased with resistance (7 proteins) (Figure 
3.4.28) and those that showed a baseline change across the cell lines (11 increased and 8 
decreased proteins) (Figures 3.4.29 and Figure 3.4.30). In the following sections some 
of the differentially expressed proteins will be discussed.
DLKP A
DLKP DLKP-A2B DLKP-A DLKP-A5F DLKP-A10
Cell Line
Figure 3.4.27 Proteins correlating with drug resistance across the adriamycin-resistant panel. 
Numbers in brackets indicate spot numbers.
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stress induced phosphoprotein 
prohibitin
synovial sarcoma X breakpoint 3 
Triose phosphate isomerase (29)
HSP70kDa protein 8 isoform 2 (27) 
Bip 
EIF5a
DLKP
Figure 3.4.28 Proteins inversely correlating with increasing resistance (Brackets indicate spot 
number where isoforms are present).
DLKP A
1.20
0.80
320
1  0.60
ok -
Q.
0.40
0.20
— VCP protein 
lamin B1 
— HNRPK
—i— Aldehyde dehydrogenase 1 (8) 
—— Aldehyde dehydrogenase 1(10) 
Rab dissociation inhibitor beta 
Annexin 1 (22)
HSP70 KDa 9B
Chaperonin containing TCP1 subunit 3 
Aldehyde dehydrogenase 1 (7) 
Succinyl-CoA 3 ketoacid CoA transferase 
HNRPH1
HSPC108 (stomatin)
Triosephosphate isomerase (28)
DLKP DLKP A DLKP A2B DLKP A5F DLKPA10
Cell Line
Figure 3.4.29 Proteins correlating with a baseline increase in resistance (Brackets indicate spot 
number where isoforms are present).
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DLKP A
4
♦ —  Ornithine mutant amine transferase Y85 chain c 
■ —  HSP 70kDa protein 8 isoform 2 (17) 
protein disulphide isomerase protein 5 
* -  Thioredoxin Peroxidase B (32)
DLKP DLKP A DLKPA2B DLKPA5F DLKPA10 
Cell Une
Figure 3.4.30 Proteins inversely correlating with a baseline resistance (Brackets indicate spot 
number where isoforms are present).
4.2.4 Overview of proteins that increased with drug resistance
4.2.4.1 Annexin A1
The annexins are a family of structurally related water-soluble calcium- and 
phospholipid-binding proteins, which total 20 (Vishwanatha et al, 2004). Annexin A1 
is a 35-kDa member of this annexin superfamily. Each annexin has a very conserved C- 
terminal domain, composed of four (or 8 for ANXA6) repeated sequences of seventy 
amino acids. In contrast, the N-terminal sequence of all annexins is unique and confers 
the biological specificity of the individual proteins. The N-terminal domain of ANXA1 
is composed of 44 amino acids and includes sites for protein kinase C, tyrosine kinase 
phosphorylation, glycosylation, acetylation and proteolysis (Mulla et al., 2004). The 
protein was first identified to be an important mediator of the anti-inflammatory actions 
of glucocorticoids in the immune system. Further work revealed that it plays important 
roles in many other physiological and pathological processes including, cell growth, 
differentiation, apoptosis, membrane fusion, endocytosis and exocytosis (John et a l7 
2004; Bai et al., 2004). It has been identified in every major peripheral endocrine organ 
in the body (pancreas, testis, ovary, thyroid, adrenal gland, thymus and placenta). Cell
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fractionation studies determined that ANXA1 is found in three distinct pools namely, 
the cytoplasm, embedded in the membrane structures and finally attached to the outer 
surface of the plasma membrane (John et al., 2004). It is a critical mediator of 
apoptosis. Overexpression has been observed in pancreatic, breast, hepatocellular, 
pituitary adenoma and gastric cancers. Reduced or no expression of annexin I has been 
reported in prostate, endometrial and esophageal cancers. Differential regulation of 
annexin I in a tissue specific manner could be associated with the development of 
cancers in these sites (Vishwanatha et al., 2004; Bai et a l 2004). Five isoforms of 
annexin Al were found to be differentially expressed across the adriamycin resistant 
panel (Figure 4.2.1). Multiple isoforms of annexin Al exist, which may be the result of 
post translational modifications.
ANXA1 (20) *  ANXA1 (21) ANXA1 (40) ANXA1 (53) ANXA1 (22)
DLKP DLKP-A2B DLKP-A DLKP-A5F DLKP-A10
Cell Line
Figure 4.2.1 Annexin A l expression in adriamycin-resistant variants o f  DLKP. (Brackets 
indicate protein number where isoforms are present).
The role of annexins in tumour biology is attracting more interest as members of the 
annexin family are being increasingly implicated in the signalling processes that 
regulate the cell cycle and also because dysregulation of annexin expression has been 
described in a variety of cancerous and precancerous cells and tissues. Decreased 
expression of annexins 1, 2, 4 and 7 have been found in prostrate cancers but not in 
benign prostatic hyperplasia (Smitherman et al., 2004). Similarly, reduced expression of
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annexins 1 and 5 have been discovered in malignant endometrial tissue (Mulla et a l , 
2004) In contrast, annexin 1 expression is significantly increased in malignant breast, 
liver, gliomas and stomach tumours (Liu et a l , 2002) Further analysis of both 
expression and function of the annexin family members may lead to the identification of 
new markers of tumour progression and of potential targets for therapeutic intervention
Annexin I is thought to be involved in cell proliferation and differentiation and has been 
shown to be expressed on the surfaces of lymphoma cells where it functions as an 
endothelial cell adhesion molecule Ahn et al (1997) used biopsy tissues to determine 
the expression of annexm I in relation to breast cancer development and progression 
Immunohistochemical analysis of paraffin-embedded ductal epithelial cells revealed 
that annexm I was generally expressed in the various types of breast cancers, including 
nonmvasive ductal carcinoma in situ, invasive and metastatic breast tumours (n = 33) 
This suggests that annexm I expression may correlate with malignant breast cancer 
progression and is most likely to be involved at an early stage of human breast cancer 
development
Muller et al (2004) suggests that ANXA1 is expressed in abundance by normal cells 
that proliferate rapidly (buccal and alveolar epithelial cells) Moreover, experiments on 
lung-denved cell lines (epithelial carcinoma and ANXAl-null fibroblast) provided 
evidence that ANXA1 mediates the inhibitory effects of glucocorticoids on EGF- 
stimulated cell growth, by disrupting EGF-signalling via a process involving tyrosine 
phosphorylation of ANXA1 However, other data suggests that tyrosine 
phosphorylation increases the growth of primary hepatoma cells 
The up-regulation of annexm I has been found to correlate with increased synthesis of 
epidermal growth factor (EGF) and therefore with increased phosphorylation of the 
tyrosine kinase, EGF receptor (EGFR) Annexm 1 is a substrate for tyrosine kinases and 
senne/threonine kinases such as protein kinase C It is able to modulate the extracellular 
signal-regulated kinase (ERK) signal cascade at an upstream site Overexpression of 
annexm 1 may result in constitutive activation of ERK 1-2 kinase in macrophages 
Abnormally high expression levels of a number of important tyrosine kinase growth 
factors and receptors, especially from the EGF family were found in pancreatic cancer 
(Bai et al 2004) This may contribute to the neoplastic growth by autocrine and 
paracrine effects Annexm 1 expression was up regulated in 84 6% of pancreatic cancers 
and multi-tissue microarrays showed that annexm 1 was 71 4% positive compared to
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normal pancreatic tissue (18 4%) (P<0 01) High expression of annexin 1 has since been 
correlated with the differentiation of pancreatic adenocarcinoma during tumourigenesis 
Detection of annexin 1 expression could be an aid to a clinical diagnosis and may assess 
the prognosis of pancreatic cancer They found that annexin 1 expression was correlated 
with the poorly differentiated type of pancreatic cancer suggesting that annexin 1 may 
be involved in histological differentiation (Bai et a l , 2004)
Both annexin 1 and annexin 5 translocate to the cell surface Annexin 5 is a marker of 
apoptosis Mulla et al (2004) examined the expression, phosphorlyation status and 
distribution of annexm 1 and 5 in 42 pituitary adenomas, normal pituitary tissue and in 
two carcinomas (an astrocytoma and a GH-secreting carcinoma) by Western blot and 
RT-PCR Their results provide evidence for the modest expression of ANXA1 by 
pituitary adenomas localised mainly but not exclusively to nonendocrme cells ANXA5 
expression was more variable and was found in both endocrine and nonendocrme cells 
However, there was marked expression of both annexins in the tumour and non-tumour 
cells of the two carcinomas The results also provide some insight into the 
phosphorylation status of ANXA1 as a senne-phosphorylated species of ANXA1 was 
detected in all pituitary tumours In contrast, only four adenomas and the GH carcinoma 
expressed a tyrosine-phosphorylated ANXA1 Expression of ANXA1 and ANXA5 in 
human pituitary tumours raise the possibility that these proteins influence the growth 
and/or functional activity of the tumours Cell surface overexpression of annexm 2 may 
contnbute to the development of metastases and invasion by increasing the detachment 
of tumour cells
Annexm Al binds to F-actin and also interacts with profilm, a G-actin binding protein 
and regulator of actin polymerization Partial overlapping intracellular localization of 
the two proteins suggests that the annexm A1-profilm interaction may participate in 
regulating the membrane-associated cytoskeleton (Gerke and Moss, 2002, Hayes et a l ,
2004) The role of annexm Al in membrane interaction with actin structures and 
regulation of the membrane-associated cytoskeleton could contnbute to differences in 
mvasiveness
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Nucleoside diphosphate kinase (NDPK) is a tumour metastasis suppressor An inverse 
correlation exists between the metastatic invasion and the level of NDPK observed in 
melanomas, hepatocellular carcinomas and, in some studies, breast carcinomas 
Overexpression of NDPK positively correlates with aggressiveness in the case of 
neuroblastomas (Lacombe, 1993) Nucleoside diphosphate kinase is decreased in DLKP 
and DLKP-A2B by 1 54-fold and 1 28-fold respectively with respect to DLKP-A 
However, the protein is increased in DLKP-A 10 by 1 27-fold Low expression of 
NDPK has been correlated with poor patient prognosis and survival, lymph node 
infiltration and histopathological indicators of high metastatic potential in a number of 
cancer types, including mammary and ovarian carcinomas and melanoma In other 
tumour types, no correlation has been established Transfection of NDPK cDNA into 
highly metastatic breast, melanoma, prostrate and squamous cell carcinomas and colon 
adenocarcinoma cells significantly reduced the metastatic competency of the cells in 
vivo In culture, cell motility, invasion and colonisation were inhibited, whereas 
tumoungemcity and cellular proliferation were not affected, indicating that NDPK acts 
as a metastasis suppressor (Hartsough and Steeg, 2000)
/
4 2.4.3 K130r mutant of human DJ-1
K130r Mutant of human DJ-1 (PARK7), originally cloned as a putative oncogene, is 
capable of transforming NIH-3T3 cells in cooperation with H-ras It has also been 
implicated in fertilisation, regulation of androgen receptor signalling and oxidative 
stress Mutations of the DJ-1 gene are associated with autosomal early-onset 
Parkinson’s disease It has been suggested that DJ-1 may play a role in tumourigenesis, 
in breast, NSCLC and prostate cancers It was identified as a negative regulator of the 
tumour suppressor PTEN, promoting cell survival in primary breast and lung cancer 
patients It has also been described as a circulating tumour antigen in serum from 37% 
of newly diagnosed patients with breast cancer (Pardo et a l , 2006) This protein is up- 
regulated in DLKP versus DLKP-A and DLKP-A versus DLKP-A 10 Mitoxantrone and 
taxane exposure also resulted in increased expression of this protein
4 2 4 2 Nucleoside diphosphate kinase 1
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4 2 4 4 Replication A2,32kDA
The replication A2 32 kDa protein correlated directly with resistance in the DLKP 
variants being 1 5-fold lower in DLKP and DLKP-A2B compared to DLKP-A 
Replication protein A (RPA) is a single-stranded DNA (ssDNA) binding protein 
involved in various processes including nucleotide excision repair and DNA replication 
It is a heterotnmer composed of three subunits - 70, 32 and 14 kDa The 32 kDa subunit 
of RPA (RPA32) differentially expressed in these studies is phosphorylated in response 
to various DNA-damaging agents Two protein kinases, ataxia-telangiectasia mutated 
(ATM) and the DNA-dependent protein kinase (DNA-PK) have been implicated in 
DNA damage-induced phosphorylation of RPA32 Phosphorylation occurs in a cell 
cycle-dependent manner and begins at the Gl/S transition and extends until late mitosis 
The DNA-damaging agents include ionising and ultraviolet radiation, camptothecin and 
adnamycin (Wang et a l, 2001) Block et al (2004) produced an RPA32 Thr21 
phosphospecifc antibody and identified Thr21 as an in vitro phosphorylation site of both 
DNA-PK and ATM Both DNA-PK and ATM phosphorylate RPA32 on Thr21 in vitro 
This phosphorylation was ATM dependent in response to IR, UV and adnamycin 
However, the relative roles of ATM and DNA-PK in the site-specific DNA damage- 
induced phosphorylation of RPA32 have not been reported Thus, the regulation of 
RPA32 Thr21 phosphorylation by multiple DNA damage response protein kinases 
suggests that Thr21 phosphorylation of RPA32 is a crucial step within the DNA damage 
response Adnamycin and VP-16, both topo II poisons, induced Thr21 phosphorylation 
However, only the adnamycin-induced Thr21 phosphorylation was ATM dependent 
Topo II poisons stabilize the topo II-DNA cleavage complexes (Powis et a l , 1994) 
These can lead to the induction of DNA double-strand breaks chromosomal 
translocations and other mutagenic events (Powis et a l , 1994) The vaned ATM 
dependency with which adnamycin and VP-16 induced RPA32 Thr21 phosphorylation 
may reflect the ability of adnamycin to generate ROS or to intercalate DNA
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4.2.5 Overview of proteins correlating with baseline drug-resistance
4.2.5.1 Aldehyde dehydrogenase 1A1
One of the toxic effects of the reactive oxygen species is the production of toxic 
aldehydes by lipid peroxidation. Aldehydes are highly reactive molecules that can be 
generated from a limitless number of endogenous sources such as amino acids, biogenic 
amines, or lipid metabolism and exogenous sources including aldehydes derived from 
xenobiotic metabolism. While some aldehyde-mediated effects such as vision are 
beneficial, many are deleterious including cytotoxicity, mutagenicity and 
carcinogenicity. The aldehyde dehydrogenase enzymes have evolved to metabolize 
aldehydes to less reactive forms (Lindahl, 1992). Three isoforms of aldehyde 
dehydrogenase are consistently up-regulated in DLKP versus DLKP-A. There are 
twelve known human ALDH genes which encode for 12 corresponding enzymes 
(Yoshida et al., 1997). The aldehyde dehydrogenases are a family of NADP-dependant 
isoenzymes, which are expressed in many tissue types and in all subcellular fractions. 
They catalyze the oxidation of a broad spectrum of aliphatic and aromatic aldehydes 
(Lindahl, 1992) e.g. benzaldehyde and aldehydes derived from the lipid peroxidation 
process and those derived from drugs which are metabolised by cells into active 
compounds (Canuto et al, 2001). Three major classes of mammalian ALDHs have been 
identified. Classes 1 and 3 both contain constitutively expressed and inducible cytosolic 
forms. Class 2 consists of constitutive mitochondrial enzymes. The classes appear to 
oxidize a variety of aldehydes (Lindahl, 1992). Aldehyde dehydrogenase is implicated 
in the sensitisation of certain cells to aldehydes. Canuto et a l (2001) developed a 
synthetic suicide inhibitor of ALDH1 which is also an irreversible inhibitor of ALDH3. 
This inhibitor induced bcl2-overexpressing cells to undergo apoptosis. Four hours after 
treatment with 25 jiM ATEM, ALDH activity using benzaldehyde or propionaldehyde 
in hepatoma cells was decreased by 40% and cell number by 15% compared with 
controls. As cell growth did not resume when the inhibitor was removed from the 
culture medium, it strongly suggested that ALDHs play a pivotal role in mediating cell 
death. ALDHs have also been attributed to a protective role against ROS-induced 
apoptosis, in particular ALDH2 (Ohsawa et al.9 2003). Tsukamoto et a l (1998) 
attributed increased aldehyde dehydrogenase with resistance to cyclophosphamide in 
mouse leukaemia cells. A link has been found between DNA-damage and apoptosis 
induced by ROS-dependent Fas aggregation (Huang et a l, 2003).
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Sladek et a l (2002) semi-quantified the cellular levels of ALDH1A1 and ALDH3A1 to 
predict the clinical responses to cyclophosphamide-based chemotherapeutic regimens. 
However, while the levels of both varied widely, retrospective analysis revealed that 
cellular levels of only ALDH1 Al were significantly higher in the metastatic breast cells 
that had survived the exposure to cyclophosphamide than in those that had not been 
exposed. Interestingly, the therapeutic outcome of cyclophosphamide-based 
chemotherapy corresponded to cellular ALDH1 Al levels in 77% of cases with partial or 
complete responses occurring 2.3 times more often when the ALDH1 Al level was low 
than when it was high. This could provide a rational basis of individualised therapeutic 
regimens.
Succinyl-CoA:3-ketoacid CoA transferase is a mitochondrial enzyme in mammals that 
is essential for the metabolism of ketone bodies. It is responsible for the transfer of 
coenzyme A (CoA) from succinyl-CoA to acetoacetate. Once activated, acetoacetyl- 
CoA is further metabolized into acetyl-CoA, which can either enter the citric acid cycle 
or be stored ultimately as a fatty acid. This protein is increased (2.3-fold) in DLKP 
versus DLKP-A.
4.2.5.2 Messenger RNA Processing Proteins - HnRNP F, K and HI
Heterogeneous nuclear ribonucleoproteins (hnRNPs/HNRPs) are a large family of 
nucleic acid-binding proteins that bind heterogeneous nuclear RNA (hnRNA), the 
transcripts produced by RNA polymerase II and precursors to mRNAs. This family of 
proteins includes, hnRPA, H, C, K and F. They are involved in the processing of RNA 
molecules from transcription to translation, including splicing, transportation from 
nucleus to cytoplasm, degradation and translation of RNAs. HnRNPs have been 
overexpressed in several cancers. In lung cancer, hnRNP A2/B1 have been suggested as 
useful early detection markers for lung carcinoma (Pino et al, 2003) with higher levels 
of hnRNP mRNA in SCLC than NSCLC. Some of these proteins (hnRNP Cl and C2) 
are substrates for activated caspases during apoptosis. All these proteins are involved in 
maintaining a balance between cell death and cell survival. Their overexpression might 
be responsible for a greater ability of cells to counteract adriamycin effects, for example 
adriamycin-induced oxidative stress is strongly limited by the overexpression of 
peroxiredoxin 1 and RNA synthesis is conserved by the overexpression of hnRNPK. 
Differential protein expression of both hnRPK and HI were seen in the adriamycin 
resistant variant of DLKP. HnRNP appeared to be involved in baseline resistance as it
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was increased by 1 52-fold from the parent and remained unchanged in the variants 
HnRPK on the other hand appeared in the more resistant variant DLKP-A10 
HnRNP F is a regulator of pre-mRNA splicing It binds preferentially to Cap Binding 
Complex-RNA complexes but not to naked RNA HnRNP F is involved in regulating 
the splicing of Bcl-x, a member of the Bcl-2 family of proteins which, are key regulators 
of apoptosis The Bcl-x pre-mRNA is alternatively spliced to yield Bcl-xs and Bcl-xL, 
two isoforms that have been associated, respectively, with the promotion and prevention 
of apoptosis A 30-nucleotide G-nch element (B2G) which is responsible for regulating 
mRNA splicing of Bcl-x was found to bind to hnRNP F Depletion of hnRNP F from 
HeLa cell nuclear extract was found to decrease the efficiency of pre mRNA splicing 
(Gamben et a l , 1997) The addition of hnRNP F to a HeLa extract improved the 
production of the Bcl-x$ variant Consistent with the in vitro results, small interfering 
RNA targeting hnRNP F and H decreased the Bc1-xs/Bc1-xl ratio of plasmid-derived 
and endogenously produced Bcl-x transcripts These results show a positive role for the 
hnRNP F proteins m the production of the proapoptotic regulator Bcl-xs (Gameau et a l ,
2005)
Heterogeneous nuclear ribonucleoprotem K protein has been found in the nucleus, 
cytoplasm and mitochondria and is implicated in chromatin remodelling, transcription, 
splicing and translation processes It contains multiple modules that on the one hand, 
bind kinases while on the other hand recruit chromatin, transcription, splicing and 
translation factors These protein-mediated interactions are regulated by signalling 
cascades These observations are consistent with hnRNP K protein acting as a docking 
platform to integrate signalling cascades by facilitating cross talk between kinases and 
factors that mediate nucleic acid directed processes (Bomsztyk et a l , 2004) HnRNP K 
binds to CU rich repetitive stretches known as DICE (differential control elements) 
elements in mRNA 3’UTRs and can block translation initiation by blocking the 
recruitment of the 60S nbosomal subunit and the formation of the translation competent 
80S ribosome (Bomsztyk et a l , 2004)
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4 2 6 Overview of proteins inversely correlating with increasing and baseline
resistance 
4 2 61  Prohibitm
Prohibitin (PHB) was decreased in DLKP-A versus DLKP-A5F and DLKP-A versus 
DLKP-A10 by 2 13-fold and 2,28-fold respectively PHB is a highly conserved 32 kDa 
protein with homologues in all animal species, yeast and plants (Gamble et a l , 2006) 
Upon discovery, it was suspected to be a tumour suppressor protein (Nuell et a l , 1991) 
It was found in the inner membrane of the mitochondria, where it acts as a chaperone in 
a complex with the structurally similar protein BaP3 7/REA (repressor of oestrogen 
receptor activity) (Coates et a l , 1997) Prohibitin has multiple functions in aging, 
epithelial cell migration, cell cycle control, apoptosis and as associated molecules in cell 
surface receptors m mammalian cells Evidence shows it has a nuclear function in 
transcription regulation (Peng et a l , 2006) PHB has been found in the nucleus of 
ovarian granulosa, breast epithelial and prostate epithelial cells (Thompson et a l , 2001, 
Wang et a l , 2002, Gamble et a l , 2004) whereby it interacts with proteins such as 
nuclear corepressor (NCoR), histone deacetylase 1 (HDAC1) and retinoblastoma (Rb) 
to repress activation of genes regulated by the E2F family of transcription factors 
(Wang et a l , 1999) This repression of E2F1 activity has been shown to be important in 
the protection of Ramos B cells from camptothecin-induced apoptosis (Fusaro et a l , 
2002) Recruitment of PHB and BRG1/BRM has been shown to inhibit E2F activation 
and cause growth arrest in breast cancer cells treated with tamoxifen It is also involved 
in the mitogen-activated protein kinase pathway (Rajahngam et a l , 2005)
4 2.6.2 Eukaryotic translation initiation factor 5A (elF 5a)
Eukaryotic translation initiation factor 5A is the only cellular protein that contains the 
unusual amino acid hypusine Vertebrates carry two genes that encode two elF 5A 
isoforms, eIF5A-l and eIF5A-2, which, are 84% identical m humans Stimulation of elF 
5A leads to methionyl-puromycm synthesis, although the true physiological activity of 
this factor has yet to be elucidated (Clement et a l , 2006) It has been proposed to be a 
mRNA-specific initiation factor (Kang and Hershey, 1994) The protein is decreased in 
DLKP versus DLKP-A by 2 63-fold The protein is further decreased m DLKP-A 
versus DLKP-A5F and DLKP-A versus DLKP-A10 by 2 04-fold and 2 85-fold 
respectively Essential for sustained proliferation of mammalian cells, elF 5A and may 
therefore contribute to malignant cell transformation and elF 5A probably acts in the
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final stage of the initiation phase of protein synthesis by promoting the formation of the 
first peptide bond (Hershey, 1991)
Chen et al (2003) examined eIF-5A expression m lung adenocarcinomas Increased 
expression was present in tumours showing poor differentiation, 12/13th codon K-ras 
mutations, p53 nuclear accumulation and tumours with positive lymphocytic response 
Patients having a higher eIF-5A protein expression showed a relatively poorer survival 
suggesting the use of eIF-5A as prognostic marker in lung adenocarcinoma 
Proteins inversely correlating with base line drug resistance include protein disulfide 
isomerase protein 5, ornithine mutant amino transferase chain c, heat shock protein 70 
kDa protein 8 isoform 2 (17) and thioredoxin peroxidase B The latter two are discussed 
in sections 4 2 6 and 4 2 7
4 2.7 Overview of proteins correlating with invasion
DLKP and the drug resistant variants also display differential invasion potential in the 
order DLKP-A2B < DLKP-A10 < DLKP < DLKP-A < DLKP-A5F with DLKP-A2B 
being the least invasive and DLKP-A5F the most invasive (section 3 4 12) A number 
of proteins were found to correlate with this increase in invasion namely, eukaryotic 
translation elongation factor ID, annexin 1, horf 6a human peroxidase enzyme and 
HPRT (Figure 4 2 2) Gamma actin is inversely correlated with invasion
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— EEF1D Actin G1 (39) Annexin 1 (40) Horf 6a human peroxidase HRPT
DLKP-A2B DLKP-A10 DLKP 
Cell Line
DLKP-A DLKP-A5F
Figure 4.2.2 Proteins correlating and inversely correlating with invasion
Actin is largely responsible for cell motility and altered expression in some 
malignancies may facilitate aggressive invasion. In vertebrates, 3 main groups of actin 
isoforms, alpha, beta and gamma have been identified. The alpha actins are found in 
muscle tissues and are a major constituent of the contractile apparatus. The beta and 
gamma actins coexist in most cell types as components of the cytoskeleton and as 
mediators of internal cell motility (Christian etal., 2001).
EEF1D was overexpressed in chemoresistant melanoma cells (Sinha et al., 2000) and its 
expression along with RPL30 and RPS20 correlated adversely with survival in 
medullobalstoma (Bortoli etal., 2006).
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4.2.8 Proteomic analysis of the mitoxantrone resistant variant of DLKP
A proteomic investigation was carried out to study the differential protein expression 
caused by mitoxantrone resistance in the already established DLKP-Mitox cell line. 
While the main mechanism of resistance in this cell line is associated with BCRP (no 
detectable levels of P-gp and MRP1), little information on cytoplasmic changes is 
available. Resistance to mitoxantrone has shown changes in ABC membrane pumps 
Pgp, MRP-1 (McMorrow et a l , 2006) and BCRP (Doyle et a l , 1998), alterations in 
topoisomerase activity or translational modification (Chen et al., 2002) and apoptosis 
induction (Nakanishi et al., 2005). This work has yielded a total of 50 differentially 
expressed proteins (61 including all isoforms) that may present targets for drug 
resistance/invasion intervention. None of the ABC transporters were identified as 
differentially expressed. This is not surprising given the limitations of detecting high 
molecular weight and hydrophobic proteins on two-dimensional gel electrophoresis.
Previous work revealed thioredoxin, stratafin, annexin 1, cofilin, Rho-GDP inhibitor, 
FaBP and APRT to be differentially regulated in mitoxantrone-resistant variants of 
colon, fibrosarcoma and pancreatic adenocarcinomas (Sinha et al., 1999a; Sinha et al 
1999b; Sinha et al., 1998). Further studies in mitoxantrone-resistant MCF-7 breast cells 
showed tropomyosin, HMG-1, prohibitin, HSP 70, heterogeneous nuclear 
ribonucleoproteins (H and K) and nucleophosmin to be differentially regulated (Fu and 
Fenselau, 2005; An et al., 2005). Many of these proteins have been differentially 
regulated in DLKP-Mitox, consistent with previous reports (PDI, annexin I, P4HB, 
thioredoxin, HMG1, NDPK and nucleophosmin). Tropomyosin, prohibitin, ER-60, 
HNRPF, TPI and cofilin are not consistent with previous results.
According to PathwayAssist, two of the most highly interacting proteins are 
tropomyosin and HMG1. Tropomyosin acts as an anti-oncogene and tumour suppressor 
and decreased expression has been observed in many transformed cells (Shah et al., 
1998). Invasion assays on DLKP and DLKP-Mitox revealed that the mitoxantrone 
variant was less invasive than the parent cell line used in these studies. A number of 
proteins directly involved in metastasis and invasion are differentially regulated, the 
majority of which are all down-regulated in DLKP-Mitox. They include nucleoside 
diphosphate kinase, nucleophosmin, phosphoglyccratc mutasc 1, prohibitin, 
tropomyosin and galectin-1. However, other proteins also linked to invasion, namely 
high mobility group box protein and annexin 1, are up-regulated. Tropomyosin, down-
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regulated m MCF-7/MX and in SNU-drug resistant gastnc cancers (Yoo et a l , 2000), 
was up regulated in DLKP-Mitox This is unexpected as DLKP-Mitox is less invasive 
than the parent and suppression of tropomyosin has been related to a metastatic 
phenotype (Barkin et a l , 2005)
4 2.8 1 Nucleophosmin
Nucleophosmin (NPM) is a nucleolar phosphoprotein that binds the tumour suppressors 
p53 and pl9Arf It is thought to be indispensable for nbogenesis, cell proliferation and 
survival after DNA damage The NPM gene is the most frequent target of genetic 
alterations in leukaemia’s and lymphomas However, its role in tumoungenesis is 
unknown Mouse cells null for both p53 and NPM grow faster than control cells and are 
more susceptible to transformation by activated oncogenes, such as mutated Ras or 
overexpressed Myc NPM regulates DNA integrity and through Arf, inhibits cell 
proliferation (Colombo et a l , 2005) Overexpression of nucleophosmin mRNA was 
independently associated with bladder cancer recurrence and progression In patients 
with muscular invasion disease, Overexpression of mRNA was associated with the 
greatest nsk of recurrence and progression (Tsui et a l , 2004)
4 2 8.2 Sorcin
Sorcm, also known as VP 19 and CP22, is a 22kDa calcium-binding protein first 
identified in a VCR-resistant Chinese hamster lung cell line, DC-3F/VCRd-5L (Van der 
Bhek et a l , 1986) A direct binding assays showed that it is a calcium-binding protein 
with four 4E-F hand’ structures typical of calcium-binding sites, two of which contain 
putative recognition sites for cAMP-dependent protein kinase It has been implicated in 
the development of resistance to a variety of chemotherapy drugs including colchicines, 
actinomycin D, taxol, vinblastine, temposide, VP-16 and doxorubicin in a variety of 
cancers (Roberts et al 1989, Wang et a l, 1995) Overexpression of sorcm in three 
MDR solid tumour cell lines including an adnamycin-resistant MCF-7/ADR (breast 
carcinoma), a cisplatin A549DDP (lung carcinoma) and a VCR-resistant KBv200 
(epidermoid carcinoma line) line was not observed This indicates that sorcin may 
represent a significant and independent indicator of leukaemia resistance to 
chemotherapies (Zhou et a l , 2006)
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Sorcin was 1 51-fold increased in DLKP-A and a further 1 47-fold increased m DLKP- 
A5F In contrast, sorcin was down-regulated by 2 33-fold in the most adnamycin- 
resistant cell line, DLKP-A10 (Figure 4 2 7) Interestingly, the protein is overexpressed 
to a greater extent (3 85-fold) in the mitoxantrone-resistant variant, DLKP-Mitox 
compared to the adnamycin-resistant variants
Its function in drug-resistance has been controversial Hamada et al (1988) reported 
that overexpression of sorcin was not sufficient or even necessary for the development 
of MDR in human myelogenous leukaemia cell line K562/ADR Further studies with 
this cell line revealed that overexpression of sorcin in K562/ADR cells may play an 
important role in the development of the multidrug resistance through its interactions 
with free ribosomes (Sugawara et a l , 1989)
Up-regulation of sorcin m patients with acute myeloid leukaemia was similar to that of 
mdrl and associated with low complete response to chemotherapies as well as poor 
overall clinical prognosis In K562 cells, sorcin-transfection resulted in increased 
resistance to adnamycin (2 7- to 7 9-fold) and like the mdrl-amplified K562 cells, were 
cross-resistant to several other chemotherapeutic agents (Zhou et a l , 2006) Sorcin- 
targeted small interfering RNA (siRNA) resulted m approximately 80% reversal of 
adnamycin resistance m human leukemia cells (Zhou et a l , 2006) However, in MDR 
lymphoma cell lines with increasing resistance, sorcin was found to be co-amplified 
with MDR-1 due to its close proximity to the mdr-1 gene (Lee, 1996, Tan et a l , 2003) 
Sorcin has been implicated in apoptosis Qi et al (2006) examined the effects of sorcin 
overexpression on both chemotherapeutic agent-induced apoptosis and the expression of 
apoptosis-related proteins Bcl-2 expression was upregulated and Bax was moderately 
reduced with increased resistance to etoposide-induced apoptosis Sorcin may also 
regulate cell apoptosis by modulating intracellular calcium level and/or distnbution as it 
may sequester significant amounts of cytosolic calcium It may be translocated to the 
endoplasmic reticulum membrane and block calcium release mediated by the cardiac 
ryanodine receptor The overexpression of sorcin in leukemia cells leads to significantly 
reduced intracellular calcium concentration which contributes to the decreased 
sensitivity of cancer cells to cytotoxic agent-mediated apoptosis, leading to the 
development of drug resistance
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Parekh et al (2002) induced low levels of resistance to taxol by transfecting a human 
breast cancer cell line with sorcin cDNA However, high expression of sorcin did not 
induce high level resistance to taxol
The results in this study together with those of previous observations, further confirm 
that sorcin plays an important role m the drug-resistant phenotype Sorcin may therefore 
represent a good target for modulation and in the development more efficacious MDR 
reversal agents
4 2 8 3 High mobility group box protein
HMG-1, the high mobility group 1 box protein, was up-regulated in MCF-7/MX and 
DLKP-Mitox HMG-1 is involved in nuclear complex formation and DNA repair, 
inflammation, apoptosis and differentiation and may contribute to drug resistance by 
enhancing these activities Significantly, HMG1 was found to elicit activation of 
metalloproteases MMP-2 and MMP-9 (Taguchi et a l , 2000), both of which were 
previously found to be increased in DLKP-Mitox (Liang et a l , 2001) Prohibitin (PHB) 
is a mitochondnal chaperone involved in cell cycle control, cellular immortalisation 
(Tsai et a l , 2006) and is up-regulated in MCF-7/MX and cisplatin-resistant head and 
neck tumors (Johnsson et a l , 2000) PHB was down-regulated in DLKP-Mitox 
Proteins such as protein disulphide isomerase and TPI are commonly found to be 
expressed m a variety of cancers and may contribute to drug resistance (Liu et a l ,
2006) Gst M4, prolyl 4-hydroxylase B and TPI were significantly overexpressed in 
lung adenocarcinomas (Chen et a l , 2002)
Sinha and colleagues (1998) suggested a mechanism of mitoxantrone resistance 
involving apoptosis (via Rho-GDP dissocation inhibitors and thioredoxin) and 
concerted actions on PKC activity (downstream effector of GST, Topo II and Pgp) 
Consistent with this, apoptosis in DLKP-Mitox may become more resistant to apoptotic 
signals through reduced expression of proteins stimulating apoptosis and elevated 
inhibitory proteins Fifteen of the differentially-expressed proteins have a role in 
apoptosis as shown in Pathway Assist Two of the three inhibitors (ALDH and PRDX3) 
are up-regulated while 7 of 12 stimulators are down-regulated
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4 2 8.4 Cathepsin 8  and Cathepsin D
Cathepsins are proteases and the best characterised of the lysosomal hydrolases They 
are among many proteolytic enzymes involved in metastasis (Krueger et a l , 1999) 
Proteases of the cathepsin family are the best-characterized lysosomal hydrolases Most 
cathepsins are cysteine-proteases (cathepsin B, C, H, F, K, L, O, S, V, W and X/Z) Two 
are aspartyl proteases (cathepsin D and E) and one is a serine protease (cathepsin G) 
(Linder and Soshan, 2005) The cytosol contains endogenous cysteine cathepsin 
inhibitors, cystatins (Turk and Bode, 1991) In contrast, no endogenous cathepsin D/E 
inhibitors have been found The degree of lysosomal permeabihzation determines the 
amounts of cathepsins released into the cytosol A complete breakdown of all lysosomes 
results in necrosis, whereas partial breakdown (sufficient to overcome protection by the 
cystatms) may trigger apoptosis (Bursch, 2001)
Cathepsin B has been linked to tumour invasion and metastasis Malignant tumour cells 
(lung, colon, breast, stomach and prostate) express higher levels of cathepsin B mRNA 
and protein and activity levels (Hughes et a l , 1998) In vitro invasion assays with 
Cathepsin B protease inhibitors such as the MMP inhibitor Batimastat, reduced invasion 
(Kobayashi et a l, 1993, Kolkhorst et al, 1998) Cathepsin B is often overexpressed in 
premahgnant lesions, primary cancers and especially in preneoplastic lesions, 
suggesting it might have pro-apoptotic features Expression of cathepsin B is regulated 
at many different levels, from gene amplification, use of alternative promoters, 
increased transcription and alternative splicing, to increased stability of transcripts 
Cathepsin B is synthesized as a preproenzyme and the primary pathways for its normal 
trafficking to the lysosome utilize mannose 6-phosphate receptors (Roshy et a l , 2003) 
A change m the localisation of cathepsin B occurs during the transition to malignancy, 
as seen by the presence of cathepsm-contaming vesicles at the cell periphery and the 
basal pole of polarized cells Active cathepsin B is also secreted from tumours, a 
mechanism likely to be facilitated by lysosomal exocytosis or extracellular processing 
by surface activators Cathepsin B is localised to caveolae on the tumour surface and 
bind to the annexin II heterotetramer Activation of cathepsin B on the cell surface leads 
to the regulation of downstream proteolytic cascades (Podgorski and Sloane, 2003) 
Cathepsin B was decreased m the less invasive subclone of DLKP-A, namely DLKP- 
A2B by 1 87-fold However, Cathepsin D was increased in this cell line also 
Cathepsin D is the major intracellular aspartyl protease and a mediator of IFN-gamma 
and TNF-alpha induced apoptosis Cathepsin D has been implicated in apoptosis
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induced by a number of conventional anti-cancer agents including adnamycm, 
etoposide, cisplatin and 5-fluorouracil (Emert-Sedlak et a l , 2005) The mechanisms 
leading to release of cathepsin from the lysosomes after treatment with these agents are 
unclear as is the relative importance of the lysosomal pathway for the cytotoxicity of 
these compounds
Injection of cathepsin D to the cytosol of fibroblasts induces caspase-dependent 
apoptosis Some cathepsins can induce pro-apoptotic cleavage of the BH3-only (Bcl-2 
homology-3) protein Bid, leading to activation of the ability of Bid to act on other pro- 
apoptotic members of the Bcl-2 family (Linder and Soshan, 2005)
Cathepsin D has been associated with p53 status mRNA levels of cathepsin were 
increased in the wild-type p53-expressing PA1, ML1 leukemia and U1752 lung cancer 
cells but not in mutant p53-expressing cells following adnamycm exposure Pepstatin 
A, a cathepsin D inhibitor, suppressed p53-dependent apoptosis in lymphoid cells 
linking cathepsin D to p53-dependent tumour suppression and chemosensitivity (Wu et 
al, 1998)
Cathepsin D expression correlates with invasion and metastasis and poor prognosis 
Overexpression of Cathepsin D inhibited growth of colon, liver and ovarian cancer cells 
(Wu et a l , 1998) Exposure to adnamycm, VP-16 or gamma-radiation increased 
cathepsin D exposure in leukaemia and ovanan cancer cells, breast cancer but not 
significantly in lung (Inoue et a l , 1998)
Cathepsins have been shown to be important in cancer development and diagnosis 
However the mechanisms by which they exert their role is still not fully understood 
Therefore the presence of cathepsin D in lung tumours should be studied further as this 
protein could be of clinical relevance for the diagnosis and/or prognosis of lung cancer 
and other types of cancer (Alfonso et a l , 2004)
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4.2.8.5 Comparison between adriamycin and mitoxantrone resistance in DLKP
It was also of interest to compare proteins altered in DLKP versus DLKP-A with DLKP 
versus DLKP-Mitox as both adriamycin and mitoxantrone are alkylating agents and 
mitoxantrone is an analogue of adriamycin with less cardiotoxicity (i.e. it is supposed to 
produce less reactive oxygen species). Interestingly, mitoxantrone exposure resulted in 
lower fold changes in the chaperon and stress response proteins namely, chaperonin 
containing TCP subunit 3, mortalin (HSPA9B) and HSP 70 proteins 8 as would be 
expected. Both drugs induced relatively similar levels of two apoptotic/redox regulation 
proteins, galectin-1 and PARK7 and the overlapping glycolytic proteins namely the 
aldehyde dehydrogenases and triosephosphate isomerase. Mitoxantrone induced a 
significantly higher fold change in the protein turnover and metabolic proteins, protein 
disulfide isomerase (PDI) and ornithine aminotransferase respectively. Adriamycin 
exposure resulted in higher levels of annexin induction. However, mitoxantrone induced 
over twice the amount of sorcin and hnRPK (Figure 3 .5.7).
F ig u re  3 .5 .7  Comparison of adriamycin and mitoxantrone resistance in DLKP.
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Proteomic analysis was carried out to study differential protein expression associated 
with taxane resistance in two cell lines developed in these studies, namely SKMES-Txt 
and SKMES-Txl (Wk3) The parental cell line, SKMES-1, not previously documented 
to be exposed to drug was selected with clinically relevant concentrations of the 
taxanes, taxol or taxotere, drugs traditionally used in the treatment of lung cancer The 
mam mechanism of resistance in these cell lines is the membrane protein P-gp and 
therefore would not be expected to be identified by proteomics Pulse selection with 
taxotere yielded a total of 40 differentially expressed proteins Of these 40 proteins, 19 
were unique to taxotere-selection Taxol exposure resulted in a total of 48 differentially 
expressed proteins Of these 48 proteins, 21 overlapped with SKMES-Txt, 23 were 
unique to SKMES-Txl (Wk3) and 4 overlapped with SKMES-Txl (Wk3) versus 
SKMES-Txl (Wk6) comparison
An unforeseen but fortunate result of taxane selection of SKMES-1 was the observed 
loss of resistance in both taxane-resistant variants Proteomic analysis was also carried 
out to study differential protein expression caused by loss of taxol resistance Twenty- 
five proteins were identified in the comparison of SKMES-Txl (Wk3) versus SKMES- 
Txl (Wk6), 11 of which overlapped with SKMES-1 versus SKMES-Txt, 4 with 
SKMES-1 versus SKMES-Txl (Wk3) and 10 were unique to SKMES-Txl (Wk3) versus 
SKMES-Txl (Wk6)
The stress response and chaperonm proteins, namely HSP 70 protein 8 isoform 2, HSP 
60, 150kDa oxygen-regulated protein, CCT3 and HSPC124 are all increased in 
SKMES-Txt In contrast, three heat shock proteins, two of which are unique to 
SKMES-Txl (Wk3), HSP 70 protein 8 isoform 2, HSP27 and HSP 70kDa 9B are all 
decreased in SKMES-Txl (Wk3) Taxol-selection resulted m a greater fold decrease in 
the chaperonm proteins when compared to taxotere exposure
Loss of taxol resistance resulted in the HSPs being both up and down-regulated HSP60 
and an isoform of HSP70A8 were 1 6-fold and 1 3-fold increased respectively 
However, the chaperonm protein KIAA0098 was decreased as well as two isoforms of 
HSPA8
4.2.9 Proteomic analysis of taxane-resistant variants of SKMES-1
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4.2.10 Comparison between taxotere and taxol resistance in SKMES-1
Currently, much is known about the mechanism of action of the taxanes, little is known 
about the differences induced by taxol and taxotere. Taxol and taxotere have similar 
mechanisms of action even though taxotere is approximately twice as potent an inhibitor 
of microtubule depolymerisation relative to taxol (Gelman, 1994). Pulse selection with 
taxotere yielded a total of 40 differentially expressed proteins. Of these 40 proteins, 19 
were unique to taxotere-selection. Taxol exposure resulted in a total of 48 differentially 
expressed proteins of which 23 were unique to SKMES-Txl (Wk3) and 21 overlapped 
with SKMES-Txt.
4.2.10.1 Overlapping proteins between taxotere and taxol resistance in SKMES-1
A number of proteins were differentially regulated in response to both taxotere and 
taxol exposure. Similar levels of regulation resulted for the majority of proteins with the 
exception of proteasome activator subunit 2 and peroxiredoxin 2, both of which are up- 
regulated at a greater level in SKMES-Txt (Figure 4.2.3).
Protein
Figure 4.2.3 Review of shared proteins in SKMES-Txt and SKMES-Txl (Wk3). Proteins are 
grouped according to ontology. Brackets indicate spot number where isoforms are present.
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4 2 10 2 Glucose-6-phosphate dehydrogenase
Glucose-6-phosphate dehydrogenase is the first and a rate limiting enzyme of the 
hexose monophosphate shunt It replenishes NADPH needed to maintain glutathione in 
concentrations to support the redox environment in the taxane-resistance cell lines This 
protein, present as three isoforms, is increased in both SKMES-Txt and SKMES-Txl 
(Wk3) to the same extent but not in SKMES-Txl (Wk6) Only taxol exposure resulted in 
the increase of the protein 6-phosphogluconolactonase, another enzyme involved in 
normal intermediary metabolism (Galpenn et a l , 2006)
Cytoskeletal disruption can lead to activation of NADPH oxidase and the production of 
intracellular ROS (Kustermans et a l , 2004) Studies have described NF-kB activation 
in response to microtubule depolymenzation such as taxol (Rosette et a l , 1995) NF-kB 
activation is characterized by a reorganization of actin filaments, such as cellular 
adhesion on fibronectin, chemotaxis or phagocytosis (Kustermans et a l , 2004) Taxol 
and taxotere exposure resulted in both increases and decreases in expression of 
cytoskeletal proteins
4 210 3 Keratin 8
The expression of keratin 8 was decreased in both taxotere and taxol resistant variants 
of SKMES There was no change in expression when SKMES-Txl (Wk3) was 
compared to SKMES-Txl (Wk6)
The intermediate filaments (IFs) constitute a large proportion of the cytoskeleton and 
nuclear envelope in most types of eukaryotic cells Although structural components of 
other major cytoskeletal proteins, like actin and tubulin are highly conserved in different 
cell types, constituent proteins of the IFs exhibit molecular diversity The keratins are a 
subfamily consisting of over 20 members (keratin 1 -20) and are preferentially expressed 
in epithelial cells (Inada et a l , 2001) Keratin 8 (K8) and 18 (K18) are the major 
components of the IFs of simple or single-layered epithelia and are found in the 
gastrointestinal tract, liver, exocrine pancreas and mammary gland, from which many 
carcinomas arise (Oshima et a l , 1996) Functional studies with different cell models 
have suggested that K8 and K18 are involved in simple epithelial cell resistance to 
several forms of stress that may lead to cell death Caulin et al (2000) found knockout 
mice are deficient in K8 and K18 are approximately 100 times more sensitive to tumour 
necrosis factor (TNF)-induced cell death K8 and K18 both bind to the cytoplasmic 
domain of TNF receptor type 2 (TNFR2) and moderate the effects of TNF While
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K8/K18 deprived hepatocytes are more sensitive to Fas mediated apoptosis (Gilbert et 
a l , 2004) This may be a fundamental function of K8/18 seen in liver regeneration, 
inflammatory bowel disease, hepatotoxin sensitivity and the persistent expression of 
these keratins in many carcinomas As these proteins have a frequent and persistent 
expression in carcinomas, they are considered as tumour markers (Oshima, 2002) They 
could also play an important role in tumoural migration and invasion (Hembrough, et 
a l , 1995) Bichat et al (1997) exposed human breast cancer cell line MCF7S to 
adnamycin The result was an increase in keratin 8 expression but no change in 
vimentin expression A much weaker ERK1/2 activation occurs in K8-null hepatocytes 
This then resulted in impaired ERK1/2 activation in K8-null hepatocytes and is 
associated with a drastic reduction in c-Flip protein This points to a new regulatory role 
of simple epithelium keratins m the c-Flip/ERKl/2 antiapoptotic-signalhng pathway
Taxol is known to inhibit cell growth and tngger significant apoptosis Park et al 
(2004) transfected lymphoblastic leukemia cells with a dominant-negative FADD 
plasmid and demonstrated for the first time that taxol induces FADD-dependent 
apoptosis primarily through activation of caspase-10 but independently of death 
receptors Taxol induced activation of caspases-10, -8, -6, and -3, cleaved Bcl-2, Bid, 
poly(ADP-nbose) polymerase, lamin B and down-regulated cellular levels of FLICE- 
hke inhibitory protein (FLIP) and X-chromosome-lmked inhibitor of apoptosis protein 
(XIAP) The drug caused a decrease of mitochondrial membrane potential and a 
significant increase in ROS generation However, increased ROS production was not 
directly involved in taxol-tnggered apoptosis Inhibitors of caspases-8, -6 or -3 partially 
inhibited taxol-mduced apoptosis, whereas the caspase-10 inhibitor totally abrogated 
this process Keratin 8 and 18 are able to modulate trafficking and interactions of many 
molecules involved in cisplatin-induced apoptosis They could play a role in acquired 
chemoresistance of IGROVI-RIO ovarian cancer cell line (Le Moguen et a l , 2005)
4 2 10 4 LASP-1
Lasp-1 is an actm binding protein, which, along with Krpl protein co-localises with 
actin at the tips of pseudopodia This localisation is maintained by continued AP-1 (a 
transcription factor) mediated down-regulation of fibronectin that in turn suppresses 
integrin and Rho-ROCK signalling and allows pseudopodial protrusion and 
mesenchyme-like invasion (Spence et a l , 2006) The function of Lasp-1 is not known
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It is necessary for cell migration on ECM but not adhesion (Lm et a l , 2004) Lasp-1 
expression is increased m metastatic breast cancers, suggesting that protein 
amplification may contribute to the migratory properties of these cells (Tomasetto et a l ,
1995) Lasp-1 is increased in both SKMES-Txt (1 61-fold) and SKMES-Txl (1 58-fold) 
both of which are more invasive than the parent In contrast, it is decreased in the more 
invasive SKMES-Txl (Wk6) cell line with respect to SKMES-Txl (Wk3) by 1 49-fold
4 2 10 5 Ubiquitin carboxy-termmal hydrolase LI (PGP9 5)
Taxane exposure resulted in an increase in the expression of ubiquitin carboxy-terminal 
hydrolase LI A large proportion of regulatory proteins are modified by conjugation 
with ubiquitin or ubiquitin-hke proteins This modification acts as a targeting signal, 
delivering the modified protein to different locations in the cell and modifying its 
activity, half-life or interaction with other molecules (Hochstrasser, 2000) Ubiquitin 
modification of proteins is important in the regulation of the cell cycle, modulation of 
the cellular response to stress and extracellular effectors, DNA repair, regulation of the 
immune and inflammatory responses, down-regulation of cell surface receptors and ion 
channels and biogenesis of organelles (Ciechanover et a l , 2000) PGP9 5 represents one 
of the members of the ubiquitin carboxy terminal hydrolase family It plays a role in 
lung cancer tumourigenesis Expression of PGP9 5 is strongly associated with advanced 
stage lung cancers It is highly expressed in 54 % of 98 primary NSCLC lung cancers 
and 22 of 24 lung cancer cell lines (Hibi et a l , 1999) Little is known regarding PGP9 5 
specific substrates or its biological activity in vivo There is an interaction between 
PGP9 5 and JAB1, a co-activator of c-jun which promotes the phosphorylation and 
cytoplasmic translocation of p27Kipl for its subsequent degradation in the cytoplasm 
(Claret et a l , 1996, Tomoda et a l , 1999) They form a heteromeric complex that 
includes p27Kipl and can co-localise to the nucleus of lung cancer cells Cells, contact 
inhibited redistributed both PGP9 5 and JAB1 in the cytoplasm PGP9 5 may therefore 
play a role in lung cancer growth by regulating the level of nuclear JAB1, which can 
then lead to an increased degradation of p27Kipl (Caballero et a l , 2002)
Liu et al (2003) showed that enzymatic activity of PGP9 5 is antiproliferative Cells do 
not grow and invade at the same time It interacts with p27, a cychn-dependant kinase 
inhibitor This results in cell cycle arrest at G1 phase Up-regulation of PGP9 5 is 
associated with cell cycle retardation and p27 over-expression in myeloma cells (Otsuki 
et a l , 2004) In vitro studies show that p27 up-regulation is essential for growth
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inhibition by EGFR-TKIs (Busse et al., 2000). Ubiquitin carboxy-terminal hydrolase LI 
is a marker for aggressive and invasive colorectal carcinoma, pancreatic and lung cancer 
(Hathout et al, 2004). The protein was also found to be over-expressed in the MCF- 
7/Adr (Hathout et al, 2004).
4.2.11 Proteins unique to taxol-resistance in SKMES-1
In contrast to the unique proteins differentially regulated in response to taxotere, taxol 
exposure resulted in the differential expression of more unique proteins (23) of which 
most were down-regulated. The majority of these proteins have functions in ion 
binding/transport, protein turnover and the stress response (Figure 4.2.4).
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Figure 4.2.4 Proteins in unique to SKMES-Txl. Proteins are grouped according to ontology. 
Brackets indicate protein number where isoforms exist.
4.2.11.1 Annexin IV
The expression of annexin IV was determined to be overexpressed in the taxol resistant 
variant of SKMES-1 and the mitoxantrone resistant variant of DLKP by 1.37-fold and 
1.51-fold respectively. Little data exists linking the expression of annexin IV to cancer. 
However, taking the functions of the annexins into consideration, alterations in the 
expression of these proteins could have important consequences on cancer cell 
behaviour. Discrepancies in the role of annexins in cancer have been observed. High 
annexin 1 expression in MCF-7 cells resulted in increased resistance to various cell 
lines while in ovarian SKOV-3 sensitivity increased (Wang et a l, 2000). Annexin IV
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expression is up-regulated in the taxol resistant lung cancer cell line (Han et al 2003) 
In contrast two cisplatin-resistant ovarian carcinoma and hormone refractory prostate 
cancer cell lines was determined to express less annexin IV (Le Moguen et al 2006, 
Stewart et a l , 2006, Xin et a l , 2003)
4 2 12 Proteins unique to taxotere-resistance m SKMES-1
Taxotere exposure resulted in the differential expression of 19 proteins of which most 
were up-regulated The majority of proteins have functions in transcription/transcription 
regulation and ion binding/transport and are all up-regulated to approximately the same 
degree Cathepsin D is the most up-regulated protein (1 98-fold) and may contribute to 
increased mvasiveness of SKMES-Txt (Figure 4 2 5)
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Figure 4 2 5 Proteins in unique to SKMES-Txt Proteins are grouped according to ontology 
Brackets indicate protein number where isoforms exist
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4 2.12 1 Vimentin
Interestingly in the DLKP-adnamycin resistant cell lines, changes in vimentin 
expression may be more related to resistance than invasion While both DLKP-A2B and 
DLKP-A10 show low invasive potential, DLKP-A10 (more resistant) has a 3 88-fold 
increased expression compared to DLKP-A and DLKP-A2B, which is less resistant 
variant with 1 64-fold decreased expression of vimentin
This protein is also down-regulated in SKMES-Txt compared to SKMES-1 and as such 
does not correlate with resistance It does however, correlate with 3D-invasion assays 
which show SKMES-Txt to be less invasive Thus in DLKP-A10 vimentin may play an 
important role in the development of increased resistance and may represent a molecular 
mechanism to replace the caspase-cleaved vimentin to maintain cell integrity and to 
counteract programmed cell death
Vimentin belongs to the type III family of intermediate filaments and plays an important 
role in the dynamic remodelling of the cell during development of the neoplastic 
phenotype Vimentin is also a caspase substrate and is therefore part of the execution 
phase of apoptosis (Byun et a l , 2001) However, evidence has accumulated which 
shows that atypical expression of vimentin in epithelial cancer cells is associated with 
invasiveness and metastasis potential for a variety of cancers including hepatocellular 
carcinoma (Hu et a l , 2004), prostate carcinoma (Lang et a l , 2002), breast carcinoma 
(Hendrix et a l , 1997) and cervical carcinoma (Gilles et a l , 1999) Analysis of vimentin 
expression in migrating MCF10A breast carcinoma cells using an in vitro wound assay 
model revealed induction of vimentin mRNA and protein in migrating cells Decreased 
vimentin expression using antisense cDNA caused a reduction in the migration of these 
cells also (Gilles et a l , 1999) These studies show that vimentin is strongly associated 
with cellular motility and mvasiveness The reduced expression of vimentin in DLKP- 
A2B cells may therefore contribute to the decreased mvasiveness of these cells 
However, other factors may be a work in the DLKP-A5F, which showed no change in 
vimentin expression, but were the most invasive of the DLKP cell lines tested in this 
study
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4.2.12.2 Galectin-1
The galectins are a conserved family of carbohydrate binding proteins, which have an 
affinity for P-galactosidases. Galectin-1 has both intracellular and extracellular 
functions. It exhibits the characteristics of typical cytoplasmic proteins as well as an 
acetylated N-terminus and a lack of glycosylations. It has also been found in cell nuclei 
as well as cytosols and translocates to the intracellular side of cell membranes. When 
secreted, it can be found on the extracellular surface of all cell membranes as well as in 
the extracellular matrices of various normal and neoplastic tissues. The p-galactoside 
binding site may be the primary targeting site for galectin export machinery using P- 
galactoside-containing surface molecules as export receptors for intracellular galectins.
Galectin-1 (Gal-1) is involved in numerous biological functions including cell-cell and 
cell-substrate interactions and the three cell migration processes, adhesion, motility and 
invasion. The protein increases adhesion of many normal and cancer cells to the ECM 
by cross-linking the integrins exposed to the cell surfaces with carbohydrate moieties of 
the ECM components e.g. laminin and fibronectin (Clausse et al., 1999). It binds to a 
number of extracellular matrix (ECM) components (laminin > cellular fibronectin > 
thrombospondin > plasma fibronectin > vitronectin > osteopontin) and is involved in 
ECM assembly and remodelling. It inhibits the incorporation of vitronectin and 
chondroitin sulphate B into the ECM of vascular smooth muscle cells. Galectin-1 binds 
integrin adhesion receptors and membrane glycoproteins which are essential for normal 
cellular function and survival. Gal-1 is secreted during skeletal muscle differentiation 
and accumulates with laminin in the basement membrane (Clausse et al., 1999). 
Galectin-1 has been implicated in Ras signalling cascade leading to increased 
transformation (Paz et al., 2001).
The expression or increased expression of galectin-1 in either a tumour or the tissue 
surrounding a tumour is considered a sign of its malignant progression and therefore a 
poor prognosis for patients. This prognosis is often related to tumour immune-escape, 
metastasis or its presence in the surrounding normal tissue. Galectin-1 could also play a 
role in tumour angiogenesis as it is expressed in both vascular smooth muscle and 
endothelial cells. Galectin-1 has been reported to increase motility in gliomal cells and 
colon cancer cells (Hittelet ei ul., 2003), Harvey Qt al, (2001) USCd a protcomic approach 
to identify membrane expression of galectin-1 as a signature of cell invasiveness in 
mammary carcinoma. Galectin-1 accumulation around prostate cancer cells could act as
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an immunological shield as it induces activated T-cell apoptosis (Van den Brule et a l , 
2001)
Galectin-1 expression was differentially expressed across the adnamycin resistant 
DLKP cell lines and did not always correlate with invasion Increased invasion 
correlated with increased expression of galectin-1 when DLKP-A was compared to the 
extremely invasive DLKP-A5F In contrast, decreased invasion correlated with 
decreased expression of galectin-1 when DLKP was compared to the less invasive 
DLKP-Mitox
Pulse selection with taxol and taxotere resulted in more invasive cell lines when 
examined in a monolayer on the Boyden Chamber Assay precoated in matngel 
However, when induced to grow as spheroids and placed in collagen type I (to try and 
mimic the in vivo situation), both taxane-selected variants were less invasive than the 
parent Proteomic analysis revealed that galctin-1 was decreased in SKMES-Txt and 
unchanged in SKMES-Txl suggesting that gal-1 may not be the mam component 
relating to invasive potential
Le et al (2005) used SELDI-TOF mass spectrometry and tandem MS to identify 
galectin-1 and CD3 (a T-cell marker) in the FaDu HNSCC cells were significant 
predictors of overall survival The results suggest hypoxia can affect the malignant 
progression and therapeutic response of solid tumours by regulating the secretion of 
proteins that modulate immune privilege
The targeted inhibition of galectin-1 expression may be novel treatment in the fight 
against cancer progression The knock-down of galectin-1 in migrating tumour cells 
(e g gliomas and melanomas) may impair malignancy development in different ways It 
could delay cancer cell migration within the host tissue or at a distance (metastases), 
and the sensitisation of migrating cancer cells to apoptosis Migrating cancer cells are 
protected against apoptosis therefore down-expressing galectin-1 could restrict 
migration as the cells would be sensitised to cell death and importantly 
chemotherapeutic drugs
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4.2.13 Proteins involved in unstable resistance to taxol in SKMES-Txl (Wk3) 
versus SKMES-Txl (Wk6)
Com parisons betw een SKM ES-1 versus SK M ES-Txl (W k3) and SK M E S-T xl (W k3) 
versus SK M ES-Txl (W k6) revealed that 4 proteins w ere shared. The cellular redox  
proteins, E R -60, peroxiredoxin 2 and protein d isu lfide isom erase protein 5 sh ow  a 
decrease in protein expression as resistance falls (Figure 4 .2 .6 ). For exam ple, PD IA 3  
w as 1.35-fold  increased in SK M E S-T xt (W k3) when resistance w as highest but w as  
1.55-fold  decreased when resistance w as at its low est. Peroxiredoxin 2 (P R D X 2) w as  
2 .02-fo ld  up-regulated in SK M ES-Txl (W k3) but -1 .3 3 -fo ld  in SK M E S-T xl (W k6). 
Peroxiredoxin 2 and 3 expression w as increased in SKM ES-1 versus SK M E S-T xt and 
SK M ES-Txl (W k3) respectively. Peroxiredoxin 2 plays an important role in regulating  
cell differentiation and proliferation by m odulating the hydrogen peroxide-m ediated  
responses and has anti-apoptotic properties (N oh  et al., 2001). The up-regulation o f  
these cellular redox proteins in the more resistant SK M E S-T xl (W k3) reflects an 
attempt o f  the cells to survive and proliferate in response to  taxol exposure. The 
glutathione-related detoxification pathway is com m only d iscussed  as one o f  the major 
m echanism s o f  M DR. B oth  isoform s o f  G ST n  were decreased in SK M E S-T xt and 
SK M ES-Txl (W k3). H ow ever, one isoform  o f  G ST n  w as increased (2 .2 9 -fo ld ) in 
SK M ES-Txl (W k6). Annexin 5 on the other hand, increases w ith decreasing resistance.
□  SKMES-1 v SK-Txl (Wk3) ■  SKMES-Txl (wk3) v SKMES-Txl (Wk6)
Protein Name
Figure 4.2.6 Review o f shared proteins in SKMES-1 versus SKMES-Txl (Wk3) and SKMES- 
Txl (Wk3) versus SKMES-Txl (Wk6).
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L oss o f  taxol-resistance also resulted in the differential expression  o f  10 proteins, o f  
w hich m ost w ere down-regulated. The majority o f  proteins have cytoskeletal and stress 
response functions. Interestingly, the three stress response proteins, K IA A 0098 and 
H SP 70kD a protein 8, are all down-regulated w hich may contribute to a fall in drug- 
resistance. (3-actin is a member o f  the actin fam ily o f  genes, w hich  play important role 
in m aintaining cytoskeletal structure, cell m otility, cell d ivision , intracellular 
m ovem ents and contractile processes. B eta actin and lamin B1 are the m ost up- 
regulated o f  the proteins and may contribute to increased invasiveness o f  SK M E S-T xl 
(W k6) (Figure 4 .2 .7).
Figure 4.2.7 Unique proteins to SKMES-Txl (Wk6) when compared to week 3.
4.2.14 Mechanism of taxane resistance
Taxol and taxotere have similar m echanism s o f  action even  though taxotere is 
approxim ately tw ice as potent an inhibitor o f  m icrotubule depolym erisation relative to  
taxol (G elm an, 1994). The taxanes prom ote the stable assem bly o f  m icrotubules from a- 
and 13-tubulin heterodim ers and inhibit their de-polym erization. Interestingly, both  
taxanes bind to the (3-subunit o f  tubulin but the m icrotubules produced by taxotere are 
larger than those produced by taxol. This may explain w hy taxotere appears to be 
approxim ately tw ice as potent as taxol (Vaisham payan e t a l . , 1999). In these studies 
taxotere exposure resulted in an increase (1 .2 1 -fold) whereas taxol exposure resulted in 
a decrease o f  1.56-fold o f  p-tubulin . L oss o f  taxol resistance also resulted in a decrease  
in P-tubulin expression by 1.94-fold. The m echanism  o f  taxol and taxotere toxicity
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remains controversial. The antitumour effects o f  these drugs m ay result from  
interference w ith the normal function o f  m icrotubules and from b locking o f  cell cyc le  
progression in late G 2-M  phases (D onaldson e t a l.9 1994). Taxol-induced apoptosis in 
hepatom a ce lls is m ediated through G2-M  arrest and D N A  fragmentation (Lin e t a l ., 
2000). C ells w ith  a defective Gi checkpoint and w ith an increased percentage o f  G 2-M  
fractions w ere found to have increased sensitivity to taxol (D iPaola, 2002). H ow ever, 
pulse exposure to taxol can cause apoptosis but not G 2-M  arrest suggesting that taxol- 
induced apoptosis m ay occur without a prior G2-M  arrest (D ziadyk e t a l ., 2004). Taxol 
has been reported to induce the formation o f  reactive oxygen  species (R O S) and alter 
m itochondrial membrane perm eability (Varbiro et a l ., 2001). M oreover, treatment o f  the 
human T -cell lym phoblastic leukem ia cell line C C R F-H SB -2 w ith an antioxidant 
show ed inhibition o f  taxol-induced ROS production but did not prevent taxol-induced  
apoptosis indicating that it is independent (Park e t a l ., 2004).
4.2.14.1 Reactive oxygen species
M any chem otherapeutic agents exert their tox ic effects on cancer ce lls  by producing  
free radicals, leading to irreversible cell injury and overproduction o f  RO S in cancer 
ce lls  m ay exhaust the capacity o f  superoxide dism utase and other adaptive antioxidant 
defences. D epletion  o f  cellular antioxidant capacity enhanced taxol tox icity  (K ong e t a l ., 
2000). Taxol chem oresistance correlates w ith intracellular antioxidant capacity, ROS  
and reactive nitrogen species, inducing the production o f  02~, H 2O 2 and N O  and causing  
oxidative D N A  damage. A gents that decrease H 2O2 and N O  production suppress taxol- 
induced D N A  dam age. The inhibition o f  superoxide dism utase or glutam ylcysteine  
synthase increases taxol-induced apoptosis. Finally, ce ll lines w ith higher total 
antioxidant capacity are more resistant to taxol cytotoxicity  (Ramanathan e t a l. , 2005).
Increases in protein d isu lfide isom erases m ay act as a protective response against D N A  
dam age and have been reported for other m odels o f  oxidative stress (Tanaka e t a l ., 
2000). Interestingly, protein d isu lfide isom erase 5 is increased in SK M E S-T xl (W k3) 
only and decreased in SK M E S-T xl (W k6). E R -60 is increased by 1.35-fold  in SK M E S- 
T xl (W k3) and decreased in SK M E S-T xl (W k6). Increases in these proteins can lead to 
a greater inhibition o f  p 53-dependent apoptosis, a decrease in the inhibition o f  c-m yc  
survival pathways and an increase in the signalling o f  Ras oncogene. D ecreases in these
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proteins in SK M E S-T xl (W k3) com pared to SK M E S-T xl (W k6) correlates with a 
decrease in drug resistance
The thioredoxins are ubiquitous redox proteins that are reduced by N A D P H  and 
thioredoxin reductase, w h ich  m  turn reduces oxid ized  cysteine groups on proteins 
Elevated levels  result in increased cell growth and resistance to the normal m echanism  
o f  programmed ce ll death M echanism s by w hich  thioredoxin increases cell growth  
include an increased supply o f  reducing equivalents for D N A  synthesis, activation o f  
transcription factors that regulate ce ll growth and an increase in the sensitivity o f  ce lls  
to other cytokines and growth factors The m echanism s for the inhibition o f  apoptosis 
by thioredoxin have been elucidated (P ow is e t a l , 2000) Thioredoxin as a stimulator o f  
cancer ce ll growth and an inhibitor o f  apoptosis, offers a target for n ew  
chem otherapeutics Thioredoxin plays an important role m  ce ll viability, activation, and 
proliferation and is w id ely  distributed in normal tissues and is h ighly expressed in a 
variety o f  cancers such as lung, cervical, pancreatic, hepatom a, gastric, and breast 
cancers (K im  et a l , 2005) This high  expression  o f  thioredoxin in cancers is associated  
with a b io logica lly  aggressive phenotype, increased proliferation and decreased  
apoptosis (K akolyris e t a l , 2001) H igh expression  has been associated  w ith  resistance 
to cisplatin, m itom ycin  C, adnam ycin, taxotere and etoposide (Y okom izo  e t a l , 1995, 
K im  et a l , 2005) Taxotere or taxol exposure m these studies did not result in the 
differential regulation o f  thioredoxin H ow ever, thioredoxin peroxidase is increased in 
SK M E S-T xl (W k3) by 2 02-fo ld  but decreased in SK M E S-T xl (W k6) w hen com pared  
to SK M E S-T xl (W k3)
The glutathione and thioredoxin system s represent tw o major m echanism s for 
m aintaining the intracellular redox environm ent through the reduction and oxidation  o f  
thiol groups The glutathione and thioredoxin system s have been studied individually, 
but both system s seem  to work cooperatively in taxotere-resistance
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4.2.15 Overall mechanisms of resistance - The stress response proteins
One o f  the major groups found to be predominantly increased in all the drug resistant 
cell lines are the group o f  stress response proteins nam ely the heat shock proteins. 
Figure 4 .2 .13  show s differentially expressed heat shock proteins that both correlate and 
inversely correlate with drug resistance across the panel o f  adriamycin cell lines. H SP  
27 kDa (25), H SP 70 kDa protein 8 isoform  2 protein (4 ) and H SP A 9B  appear to  be 
involved in baseline resistance as they are increased in D L K P -A  versus D LK P and have 
similar expression in all the resistant variants. In contrast, H SP 70A 8 (1 7 ) is consistently  
decreased in the resistant variants. H SP 70 kDa protein 8 isoform  2 (4 ) correlated w ith  
increasing drug resistance and H SPA 8 (27), except for D L K P-A 2B , inversely correlated  
with drug-resistance.
HSPB1 (25) HSPA8 (4) HSPA8 (27) HSPA9B HSPA8(17)
DLKP DLKP-A2B DLKP-A 
Cell Line
DLKP-A5F DLKP-A10
Figure 4.2.8 Heat shock proteins correlating and inversely correlating with adriamycin 
resistance. Numbers in brackets indicate protein identification number where isoforms existed.
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4 2 15 1 Heat Shock Proteins -function and background
Heat shock proteins are the products o f  several distinct gene fam ilies that are required 
for cell survival during stress and are nam ed according to the approxim ate relative 
m olecular m ass o f  their encoded proteins They include the fo llow in g  - H SP 10, H SP27, 
H SP 40, H SP60, H SP 70, H SP 90 and H SP 110 They interact with diverse protein  
substrates to assist in the recovery from stress by repainng dam aged proteins (protein  
refolding), thus restoring protein h om eostasis and prom oting cell survival (C alderw ood  
et a l , 2006) The cytoprotective properties o f  the H SP s are c lo se ly  associated  w ith  their 
m am  functions as chaperones The intracellular reactions catalyzed by H SP s are divided  
into tw o ca tegon es nam ely, ‘protein hold in g’ and ‘protein fo ld in g’ The major holding  
proteins belong to the H SP 70 and H SP 90 fam ilies They bind to unfolded sequences in 
polypeptide substrates and prefer hydrophobic regions H olding interactions occur (a) 
during m R N A  translation, w hen H SP 70 binds to the elongating polypeptide chain to 
prevent premature self-association  in the nascent protein, (b) during heat shock, w hen  
proteins partially unfold  and exp ose hydrophobic sequences that are subsequently bound  
by H SP and (c) constitutively, w hen  H SP 90 binds to proteins w ith unstable tertiary 
structures (C alderw ood e t a l , 2 006)
H SP 70 and H SP 90 function in large com p lexes or ‘chaperone m achines’ containing  
several accessory proteins or co-chaperones that bind the primary chaperone to m ediate 
substrate selection  and cyc les o f  association  w ith, and d isassociation  from, the substrate 
After com pletion  o f  their m olecular chaperone function, H SP 70 and H SP 90 are actively  
released from protein substrates by m eans o f  their intrinsic A T Pase dom ains They have 
therefore becom e targets for rational anti-cancer drug design  (C alderw ood e t a l , 2006)  
O verexpression o f  H SPs in tumour ce lls  is due to the loss o f  p53 function and to 
increased expression  o f  the proto-oncogenes H ER2 and c-M yc and is crucial to 
tum ourigenesis
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4 2 15 2 HSPs Molecular mechanisms in cancer
The m olecular m echanism s involv ing  H SP 27 and other H SP s in cancer and 
chem otherapy resistance can be explained in several w ays (1) they can confer  
cytoprotection by repairing m ore efficien tly  the dam aged proteins resulting from  
cytotoxic drug administration as they are m olecular chaperones, (2) they protect tumour 
ce lls from apoptosis (Arrigo e t a l , 2 0 0 3 ), (3) they protect the m icrovasculature inside  
tumours (H SP 27 is found in endothelial ce lls) (C iocca  e t a l , 2003) and finally  (4) they  
enhance D N A  repair (N adin  e t a l , 2 003)
The rate o f  tumour growth depends on the relative rate o f  turnover o f  tumour ce lls  
Figure 4 2 14 illustrates cell death inhibition through the ability o f  H SP 70 and H SP 27 to 
block program med ce ll death (PC D ) The intrinsic pathway o f  caspase-m ediated  
apoptosis is stim ulated by c-Jun kinase, leading to a release o f  signals including  
cytochrom e c from the m itochondria and activation o f  a caspase cascade, involving  
caspase 8 and 3 Increases in H SP 70 (red triangles) inhibit this pathway at several 
stages, including at the level o f  c-Jun kinase, cytochrom e c  release and after the caspase  
3 step The extrinsic pathway is stim ulated through death receptors such as Fas and via  
downstream  activation o f  the caspase cascade by caspase 9, a step that is inhibited by 
increased levels  o f  H SP 27 (red squares) M em bers o f  the H SP 70 fam ily  are also  
inhibitors o f  replicative sen escen ce Several H SP 70 fam ily m em bers inhibit senescence  
by acting upstream to b lock  the pro-senescence effects o f  the w ild-type p53 protein
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APOPTOSIS SENESCENCE
— I ( c-JunK^
p53
Caspase 9 h D Telomerase P21
—  Cyt c  O
Caspase 8 —► Caspase 3
O
I Cell senescence
iCk--------------- 1 Apoptolic death
Key: GROWTH
HSP70 
□  HSP27 
O  HSP90
CELL DEATH CELL BIRTH
REGRESSION
Figure 4.2.14 Summary o f HSP inhibition o f programmed cell death (PCD) and senescence 
(Calderwood et al., 2006).
In addition, the enzym e telom erase binds H SP 90 (w hite oval), delaying the onset o f  
replicative senescence. Increased expression o f  H SPs in cancer thus further shifts the 
balance betw een cell death and birth, and prom otes tumour growth.
Mortalin (H SP A 9B ), a member o f  the H SP 70 fam ily o f  proteins has differential 
subcellular distribution in normal and immortal cells (W adhw a e t a l ., 2003). It has 
previously been identified as an intracellular FG F-1-binding protein and appears to  be 
involved  in diverse regulatory processes including cellular senescence, g lu cose  
regulation, mitochondrial transport, nephrotoxicity and antigen processing. W hile heat 
shock proteins are generally considered to function in folding, assem bly and 
degradation o f  new ly synthesised proteins, increasing ev idence indicates that they also  
associate with regulatory proteins such as receptor kinases and transcription factors 
(M izukoshi et a l ., 2001).
In contrast to H SP 27 and 90 w hich  are phosphorylated on Ser/Thr residues, H SP 75 and 
H SP A 8 undergo acute tyrosine phosphorylation in response to  vanadate and hydrogen  
peroxide suggesting that H SP proteins could be involved  in the regulation o f  signalling  
pathways (W adhwa e t a l 2003). H SP 70 is found in many subcellular sites and is 
know n to bind p53 causing its inactivation. The leukaem ia cell line, H L -60, developed  a 
grow th advantage with the overexpression  o f  mortalin. O verexpression also resulted in
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m alignant transformation o f  m ouse N IH  3T3 ce lls  and life  span extension  o f  normal 
hum an fibroblasts (W adhwa e t a l , 2 003)
H SP is a potential target for apoptosis-based cancer chem otherapy H SP 70 and H SPA 8  
can interact, via  the B a g l protein, w ith  several proteins, w hich  participate in signal 
transduction and apoptosis, including the B cl-2  protein The transient com plex  
ch ap eron e-B agl-B cl-2  could  facilitate the insertion o f  the anti-apoptotic protein into the 
m itochondrial m embrane thus preventing apoptosis (Takayam a e t a l , 1998) H SP70  
does not inhibit fas-induced apoptosis suggesting that its inhibitory function is only  
effective against those agents that produce RO S Protection against TNF-induced  
apoptosis, has been show n to involve H SP 70 (Creagh and Cotter, 1999)
Direct or indirect association  w ith  antiapoptotic bcl-2  fam ily m em bers may confer  
H SP 70 protection Inducible and constitutive form s o f  H SP 70 associate w ith  the bcl-2  
binding protein, BAG -1 inhibiting apoptosis A s a result an increased bcl-2  expression  
often occurs w ith  H SP 70 overexpression  (T ow nsend e t a ! , 2 0 0 3 ) Zhao e t a l  (2005)  
inhibited H SP 70 using antisense R N A  resulting in accelerated apoptosis
4 2.15 4 HSP and chemotherapy treatment
H SPs are overexpressed in a w ide range o f  human cancers and have been im plicated in 
tumour cell proliferation, differentiation, invasion, m etastasis, death and recogm tion by 
the im m une system  (C iocca and Calderw ood, 2 0 0 5 ) They are useful biom arkers for 
carcinogenesis in som e tissues and signal the degree o f  d ifferentiation and the 
aggressiveness o f  som e cancers, hyperplastic endom etrium , uterine cervix, co lon  and 
hepatocellular carcinom a (C iocca and C alderw ood, 2 005)
Circulating levels  o f  H SP and anti-H SP antibodies in cancer patients could  be useful in 
tumour diagnosis H SP27 expression  is associated w ith  poor prognosis in gastric, liver, 
and prostate carcinom a (Takeno e t a l , 2 0 0 1 , K ing e t a l , 2000  and B ostw ick , 2000)  
H SP 70 is correlated w ith  poor prognosis in breast, endom etrial, utenne cervical, and 
bladder carcinom as (C iocca  and Calderw ood, 2005) Increased H SP expression  may  
also predict the response to som e anticancer treatments B oth H SP 27 and H SP70  
expression  are im plicated in chem otherapy resistance in breast cancer (V argas-R oig et 
a l , 1998) H SP 27 expression  is correlated w ith  a poor response to chem otherapy in 
leukem ia patients
The im plication o f  heat shock proteins in  tumour progression and response to therapy 
has led to its successfu l targeting in therapy by 2 m am  strategies Firstly,
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pharm acological m odification  o f  H SP expression  or m olecular chaperone activity and 
secondly, their use in anticancer vaccines, exp loiting their ability to act as 
im m unological adjuvants (C alderw ood e t a l , 2006)
H SP 70 is a weak predictive marker in lung caner (V olm  and Rittgen, 2 0 0 0 ) but a 
predictor o f  better response to chem otherapy in osteosarcom a (T neb  e t a l , 1998) 
Chauhan e t a l  (2 0 0 3 ) identified several H SP s including H SP 70 to confer resistance to 
dexam ethasone in m ultiple m yelom a and oestrogen receptor-a in breast cancer H SP27  
overexpression  has been correlated w ith  a shorter d isease-free survival in advanced  
breast cancer and in ovarian cancers (Langdon e t a l , 1995) L ow  constitutive levels o f  
H SP 27 in testicular germ cell tumours has facilitated the successfu l use o f  cisplatin  
(80%  cure rate) Co-transfection o f  H SP 27 plasm id resulted in resistance to cisplatin  
(Richards e t a l , 1996) Sim ilarly suppression o f  H SP 27 w ith anti-sense im proved the 
sensitivity o f  the gastric carcinom a SG 7901 ce ll line to vincristine (Y ang e t a l , 2006)  
M orino et a l  (1997) revealed that H SP 27 expression  correlated w ith m etastasis and 
tum ouregenisis in mam mary and prostate cancers The results also correlated  
overexpression  o f  H SP27 w ith  a shorter disease-free survival period, suggesting that it 
could be a prognostic marker for m alignancy o f  these tumours
In predictory responses to chem otherapy (table 4 2 2), overexpression  o f  H SP 27 has 
been linked to adnam ycin  resistance in breast cancer ce lls  (O esterreich e t a l , 1993) by 
increasing the effic ien cy  o f  repair o f  adnam ycin-induced D N A  dam age (N adin e t a l , 
2003) Both H SP 27 and H SP 70 w ere show n to inhibit apoptosis caused by  
chem otherapeutic drugs especia lly  those that target topoisom erase II en zym es l e the 
anthracyclm es, V P -16, H 2O2 and staurosponne (Garrido e t a l , 1999) H SP 27 can  
decrease the level o f  reactive oxygen  sp ecies (R O S) and increase lev e ls  o f  glutathione 
H igh levels  o f  G SH  are effective against intracellular stress caused by ROS H SP 27 can  
stabilise m icrofilam ents and protect against toxicants (L avoie e t a l , 1995) 
Phosphorlyation o f  H SP 27, a result o f  PKC up-regulation, w as found in gefitim b- 
resistant colorectal ce ll lines H SP 27 antisense techniques reversed resistance 
m echanism s in lym phom a ce lls to the proteasom e inhibitor bortezom ib (Chauhan e t a l , 
2003) H SP 27 directly interacts w ith  cytochrom e C and tw o effectors o f  the EGFR  
pathway, nam ely A K T  and p38 M A PK , to confer protection against cell death 
(L oeffler-R agg e t a l , 2 005)
331
Sinha e t a l (2003) used 2-D E  to analyse chem oresistance in m elanom a, stom ach, 
pancreatic, fibrosarcom a and colorectal carcinom a ce ll lines A ll cell lines were grown  
m  the presence o f  cisplatin and daunorubicin, leading to the developm ent o f  classical 
M D R  and m itoxantrone, V P -16, vindesine and fotem ustine leading to atypical M D R  
The heat shock proteins 27 , 70, 60  and 60 variant were all found to be overexpressed in  
the resistant m elanom a variants Creagh e t a l  (2 0 0 0 ) show ed that these drugs produce 
RO S, w hich  play a major role in apoptosis induction Treatment w ith antioxidants 
increases cellular resistance to these agents H SP 27 can reduce intracellular levels o f  
ROS in a glutathione-dependant manner It can inhibit apoptosis-m ediated ce ll death v ia  
receptor induced pathways e g death receptors Fas/C D 95 and tumour necrosis factor 
alpha It increases glutathione (G SH ) as high G SH  is effective against cellular stress 
caused by ROS K oom agi e t a l (1996) used im m unohistochem istry techniques to 
analyze 20  tumoural and peritumoural tissues from  patients w ith  lung cancer (14  
sm okers and 6 non-sm okers) for drug resistance proteins P-gp, topoisom esare II (topo- 
II), glutathione S-transferase-rc (GST-7e), m etallothionein  (M T), H SP -70 and the 
putative regulators o f  resistance (ErbBl, Fos and Jun) The study set out to look  for a 
link betw een expression  o f  resistance-related proteins w ith their regulators and 
sm oking Results revealed that protein expression  o f  topo-II, G ST -71, MT, H SP -70, 
ErbB 1, Fos and Jun were overexpressed in tumour tissue com pared to normal tissue  
The expression  o f  the proteins (especia lly  H SP 70 and M T) w as frequently increased in 
sm okers and correlated w ith  differences betw een  the tumoural and non-tumoural tissue
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Zhang e t a l  (2006) exposed  the H L -60 leukaem ia cell line to the natural tyrosine kinase 
inhibitor geneticin  and applied 2 -D E  to analyse the response Forty protein spots out o f  
600  in total show ed a greater than 2-fo ld  changes in spot intensity, 15 o f  w hich  were  
identified by M A LD I-TO F H SP 70 kD a protein 8 isoform  2 w as up-regulated (5 9- 
fo ld ) Proteins involved  in g ly co ly sis  and A TP production such pyruvate kinase and 
isocitrate dehydrogenase were also h ighly over expressed  Proteins im plicated in R N A  
processing (hnR P A l and hnRPC) were decreased due to genetisin  H ow ever, hnR PH l 
w as 5 1-fold up-regulated The R N A  processing proteins hnR P H l and hnRPK  w as also  
up-regulated in D LK P versus D L K P -A  HnRPF w ere increased in D L K P-A  versus
Hsp Authors) Findings
Breast cancer
Hsp27 Seymour et si (1990) * better response to combination therapy {chemotherapy 
anti tamo* ¡ten tor Eft+j
Damstjup e? al 0932) Does not predBct response to endocrine therapy
Ciocca et a) (1938) Does not precBct response to tamoxifen
Vargas Roig et al (1998) Shorter DFS {neoadjuvant chemotherapy)
HspTO Ciocca et al (1993) Predictor «1 recurrence (ai^ uvani therapy)
Im et al (1998) Higher <r©sp, radiation and hyperthermia
Ciocca et t i o$38) Does not pfadjct response to tamaxkten
Vargas Roig et al {1998) Shorter DFS {neoadjuvant chemotherapy)
Ovarian cancer
Hsp27 Ungdon et al 0995) ■>Hsp27 resistant to chemotherapy
Oermam et af (199SJ No correlation wS{h ctiomorastssanco
Arts et al (1999) Univariate analysts absence of Hsp27 correlated wtth loo 
ger median progression free curvtval
Pìura et al (2002) Ovcroxpressian poor response to chamoth
CwtvtcaJ (utenno} cancer
Hsp27 vargas-ftoig m ai |1S33Ì Hsp27 rto eofralaitein w?th response to tamoaiten
Hoad and nod* cancer
Hsp27 Forfen et a! (2000) Expression' c&d not correlate w lh local response to radio* 
therapy (transfected colls with >Hsp2? themtores&t 
anco and chemoresistanee)
Oosopfcagsal cancer
HSPB7 Takeno ai al {200tb> Hsp27 involved m resistance to neoadjuvant C+R (see)
Rocta) cancer
Hsp27/70 Rao et BÍ (1999) No correlation wrth treatment (H-R*C)
Lung cancer
Msp70 Vo5m and Riìtgon (2000) Weak correlation with resistance to doxooÆwctn (nscte)
Bladder cancar
Htp27 Kassem et si (2002) Oownroguta?io<rt in radiosensifive bed
Hsp60 Stolta et al (¡597) increased ant^ -Hsp 60 IgG alter 6CG therapy stumor re* 
currence
Prostata cancar
Hsp27 Qubendorf at ai (1999) Oete*pres5»on 31% oí hormona refractory tumors 5% 
OT primary tumors
leucemia
Hsp27 Kasimir Bauer et ai (lößä) Coexpresaon oí Hsp27 and other molecules predicts re­
sponse to ¡nductson chsmother
CNS tumors
HepS? 70 90 Harmisson et aü (ÍOOO) Does not predict responso to induction rat&ocbamothera 
py However gtwWastoma celts express high levels of
Hsns
Osteosarcomas
Hsp60 70 Tneb et al (1S9S) Hsp72 * better response to neoadjuvam chemotherapy
Hsp90 Trieb et al (2000a) Antibodies -»response to neoadjuvant chemotherapy
MaJignant Hbrous htstocyîoma
Hsp27 Têtu fit al (1992) Expression no correlation With response to chemotherapy
Abbreviations beef bladder carcinoma ceil tine C chemotherapy see, squamous ce9 carcinoma H hyperthamwa, rtscSe non-small ceil 
iung carcinoma R radiotherapy
D L K P-A  10
Table 4 2 2 Review o f studies exploring the use o f the HSPs to predict the response (or lack of  
response) of a set of cancer patients to a specific treatment(s) (Cioccaand Calderwood, 2005)
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A  com parison o f  lung tumoural and pentum oural tissue revealed that several tumour 
proteins w ere differentially expressed including, annexin 2, prohibitin, stathmin, 
Cathepsin D  The normal tissue 2-D E  patterns w ere reasonably reproducible am ong  
patients, the tumour sam ples show ed notable variation depending on tumour type (1 e 
adenocarcinom a, squam ous cell carcinom a and neuroendocrine carcinom a) and on  
stage Som e proteins w ere found in m ost patients e g H SP 27, but som e w ere on ly  found  
in one patient Cathepsin D  and H SP 27 are markers in current use for breast and lung  
cancer respectively The induction o f  H SP 27, prohibitin and chaperones under stress 
conditions has been linked to apoptosis (A lfonso  e t  a l , 2 004)
The H SP fam ily could  provide a true A ch illes  heel for cancer therapy because they  
seem  to be required for ce ll survival dunng tumour progression and m etastasis N e w  
classes o f  drugs targeting H SPs are beginning to be generated, for exam ple H SP 90  
inhibitors are currently show ing m uch prom ise in clin ical trials, w hereas the increased  
expression o f  H SP s in tumours are form ing the basis o f  chaperone-based  
immunotherapy (C alderw ood e t a l , 2 006)
The A TPase dom ain o f  H SP 90 has been effec tively  targeted A  very active and unique 
fam ily o f  anti-cancer drugs has been produced and are sh ow ing considerable prom ise in 
phase I and II clin ical trials w hereby tumour ce lls  are se lectively  sensitised  w ith anti- 
H SP 90 drug 17A A G  (W orkm an, 2 0 0 4 , N eckers, 2 0 0 2 ) In tumour ce lls, the principal 
effect o f  H SP 90 inhibition is the degradation o f  proteins required for autonom ous 
growth and cytoprotection The selectiv ity  o f  H SP90-targeted drugs also affects the 
increased concentration o f  H SP 90 substrates found in tumor ce lls, including  
overexpressed on cogen es and mutant proteins generated through the ‘mutator 
phenotype5 o f  advanced cancers (Calderw ood e t a l , 2006)
The other H SPs have not been effec tively  targeted yet, although efforts to do this are 
proceeding There is great prom ise for such drugs ow in g  to the w idespread role o f  
H SP 27 and H SP70 in b locking PCD  and sen escen ce dunng tumour progression  
H ow ever, the high concentrations o f  these proteins m ight place constraints on the 
feasib ility  o f  this approach D rugs that target H SP 70 fam ily proteins in general are 
likely  to be tox ic through inhibition o f  the basic m olecular chaperone function  needed to 
fold  m ost intracellular proteins H ow ever, individual m em bers o f  the H SP 70 fam ily, 
m any o f  w hich  are overexpressed in cancer, have distinct m echanism s for increasing  
cell survival and could be targeted ind ividually (Tang e t a l , 2 005)
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Immunotherapy treatment m ay be a tem pting target as they are able to  chaperone 
tumour antigens and act as b io logica l adjuvants to break tolerance to tumour antigens 
and cause im m une k illing by cytotoxic T lym phocytes and tumour regression The 
identification o f  proteins already in use as cancer markers (H SP 27, stathmin and 
cathepsin) support the valid ity  o f  the technique and stresses the potential o f  proteom ics
4 2 16 Cellular redox system
Generation o f  oxidative stress in response to various external stim uli has been  
im plicated in the activation o f  transcription factors and in the triggering o f  apoptosis 
Several anticarcinogenic agents have been show n to inhibit RO S production and 
oxidative D N A  dam age, inhibiting tumour prom otion Other m echanism s, apart from P- 
gp are also responsible for the developm ent o f  M D R  A ntioxidants govern intracellular 
redox status Inside ce lls, G SH , glutaredoxin and thioredoxin represent the major 
reducing agents (Figure 4 2 15) The glutathione-related detoxification  pathway is 
com m only d iscussed  as one o f  the major m echanism s o f  M D R  how ever, G ST pi 
expression  w as unchanged across the adnam ycin  resistant ce ll lines in the panel but 
increased in D L K P-M itox (1 8-fold)
Other m em bers o f  the thioredoxin system  include peroxiredoxm  1, 2 and 3 
Peroxiredoxin 1 w as overexpressed in the least-resistant variant D L K P -A 2B  
Thioredoxin reductase, thioredoxin, and thioredoxin peroxidase/peroxiredoxin are three 
linked com ponents in a redox chain that couple peroxide reduction to N A D P H  
oxidation T hioredoxin (T R X ), th ioredoxin peroxidase, peroxiredoxm  2 and 2 w ere all 
down-regulated in each o f  the other proteom ic com parisons w ith  the exception  o f  
thioredoxin peroxidase w hich  is increased in D L K P -A  versus D L K P-A 5F  
The low er level o f  these proteins m ay therefore render these ce lls m ore susceptible to 
oxidant injury Interestingly, reduced expression  o f  T R X  led to the sensitisation o f  
bladder cancer cell lines towards adnam ycin, etoposide and m itom ycin  C (Y okom izo  e t 
a l , 1995) T hioredoxin regulates the activity o f  D N A -b ind ing proteins including, 
Jun/Fos and nuclear factor B It also interacts w ith  an intranuclear reducing m olecu le  
redox factor 1, w h ich  enhances the activity o f  Jun/Fos
T um oungenesis results in the disruption o f  the fine balance betw een  ce ll death and 
survival Increased levels  o f  antioxidant en zym es such as M nSO D , peroxiredoxm  2, 
peroxiredoxm  6, aldehyde dehydrogenase A 2, and thioredoxin 1 are associated w ith  
accum ulation o f  R O S A ccum ulation o f  RO S m ay lead to activation o f  the
335
protooncogene N F-kb, induces D N A  dam age but inhibits the function o f  the AP-1 
transcription factor
Figure 4 2 15 The Cellular Redox System Small arrows in bold next to the protein indicate 
changes in level during tumour progression
The R A S-R A F -M A P kinase on cogen ic pathway can be activated by an increase in the 
levels  o f  galectin-1, w hich  acts as an am plifier o f  Ras signaling (E lad-Sfadia e t a l , 
2002) and by a decrease in the R a f kinase inhibitor protein (Y eung e t a l , 1999) 
Increases in protein d isulfide isom erases m ay act as a protective response against D N A  
dam age and have been reported for other m odels o f  oxidative-reductive stress (Tanaka 
e t a l , 2 0 0 0 ) Interestingly, protein d isu lfide isom erase 5 is down-regulated in DLK P  
versus D L K P-A  by - 2  18-fold  w hereas E R -60 is increased by 1 45 -fo ld  in D L K P-A 5F  
T hese changes in the levels  o f  these proteins can lead to a greater inhibition o f  p53- 
dependent apoptosis, a decrease in  the inhibition o f  c-m yc survival pathw ays and an 
increase in the signaling o f  Ras oncogene
N ucleophosm in  (N P M ) is up-regulated in cancer ce lls  and has been described as a 
repressor o f  p53 activity (M aiguel e t a l , 2 0 0 4 ) S ince p53 transcriptional activity can be 
activated by D N A  dam age caused by the increase o f  RO S lev els  in tumour ce lls, the
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increased expression  o f  nucleophosm in can be important to m aintain ce ll viability  and 
to aid escaping apoptotic signalling N ucleophosm in  (N P M ) is unchanged in the 
adriam ycin resistant variants but decreased in D L K P -M itox
Liu e t a l (2006) com pared the protein profiles o f  parental M C F-7 and an adriam ycin  
resistant variant Proteom ic analysis identified 17 proteins including nucleophosm in (- 
1 7-fold), peroxiredoxin 1 (2 3-fo ld ) and peroxiredoxin 2 (-4 5-fold), protein disulfide  
isom erase (2 3-fold) cathepsin D  chain B  (3 5-fold ), H SP 27 (1 6-fold ), tnosephosphate  
isom erase (2 2-fo ld ) and inorganic pyrophosphatase (-1 9-fo ld ) N ucleophosm in, protein  
disulfide isom erase, H SP 27 and cathepsin D  have all been  associated  w ith  the 
developm ent o f  drug resistance and poor prognosis In these studies an isoform  o f  
tnosephosphate isom erase is increased in D LK P versus D L K P -A  (1 89-fo ld ) and further 
increased in D L K P-A  versus D L K P -A 2B  (1 87-fo ld ) but decreased in D L K P -A  versus 
D L K P-A 5F (-2 26-fo ld ) In contrast, a second isoform  o f  tnosephosphate isom erase is 
decreased in D LK P versus D L K P-A  (-1 46 -fo ld ) and further decreased in D L K P-A  
versus D L K P-A  10 (-3 2 1 -fold) Peroxiredoxin 2, a protein um quely differentially  
regulated m D L K P-A  versus D L K P-A  10, the ce ll line m ost resistant to adriam ycin is 
also decreased (-1 86-fold )
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Section 5.0: Conclusions and Future Work
5.1 Conclusions
The objectives o f  this thesis were to investigate the factors involved  in the developm ent
o f  resistance to a number o f  chem otherapeutic drugs. This work has generated valuable
m odels for the study o f  drug resistance and invasion, w hich  reflect the clin ical scenario.
•  Pulse selections w ith clin ica lly  relevant drug concentrations w ere carried out on four 
lung cancer cell lines, tw o squam ous (SK M ES-1 and D LR P) and tw o sm all cell 
(N C I-H 69 and D M S-53) lung carcinom a cell lines w ith  either taxol, taxotere, 
carboplatin or V P -16. The result w as tw elve novel cell lines w ith relatively low  
clin ically-relevant resistance.
•  A ll selected  cell lines developed  resistance to the selecting drug (except DLRP-C pt) 
and cross-resistance to structurally unrelated drugs. Taxotere selection  o f  SKM ES-1  
resulted in increased expression  o f  P-gp com pared to the taxol-se lected  variant o f  
SK M ES-1. Pulse selection  o f  D M S-53, a ce ll line intrinsically resistant to the 
taxanes, induced low  leve ls  o f  resistance to the drugs and also resulted in increased  
P-gp expression.
•  U nstable resistance to both taxol and taxotere resulted in SK M E S-T xt and SK M E S- 
Txl. R esistance in both cell lines w as unstable over tim e in culture and fo llow in g  
storage in liquid nitrogen.
•  Stable cross-resistance to 5-FU  w as observed in both taxane-selected  variants o f  
SK M E S-1, each o f  the N C I-H 69 drug selected  variants and SKM ES-CptlOO  
suggesting a different m echanism  o f  resistance in each o f  these cell lines.
•  The resistance in D M S-C pt and SKM ES-1 and D M S taxane-selected  variants may  
be due to a com bination o f  m echanism s including alterations in tubulin dynam ics, 
m utations in tubulin (P -tu bu lin  expression  is increased in SK M E S-T xt) and 
increased expression  o f  P-gp.
• Pulse selection of N C I-H 69 w ith VP-16 and carboplatin resulted in cross-resistance  
to taxotere and sensitisation  to adriam ycin, vincristine and taxol in each case. In
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contrast, SKM ES-CptlOO becam e cross-resistant to taxol and sensitised  to 
vincristine and adnam ycin, whereas SK M E S-C pt30 developed  cross-resistance to 
both taxanes and w as sensitised  to vincristine, adnam ycin  and 5-FU
•  Drug resistance has been  previously associated w ith  an invasive phenotype in cancer 
ce lls In the work d escn b ed  here how ever, no consistent correlation w as observed  
Invasion w as not induced in either o f  the non-invasive ce ll lines w hen pulsed w ith  
carboplatin and/or taxotere, taxol and V P -16 H ow ever, pulse selection  o f  an already 
invasive cell line w as found to alter the invasiveness Pulse selection  o f  SKM ES-1  
w ith both taxanes resulted in more invasive variants, w ith the taxotere variant being  
the m ore invasive o f  the tw o w hen checked over tw o  and seven  w eek s A  correlation  
betw een a fall in drug resistance and adhesiveness w ith  increase in the invasive  
phenotype w as observed in both SK M E S-T xt and SK M E S-T xl over this period  
Exposure o f  DLRP to taxotere resulted in the D L R P-T xt cell line becom ing only  
slightly m ore invasive and as seen  in SK M E S-T axane selected  vanants a loss o f  
adhesion w as observed Pulse selection  o f  the non-invasive sm all cell lung  
carcinom a cell line, D M S-53 to taxol and taxotere did not induce an invasive or 
m otile phenotype or a change in adhesiveness
•  Selection  o f  SKM ES-1 w ith  a high  concentration o f  carboplatin resulted in a more 
invasive ce ll line w hereas pulse selection  w ith  a lower, m ore clin ica lly  relevant 
concentration resulted in  a less invasive and less m otile ce ll line T hese cell lines  
therefore provide a m odel for the future study o f  invasion  N o  change in m otility  
w as observed in SKM ES-CptlOO Both carboplatin selections are m ore adhesive  
than the parent cell line Carboplatin selection  had no effect on drug resistance, 
m otility  or invasiveness o f  D LRP-C pt H ow ever, this ce ll line w as considerably less  
adhesive than the parent Sim ilar results to the taxane selections on the D M S-53 cell 
line were observed w ith  carboplatin selection  on N C I-H 69 and D M S-53 N o  change 
in the invasive and m otile phenotype w as observed
•  A  fall in taxol and taxotere resistance in SK M E S-T axane-selected  ce lls  resulted in 
more invasive and less adhesive ce ll lines
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The second major section  o f  the thesis investigated the altered protein expression  
resulting from adriamycin exposure in a m odel system  d isplaying varying levels  o f  
resistance to adriamycin.
It is also o f  interest to com pare proteins altered in the adriam ycin-resistant m odel w ith  
a m itoxantrone-resistant cell line as both drugs are alkalyating agents and m itoxantrone 
has less cardiotoxicity. Finally, resistance to the taxane drugs and the loss o f  resistance  
to taxol in SK M E S-T xl (W k3) w as also exam ined by proteom ic technologies.
A s resistance to chem otherapy drugs is considered to be m ultifactorial, proteom ic  
strategies have provided insights into the global changes in protein expression. The 
com bination o f  proteom ic techniques and suitable in vitro  m odels presents an excellen t 
setting for d issecting the processes and players involved  in drug resistance.
•  Proteom ic analysis w as carried out to study differential protein expression  
associated w ith adriamycin resistance in a series o f  clonal subpopulations o f  the 
adriam ycin-resistant cell line D L K P-A , d isp laying varying levels  o f  resistance to 
adriamycin and a number o f  other chem otherapeutic drugs (D L K P -A 2B , -A 5F  and - 
A 10). W hile the main m echanism  o f  resistance in these cell lines is associated  w ith  
P-gp, little inform ation on cytoplasm ic changes w as available. This work identified  
eight proteins w h ose expression  p ositively  correlated w ith increasing resistance (e .g . 
the heat shock proteins 70kD a and 27 kDa, chaperonin containing TCP subunit 2, 
annexin A l ,  replication A 2, K 130r mutant o f  human Dj-1 and nucleoside  
diphosphate kinase 1). The expression  o f  fourteen proteins correlated w ith  baseline  
adriamycin resistance (A L D H 1A 1, V C P, H SP B 1, C CT3, hnRPK, O X C T1, 
h nR N P H l, G D I2, STO M L2 and A N X A 1). T hese proteins represent ideal targets for 
future inhibitory work. The expression  o f  tw elve proteins inversely correlated with  
increasing adriam ycin resistance (e.g . prohibitin and elF  5 A ).
•  DLK P and the adriam ycin resistant variants also display differential invasion  
potential in the order D L K P-A 2B  < D L K P -A  10 <  DLK P < D L K P -A  < D L K P-A 5F  
w ith D L K P -A 2B  being the least invasive and D L K P-A 5F the m ost invasive. The 
expression  o f  four proteins w as found to p ositively  correlate w ith  this increase in 
invasion nam ely, eukaryotic translation elongation  factor ID , annexin 1, horf 6 a
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hum an peroxidase enzym e and HPRT The expression  o f  gam m a actin inversely  
correlated w ith  invasion
•  Proteom ic analysis w as earned out to study differential protein expression
associated w ith  m itoxantrone resistance in the D L K P-M itox cell line W hile the
m am  m echanism  o f  resistance in this ce ll line is associated w ith  BCRP  
overexpression  (no detectable levels  o f  P-gp and M R P1), little inform ation on  
cytoplasm ic changes is available This work identified 60  proteins w ith differential 
expression  relating to m itoxantrone exposure The m ajonty are involved  in protein  
turnover and have cytoskeletal functions (e g nucleophosm in  and h igh  m obility  
group box protein)
•  O f the sixty  proteins identified  as differentially expressed w ith  regards to
m itoxantrone resistance, m neteen w ere also differentially expressed m the DLK P
versus D L K P -A  com pan son  and tw elve w ith  the other adnam ycin-resistant variants 
o f  DLK P M itoxantrone exposure resulted in  low er fo ld  changes in the chaperone 
and stress response proteins nam ely, chaperonm  containing TCP subunit 3, mortalm  
(H SP A 9B ) and H SP 70  proteins 8 as w ould  be expected  B oth  drugs induced  
relatively sim ilar lev e ls  o f  tw o apoptotic/redox regulation proteins, galectin-1 and 
PA R K 7 and the overlapping g lyco ly tic  proteins, nam ely the aldehyde  
dehydrogenases and tnosephosphate isom erase H ow ever, m itoxantrone induced a 
significantly higher fo ld  change in the protein turnover and m etabolic proteins, 
protein d isulfide isom erase and ornithine aminotransferase respectively  A dnam ycin  
exposure resulted in higher lev e ls  o f  annexin induction H ow ever, m itoxantrone 
induced over tw ice the am ount o f  sorcin and hnRPK  M itoxantrone w as designed  to 
produce less free radicals in com panson  to adnam ycin, sim ilar levels  o f  
apoptotic/redox response proteins were differentially regulated in both cell lines 
H ow ever, in contrast to D L K P-A , the m ajority o f  these proteins are up-regulated in 
D L K P-M itox
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•  Proteom ic analysis w as carried out to study differential protein expression  caused by  
taxane resistance in tw o cell lines developed  in these studies, nam ely SK M ES-Txt 
and SK M E S-T xl (W k3) The parental ce ll line, SK M E S-1, not previously  
docum ented to be exposed  to drug w as selected  w ith clim cally-relevant 
concentrations o f  the taxanes, taxol and taxotere The m am  m echanism  o f  resistance  
in these cell lines is the overexpression  o f  the membrane protein P-gp Pulse  
selection  w ith taxotere yielded  a total o f  40  differentially expressed proteins O f  
these 40  proteins, 19 w ere unique to taxotere-selection  (e g vim entin  and galectin-1) 
when com pared to SK M E S-T xl (W k3) and SK M E S-T xl (W k6) The majority o f  the 
differentially-regulated proteins have functions, as expected, in protein turnover and 
the stress response T hese proteins are know n to increase resistance to ce ll death 
induced by a variety o f  stim uli
•  Taxol exposure in SK M ES-1 resulted in a total o f  48  differentially-expressed  
proteins O f these 48  proteins, 21 overlapped w ith  SK M E S-T xt (e g keratin 8 and 
glucose-6-phosphate dehydrogenase) Taxol and taxotere exposure resulted in 
sim ilar expression  levels o f  the majority o f  these proteins w ith  the exception  o f  
proteasom e activator subunit 2 and peroxiredoxin 2, both o f  w hich  are increased to a 
greater extent in SK M E S-T xt In contrast to the unique proteins differentially- 
regulated in  response to taxotere exposure, taxol exposure resulted in the differential 
expression  o f  23 unique proteins, o f  w hich  m ost w ere dow n-regulated The majority 
o f  these proteins have function in ion binding/transport, protein turnover and the 
stress response
•  A n unforeseen but fortunate result o f  taxane-selection  o f  SK M ES-1 w as the 
observed loss o f  resistance in both taxane-resistant variants w h ich  resulted from  
culturing and storage in liquid nitrogen Proteom ic analysis w as also carried out to 
study differential protein expression  caused by lo ss  o f  taxol resistance T w enty-five  
proteins w ere identified in the com parison o f  SK M E S-T xl (W k3) versus SK M ES- 
T xl (W k6) Four o f  these proteins show ed contrasting protein-fold level in 
com parison to SK M ES-1 versus SK M E S-T xl (W k3) Ten proteins w ere found to be 
unique to SK M E S-T xl (W k3) versus SK M E S-T xl (W k6) T hese shared proteins 
involved  in lo ss o f  resistance function in the cellular redox cycle  They are involved
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in the regulation o f  cellular differentiation and proliferation v ia  the m odulation o f  
hydrogen peroxide m ediated responses The up-regulation o f  these cellular redox 
proteins in the m ore resistant SK M E S-T xl (W k3) m ay reflect an attempt by the cells  
to survive and proliferate in response to taxol exposure This response is no longer 
required once taxol is rem oved
•  Exposure to adnam ycin, m itoxantrone, taxol and taxotere predom inantly resulted in 
differential expression  o f  the stress and cellular redox proteins w hich  m ay contribute 
to drug resistance m  these ce ll lm es
343
Proteom ic strategies have allow ed the sim ultaneous analysis o f  differential protein  
expression  that m ay contribute to the understanding o f  drug resistance and/or invasion  
T hese results confirm  the m ultifactonal nature o f  both processes (1 e drug resistance and 
invasion) and proteins involved  in drug resistance and m ay provide biom arkers for 
future intervention o f  drug-induced resistance
•  The taxol, taxotere and carboplatm -selected ce ll lines m  this thesis represent 
valuable m odels for the study o f  m echanism s o f  resistance to these drugs M ost o f  
the analysis in this thesis focussed  on the taxane-resistant ce ll lines o f  SKM ES-1  
Sim ilar proteom ic analysis on the other taxane-selected  ce ll lines w ould  be 
necessary to check for sim ilar patterns in these other m odels
•  The carboplatin-resistant ce ll lines could  also be exam ined by proteom ic analysis 
and candidate proteins for developm ent o f  carboplatin resistance could  be identified
•  During p u lse-selection  o f  the cell lines SK M E S-T xt ce ll stocks were frozen in liquid  
nitrogen after 2, 4 ? 6 and 8 pulses before the ce lls  received  the full ten pulses These  
interm ediate ce ll lines have not been characterised for drug resistance, invasion  or 
expression  o f  any markers U sing  these ce ll lines, it m ay be p ossib le to track the 
developm ent o f  resistance to taxotere through proteom ic tech nolog ies
•  The proteins identified v ia  proteom ic analysis in this thesis as potentially involved  
in drug-resistance should be further validated by W estern blotting and analysed by  
inhibitory work (siR N A ) D rug-resistance rem ains a serious problem  in the 
treatment o f  cancer and the proteins identified  here could  help  increase our 
know ledge o f  the com plex m echanism s involved
5 2 Future Work
i
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Appendix 1 - Identified proteins from DLKP versus DLKP-A
Spot
No
Protein Name Fold P value SequenceCoverage
No of 
Peptides
1 Valosin containing Protein 2 32 0 03 26 4 15 o f 32
2 HSP70 kDa 9B (MTHsp75) 1 97 0 026 28 8 o f 17
3 Lamin B 1 3 07 0 001 24 15 o f  27
4 HSP 70 protein 8 isoform 2 3 21 0 0052 23 3 8 o f  22
5 Chaperonin containing TCP1 subunit 3 2 58 0 04 26 3 13 o f  19
6 hnRPK 1 93 0 0087 20 6 o f 14
7 Aldehyde dehydrogenase A1 1 65 0 023 23 8 8 o f  18
8 Aldehyde dehydrogenase A1 1 52 0 0067 12 6 5 o f  10
9
Succinyl-CoA 3 ketoacid CoA 
transferase 2 3
0 0012 24 7 o f  17
10 Aldehyde dehydrogenase A1 1 47 0 046 6 3 lO o f 15
11 CCT2 2 58 0013 43 10 o f  17
12 hnRPHl 1 52 0 025 23 6 7 o f 19
13 Rab dissociation inhibitor beta 1 69 0 012 22 6 5 o f 12
14 Chain C, OAT Mutant Y85i -3 45 0 052 164 6 o f  11
15 HSPC108 (stomatin) 2 03 0 0084 175 4 o f  8
16 elF 2b 1 42 0 029 184 7 o f 14
17 HSP 70 protein 8 isoform 2 -2 15 0 0013 177 7 o f  16
18 K alpha 1 protein -1 55 0 034 29 4 9 o f  16
19 Stress induced phosphoprotein -1 43 0 047 12 3 5 o f 14
20 Annexin A 1 2 29 0 0 1 7 32 8 9 o f  14
21 Annexin A 1 251 0 0033 38 7 7 o f  15
22 Annexin A1 1 63 0 027 26 4 7 o f  15
23 Replication A2 32, kDa 1 5 0 033 26 3 6 o f 13
24 Protein disulphide isomerase protein 5 -2 18 0 0032 20 9 6 o f  11
25 HSP 27 kDa 1 47 0 031 30 9 5 o f 11
26 Actin G protein -1 45 0 012 40 7 6 o f 14
27 HSP 70 kDa protein 8 isoform 2 -1 25 0 021 23 3 8 o f 22
28 Tnosephosphate isomerase 1 89 0 00077 21 6 4 o f  9
29 Tnosephosphate isomerase -1 46 001 5 52 8 8 o f  19
30 Thioredoxin peroxidase B chain J -2 33 0 037 40 1
31 K130r mutant o f human DJ-1 1 54 0 0022 50 3 lO o f 19
32 Thioredoxin peroxidase B -1 95 0 0027 177 3 o f 7
33 Sorcin isoform b 1 51 0 0 1 8 48 6 10 o f  25
34 Nucleoside diphosphate kinase 1 54 0011 51 4 7 o f  12
35 elF 5a -2 63 0 027 19 5 4 o f  11
36 Human tubulin chaperone cofactor A -1 26 0 012 24 1 4 o f  8
37 Galectin-1 -1 55 001 3 41 5 o f  9
38 Thioredoxin delta 3 -1 17 0 0 1 8 43 8 4 o f  13
Table 3 4 4a-ctd
Aminotransferase)
Identified proteins from DLKP versus DLKP-A (OAT Ornithine
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Appendix 2 - Identified proteins from DLKP-A versus DLKP-A2B
Spot
No
Protein Name Fold P value SequenceCoverage
No of 
Peptides
23 Replication A2, 32 kDa -1 29 0 0044 26 3 6 o f  13
26 Actin G1 protein 2 95 0 032 40 7 6 o f 14
27 HSP 70 kDa protein 8 isoform 2 2 87 0 0017 23 3 8 o f  22
28 Triosephosphate isomerase 1 87 0 0047 46 7 o f  15
34 Nucleoside diphosphate kinase 1 -1 28 0013 51 4 7 o f 12
36 Human tubulin chaperone cofactor A -1 88 0 0 1 2 24 1 4 o f  8
37 Galectin-1 1 71 0 014 50 7 5 o f  12
38 Thioredoxin delta 3 1 6 0 0035 43 8 4 o f  13
Table 3 4 6-ctd Fold difference o f  overlapping protein spots between t 
versus DLKP-A and DLKP-A versus DLKP-A2B
le comparisons DLKP
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
39 Actm G1 protein 6 0 018 40 7 6 o f  16
40 Annexin 1 -1 6 0 013 60 8 9 o f  22
41
Chloride intracellular channel 1 
variant
-1 66 0 0011 54 8 9 o f 14
42 HSP 70 kDa protein 8 isoform 2 7 9 0 0034 32 9 12 o f  15
43
Chain B, Horf 6 a novel human 
peroxidase enzyme
-1 61 0 05 41 1 14 o f  26
44
Eukaryotic translation elongation 
factor 1 delta isoform
-2 48 0 02 26 7 5 o f  15
45 Vimentin -1 64 0 046 30 7 13 o f  22
46 HPRT -1 71 001 3 24 2 8 o f  15
Table 3 4 7-ctd The 8 overlapping protein spots between the comparisons DLKP versus DLKP- 
A2B and/or DLKP-A versus DLKP-ASF, DLKP-A 10
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
41
Chloride intracellular channel 1 
variant -1 66 0 0011 54 8 9 o f  14
52 alpha tubulin 6 variant 1 81 001 5 29 4 9 o f  16
53 Annexin 1 2 42 0 0064 49 6 o f  13
54 Beta Actin -1 8 0 0018 27 5 7 o f 13
55 Chain D, Cathepsin B (E C 3 4 22 1) -1 87 0 0 1 6 29 3 4 o f  14
56 Chain H Cathepsin D at pH 7 5 1 54 0 0 1 2 44 7 o f  16
57 HSP 70 kDa protein 8 isoform 2 3 42 0 0098 21 9 7 o f  12
58 KIAA0002 -2 02 0 041 21 8 o f 14
59 Peroxiredoxin 1 72 0 041 28 5 7 o f  12
60 Prolyl 4-hydrolase, beta subunit -1 89 0 046 15 6 o f  12
61
Proteasome (prosome, macropain) 
subunit, alpha type 5
1 6 0 034 42 3 7 o f  16
Table 3 4 8-ctd Proteins unique to DLKP-A versus DLK 3-A2B
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Appendix 3 - Identified proteins from DLKP-A versus DLKP-A5F
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
16 elF 2b -1 38 0 0059 184 7 o f  14
19 Stress induced phosphoprotein -1 35 0 0 1 7 12 3 5 o f  14
25 HSP 27 kDa protein 1 55 0 023 30 9 5 o f 11
27 HSP 70 kDa protein 8 isoform 2 -2 15 0 004 23 3 8 o f  22
28 Triosephosphate isomerase -2 26 0 002 52 8 8 o f  19
29 Tnosephosphate isomerase 001 5 52 8 8 o f  19
30 Thioredoxin peroxidase B 1 44 0 014 40 1 16 o f  21
33 Sorcin 1 47 0013 48 6 10 o f 25
35 elF 5a -2 04 0 0022 19 5 4 o f  11
37 Galectin-1 1 65 0 04 41 5 o f  9
Table 3 4 10-ctd Overlapping protein spots between the 
and DLKP-A versus DLKP-A5F Comparisons between 
proteins were shared
comparisons DLKP versus DLKP-A 
both experiments revealed that ten
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
39 Actin G1 protein -4 07 0 015 40 7 6 o f 16
43
Chain B, Horf 6 a novel human 
peroxidase enzyme
1 34 0 0 1 8 41 1 14 o f 26
46 HPRT -1 33 0 041 24 2 8 o f 15
47 Synovial sarcoma breakpoint 3 -1 73 0 0025 34 4 o f  11
48 BiP -2 04 0 0022 19 5 4 o f 11
49 Prohibitin -2 13 0 044 39 3 9 o f  13
50 Heat shock 27kDa protein 1 48 0 0074 22 8 4 o f  7
51 Beta tubulin -1 93 0 038 30 8 o f 19
Table 3 4 11-ctd Overlapping protein spots between the comparisons D 
and DLKP-A versus DLKP-A2B, A10
X P  versus DLKP-A5F
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
62 Putative protein ofN bla 10058 -1 76 0 0013 27 9 9 o f  15
63 Alpha tubulin 6 variant -1 38 0 023 31 4 lO o f 15
64 ER-60 1 45 0 033 37 17 o f 30
Table 3 4 12-ctd Protein spots unique to DLKP-A5F
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Appendix 4- Identified proteins from DLKP-A versus DLKP-A10
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
4 HSP 70 protein 8 isoform 2 1 44 0 045 40 4 14 o f 27
11 CCT2 1 8 0013 26 4 10 o f 17
16 elF 2b -1 63 0 026 184 7 o f  14
18 K alpha 1 protein 1 81 0 001 29 4 9 o f 16
20 Annexin A1 2 06 0 0062 32 8 9 o f  14
21 Annexm A1 2 19 0 00064 38 7 7 o f 15
27 HSP 70 kDa protein 8 isoform 2 -6 5 0 003 23 3 8 o f  22
29 Triosephosphate isomerase -3 21 0 026 52 8 8 o f  19
31 K130r mutant 1 54 0 0022 49 6 o f 11
33 Sorcin -2 33 0 031 48 6 10 o f  25
34 Nucleoside diphosphate kinase 1 1 27 0 046 35 5 o f 7
35 eIF5a -2 85 0 046 195 4 o f 11
Table 3 4 18-ctd Overlapping protein spots between the comparisons DLKP-A versus DLKP- 
A 10 and DLKP versus DLKP-A
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
39 Actin G -4 69 0 041 40 7 6 o f  16
40 Annexin 1 -2 27 0 023 60 8 9 o f  22
42 HSP 70 kDa protein 8 isoform 2 -1 51 0 014 32 9 12 o f  15
44
Eukaryotic translation elongation 
factor 1 delta isoform
-1 67 0 028 26 7 5 o f  15
45 Vimentin 3 88 0 0048 30 7 13 o f  22
47 Synovial sarcoma breakpoint 3 -1 9 0 0057 34 4 o f 11
48 BiP -3 0 022 15 8 9 o f  17
49 Prohibitin -2 28 0 025 39 3 9 o f  13
51 Beta tubulin -5 23 0 0043 30 8 o f  19
Table 3 4 19-ctd Overlapping protein spots between the comparisons DLKP versus D 
and/or DLKP-A versus DLKP-A5F, -A2B
,KP-A10
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Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
65
26S proteasome-associated padl 
homolog variant
-1 54 0 038 30 1 4 o f 8
66 Beta Actin 1 64 0 04 24 2 6 o f  16
67 Beta Actin 1 63 0 01 189 5 o f 8
68 Beta Actin -2 03 0 02 21 1 6 o f  11
69 Aldehyde Dehydrogenase A1 1 45 0 0096 21 8 9 o f 16
70 Actin G 1 -2 85 0 041 40 7 6 o f  16
71 Chloride intracellular channel 4 -4 69 0 0 1 7 37 9 5 o f  12
72 hnRPF 1 92 0 0 1 8 26 7 o f  14
73 HSP 60 kDa 1 33 0 037 26 4 9 o f  11
74 HSPC124 -2 48 0 023 24 8 5 o f 8
75 LASP 1 -1 48 0 0 1 8  n 35 6 9 o f  15
76
Peroxiredixin 3 isoform a precursor 
variant
-1 45 0 0039 23 8 5 o f  10
77 Retinoblastoma binding protein 7 -2 43 0 045 11 9 5 o f 12
78
Rho GDP dissociation inhibitor 
(GDI) alpha
-1 83 0 0078 25 5 6 o f  17
79 Peroxiredoxin 2 -1 86 0 021 28 7 5 o f  15
80 Vimentin -2 24 0 0038 15 1 7 o f 13
Table 3 4 20-ctd Proteins unique to DLKP-A versus DLKP-A10
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Appendix 5 - Identified proteins from DLKP versus DLKP-Mitox
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
1 Valosin containing Protein -2 0 0 0059 26 4 15 o f 32
2 HSP70 kDa 9B (MTHsp75) -2 53 0 0066 28 8 o f  17
3 Lamin B1 -2 1 001 5 24 15 o f  27
4 HSP 70 protein 8 isoform 2 -2 99 0011 25 6 9 o f 19
5 Chaperonin containing TCP1 subunit 3 -2 02 0 0 1 9 21 7 6 o f 15
6 hnRPK -2 69 9 80E-05 19 5 6 o f  13
8 Aldehyde dehydrogenase A1 1 64 0 0011 26 7 12 o f  19
10 Aldehyde dehydrogenase A1 1 61 0 0015 20 4 8 o f  13
14 Chain C, OAT Mutant Y85i 1 96 0 043 164 6 o f  11
16 elF 2b -1 32 0 035 184 7 o f  14
21 Annexin A1 1 89 0 00049 35 8 o f  15
22 Annexin A 1 1 2 0 039 36 6 9 o f 22
24 Protein disulphide isomerase protein 5 2 82 0 004 20 9 6 o f  10
26 Actin G protein -2 45 0 0067 40 7 6 o f  14
29 Tnosephosphate isomerase -1 25 0 035 52 8 8 o f  19
31 K130r mutant o f human DJ-1 1 25 0 0059 50 3 6 o f 16
33 Sorcin isoform b 3 85 0 0049 48 6 10 o f  25
34 Nucleoside diphosphate kinase -1 45 0 0 1 6 51 4 7 o f  12
37 Galectm-1 -1 4 0 0024 41 5 o f 9
38 Thioredoxin delta 3 1 98 0 007 43 8 4 o f  13
Table 3 5 2-ctd Overlapping proteins form DLKP versus DLKP-Mitox and DLKP versus 
DLKP-A
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Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
39 Actm G protein 3 19 0 035 40 7 6 o f  16
40 Annexin A1 2 21 0 0 1 9 44 6 7 o f  12
49 Prohibitin -1 36 0 025 39 3 9 o f  13
43
Chain B, Horf 6 a novel human 
peroxidase enzyme
-1 62 1 10E-05 41 1 14 o f 26
44
Eukaryotic translation elongation 
factor delta isoform 2
2 04 0 0013 26 7 5 o f  15
57 HSP 70 kDa protein 8 isoform 2 1 79 0 0035 32 9 12 o f  15
46 Human Hprt 2 25 0 0011 24 2 8 o f  15
59 Peroxiredoxin 2 2 0 048 28 5 7 o f  12
60 Prolyl 4-hydrolase beta subunit 1 28 0 035 15 6 o f 12
61 Proteasome subunit alpha type 5 -1 28 0 025 42 3 7 o f  16
65
26S Proteasome-associated Pad 1 
homologue variant
1 44 0 028 30 1 4 o f  8
68 Beta Actin 2 01 0 0042 21 1 6 o f  11
69 Aldehyde dehydrogenase 1A1 1 57 0 01 27 9 12 o f  25
41 Chloride intracellular channel 1 -1 34 0 043 54 8 9 o f 14
72 HNRPF -1 71 001 5 26 7 o f  14
76
Peroxiredixin 3 isoform a precursor 
variant 2
1 61 1 00E-05 28 5 7 o f 12
62 putative protein ofN b lal0058 -1 25 0 034 27 9 9 o f  18
63 Alpha tubulin 6 1 39 0 022 31 4 lO o f 15
64 ER-60 protease -1 57 0 0 1 4 28 5 11 o f 18
51 Beta Tubulin -1 48 0 035 30 8 o f 19
Table 3 5 3-ctd Overlapping proteins form DLKP versus 
DLKP-A2B, -A5F and -A10
DLKP-Mitox, and DLKP-A versus
380
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
81 Aldehyde dehydrogenase 1A1 1 32 0 0011 26 7 12 o f 19
82 Annexin A4 1 51 0 0 1 9 33 5 lO o f 13
83 Beta Actm 2 97 0 032 21 1 6 o f 11
84 Beta Actin 2 53 0 0049 27 5 7 of 13
85 Beta Actin -1 37 0 0048 26 2 6 o f  12
86 Tropomyosin 3 1 0 012 28 6 7 o f 14
87 CGI-46 Protein -1 35 0 043 31 7 11 o f 23
88 GST-pi chain B 1 8 0 035 54 1 9 of 21
89 High mobility Group box 1 2 4 1 80E-07 35 8 9 o f  22
90 HLA-B associated transcript 1 -2 05 0 0001 22 2 8 o f 12
91 HSP 70kDa protein 8 isoform 2 -2 3 0 0 1 7 23 3 8 o f  22
92 KIAA0098 -1 73 0 025 23 1 14 o f 19
93
Mannose-6-phosphate receptor binding 
protein
-1 26 0 034 30 4 9 o f  18
94 nucleophosmin -1 37 0 05 23 6 4 o f 12
95
Phosphoglycerate mutase 1 (brain) 
variant
-3 34 0 00029 37 4 7 o f 11
96 PKCq-interacting protein -1 58 0 0038 28 1 8 o f  18
97 PP protein -2 88 0 00021 48 7 12 o f  24
98 Proteasome activator subunit 3 -1 71 0 016 33 4 6 o f  11
99 Proteasome beta 3 subunit 1 45 0 0076 30 7 4 o f  7
100 Purine nucleoside phosphorlyase 1 38 0 034 27 3 6 o f 13
101 Cofilm (non muscle) -3 77 0 00015 28 2 6 o f 12
Table 3 5 5-ctd Proteins unique to DLKP versus DLKP-Mitox
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Appendix 6 - Identified proteins from SKMES-l versus SKMES-Txt
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
1 150kDa oxygen-regulated precursor 1 33 0 019 176 13 o f  22
2 Valosm containing Protein -1 58 0 036 185 9 o f 16
3 Valosin containing Protein -1 87 0 0004 154 8 o f  16
4 Lamm A/C 1 58 0 0082 24 1 lO o f 17
5
Chaperonm containing TCP1 subunit 
3
1 23 0 0077 21 7 6 o f  15
6 HSP 70 protein 8 isoform 2 1 24 0 041 17 6 6 o f  11
7 Dihydropyrimidinase-like variant 2 1 42 0 023 14 3 5 o f 10
8 HSP 60 kDa 145 0 00027 32 7 11 o f 17
9 HSP 60 kDa 1 35 0 0019 31 8 11 o f 18
10 Glucose 6 phosphate dehydrogenase 1 22 0 032 15 6 o f  11
11 Glucose 6 phosphate dehydrogenase 1 55 0 0068 33 7 13 o f  16
12 Glucose 6 phosphate dehydrogenase 1 2 0 036 27 2 10 pf 19
13 Vimentin -1 63 0 0074 25 8 11 o f 36
14 hnRPHl 1 57 5 80E-06 31 9 o f  27
15 Keratin 8 -1 51 9 10E-05 31 7 18 o f 24
16 PMPCA protein 1 73 0 0029 173 7 o f 16
17
TATA binding protein interacting 
protein 49 kDa variant
1 32 0 0009 37 3 12 o f 24
18
Mannose-6-phosphate receptor 
binding protein
-1 22 0 042 20 7 7 o f  19
19 Beta tubulin 1 21 0 041 164 6 o f 9
20 Septin 2 1 31 0 0081 26 6 6 o  16
21 HNRPC protein 1 32 0 0005 29 2 6 o f 15
22 Mitochondrial ribosomal s22 1 19 0 0018 175 6 o f  10
23 Annexin A1 1 43 0 02 32 8 9 o f  17
Table 3 6 3a-ctd Identified proteins form SKM iS-1 versus SKMES-Txt
382
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
24 LASP 1 1 61 0 0051 35 6 9 o f  15
25 Annexin A3 1 48 0 05 49 8 13 o f 20
26 HSPC124 1 77 4 40E-06 24 8 5 o f 8
27 Proteasome activator subunit 2 1 62 0 0043 26 8 6 o f  10
28 Chain H Cathepsin D at pH 7 5 1 98 0 0069 29 3 4 o f 14
29
Proteasome (prosome, macropain) 
subunit, alpha type 5
-1 26 , 0 032 34 5 o f  10
30
Proteasome (prosome, macropain) 
subunit, a  type 5
1 27 0 0021 42 6 7 o f 16
31 Prohibitin 1 43 0 0021 21 3 4 o f  9
32 Chloride intracellular channel 4 1 74 0 028 37 9 5 o f 12
33 High mobility Group box 1 1 46 0 0047 28 7 6 o f 14
34
Chain B, Horf 6 a novel human 
peroxidase enzyme
1 36 0 0028 31 7 7 o f  16
35 Ubiquitin Carboxy Hydrolase LI 1 27 0 0055 46 2 7 o f  16
36 K130r mutant o f human DJ-1 1 23 0 0013 40 6 6 o f  13
37 Peroxiredoxin 2 1 72 0 001 185 4 o f 7
38 GST-pi -1 68 1 20E-05 31 6 4 o f  7
39 GST-pi chain B -1 37 0 0032 31 6 4 o f  7
40 Galectin-1 -1 55 0 019 50 7 5 o f 12
Table 3 6 3b-ctd Identified proteins form SKMES-1 versus SKMES-Txt
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Appendix 7 - Identified proteins from SKMES-1 versus SKMES-Txl (Wk3)
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
1 150kDa oxygen-regulated precursor 1 94 3 50E-05 176 13 o f 22
2 Valosin containing Protein -1 31 0011 185 9 o f  16
3 Valosin containing Protein -1 4 0 0088 154 8 o f 16
4 Lamm A/C 1 71 7 60E-05 24 1 10 o f 17
5
Chaperonin containing TCP1 subunit 
3
1 41 0 00013 21 7 : 6 o f  15
6 HSP 70 protein 8 isoform 2 -1 55 0 0001 176 6 o f  11
10 Glucose 6 phosphate dehydrogenase 1 23 0 0036 15 6 o f  11
12 Glucose 6 phosphate dehydrogenase 1 43 0 0036 27 2 10 pf 19
15 Keratin 8 -1 57 0 00023 31 7 18 o f  24
22 HNRPC 1 4 7 50E-05 175 6 o f  10
24 LASP 1 1 58 0 0067 35 6 9 o f 15
26 HSPC124 1 58 4 10E-08 24 8 5 o f  8
27 Proteasome activator subunit 2 -1 43 0 00075 26 8 6 o f  10
30
Proteasome (prosome, macropain) 
subunit, alpha type 5
1 21 0 043 42 6 7 o f  16
31 Prohibitin 1 44 0 025 21 3 4 o f  9
34
Chain B, Horf 6 a novel human 
peroxidase enzyme
1 37 0 0013 31 7 7 o f 16
35 Ubiquitin Carboxy Hydrolase LI 1 21 0 0098 46 2 7 o f  16
36 K 13 Or mutant o f  human DJ-1 1 29 0 00061 40 6 6 o f  13
37 Peroxiredoxin 2 1 19 0 0047 185 4 o f  7
38 GST-pi -1 37 0 00011 31 6 4 o f  7
39 GST-pi chain B -1 92 4 50E-05 31 6 4 o f  7
Table 3 6 5 Overlapping proteins form SKMES- 
versus SKMES-Txt
1 versus SKMES-Txl (wk3) and SK WES-1
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
41 ER-60 protease 1 35 0 03 37 17 o f  30
42 Annexin V 1 56 0 0045 49 8 11 o f  19
43 Thioredoxin peroxidase B 2 02 0 00016 40 1 16 o f  21
44
Protein disulphide isomerase 
protein 5
1 65 8 50E-07 20 9 6 o f 10
Table 3 6 6-ctd The overlapping protein spots between the comparisons SKMES versus 
SKMES-Txl (wk3) with SKMES-Txl (wk3) versus SKMES-Txl (Wk6)
384
Spot
No Protein Name
Fold P value SequenceCoverage
No of 
Peptides
50 Annexin A1 -1 26 0 02 35 8 o f 15
51 Annexin A1 -1 29 0 038 36 6 9 o f 22
52 Annexin A1 1 25 0 03 32 2 9 o f  19
53 Annexin A1 -1 31 0 0 1 4 53 4 8 o f  18
54
26S Proteasome-associated Padl 
homologue variant
1 22 0 028 30 1 4 o f  8
55 Cham D, Cathepsm B (E C 3 4 22 1) -1 77 0 007 29 3 4 o f  14
56
Proteasome (prosome, macropain) 
subunit, alpha type 5
1 2 0 043 42 3 7 o f 16
57 Beta tubulin -1 56 1 60E-05 164 6 o f  9
58 Prolyl 4-hydroxlyase, beta subunit 1 26 0 025 15 6 o f  12
59 Beta Actin -1 42 0 042 21 1 6 o f  11
60 Nucleophosmin -1 15 0 0028 23 6 4 o f  12
60 HSP 27 kDa -1 41 0011 30 9 5 o f 11
62 HSPC108 1 31 0 0075 175 4 o f  8
63 Annexin A4 1 37 0 0011 33 5 10 o f 13
64
HLA-B associated transcript 1 
variant
1 26 0 022 22 2 8 o f  12
65 6 phosphogluconolactonase 1 22 0 032 26 4 o f  9
66 ATP Synthase 1 61 2 00E-05 21 7 8 o f 16
67 ATPase beta subunit -1 33 0 0038 35 7 15 o f 20
68 Actin G 1 protein -1 26 001 3 40 7 6 o f 16
69 HSP70 kDa 9B (MTHsp75) -1 33 0 00042 28 9 o f  20
70 CCT2 1 32 0 0013 43 8 o f 24
71 Replication A2 32, kDa 1 22 0 0039 26 3 6 o f  13
72 eiF 3 subunit 2 beta 36 kDa -1 79 0 025 21 8 6 o f 13
Table 3 6 7-ctd Proteins unique to SKMES versus SKM 
in Figure 3 6 8
!S-Txl(Wk2), Spots marked dark blue
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
2 Valosin containing Protein -1 31 1 50E-05 185 9 o f  16
8 HSP 60 kDa 1 6 3 40E-06 32 7 11 o f  17
6 HSP 70 protein 8 isoform 2 1 30 0011 176 6 o f  11
14 hnRPHl -1 24 0 037 31 9 o f  27
19 ”1 Beta tubulin -1 94 0 014 164 6 o f  9
24 LASP 1 -1 49 0 00065 35 6 9 o f  15
25 Annexin A3 -1 39 0 0019 49 8 13 o f 20
33 High mobility Group box 1 1 2 0 0057 28 7 6 o f 14
37 Peroxiredoxin 2 -1 25 0 033 185 4 o f  7
38 GST-pi 2 29 0 00021 31 6 4 o f  7
40 Galectin-1 -1 32 0 012 50 7 5 o f  12
Table 3 6 9-ctd Overlapping proteins between SKMES-Txl (Wk3) versus SKMES-Txl (Wk6) 
and SKM ES-1 versus SKMES-Txt
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Spot
No Protem Name Fold
P value SequenceCoverage
No of 
Peptides
50 Annexin A1 -1 26 0 02 35 8 o f 15
51 Annexin A1 -1 29 0 038 36 6 9 o f  22
52 Annexin A1 1 25 0 03 32 2 9 o f  19
53 Annexin A 1 -1 31 0 014 53 4 8 o f  18
54
26S Proteasome-associated Padl 
homologue variant
1 22 0 028 30 1 4 o f 8
55 Chain D, Cathepsin B (E C 3 4 22 1) -1 77 0 007 29 3 4 o f  14
56
Proteasome (prosome, macropain) 
subunit, alpha type 5
1 2 0 043 42 3 7 o f  16
57 Beta tubulin -1 56 1 60E-05 164 6 o f  9
58 Prolyl 4-hydroxlyase, beta subunit 1 26 0 025 15 6 o f 12
59 Beta Actin -1 42 0 042 21 1 6 o f  11
60 Nucleophosmin -1 15 0 0028 23 6 4 o f 12
60 HSP 27 kDa -1 41 0011 30 9 5 o f 11
62 HSPC108 1 31 0 0075 175 4 o f  8
63 Annexin A4 1 37 0 0011 33 5 lO o f 13
64 HLA-B associated transcript 1 
variant 1 26 0 022 22 2 8 o f  12
65 6 phosphogluconolactonase 1 22 0 032 26 4 o f  9
66 ATP Synthase 1 61 2 00E-05 21 7 8 o f  16
67 ATPase beta subunit -1 33 0 0038 35 7 15 o f  20
68 Actin G 1 protein -1 26 001 3 40 7 6 o f  16
69 HSP70 kDa 9B (MTHsp75) -1 33 0 00042 28 9 o f  20
70 CCT2 1 32 0 0013 43 8 o f 24
71 Replication A2 32, kDa 1 22 0 0039 26 3 6 o f 13
72 eiF 3 subunit 2 beta 36 kDa -1 79 0 025 21 8 6 o f  13
Table 3 6 7-ctd Proteins unique to SKMES versus SKM 
in Figure 3 6 8
ES-Txl(Wk2), Spots marked dark blue
Spot
No Protein Name Fold P value
Sequence
Coverage
No of 
Peptides
2 Valosin containing Protem -1 31 1 50E-05 185 9 o f 16
8 HSP 60 kDa 1 6 3 40E-06 32 7 11 o f  17
6 HSP 70 protein 8 isoform 2 1 30 0011 176 6 o f  11
14 hnRPHl -1 24 0 037 31 9 o f 27
19 Beta tubulin -1 94 0 0 1 4 164 6 o f  9
24 LASP 1 -1 49 0 00065 35 6 9 o f  15
25 Annexin A3 -1 39 0 0019 49 8 13 o f  20
33 High mobility Group box 1 1 2 0 0057 28 7 6 o f 14
37 Peroxiredoxin 2 -1 25 0 033 185 4 o f  7
38 GST-pi 2 29 0 00021 31 6 4 o f  7
40 Galectin-1 -1 32 0 0 1 2 50 7 5 o f  12
Table 3 6 9-ctd Overlapping proteins between SKMES-Txl (Wk3) versus SKMES-Txl (Wk6) 
and SKMES-1 versus SKMES-Txt
Spot
No
Protein Name Fold P value
Sequence
Coverage
No o f  
Peptides
41 ER-60 protease -1 55 2 60E-06 37 17 o f 30
42 Annexin V 2 10 0 0 1 7 49 8 11 o f 19
43 Thioredoxin peroxidase B -1 33 0 0 1 7 40 1 16 o f  21
44
Protein disulphide isomerase 
protein 5
-1 48 9 80E-06 20 9 6 o f  10
Table 3 6 10-ctd The 4 overlapping protein spots between the comparisons SKMES-1 vs 
SKMES-Txl (wk3) and SKMES-Txl (wk3) vs SKMES-Txl (Wk6)
Spot
No
Protein Name Fold P value
Sequence
Coverage
No o f  
Peptides
73 K1AA0098 -1 31 0 0051 23 1 14 o f 19
74 HSP 70 protein 8 isoform 2 -1 29 0 006 25 6 9 o f  19
75 HSP 70 protein 8 isoform 2 -1 3 0 011 23 3 8 o f  22
76 Beta Actin 2 38 0 0061 27 5 7 o f  13
77 Lamm B 1 1 7 0 00051 24 15 o f  27
78 Rab dissociation inhibitor beta 1 69 0 022 22 6 5 o f  12
79 Stathmin -1 24 0 0 1 9 35 6 5 o f  12
80 hnRPK -1 33 0 00094 20 6 o f  14
81 Chloride intracellular channel 1 -1 21 0 05 54 8 9 o f 14
82 RPLPO 1 39 0 026 32 3 4 o f 7
Table 3 6 11-ctd Proteins unique to SKMES-" fxl (Wk3)\ versus SKV ES-Txl (Wk6)
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Abstract
This thesis sets out to increase our know ledge o f  m echanism s by which lung cancer cells  
develop resistance to chemotherapeutic agents To further investigate drug resistance in 
lung cancer, a panel o f  four cell lm es were chosen for pulse-selection with  
chemotherapeutic agents The cell lm es mclude two squamous (SKM ES and DLRP) and 
two small cell lung carcinoma (D M S-53 and N C I-H 69) cell lm es The chemotherapy naive 
cell lines were purposely pulse-selected rather than contm uously selected with clin ically  
relevant concentrations o f  taxotere, taxol, carboplatin and/or V P -16 The resulting tw elve  
novel cell lm es were tested for resistance to a cross-section o f  chemotherapeutic agents, for 
changes m m vasiveness, motility, adhesiveness and for expression o f  the multidrug 
resistance (M D R) efflux pump proteins, P-gp and MRP-1 The SKM ES-taxane selected  
variants were chosen for further analysis because the resistance profile was unstable and 
the concentration o f  drug used for selection w as at a clinically achievable level Proteomic 
analysis was used to identify protems associated with the developm ent o f  taxol and 
taxotere resistance m these cell lines Proteomic analysis also revealed the differences 
between resistance to taxol and taxotere Loss o f  resistance w as observed in both taxane 
resistant variants o f  SKM ES B y monitoring the differential protein expression over time, 
protems involved in the loss o f  resistance were identified
Adriamycin and mitoxantrone resistance w as also studied in the squamous lung cell lme 
DLK P W hile the mam mechanism o f  resistance in these cell lm es is associated with a drug 
pump, little information on cytoplasm ic changes is available Proteomic analysis 
investigated these changes and elucidated the m echanisms m volved in adriamycin and 
mitoxantrone resistance to identify putative markers with possible prognostic/diagnostic  
value A  comparison o f  the protems altered m adriamycin and mitoxantrone-resistant 
variants w as carried out as these drugs are alkylating agents with mitoxantrone bem g an 
analogue o f  adriamycin and m ducing less cardiotoxicity Multidrug resistance is a major 
problem in lung cancer, there is a need to understand the com m on m echanism s m volved  
The protems m volved m the developm ent o f  taxane resistance m SKM ES show ed some 
cross over with other chemotherapeutic drugs namely adnam ycin or mitoxantrone m
